<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">59629</article-id><article-id pub-id-type="doi">10.7554/eLife.59629</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Use of signals of positive and negative selection to distinguish cancer genes and passenger genes</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-192858"><name><surname>Bányai</surname><given-names>László</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-192861"><name><surname>Trexler</surname><given-names>Maria</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-192860"><name><surname>Kerekes</surname><given-names>Krisztina</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-192859"><name><surname>Csuka</surname><given-names>Orsolya</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-191070"><name><surname>Patthy</surname><given-names>László</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1329-0484</contrib-id><email>patthy.laszlo@ttk.mta.hu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Institute of Enzymology, Research Centre for Natural Sciences</institution><addr-line><named-content content-type="city">Budapest</named-content></addr-line><country>Hungary</country></aff><aff id="aff2"><label>2</label><institution>Department of Pathogenetics, National Institute of Oncology</institution><addr-line><named-content content-type="city">Budapest</named-content></addr-line><country>Hungary</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Eyras</surname><given-names>Eduardo</given-names></name><role>Reviewing Editor</role><aff><institution>Australian National University</institution><country>Australia</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Wittkopp</surname><given-names>Patricia J</given-names></name><role>Senior Editor</role><aff><institution>University of Michigan</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>11</day><month>01</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e59629</elocation-id><history><date date-type="received" iso-8601-date="2020-06-03"><day>03</day><month>06</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2021-01-10"><day>10</day><month>01</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Bányai et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Bányai et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-59629-v2.pdf"/><abstract><p>A major goal of cancer genomics is to identify all genes that play critical roles in carcinogenesis. Most approaches focused on genes positively selected for mutations that drive carcinogenesis and neglected the role of negative selection. Some studies have actually concluded that negative selection has no role in cancer evolution. We have re-examined the role of negative selection in tumor evolution through the analysis of the patterns of somatic mutations affecting the coding sequences of human genes. Our analyses have confirmed that tumor suppressor genes are positively selected for inactivating mutations, oncogenes, however, were found to display signals of both negative selection for inactivating mutations and positive selection for activating mutations. Significantly, we have identified numerous human genes that show signs of strong negative selection during tumor evolution, suggesting that their functional integrity is essential for the growth and survival of tumor cells.</p></abstract><abstract abstract-type="executive-summary"><title>eLife digest</title><p>The DNA in the cells of the human body is usually copied correctly when a cell divides. However, errors (mutations) are sometimes introduced during the copying process. Although the majority of mutations have no major impact on cells, many mutations are harmful: they decrease the ability of cells to survive. There are, however, mutations that can lead to cells dividing more frequently or gaining the ability to spread, which can lead to cancer. These mutations are known as ‘driver mutations’ because they drive the growth of tumors. Since such ‘driver mutations’ provide a growth advantage to tumor cells, they are subject to positive selection, this is, their frequency in the tumor increases over time. Because of their selective advantage, driver mutations accumulate at significantly higher rates than the neutral ‘passenger mutations’ that do not play a role in tumor growth.</p><p>Genes that carry driver mutations are called driver genes, while genes that carry only passenger mutations are known as passenger genes. Certain genes, however, do not fit into either category. For example, some genes that are essential for tumor growth must get rid of harmful mutations to maintain activity. Mutations of such ‘tumor essential genes’ are thus subject to ‘negative’ or ‘purifying selection’.</p><p>A major goal of cancer research is to identify genes that play critical roles in tumor growth. Earlier studies have identified numerous driver genes positively selected for driver mutations, exploiting the fact that driver genes show significantly higher mutation rates than passenger genes. Identification of tumor essential genes, however, is inherently more difficult since the paucity of mutations of negatively selected genes hinders the analysis of the mutation data. The failure to provide convincing evidence for negative selection in tumors has led to suggestions that it has no role in cancer evolution.</p><p>Bányai et al. used a novel approach to address the question of whether negative selection occurs in cancer. Based on characteristic differences in the patterns of mutations in cancer they distinguished clusters of passenger genes, driver genes and tumor essential genes. The group of tumor essential genes includes genes that serve to satisfy the increased demand of rapidly dividing tumor cells for nutrients’ and genes that are essential for cell migration and metastasis (the spread of cancer cells to other areas of the body).</p><p>The tumor essential genes that Bányai et al. identified may prove to be valuable targets for cancer therapy, illustrating the importance of genome sequencing in cancer research. Identification of additional tumor essential genes is, however, hindered by the fact that they are likely to have low levels of mutations, which can exclude them from meaningful analyses. Progress with genomic sequencing of tumors is expected to overcome this limitation and help identify additional genes that are essential for cancer growth.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>cancer gene</kwd><kwd>negative selection</kwd><kwd>positive selection</kwd><kwd>passenger gene</kwd><kwd>neutral evolution</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>Hungarian National Research, Development and Innovation Office</institution></institution-wrap></funding-source><award-id>GINOP-2.3.2-15-2016-00001</award-id><principal-award-recipient><name><surname>Bányai</surname><given-names>László</given-names></name><name><surname>Trexler</surname><given-names>Maria</given-names></name><name><surname>Kerekes</surname><given-names>Krisztina</given-names></name><name><surname>Patthy</surname><given-names>László</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>Hungarian National Research, Development and Innovation Office</institution></institution-wrap></funding-source><award-id>NVKP_16-1-2016-0005</award-id><principal-award-recipient><name><surname>Csuka</surname><given-names>Orsolya</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>In contrast with earlier conclusions, negative selection has a major role in cancer evolution.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><sec id="s1-1"><title>Genetic, epigenetic, transcriptomic, and proteomic changes driving carcinogenesis</title><p>In the last two decades, the rapid advance in genomics, epigenomics, transcriptomics, and proteomics permitted an insight into the molecular basis of carcinogenesis. These studies have confirmed that tumors evolve from normal tissues by acquiring a series of genetic, epigenetic, transcriptomic, and proteomic changes with concomitant alterations in the control of the proliferation, survival, and spread of affected cells.</p><p>The genes that play key roles in carcinogenesis are usually assigned to two major categories: proto-oncogenes that have the potential to promote carcinogenesis when activated or overexpressed and tumor suppressor genes (TSGs) that promote carcinogenesis when inactivated or repressed.</p><p>Several alternative mechanisms can modify the structure or expression of a gene in a way that promotes carcinogenesis. These include subtle genetic changes (single nucleotide substitutions, short indels), major genetic events (deletion, amplification, translocation and fusion of genes to other genetic elements), as well as epigenetic changes affecting the expression of cancer genes. These mechanisms are not mutually exclusive: there are many examples illustrating the point that multiple types of the above mechanisms may convert the wild-type form of a cancer gene to a driver gene.</p><p>Exomic studies of common solid tumors revealed that usually several cancer genes harbor subtle somatic mutations (point mutations, short deletions, and insertions) in their translated regions but malignancy-driving subtle mutations can also occur in all genetic elements outside the coding region, namely in enhancer, silencer, insulator, and promoter regions as well as in 5'- and 3'-untranslated regions. Intron or splice site mutations that alter the splicing pattern of cancer genes can also drive carcinogenesis (<xref ref-type="bibr" rid="bib61">Diederichs et al., 2016</xref>). A recent study has presented a comprehensive analysis of driver point mutations in non-coding regions across 2658 cancer genomes (<xref ref-type="bibr" rid="bib197">Rheinbay et al., 2020</xref>). A noteworthy example of how subtle mutations in regulatory regions may activate proto-oncogenes is the telomerase reverse transcriptase gene <italic>TERT</italic> that encodes the catalytic subunit of telomerase. Recurrent somatic mutations in melanoma and other cancers in the <italic>TERT</italic> promoter cause tumor-specific increase of <italic>TERT</italic> expression, resulting in the immortalization of the tumor cell (<xref ref-type="bibr" rid="bib94">Heidenreich et al., 2014</xref>).</p><p>In addition to subtle mutations, tumors also accumulate major chromosomal changes (<xref ref-type="bibr" rid="bib138">Li et al., 2020</xref>). Most solid tumors display widespread changes in chromosome number, as well as chromosomal deletions and translocations (<xref ref-type="bibr" rid="bib131">Lengauer et al., 1998</xref>). Homozygous deletions of a few genes frequently drive carcinogenesis and the target gene involved in such deletions is always a TSG (<xref ref-type="bibr" rid="bib47">Cheng et al., 2017</xref>). Somatic copy-number alterations, amplifications of cancer genes are also widespread in various types of cancers. Amplifications usually contain an oncogene (OG) whose protein product is abnormally active simply because the tumor cell contains 10–100 copies of the gene per cell, compared with the two copies present in normal cells (<xref ref-type="bibr" rid="bib23">Beroukhim et al., 2010</xref>; <xref ref-type="bibr" rid="bib253">Verhaak et al., 2019</xref>). Chromosomal translocations may also convert wild-type forms of TSGs into forms that drive carcinogenesis if the translocation inactivates the genes by truncation or by separating them from their promoter. Similarly, translocations may activate proto-oncogenes by changing their regulatory properties (<xref ref-type="bibr" rid="bib85">Haller et al., 2019</xref>).</p><p>Epigenetic mechanisms such as DNA methylation and histone modifications may also alter the activity of cancer genes. It is now widely accepted that genetic and epigenetic changes go hand in hand in carcinogenesis: numerous genes involved in shaping the epigenome are mutated in common human cancers, and epigenetic changes affect many genes carrying driver mutations (<xref ref-type="bibr" rid="bib299">Yang and Yu, 2013</xref>; <xref ref-type="bibr" rid="bib39">Chen et al., 2017b</xref>; <xref ref-type="bibr" rid="bib59">Di Domenico et al., 2017</xref>; <xref ref-type="bibr" rid="bib203">Roussel and Stripay, 2018</xref>; <xref ref-type="bibr" rid="bib35">Chatterjee et al., 2018</xref>). For example, promoter hypermethylation events may promote carcinogenesis if they lead to silencing of TSGs; the tumor-driving role of promoter methylation is obvious in the case of TSGs that are frequently inactivated by mutations in cancer (<xref ref-type="bibr" rid="bib183">Pfeifer, 2018</xref>). Conversely, there is now ample evidence that promoter hypomethylation can promote carcinogenesis if it leads to increased expression of proto-oncogenes (<xref ref-type="bibr" rid="bib251">Van Tongelen et al., 2017</xref>).</p><p>Non-coding RNAs (ncRNAs) also play key roles in carcinogenesis (<xref ref-type="bibr" rid="bib223">Slack and Chinnaiyan, 2019</xref>). An explosion of studies has shown that – based on complementary base pairing – ncRNAs may function as OGs (by inhibiting the activity of TSGs), or as tumor suppressors (by inhibiting the activity of OGs or tumor essential genes [TEGs]).</p><p>Alterations in the splicing of primary transcripts of protein-coding genes also contribute to carcinogenesis. Recent studies on cancer genomes have revealed that recurrent somatic mutations of genes encoding RNA splicing factors (e.g. <italic>SF3B1</italic>, <italic>U2AF1</italic>, <italic>SRSF2</italic>, <italic>ZRSR2</italic>) lead to altered splice site preferences, resulting in cancer-specific mis-splicing of genes. In the case of proto-oncogenes, changes in the splicing pattern may generate active oncoproteins, whereas abnormal splicing of TSGs is likely to generate inactive forms of the tumor suppressor protein (<xref ref-type="bibr" rid="bib65">Dvinge et al., 2016</xref>).</p><p>There is now convincing evidence that dysregulation of processes responsible for proteostasis also contributes to the development and progression of numerous cancer types (<xref ref-type="bibr" rid="bib165">Mofers et al., 2017</xref>; <xref ref-type="bibr" rid="bib40">Chen et al., 2017c</xref>; <xref ref-type="bibr" rid="bib258">Voutsadakis, 2017</xref>). Recent studies on tumor tissues have revealed that genetic alterations and abnormal expression of various components of the protein homeostasis pathways (e.g. <italic>FBXW7</italic>, <italic>VHL</italic>) contribute to progression of human cancers by excessive degradation of tumor-suppressor molecules or through impaired disposal of oncogenic proteins (<xref ref-type="bibr" rid="bib76">Ge et al., 2018</xref>; <xref ref-type="bibr" rid="bib22">Bernassola et al., 2019</xref>).</p></sec><sec id="s1-2"><title>Hallmarks of cancer and the function of genes involved in carcinogenesis</title><p>Hanahan and Weinberg have defined a set of hallmarks of cancer that allow the categorization of cancer genes with respect to their role in carcinogenesis (<xref ref-type="bibr" rid="bib87">Hanahan and Weinberg, 2011</xref>). These hallmarks describe the biological capabilities usually acquired during the evolution of tumor cells: these include sustained proliferative signaling, evasion of growth suppressors, evasion of cell death, acquisition of replicative immortality, acquisition of capability to induce angiogenesis and activation of invasion and metastasis. Underlying all these hallmarks are defects in genome maintenance that help the acquisition of the above capabilities. Additional emerging hallmarks of potential generality have been suggested to include tumor promoting inflammation, evasion of immune destruction and reprogramming of energy metabolism in order to most effectively support neoplastic proliferation (<xref ref-type="bibr" rid="bib87">Hanahan and Weinberg, 2011</xref>).</p><p><xref ref-type="fig" rid="fig1">Figure 1</xref> summarizes our current view of the cellular processes that play key roles in tumor evolution to emphasize their contribution to the various major hallmarks of cancer. Changes in the maintenance of the genome, epigenome, transcriptome, and proteome occupy a central position because they increase the chance that various constituents of other cellular pathways will experience alterations that favor the acquisition of capabilities that permit the proliferation, survival, and metastasis of tumor cells.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Changes of key cellular processes contributing to carcinogenesis.</title><p>The central circle refers to processes involved in the maintenance of the integrity of the genome, epigenome, transcriptome, and proteome: defects in these processes increase the chance that genes and proteins of other cellular pathways (represented by segments of the outer circle) will suffer alterations that favor the acquisition of capabilities that permit the proliferation, survival, and metastasis of tumor cells.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59629-fig1-v2.tif"/></fig></sec><sec id="s1-3"><title>Chronology of tumor evolution: initiation and progression</title><p>In the first phase of carcinogenesis, a cell may acquire a mutation that permits it to proliferate abnormally, and in the next phase, other mutations allow the expansion of cell number and this process of mutations (and associated epigenetic, transcriptomic and proteomic alterations) continues, thus generating a primary tumor that can eventually metastasize to distant organs. Recent studies on the chronology and genomic landscape of the events that drive carcinogenesis suggest that complex structural changes of the genome occur early, whereas point mutations occur in later disease phases (<xref ref-type="bibr" rid="bib156">Maura et al., 2019</xref>; <xref ref-type="bibr" rid="bib257">Voronina et al., 2020</xref>).</p><p>According to current estimates, the number of cancer driving mutations needed for the full development of cancer ranges from two-eight depending on cancer type (<xref ref-type="bibr" rid="bib256">Vogelstein and Kinzler, 2015</xref>; <xref ref-type="bibr" rid="bib10">Anandakrishnan et al., 2019</xref>). A recent integrative analysis of 2658 whole-cancer genomes and their matching normal tissues across 38 tumor types revealed that, on average, cancer genomes contain four to five driver mutations (<xref ref-type="bibr" rid="bib30">Campbell et al., 2020</xref>).</p><p>Although the temporal order of the mutations affecting genes of key pathways differs among cancer types, it appears that a common feature is that mutations of genes that regulate apoptosis occur in the early phases of tumor progression, whereas mutations of genes involved in invasion pathways occur only in the last stages of carcinogenesis (<xref ref-type="bibr" rid="bib77">Gerstung et al., 2011</xref>). It has been suggested that the reason why the loss of apoptotic control is a critical step for initiating cancer is that the larger the surviving cell population, the higher the number of cells at risk of acquiring additional mutations.</p><p>Analyses of the mutation landscapes and evolutionary trajectories of various tumor tissues have identified <italic>BRAF, KRAS, TP53, RB</italic>, or <italic>APC</italic> as the key genes whose mutation is most likely to initiate carcinogenesis, permitting the cell to divide abnormally (<xref ref-type="bibr" rid="bib256">Vogelstein and Kinzler, 2015</xref>). In the case of ovarian cancers, <italic>TP53</italic> mutation is believed to be the earliest tumorigenic driver event, with presence in nearly all cases of ovarian cancer (<xref ref-type="bibr" rid="bib19">Bashashati et al., 2013</xref>). The prevalence of <italic>TP53</italic> mutations and <italic>BRCA</italic> deficiency in these tumors leads to incompetent DNA repair promoting subsequent steps of carcinogenesis. Studies on the evolution of melanoma from precursor lesions have revealed that the vast majority of melanomas harbor <italic>TERT</italic> promoter mutations, indicating that these immortalizing mutations are selected at an unexpectedly early stage of neoplastic progression (<xref ref-type="bibr" rid="bib215">Shain et al., 2015</xref>).</p><p>The life history and evolution of mutational processes and driver mutation sequences of 38 types of cancer has been analyzed recently by whole-genome sequencing analysis of 2658 cancers. This study has shown that early oncogenesis is characterized by mutations in a constrained set of driver genes and that the driver mutations that most commonly occur in a given cancer also tend to occur the earliest (<xref ref-type="bibr" rid="bib78">Gerstung et al., 2020</xref>).</p></sec><sec id="s1-4"><title>Cancer genes and passenger genes</title><p>The prominent role of <italic>KRAS</italic> and <italic>TP53</italic> genes in initiating carcinogenesis has been evident from the observation that their mutation rate in tumors far exceeds those of other genes, suggesting that their mutations are subject to positive selection during tumor evolution.</p><p>Several types of approaches exploit this principle for the identification of genes that drive carcinogenesis: the rate of mutation of ‘driver genes’ must be significantly higher in the tumor tissue than those of ‘passenger genes’ (PGs) that have no role in the development of cancer but simply happen to mutate in the same tumor (<xref ref-type="bibr" rid="bib178">Parmigiani et al., 2009</xref>; <xref ref-type="bibr" rid="bib161">Meyerson et al., 2010</xref>).</p><p>Unfortunately, methods based on mutation frequency alone cannot reliably indicate which genes are cancer drivers because the background mutation rates differ significantly as a consequence of intrinsic characteristics of DNA sequence and chromatin structure (<xref ref-type="bibr" rid="bib163">Michaelson et al., 2012</xref>). Intrinsic mutation hotspots are mutation hotspots that depend on the nucleotide sequence context, the mechanism of mutagenesis and the action of the repair and replication machineries (<xref ref-type="bibr" rid="bib200">Rogozin and Pavlov, 2003</xref>). Genes enriched in intrinsic mutation hotspots may accumulate mutations at a significantly higher rate than other genes, creating the illusion of positive selection; based on recurrent mutations they may be mistakenly identified as cancer driver genes (<xref ref-type="bibr" rid="bib33">Carter, 2019</xref>; <xref ref-type="bibr" rid="bib27">Buisson et al., 2019</xref>).</p><p>In principle, we can avoid this danger if we compare the mutation pattern of the gene in the tumor tissue with that in the normal tissue the tumor has originated from. However, since the rate of mutation in such hotspots depends not only on the nucleotide sequence but also on the mechanism of mutagenesis and the integrity of DNA repair pathways (<xref ref-type="bibr" rid="bib27">Buisson et al., 2019</xref>; <xref ref-type="bibr" rid="bib188">Poulos et al., 2018</xref>) mutation hotspots that arise during carcinogenesis could still create the illusion of positive selection.</p><p>Chromatin organization also has a major influence on regional mutation rates in human cancer cells (<xref ref-type="bibr" rid="bib210">Schuster-Böckler and Lehner, 2012</xref>; <xref ref-type="bibr" rid="bib81">Gonzalez-Perez et al., 2019</xref>). Since large-scale chromatin features, such as replication time and accessibility influence the rate of mutations, this may hinder the distinction of cancer driver genes whose high mutation rate reflects positive selection and PGs whose high mutation rate is the result of the distinctive features of the chromatin region in which they reside. Moreover, since the cell-of-origin chromatin organization shapes the mutational landscape, rates of somatic mutagenesis of genes in cancer are highly cell-type-specific (<xref ref-type="bibr" rid="bib186">Polak et al., 2015</xref>). Actually, since regional mutation density of ‘passenger’ mutations across the human chromosomes correlates with the cell type the tumor had originated from, this feature may be used to classify human tumors (<xref ref-type="bibr" rid="bib204">Salvadores et al., 2019</xref>).</p><p>Through the comparison of the exome sequences of 3083 tumor-normal pairs <xref ref-type="bibr" rid="bib128">Lawrence et al., 2013</xref> have discovered an extraordinary variation in mutation frequency and spectrum within cancer types across the genome, which is strongly correlated with DNA replication timing and transcriptional activity. The authors have shown that by incorporating mutational heterogeneity into their analyses, they could eliminate many of the apparent artefactual findings, improving the identification of genes truly associated with cancer. In a more recent study <xref ref-type="bibr" rid="bib129">Lawrence et al., 2014</xref> compared the frequency of somatic point mutations in exome sequences from 4742 human cancers and their matched normal-tissue samples across 21 cancer types and identified 33 genes that were not previously known to be significantly mutated in cancer. They have concluded that 224 genes are significantly mutated in one or more tumor types.</p><p>However, since background mutational frequency estimates are not sensitive enough, the list of driver genes (defined as genes with increased somatic mutation rate) is likely to be incomplete, but may also contain false positives. To overcome these limitations of mutation rate-based approaches, several methods use additional features that may distinguish driver genes and PGs. A major group of such approaches incorporates observations about the impact of mutations on the structure and function of well-characterized proteins encoded by proto-oncogenes and TSGs. Several computational methods aim to identify driver missense mutations most likely to generate functional changes that causally contribute to tumorigenesis (<xref ref-type="bibr" rid="bib118">Kaminker et al., 2007</xref>; <xref ref-type="bibr" rid="bib32">Carter et al., 2009</xref>; <xref ref-type="bibr" rid="bib170">Nussinov et al., 2019</xref>).</p><p>In a different type of approach <xref ref-type="bibr" rid="bib302">Youn and Simon, 2011</xref> identified cancer driver genes as those for which the non-silent mutation rate is significantly greater than a background mutation rate estimated from silent mutations, indicating that the non-silent mutations are subject to positive selection. The authors have identified 28 genes as driver genes, the majority of the significant matches (e.g. <italic>EGFR, CDKN2A, KRAS, STK11, TP53, NF1, RB1 PTEN</italic>, and <italic>NRAS</italic>), were well-characterized OGs or TSGs known from earlier studies.</p><p>In a more recent study, <xref ref-type="bibr" rid="bib318">Zhou et al., 2017</xref> have identified 365 genes for which the ratio of the nonsynonymous to synonymous substitution rate was significantly increased, suggesting that they are subject to the positive selection of driver mutations. However, an obvious limitation of such approaches is that they implicitly assume that synonymous substitutions are selectively neutral and therefore the ratio of the nonsynonymous to synonymous substitution rate properly monitors selection. This is not necessarily true: some synonymous mutations may have a significant impact on splicing, RNA stability, RNA folding and translation of the transcript of the affected gene and may thus actually act as driver mutations (<xref ref-type="bibr" rid="bib236">Supek et al., 2014</xref>; <xref ref-type="bibr" rid="bib106">Hurst and Batada, 2017</xref>; <xref ref-type="bibr" rid="bib216">Sharma et al., 2019</xref>). Furthermore, some mutation hotspots may significantly increase the rate of synonymous mutations therefore a low ratio of nonsynonymous to synonymous substitution rate does not necessarily indicate the absence of positive selection or the action of purifying selection.</p><p><xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref> have used a heuristic approach to identify cancer driver genes. Since the patterns of mutations in the first and best-characterized OGs and TSGs were found to be highly characteristic and nonrandom, the authors assumed that the same characteristics are generally valid and may be used to identify previously uncharacterized cancer genes. For example, since many known OGs were found to be recurrently mutated at the same amino acid positions, to classify a gene as an OG, it was required that &gt;20% of the recorded mutations in the gene are at recurrent positions and are missense. Similarly, since in the case of known tumor suppressors the driver mutations most frequently truncate the tumor suppressor proteins, to be classified as a TSG, it was required that &gt;20% of the recorded mutations in the gene are truncating (nonsense or frameshift) mutations. Along these lines, <xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref> have analyzed the patterns of the subtle mutations in the Catalogue of Somatic Mutations in Cancer (COSMIC) database to identify driver genes. As a proof of the reliability of this ‘20/20 rule’, the authors emphasized that all well-documented cancer genes passed these criteria (<xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref>). Although this indicates that the approach detects known cancer genes, it does not guarantee that it detects all driver genes. Acknowledging that additional cancer driver genes might exist, the authors have introduced the term ‘Mut-driver gene’ for genes that contain a sufficient number or type of driver gene mutations to distinguish them from other genes, whereas for cancer genes that are expressed aberrantly in tumors but not frequently mutated they proposed the term ‘Epi-driver gene’.</p><p>Based on these analyses, the authors have concluded that out of the 20,000 human protein-coding genes, only 125 genes qualify as Mut-driver genes, of these, 71 are TSGs and 54 are OGs (<xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref>). The authors have expressed their conviction that nearly all genes mutated at significant frequencies had already been identified and that the number of Mut-driver genes is nearing saturation. This conclusion may not be justified since the criteria used to identify OGs and tumor suppressors appear to be too stringent and somewhat arbitrary.</p><p>In search of additional driver genes, <xref ref-type="bibr" rid="bib238">Tamborero et al., 2013</xref> employed five complementary methods to find genes showing signals of positive selection and identified a list of 291 ‘high-confidence cancer driver genes’ acting on 3205 tumors from 12 different cancer types. <xref ref-type="bibr" rid="bib16">Bailey et al., 2018</xref> used multiple advanced algorithms to identify cancer driver genes and driver mutations. Based on their PanCancer and PanSoftware analysis spanning 9423 tumor exomes, comprising all 33 of The Cancer Genome Atlas projects and using 26 computational tools they have identified 299 driver genes showing signs of positive selection. Their sequence and structure-based analyses detected &gt;3400,400 putative missense driver mutations and 60–85% of the predicted mutations were validated experimentally as likely drivers.</p><p><xref ref-type="bibr" rid="bib314">Zhao et al., 2019a</xref> have developed driverMAPS (Model-based Analysis of Positive Selection), a model-based approach for driver gene identification that captures elevated mutation rates in functionally important sites and spatial clustering of mutations. The authors have identified 255 known driver genes as well as 170 putatively novel driver genes.</p><p>Currently, COSMIC (the Catalogue Of Somatic Mutations In Cancer, <ext-link ext-link-type="uri" xlink:href="https://cancer.sanger.ac.uk/cosmic">https://cancer.sanger.ac.uk/cosmic</ext-link>) is the most detailed and comprehensive resource for exploring the effect of subtle somatic mutations of driver genes in human cancer (<xref ref-type="bibr" rid="bib242">Tate et al., 2019</xref>) but COSMIC also covers all the genetic mechanisms by which somatic mutations promote cancer, including non-coding mutations, gene fusions, and copy-number variants. In parallel with COSMIC's variant coverage, the Cancer Gene Census (CGC, <ext-link ext-link-type="uri" xlink:href="https://cancer.sanger.ac.uk/census">https://cancer.sanger.ac.uk/census</ext-link>) describes a curated catalogue of genes driving every form of human cancer (<xref ref-type="bibr" rid="bib224">Sondka et al., 2018</xref>). CGC has recently introduced functional descriptions of how each gene drives disease, summarized into the cancer hallmarks. CGC describes in detail the effect of a total of 719 cancer-driving genes, encompassing Tier 1 genes (574 genes) and a list of Tier 2 genes (145 genes) from more recent cancer studies that show less detailed indications of a role in cancer.</p><p>In a different type of approach, <xref ref-type="bibr" rid="bib246">Torrente et al., 2016</xref> used comprehensive maps of human gene expression in normal and tumor tissues to identify cancer related genes. These analyses identified a list of genes with systematic expression change in cancer. The authors have noted that the list is significantly enriched with known cancer genes from large, public, peer-reviewed databases, whereas the remaining ones were proposed as new cancer gene candidates. A recent study has provided a comprehensive catalogue of cancer-associated transcriptomic alterations with the top-ranking genes carrying both RNA and DNA alterations. The authors have noted that this catalogue is enriched for cancer census genes (<xref ref-type="bibr" rid="bib28">Calabrese et al., 2020</xref>).</p><p>Using transposon mutagenesis in mice, several laboratories have conducted forward genetic screens and identified thousands of candidate genetic drivers of cancer that are highly relevant to human cancer. The Candidate Cancer Gene Database (CCGD, <ext-link ext-link-type="uri" xlink:href="http://ccgd-starrlab.oit.umn.edu/">http://ccgd-starrlab.oit.umn.edu/</ext-link>) is a manually curated database containing a unified description of all identified candidate driver genes (<xref ref-type="bibr" rid="bib1">Abbott et al., 2015</xref>).</p><p>In summary, although a variety of approaches have been developed to identify ‘cancer genes’, there is significant disagreement as to the number of genes involved in carcinogenesis. Some of the studies argue that the number is in the 200–700 range, other approaches suggest that their number may be much higher. Since the ultimate goal of cancer genome projects is to discover therapeutic targets, it is important to identify all true cancer genes and distinguish them from PGs and candidates that do not play a significant role in the process of carcinogenesis.</p><p>We must point out, however, that the majority of genomics-based methods were biased as they defined the aim of cancer genomics as the identification of mutated driver genes (equating them with ‘cancer genes’) that are causally implicated in oncogenesis (<xref ref-type="bibr" rid="bib70">Futreal et al., 2004</xref>). In all these studies, the underlying rationale for interpreting a mutated gene as causal in cancer development is that the mutations are likely to have been positively selected because they confer a growth advantage on the cell population from which the cancer has developed. An inevitable consequence of this focus on positive selection was that most studies neglected the possibility that negative selection may also play a significant role in tumor evolution.</p></sec><sec id="s1-5"><title>Carcinogenesis as an evolutionary process</title><p>In principle, with respect to its effect on carcinogenesis, a somatic mutation may promote or may hinder carcinogenesis or may have no effect on carcinogenesis. In cancer genomics, the mutations that promote carcinogenesis (and are subject to positive selection during tumor evolution) are called ‘driver mutations’ to distinguish them from ‘passenger mutations’ that do not play a role in carcinogenesis (and are not subject to positive or negative selection during tumor evolution). Mutations that impair the growth, survival, and invasion of tumor cells have received much less attention, although they could also play a significant role in shaping the mutation pattern of genes during carcinogenesis. Hereafter, we will refer to this category of mutations as ‘cancer blocking mutations’ because they are deleterious from the perspective of tumor growth.</p><p>As discussed above, in cancer genomics, genes are usually assigned to just two categories with respect to their role in carcinogenesis: (1) ‘PGs’ (or bystander genes) that play no significant role in carcinogenesis and their mutations are passenger mutations; (2) ‘driver genes’ that drive carcinogesis when they acquire driver mutations.</p><p>The problem with this binary driver gene-PG categorization is that some genes with functions essential for the growth and survival of tumor cells (hereafter referred to as ‘tumor essential genes’) may not easily fit into either category. The coding sequences of driver genes (TSGs, proto-oncogenes), PGs, and TEGs are predicted to experience markedly different patterns of selection during tumor evolution.</p><p>The mutation patterns of selectively neutral, bona fide PGs are likely to reflect the lack of positive and negative selection, whereas in the case of TEGs purifying selection is predicted to dominate. In the case of TSGs, the mutation pattern is expected to reflect positive selection for inactivating driver mutations. Proto-oncogenes, however, are expected to show signs of both positive selection for activating mutations and negative selection for inactivating, ‘cancer blocking’ mutations as their activity is essential for their oncogenic role. In the coding regions of proto-oncogenes positive selection for driver mutations is expected to favor nonsynonymous substitutions over synonymous substitutions only at sites that are critical for the novel, oncogenic function. For these sites (and these sites only), the ratio of nonsynonymous to synonymous rates is expected to be significantly greater than one reflecting positive selection. If there are many such sites in a protein, or selection is extremely strong the overall nonsynonymous to synonymous ratio for the entire protein may also be significantly higher than one, otherwise the effect of positive selection on the synonymous to nonsynonymous ratio may be overridden by purifying selection at other sites (<xref ref-type="bibr" rid="bib180">Patthy, 1999</xref>).</p><p>In harmony with some of these expectations, using just the ratio of the nonsynonymous to synonymous substitution rate as a measure of positive or negative selection, <xref ref-type="bibr" rid="bib318">Zhou et al., 2017</xref> have shown that in cancer genomes, the majority of genes had nonsynonymous to synonymous substitution rate values close to one, suggesting that they belong to the PG category. The authors have identified a total of 365 potential cancer driver genes that had nonsynonymous to synonymous substitution rate values significantly greater than one (reflecting the dominance of positive selection). Conversely, 923 genes had nonsynonymous to synonymous substitution rate values significantly less than one (reflecting the dominance of negative selection), leading the authors to suggest that these negatively selected genes may be important for the growth and survival of cancer cells.</p><p><xref ref-type="bibr" rid="bib192">Pyatnitskiy et al., 2015</xref> have also used the dN/dS ratio (the ratio of nonsynonymous and synonymous substitution rates) as an indicator of selective pressure and have identified 91 protein-coding genes (’essential cancer proteins’) with amino acid sequences under negative selection.</p><p>Realizing that genes whose wild-type coding sequences are needed for tumor growth are also of key interest for cancer research, <xref ref-type="bibr" rid="bib278">Weghorn and Sunyaev, 2017</xref> have also focused on the role of negative selection in human cancers. The authors have used an approach based on the principle that both positive and negative selection can be inferred by comparing the observed mutation rates to the expectation under the sole action of the mutation process. As the authors have pointed out, identification, and analysis of true negatively selected,’ undermutated’ genes is particularly difficult since the sparsity of mutation data results in lower statistical power, making conclusions less reliable. Although the signal of negative selection was exceedingly weak, the authors have noted that the group of negatively selected candidate genes is enriched in cell-essential genes identified in a CRISPR screen (<xref ref-type="bibr" rid="bib264">Wang et al., 2015a</xref>), consistent with the notion that one of the potential causes of negative selection is the maintenance of genes that are responsible for basal cellular functions. Based on pergene estimates of negative selection inferred from the pan-cancer analysis the authors have identified 147 genes with significant negative selection. The authors have noted that among the 13 genes showing the strongest signs of negative selection there are several genes (<italic>ATAT1, BCL2, CLIP1, GALNT6, CKAP5,</italic> and <italic>REV1</italic>) that are known to promote carcinogenesis.</p><p>In a similar work, <xref ref-type="bibr" rid="bib153">Martincorena et al., 2017</xref> have used the normalized ratio of non-synonymous to synonymous mutations, to quantify selection in coding sequences of cancer genomes. Using a nonsynonymous-to-synonymous substitution rate value &gt;1 as a marker of cancer genes under positive selection, they have identified 179 cancer genes, with about 50% of the coding driver mutations being found to occur in novel cancer genes. The authors, however, have concluded that purifying selection is practically absent in tumors since nearly all (&gt;99%) coding mutations are tolerated and escape negative selection. The authors have suggested that this remarkable absence of negative selection on coding point mutations in cancer indicates that the vast majority of genes are dispensable for any given somatic lineage, presumably reflecting the buffering effect of diploidy and the inherent resilience and redundancy built into most cellular pathways.</p><p>The key message of <xref ref-type="bibr" rid="bib153">Martincorena et al., 2017</xref> that negative selection has no role in cancer evolution had a major impact on cancer genomics research as reflected by several commentaries in major journals of the field that have propagated this conclusion (<xref ref-type="bibr" rid="bib17">Bakhoum and Landau, 2017</xref>; <xref ref-type="bibr" rid="bib124">Koch, 2017</xref>; <xref ref-type="bibr" rid="bib254">Vitale and Galluzzi, 2018</xref>).</p><p>Some more recent studies, however, contradict this conclusion. Although <xref ref-type="bibr" rid="bib307">Zapata et al., 2018</xref> have also used the ratio of nonsynonymous-to-synonymous substitutions to identify genes that are under selection, they have detected significant negative selection in the case of 25 genes. <xref ref-type="bibr" rid="bib146">López et al., 2020</xref>, focusing on dN/dS values for truncating mutations, have shown that purifying selection of essential genes is significant in early phases of tumor evolution (before whole genome duplications), whereas whole-genome doubling allows the accumulation of deleterious alterations. <xref ref-type="bibr" rid="bib244">Tilk et al., 2020</xref> have shown that appreciable negative selection (dN/dS ~ 0.4) is present in tumors with a low mutational burden, while the majority of tumors exhibit dN/dS ratios approaching 1, suggesting that tumors with higher mutational burden do not remove deleterious mutations.</p><p><xref ref-type="bibr" rid="bib249">Van den Eynden and Larsson, 2017</xref>, however, cautioned that it is crucial to take into account mutational signatures when applying the dN/dS metric to cancer somatic mutation data. For example, the authors have shown that the low dN/dS values observed in malignant melanoma may be due to the predominance of C to T mutations in this tumor and do not necessarily indicate gene essentiality. The authors have also shown that purifying selection is very limited and similar in all tumor types if the dN/dS metric uses mutational signature-derived substitution probabilities.</p><p>In view of the contradicting conclusions about the significance of negative selection in tumor evolution, in the present work we have reexamined this question using an approach that attempts to overcome some of the problems highlighted by earlier studies.</p><p>First, most studies used a single dN/dS metric to measure nonsynonymous to synonymous substitution rates as indicators of selective pressure and paid less attention to the fact that the strength of purifying selection is an order of magnitude greater for nonsense mutations than for missense mutations (<xref ref-type="bibr" rid="bib82">Gorlov et al., 2006</xref>). Furthermore, the use of a single dN/dS value for a transcript may preclude the simultaneous detection of positive and negative selection of activating and inactivating mutations, both of which might operate for a given gene. To overcome these limitations, in the present study we have used a clustering-based approach that can detect different signals of selection manifested in rates of nonsense, missense <italic>versus</italic> silent substitutions in the coding regions of genes.</p><p>Second, an inherent problem with the detection of purifying selection in tumor tissues is that putative TEGs are likely to be undermutated relative to PGs and driver genes, resulting in low statistical power of their analyses based on dN/dS metrics. We have reduced this problem by combining subtle somatic mutations from different tumors types and limiting our work to transcripts that have at least 100 somatic mutations in tumors. (Note that the requirement of a minimum number of mutations does not place a theoretical limit on this approach; progress with genome-wide screens and collection of more data is overcoming this limitation.)</p><p>In harmony with earlier observations, our analyses have confirmed that the vast majority of human genes are PGs that do not show detectable signals of selection, whereas known TSGs are positively selected for inactivating (primarily nonsense and frame-shift) mutations. Known OGs, however, were found to display signals of both negative selection for inactivating (nonsense, frame-shift) mutations and positive selection for activating (missense) mutations. Improved detection of signals of selection has permitted the identification of a number of novel driver genes that are likely to play important roles in carcinogenesis as TSGs or as OGs.</p><p>Significantly, we have identified a cluster of human genes that show clear signs of negative selection during tumor evolution, suggesting that their functional integrity is essential for the growth and survival of tumor cells. The group of negatively selected genes includes genes known to play critical roles in the Warburg effect of cancer cells, others are known to mediate invasion and metastasis of tumor cells, indicating that negatively selected TEGs may prove a rich source for novel targets for tumor therapy.</p></sec></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Distinguishing PGs and cancer genes</title><p>The rationale of the analyses described in the present work is that — due to their different roles in carcinogenesis — proto-oncogenes, TSGs, TEGs, and PGs are expected to experience different patterns of selection during tumor evolution and this is reflected in the relative rates of missense, nonsense, and silent mutations of their protein-coding regions. To monitor these differences, we have calculated for each transcript the fraction of somatic substitutions that could be assigned to the silent (fS), misssense (fM), and nonsense (fN) category and analyzed their relative rates. (For details, the reader should consult the Materials and methods section).</p><p>Our analyses have shown that in 3D scatter plots of the fS, fM, and fN values of transcripts the majority of genes are present in a central cluster characterized by fS, fM, and fN values close to those expected assuming no mutation bias and absence of selection, consistent with the view that they correspond to PGs (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Known OGs, however, were found in a separate cluster characterized by higher fM values, reflecting positive selection for missense mutations, whereas the cluster of known TSGs has higher fN values, reflecting positive selection for truncating nonsense mutations (<xref ref-type="fig" rid="fig2">Figure 2B and C</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Analyses of fS, fM, and fN parameters of human protein-coding genes of tumor tissues.</title><p>The figure shows the results of the analysis of 13,803 transcripts containing at least 100 subtle, confirmed somatic mutations from tumor tissues, including only mutations identified as not single-nucleotide polymorphisms (SNPs). Axes <italic>x, y</italic>, and <italic>z</italic> represent the fractions of somatic single-nucleotide substitutions that are assigned to the synonymous (fS), nonsynonymous (fM), and nonsense (fN) categories, respectively. In Panel A, each gray ball represents a human transcript; note that the majority of human genes are present in a dense cluster. Panel B highlights the positions of transcripts of the genes identified by <xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref> as oncogenes (OGs, large red balls) or tumor suppressor genes (TSGs, large blue balls). It is noteworthy that these driver genes separate significantly from the central cluster and from each other: OGs have a significantly larger fraction of nonsynonymous, whereas TSGs have significantly larger fraction of nonsense substitutions. Panel C shows data only for candidate cancer genes present in the CG_SO<sup>2SD</sup>_SSI<sup>2SD</sup> list (see Materials and methods). The positions of novel cancer gene transcripts validated in the present work are highlighted as large green balls.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59629-fig2-v2.tif"/></fig><p>Known cancer genes also separate from the majority of human genes in 3D scatter plots of rSM, rNM, rNS parameters, defined as the ratio of fS/fM, fN/fM, fN/fS, respectively (<xref ref-type="fig" rid="fig3">Figure 3</xref>). In these scatter plots, OGs separate from the central cluster in having lower rSM and rNM values, whereas TSGs have higher rNS and rNM values than those of the central cluster (<xref ref-type="fig" rid="fig3">Figure 3</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Analyses of rSM, rNM, rNS parameters of human protein-coding genes of tumor tissues.</title><p>The figure shows the results of the analysis of 13,803 transcripts containing at least 100 subtle, confirmed somatic mutations from tumor tissues, including only mutations identified as not single-nucleotide polymorphisms (SNPs). Axes <italic>x, y</italic>, and <italic>z</italic> represent the rSM, rNM, rNS values defined as the ratio of fS/fM, fN/fM, fN/fS, respectively. Each ball represents a human transcript; the positions of transcripts of the genes identified by <xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref> as oncogenes (OGs, large red balls) or tumor suppressor genes (TSGs, large blue balls) are highlighted. Panels A1, A2 show the distribution of the 13,803 transcripts at different magnification. Note that the majority of human genes are present in a dense cluster but known OGs and TSGs separate significantly from the central cluster and from each other. The rNS and rNM values of TSGs are higher, whereas the rSM and rNM values of OGs are lower than those of passenger genes. Panels B1, B2 show data only for candidate cancer genes present in the CG_SO<sup>2SD</sup>_SSI<sup>2SD</sup> list (see Materials and methods). The positions of novel cancer gene transcripts validated in the present work are highlighted as large green balls.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59629-fig3-v2.tif"/></fig><p>The separation of known cancer genes from the majority of human genes is even more manifest in 3D scatter plots of parameters rSMN, rMSN, and rNSM defined as the ratio of fS/(fM+fN), fM/(fS+fN), and fN/(fS+fM), respectively (<xref ref-type="fig" rid="fig4">Figure 4</xref>). In these plots, the transcripts form a three-pronged cluster, with known OGs and TSGs being present on separate spikes of this cluster, the rMSN and rNSM spikes, respectively (<xref ref-type="fig" rid="fig4">Figure 4</xref>).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Analyses of rSMN, rMSN, and rNSM parameters of human protein-coding genes of tumor tissues.</title><p>The figure shows the results of the analysis of transcripts containing at least 100 subtle, confirmed somatic mutations from tumor tissues, including only mutations identified as not single-nucleotide polymorphisms (SNPs). Axes <italic>x, y</italic>, and <italic>z</italic> represent the rSMN, rMSN, and rNSM defined as the ratio of fS/(fM+fN), fM/(fS+fN), and fN/(fS+fM). Each ball represents a human transcript; the positions of transcripts of the genes identified by <xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref> as oncogenes (OGs, large red balls) or tumor suppressor genes (TSGs, large blue balls) are highlighted. Panels A1, A2 show the distribution of the 13,803 transcripts at different magnification. Note that the majority of human genes are present in a dense cluster but known OGs and TSGs separate significantly from the central cluster and from each other. The rNSM values of TSGs are higher, their rMSN and rSMN are lower than those of passenger genes (PGs). OGs also separate from PGs in that their rMSN values are higher and their rSMN and rNSM values are lower than those of PGs. Panels B1, B2 show data only for candidate cancer genes present in the CG_SO<sup>2SD</sup>_SSI<sup>2SD</sup> list (see Materials and methods). The positions of novel cancer gene transcripts validated in the present work are highlighted as large green balls.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59629-fig4-v2.tif"/></fig><p>There is, however, a fourth cluster of genes that deviates from the clusters of PGs, OGs, and TSGs (<xref ref-type="fig" rid="fig2">Figures 2</xref>, <xref ref-type="fig" rid="fig3">3</xref> and <xref ref-type="fig" rid="fig4">4</xref>). The high fS, rSM, and rSMN values of the transcripts in this group suggest that they are subject to purifying selection during tumor evolution, raising the possibility that this group may contain genes essential for the survival of tumors.</p><p>The analyses discussed above did not take into account the impact of differences in mutation probability on the fN, fM, and fS values of transcripts. To check the influence of this factor, we have calculated the expected fN*, fM*, and fS* values for all human transcripts using the probabilities of the six substitution classes (C&gt;A, C&gt;G, C&gt;T, T&gt;A, T&gt;C, and T&gt;G) observed across tumors (for deatails the reader should consult the Materials and methods section).</p><p>The various types of observed/expected ratios (rN*, rM*, rS*; rSM*, rNM*, rNS*; rSMN*, rMSN* and rNSM*) were calculated for each transcript and the data were analyzed in 3D scatter plots as described above for the observed values. As shown in <xref ref-type="fig" rid="fig5">Figures 5</xref>, <xref ref-type="fig" rid="fig6">6</xref> and <xref ref-type="fig" rid="fig7">7</xref>, the distribution of transcripts in these 3D scatter plots are similar to those observed in the corresponding <xref ref-type="fig" rid="fig2">Figures 2</xref>, <xref ref-type="fig" rid="fig3">3</xref> and <xref ref-type="fig" rid="fig4">4</xref>, indicating that the separation of the clusters of PGs, OGs, TSGs, and TEGs is relatively insensitive to transcript-specific differences in mutation probabilities.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Analyses of rS*, rM*, and rN* parameters of human protein-coding genes of tumor tissues.</title><p>The figure shows the results of the analysis of transcripts containing at least 100 subtle, confirmed somatic mutations from tumor tissues. Axes <italic>x, y,</italic> and <italic>z</italic> represent rS*, rM*, and rN* values, respectively. In Panel A, each gray ball represents a human transcript; note that the majority of human genes are present in a dense cluster. Panel B highlights the positions of transcripts of the genes identified by <xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref> as oncogenes (OGs, large red balls) or tumor suppressor genes (TSGs, large blue balls). It is noteworthy that these driver genes separate significantly from the central cluster and from each other: OGs have a significantly larger fraction of nonsynonymous, whereas TSGs have significantly larger fraction of nonsense substitutions than expected. Panel C shows data only for candidate cancer genes present in the CG_SO<sup>2SD</sup>_SSI<sup>2SD</sup> list (see Materials and methods). The positions of novel cancer gene transcripts validated in the present work are highlighted as large green balls.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59629-fig5-v2.tif"/></fig><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Analyses of rSM*, rNM*, rNS* parameters of human protein-coding genes of tumor tissues.</title><p>The figure shows the results of the analysis of transcripts containing at least 100 subtle, confirmed somatic mutations from tumor tissues. Axes <italic>x, y,</italic> and <italic>z</italic> represent rSM*, rNM*, rNS* values, respectively. Each ball represents a human transcript; the positions of transcripts of the genes identified by <xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref> as oncogenes (OGs, large red balls) or tumor suppressor genes (TSGs, large blue balls) are highlighted. Panels A1 and A2 show the distribution of the transcripts at different magnification. Note that the majority of human genes are present in a dense cluster but known OGs and TSGs separate significantly from the central cluster and from each other. The rNS* and rNM* values of TSGs are higher, whereas the rSM* and rNM* values of OGs are lower than those of passenger genes. Panels B1, B2 show data only for candidate cancer genes present in the CG_SO<sup>2SD</sup>_SSI<sup>2SD</sup> list (see Materials and methods). The positions of novel cancer gene transcripts validated in the present work are highlighted as large green balls.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59629-fig6-v2.tif"/></fig><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Analyses of rSMN*, rMSN*, and rNSM* parameters of human protein-coding genes of tumor tissues.</title><p>The figure shows the results of the analysis of transcripts containing at least 100 subtle, confirmed somatic mutations from tumor tissues. Axes <italic>x, y</italic>, and <italic>z</italic> represent the rSMN*, rMSN*, and rNSM* values, respectively. Each ball represents a human transcript; the positions of transcripts of the genes identified by <xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref> as oncogenes (OGs, large red balls) or tumor suppressor genes (TSGs, large blue balls) are highlighted. Panels A1, A2 show the distribution of the transcripts at different magnification. Note that the majority of human genes are present in a dense cluster but known OGs and TSGs separate significantly from the central cluster and from each other. The rNSM* values of TSGs are higher, their rMSN* and rSMN* are lower than those of passenger genes (PGs). OGs also separate from PGs in that their rMSN* values are higher and their rSMN* and rNSM* values are lower than those of PGs. Panels B1, B2 show data only for candidate cancer genes present in the CG_SO<sup>2SD</sup>_SSI<sup>2SD</sup> list (see Materials and methods). The positions of novel cancer gene transcripts validated in the present work are highlighted as large green balls.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59629-fig7-v2.tif"/></fig></sec><sec id="s2-2"><title>Analyses of candidate cancer gene sets</title><p>We assumed that the genes whose patterns of subtle mutations deviate significantly (by more than 2SD) from those of prototypical PGs are enriched in cancer genes that play important role in carcinogenesis. The patterns of subtle mutations of candidate cancer genes assign them to one of the three main clusters that show signs of positive and/or negative selection (see <xref ref-type="fig" rid="fig2">Figures 2</xref>–<xref ref-type="fig" rid="fig7">7</xref>). (A) Genes positively selected for inactivating (nonsense and frame-shift) mutations – putative TSGs; (B) genes positively selected for missense mutations and negatively selected for inactivating mutations – putative proto-oncogenes; (C) negatively selected genes – putative TEGs.</p><p>The assumption that the cancer genes assigned to these three clusters play significant roles in carcinogenesis has strong support in the case of the first two categories: the approach used in the present study correctly assigned the known, ‘gold standard’ TSGs and OGs (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). In the case of the third category, however, no similar gold standard exists for TEGs.</p><p>To check the validity and predictive value of the assumption that the genes assigned to the three clusters play critical roles in carcinogenesis, we have selected a number of genes at random from each cluster for further in-depth analyses. We have used three criteria to select genes for detailed analyses from the combined list of candidate cancer genes that deviate from the central clusters of PGs by more than 2SD (see Materials and methods). (1) The candidate gene is among the genes showing the strongest signals of selection characteristic of the given group. (2) The candidate gene is novel in the sense that it is not listed among the 145’ gold standard’ OGs and TSGs of <xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref> or among the 719 cancer genes of CGC (<xref ref-type="bibr" rid="bib224">Sondka et al., 2018</xref>). (3) There is substantial experimental information in the scientific literature on the given gene to permit the assessment of its role in carcinogenesis.</p><p>The genes discussed below include genes positively selected for truncating mutations (putative TSGs), genes positively selected for missense mutations and negatively selected for inactivating mutations (putative proto-oncogenes) and negatively selected genes (putative TEGs). In the main text, we summarize only the major conclusions of our analyses; for annotations of the individual genes, the reader should consult Appendix 1. We discuss examples of negatively selected genes in the main text in more detail since earlier studies that focussed on positive selection of driver mutations inevitably missed these genes. We also discuss some instructive examples of’ false’ hits, that is cases where the mutation parameters deviate significantly from those of PGs, but this deviation is not due to selection.</p></sec><sec id="s2-3"><title>Novel cancer genes positively selected for nonsense mutations</title><p>We have selected genes positively selected for truncating mutations from the combined list of candidate transcripts, that is, transcripts whose parameters deviate from those of PGs by more than 2SD (for details see Materials and methods). We have used the additional restriction that genes with indel_rNSM &lt;0.125 were excluded (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>), thereby removing OGs and TEGs. Out of the 624 genes that satisfy these criteria, we have subjected <italic>B3GALT1</italic>, <italic>BMPR2, BRD7, ING1, MGA, PRRT2, RASA1, RNF128, SLC16A1, SPRED1, TGIF1, TNRC6B, TTK, ZNF276</italic>, <italic>ZC3H13, ZFP36L2</italic>, and <italic>ZNF750</italic> to further analysis.</p><p>Annotation of the majority of these genes (<italic>BMPR2, BRD7, ING1, MGA, PRRT2, RASA1, RNF128, SLC16A1, SPRED1, TGIF1, TNRC6B, ZC3H13, ZFP36L2</italic>, and <italic>ZNF750</italic>) has provided convincing evidence for their role in carcinogenesis as tumor suppressors. Interestingly, experimental evidence suggests that <italic>TTK,</italic> encoding dual specificity protein kinase TTK, is a proto-oncogene that may be converted to an OG by truncating mutations affecting the very C-terminal end of the protein, downstream of its kinase domain (for further details see Appendix 1). Our annotations suggest that <italic>B3GALT1</italic>, <italic>ZNF276</italic> are false positives whose apparent mutation pattern deviates significantly from those of PGs, but this deviation is not due to selection.</p><p>Based on functional annotation of the TSGs identified and validated in the present work (see Appendix 1), we have assigned them to various cellular processes of cancer hallmarks in which they are involved (<xref ref-type="table" rid="table1">Table 1</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Assignment of novel positively or negatively selected cancer genes to key cellular processes of carcinogenesis.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Hallmarks of cancer</th><th valign="top">Gene symbol</th></tr></thead><tbody><tr><td valign="top">Defects of genome, epigenome, <break/>transcriptome, or proteome maintenance</td><td valign="top"><italic>CDK8, FOXG1, IDH3B, MARCH7, MGA, <bold>NOVA1</bold>,</italic> <break/><bold><italic>PNCK</italic></bold><italic>, RNF128, TGIF1, TNRC6B, <bold>TWIST1</bold>, ZC3H13,</italic> <break/><italic>ZFP36L1, ZFP36L2, ZNF750</italic></td></tr><tr><td valign="top">Sustained proliferation</td><td valign="top"><italic>AURKA, BRD7, ING1, <bold>FOXG1</bold>, <bold>MAPK13</bold>, <bold>PNCK</bold>,</italic> <break/><italic>PRRT2, RASA1, RIT1, SPRED1, <bold>TRIB2</bold>, TTK, YAP1,</italic> <break/><italic>YES1, ZFP36L1, ZFP36L2, ZNF750</italic></td></tr><tr><td valign="top">Evasion of growth suppressors</td><td valign="top"/></tr><tr><td valign="top">Reprogramming of metabolism</td><td valign="top"><italic>BRD7, <bold>G6PD</bold>, SLC16A1, <bold>SLC16A3</bold>, <bold>SLC2A1</bold>, <bold>SLC2A8</bold>,</italic> <break/><italic>YAP1, YES1</italic></td></tr><tr><td valign="top">Replicative immortality</td><td valign="top"><bold><italic>NOVA1</italic></bold></td></tr><tr><td valign="top">Evasion of cell death</td><td valign="top"><italic>BRD7, ING1, <bold>MAPK13</bold>, <bold>PNCK</bold>, PRRT2, <bold>TP73</bold>, TRIB2,</italic> <break/><italic>TTK, YAP1, YES1, ZNF750</italic></td></tr><tr><td valign="top">Evasion of immune destruction</td><td valign="top"/></tr><tr><td valign="top">Tumor promoting inflammation</td><td valign="top"><italic>BMP2R, <bold>CCR2</bold>, <bold>CCR5</bold>, <bold>CX3CR1</bold>, <bold>MAPK13</bold></italic></td></tr><tr><td valign="top">Inducing angiogenesis</td><td valign="top"><bold><italic>CCR2</italic></bold></td></tr><tr><td valign="top">Activation of invasion and metastasis</td><td valign="top"><bold><italic>CCR2</italic></bold><italic>, <bold>CCR5</bold>, <bold>CX3CR1</bold>, RASA1, <bold>TBXA2R</bold></italic></td></tr></tbody></table><table-wrap-foot><fn><p>For annotation of novel genes identified in the present study see Appendix 1. The names of negatively selected genes are marked by bold underline.</p></fn></table-wrap-foot></table-wrap><p>Comparison of the list of 624 genes present in this dataset (CG_SSI<sup>2SD</sup> rNSM &gt;0.125) with lists identified by others (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>) revealed that ~60–100 of our candidate TSG-like genes are also found in several gene lists identified by others through analyses of somatic mutations of tumor tissues. Many of the genes selected for annotation are present in at least one of the candidate gene lists identified by others; the genes of <italic>MGA, RASA1, TGIF1, ZFP36L2</italic>, and <italic>ZNF750</italic> are present in multiple cancer gene lists (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). It is noteworthy, however, that <italic>RNF128, SLC16A1, SPRED1, TNRC6B,</italic> and <italic>TTK</italic> are novel in that they are found only among the candidate cancer genes identified by forward genetic screens in mice (<xref ref-type="bibr" rid="bib1">Abbott et al., 2015</xref>) or among the genes whose expression changes in cancer (<xref ref-type="bibr" rid="bib246">Torrente et al., 2016</xref>).</p><p>We have also analyzed the genes present in dataset CG_SO*<sup>2SD</sup>_rNSM &gt;3, that is, candidate cancer genes for which the observed rNSM values are more than threefold higher than expected taking into account mutational signature-derived substitution probabilities of tumors (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). We have found that 164 (100%) of the 164 genes present in this dataset are also present in the dataset CG_SSI<sup>2SD</sup> rNSM &gt;0.125. It is noteworthy that the majority of candidate TSGs selected for annotation (<italic>B3GALT1, BMPR2, BRD7, ING1, MGA, PRRT2, RASA1, SLC16A1, SPRED1, TGIF1, ZNF276, ZFP36L2,</italic> and <italic>ZNF750</italic>) are present among the genes shared by the two datasets that show the strongest signals of positive selection for nonsense substitutions.</p></sec><sec id="s2-4"><title>Novel cancer genes positively selected for missense and negatively selected for nonsense mutations</title><p>We have selected genes positively selected for missense and negatively selected for inactivating mutations from the list of candidate transcripts using the restriction that genes with rMSN &lt;3.00 (440) were excluded, thereby removing the majority of TSGs and TEGs (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Out of the 440 genes that satisfy these criteria, we have subjected <italic>AURKA, CDK8, IDH3B, MARCH7, RIT1, YAP1</italic>, and <italic>YES1</italic> to further analysis.</p><p>Annotation of these genes has confirmed that they play important roles in carcinogenesis as OGs. Three of these genes encode kinases (Aurora kinase A, also known as breast tumor-amplified kinase; cyclin-dependent kinase 8; tyrosine-protein kinase Yes, also known as proto-oncogene c-Yes) but unlike many other oncogenic kinases, these OGs do not show significant clustering of missense mutations. In fact, only in the case of <italic>IDH3B</italic> and <italic>RIT1</italic> did we observe clustering of missense mutations, indicating that recurrent mutation is not an obligatory property of proto-oncogenes.</p><p>Based on functional annotation of the novel OGs identified and validated in the present work (see Appendix 1), we have assigned them to various cellular processes of cancer hallmarks in which they are involved (<xref ref-type="table" rid="table1">Table 1</xref>).</p><p>Comparison of this list of 440 genes (CG_SO<sup>2SD</sup> rMSN &gt;3.00) with the lists of cancer genes identified by others (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>) revealed that ~60–100 of our candidate OG-like genes are present in cancer gene lists identified by others through analyses of somatic mutations of tumor tissues.</p><p>Out of the genes that we have selected for annotation only the <italic>RIT1</italic> gene has been identified by others as an OG, based on the analysis of somatic mutations (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). <italic>AURKA</italic> and <italic>IDH3B</italic> are not present in any of the lists of cancer genes, whereas <italic>CDK8, MARCH7</italic>, <italic>YAP1</italic>, and <italic>YES1</italic> are found among the more than 9000 candidate cancer genes identified by forward genetic screens in mice (<xref ref-type="bibr" rid="bib1">Abbott et al., 2015</xref>). Interestingly, <italic>TTK</italic>, identified as a gene positively selected for truncating mutations (see list CG_SSI<sup>2SD</sup> rNSM &gt;0.125), but annotated as an OG, is also present in the list of genes positively selected for missense mutations (CG_SO<sup>2SD</sup> rMSN &gt;3.00).</p><p>We have also analyzed the genes present in dataset CG_SO*<sup>2SD_</sup>rMSN &gt;1.50, that is, genes for which the observed rMSN values are more than 1.5-fold higher than expected taking into account mutational signature-derived substitution probabilities of tumors (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). We have found that 119 (98.3%) of the 121 genes present in this dataset are also present in the dataset CG_SO<sup>2SD</sup> rMSN &gt;3.00. It should be noted that the majority of candidate OGs selected for annotation (<italic>AURKA, RIT1, YAP1</italic>, and <italic>YES1</italic>) are found among the genes shared by the two datasets, showing strong signals of positive selection for missense substitutions.</p></sec><sec id="s2-5"><title>Negatively selected genes</title><p>We have selected putative TEGs from the list of candidate cancer genes using the restriction that we have excluded genes with rSMN &lt;0.5 to eliminate OGs and TSGs (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). Out of the 505 genes, we have subjected <italic>CX3CR1, FOXG1, FOXP2, G6PD, MAPK13, MLLT3, NOVA1, PNCK, RUNX2, SLC16A3, SLC2A1, SLC2A8, TBP, TBXA2R, TP73</italic>, and <italic>TRIB2</italic> to further analysis.</p><p>Our analyses have confirmed that in the majority of cases (<italic>CX3CR1, FOXG1, G6PD, MAPK13, NOVA1, PNCK, SLC16A3, SLC2A1, SLC2A8, TBXA2R, TP73, TRIB2</italic>) the high synonymous-to-nonsynonymous and nonsense mutation rates could be interpreted as evidence for purifying selection during tumor evolution. There were, however, several examples (e.g. <italic>DSPP, FOXP2, MLLT3, RUNX2, TBP</italic>) where high synonymous-to-nonsynonymous and nonsense mutation rates were found to reflect increased rates of synonymous substitution (due to the presence of mutation hotspots), rather than decreased rates of nonsynonymous and nonsense substitutions that could be due to purifying selection (for details see Appendix 1).</p><p>Annotations of the genes <italic>CX3CR1, FOXG1, G6PD, MAPK13, NOVA1, PNCK, SLC16A3, SLC2A1, SLC2A8, TBXA2R, TP73,</italic> and <italic>TRIB2</italic> have confirmed that all of them play important roles in carcinogenesis (see Appendix 1) permitting their assignment to various cellular processes of cancer hallmarks (<xref ref-type="table" rid="table1">Table 1</xref>.). As discussed below (and in Appendix 1), they fulfill pro-oncogenic functions by promoting cell proliferation (<italic>FOXG1, MAPK13, PNCK, TRIB2</italic>), evasion of cell death (<italic>MAPK13, PNCK, TP73</italic>), replicative immortality (<italic>NOVA1</italic>), reprogramming of energy metabolism of cancer cells (<italic>G6PD, SLC16A3, SLC2A1, SLC2A8</italic>), inducing tumor promoting inflammation (<italic>CX3CR1, MAPK13</italic>) and invasion and metastasis (<italic>CX3CR1, TBXA2R</italic>). In view of the pro-oncogenic role of these proteins, it is noteworthy, that <italic>G6PD, MAPK13, PNCK, SLC16A3</italic>, and <italic>SLC2A1</italic> are among the candidate cancer genes identified by forward genetic screens in mice (<xref ref-type="bibr" rid="bib1">Abbott et al., 2015</xref>).</p><p>Comparison of our list of 505 negatively selected genes (CG_SO<sup>2SD</sup>_rSMN &gt; 0.5) with those identified by others have revealed very little similarity (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). Out of the 147 genes of <xref ref-type="bibr" rid="bib278">Weghorn and Sunyaev, 2017</xref>, only one is present in the list of top-ranking negatively selected genes identified in the present study. Similarly, only four of the 25 genes of <xref ref-type="bibr" rid="bib307">Zapata et al., 2018</xref> and only five of the 91 genes of <xref ref-type="bibr" rid="bib192">Pyatnitskiy et al., 2015</xref> are found in our list of negatively selected genes (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>).</p><p>We observed a greater similarity when we compared our list of negatively selected genes with that of <xref ref-type="bibr" rid="bib318">Zhou et al., 2017</xref>; 32 of the 112 genes identified by <xref ref-type="bibr" rid="bib318">Zhou et al., 2017</xref> are also present among the 505 negatively selected genes identified in the present work (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). It is noteworthy that top-ranking genes present in both lists include the <italic>ACKR3</italic>, <italic>TBP</italic>, and <italic>MLLT3</italic> genes. As discussed in Appendix 1, the apparent signals of negative selection (high synonymous-to-nonsynonymous rates) of genes like <italic>DSPP, FOXP2, MLLT3, RUNX2</italic>, and <italic>TBP</italic> may reflect the presence of mutation hotspots generating silent mutations and not purifying selection. <xref ref-type="bibr" rid="bib318">Zhou et al., 2017</xref> have also noted that &quot;some cancer genes also show negative selection in cancer genomes, such as the OG <italic>MLLT3&quot;</italic> and that &quot;interestingly, <italic>MLLT3</italic> has recurrent synonymous mutations at amino acid positions 166 to 168&quot;. Apparently, the authors did not realize that this observation of recurrent silent substitutions (in a poly-Ser region of the protein) questions the validity of the claim that the unusually low nonsynonymous to synonymous rate is due to negative selection (for more detail see Appendix 1).</p><p>In summary, the pro-oncogenic, negatively selected genes annotated and validated in the present work are missing from the earlier lists of negatively selected genes (<xref ref-type="bibr" rid="bib318">Zhou et al., 2017</xref>; <xref ref-type="bibr" rid="bib192">Pyatnitskiy et al., 2015</xref>; <xref ref-type="bibr" rid="bib278">Weghorn and Sunyaev, 2017</xref>; <xref ref-type="bibr" rid="bib307">Zapata et al., 2018</xref>). A possible explanation for the lack of similarity of top-ranking negatively selected genes identified in the present study with those identified by others is that we have limited our work to transcripts that have at least 100 somatic mutations. It is noteworthy that a large fraction of genes identified by others did not pass this requirement (see Materials and methods).</p><p>We have also analyzed the genes present in dataset CG_SO*<sup>2SD</sup> rSMN &gt;1.50, that is, candidate cancer genes for which the observed rSMN values are more than 1.5-fold higher than expected taking into account mutational signature-derived substitution probabilities of tumors (<xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>). We have found that 200 (86.5%) of the 231 genes present in this dataset are also present in dataset CG_SO<sup>2SD</sup> rSMN &gt;0.5. It should be noted that the majority of candidate TEGs selected for annotation (<italic>CX3CR1, FOXG1, FOXP2, MAPK13, MLLT3, NOVA1, RUNX2, SLC16A3, SLC2A8, TBP, TBXA2R</italic>, and <italic>TRIB2</italic>) are found among the 200 genes shared by the two datasets and that show the strongest signals of negative selection for missense and nonsense substitutions.</p></sec><sec id="s2-6"><title>Negative selection, cell essentiality, and tumor essentiality of genes</title><p>As we have emphasized in the Introduction, the conclusions drawn from earlier studies searching for signs of negative selection are highly controversial. A highly publicized study has propagated the conclusion that negative selection has no role in tumor evolution (<xref ref-type="bibr" rid="bib153">Martincorena et al., 2017</xref>; <xref ref-type="bibr" rid="bib17">Bakhoum and Landau, 2017</xref>; <xref ref-type="bibr" rid="bib124">Koch, 2017</xref>; <xref ref-type="bibr" rid="bib254">Vitale and Galluzzi, 2018</xref>). <xref ref-type="bibr" rid="bib153">Martincorena et al., 2017</xref> have argued that the practical absence of purifying selection during tumor evolution is due to the buffering effect of diploidy and functional redundancy of most cellular pathways.</p><p>A recent study has examined the influence of functional redundancy on the essentiality of genes (<xref ref-type="bibr" rid="bib53">De Kegel and Ryan, 2019</xref>). The authors have used CRISPR score profiles of 558 genetically heterogeneous tumor cell lines and converted continuous values of gene CRISPR scores to binary essential and nonessential calls. These analyses have shown that 1014 genes belong to a category of ‘broadly essential genes’, that is, these genes were found to be essential in at least 90% of the 558 cell lines. <xref ref-type="bibr" rid="bib53">De Kegel and Ryan, 2019</xref> have shown that, compared to singleton genes, paralogs are less frequently essential and that this is more evident when considering genes with multiple paralogs or with highly sequence-similar paralogs. In harmony with these conclusions, <xref ref-type="bibr" rid="bib146">López et al., 2020</xref> have found that purifying selection of essential genes is significant in early phases of tumor evolution but in later phases whole-genome doubling allows the accumulation of deleterious alterations.</p><p>Since the group of negatively selected genes identified by <xref ref-type="bibr" rid="bib278">Weghorn and Sunyaev, 2017</xref> were shown to be enriched in cell-essential genes (<xref ref-type="bibr" rid="bib264">Wang et al., 2015a</xref>), the authors have proposed that the major cause of negative selection during tumor evolution is the maintenance of genes that are responsible for basal cellular functions. Nevertheless, <xref ref-type="bibr" rid="bib278">Weghorn and Sunyaev, 2017</xref> have pointed out that negative selection is also expected to act on neoantigens, expanding the possible scope of purifying selection beyond cell essentiality.</p><p>Although analyses of negatively selected genes have led <xref ref-type="bibr" rid="bib307">Zapata et al., 2018</xref> to conclude, &quot;Processes that are most strongly conserved are those that play fundamental cellular roles such as protein synthesis, glucose metabolism, and molecular transport&quot; they also emphasized the possible importance of less basic functions. Since the immune system is capable of discriminating cancer cells by recognizing mutated epitope sequences the authors have hypothesized that native epitope sequences would be protected from nonsynonymous mutations during tumor evolution. In harmony with this hypothesis, the authors have observed signals of selection in the immunopeptidome and proteins of the epitope presentation machinery, arguing for their importance in the evasion of immune surveillance by tumors.</p><p>Gene Ontology analysis of the negatively selected ‘essential cancer proteins’ identified by <xref ref-type="bibr" rid="bib192">Pyatnitskiy et al., 2015</xref> have revealed enrichment of essential proteins related to membrane and cell periphery, leading the authors to speculate that this could be a sign of immune system-driven negative selection of cancer neo-antigens.</p><p>In summary, there is some disagreement about the significance of purifying selection in tumor evolution and whether tumor essential functions can be equated with basic cellular functions.</p><p>In order to assess the contribution of cell-essentiality to purifying selection during tumor evolution, we have plotted various measures of negative selection of human genes as a function of their cell-essentiality scores determined by <xref ref-type="bibr" rid="bib53">De Kegel and Ryan, 2019</xref>. These analyses have shown that there is a very weak, positive correlation (Pearson's r = 0.05345, p&lt;0.05) between rSMN (a measure of purifying selection) and the cell-essentiality scores of transcripts (<xref ref-type="fig" rid="fig8">Figure 8</xref>, <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>). Since, by definition, there is a negative correlation between the essentiality of genes and their cell-essentiality scores (<xref ref-type="bibr" rid="bib53">De Kegel and Ryan, 2019</xref>), our data indicate that cell essentiality does not contribute significantly to purifying selection during tumor evolution.</p><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Cell-essentiality scores of human genes and negative selection during tumor evolution.</title><p>The figure shows the results of the analysis of transcripts containing at least 100 subtle, confirmed somatic, non-polymorphic mutations from tumor tissues. The abscissa indicates the cell-essentiality score of the genes, the ordinate shows the rSMN parameters of the transcripts. Each ball represents a human transcript. Transcripts showing strongest signals of negative selection (CG_SO<sup>2SD</sup> rSMN &gt;0.5) are represented by dark orange balls.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59629-fig8-v2.tif"/></fig><p>It is also noteworthy that the cell essentiality scores of negatively selected genes (CG_SO<sup>2SD</sup> rSMN &gt;0.5) are not significantly different from those of PGs (<xref ref-type="fig" rid="fig8">Figure 8</xref>, <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>). Comparison of CRISPR scores (−0.07665 ± 0.17269) of the cluster of negatively selected genes of CG_SO<sup>2SD</sup> rSMN &gt;0.5 listed in <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref> with CRISPR scores (−0.09506 ± 0.24168) of the cluster of PGs (PG_SO<sup>r3_1SD</sup>) revealed that they are not significantly different (p&gt;0.05). This indicates that basic cell-essentiality per se does not explain the purifying selection observed for this cluster of genes.</p><p>Comparison of the lists of negatively selected genes identified in the present work with the 1014 ‘broadly essential genes’ defined by <xref ref-type="bibr" rid="bib53">De Kegel and Ryan, 2019</xref> has revealed that there is practically no overlap between the two groups. Only six of the 1014 broadly essential genes are included in our list of negatively selected genes (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). This observation also suggests that cell-essentiality defined by CRISPR scores determined experimentally on cell lines is not relevant for negative selection during tumor evolution in vivo.</p><p>Our analyses of cases of strong purifying selection suggest that it has more to do with a function <italic>specifically</italic> required by the tumor cell for its growth, survival, and metastasis than with general basic cellular functions (<xref ref-type="table" rid="table1">Table 1</xref>). It is noteworthy in this respect, that the genes showing the strongest signals of negative selection include several plasma membrane receptor proteins (e.g. <italic>ACKR3, CCR2, CCR5, CX3CR1, TBXA2R</italic>) that cancer cells utilize to promote migration, invasion, and metastasis (Appendix 1). Significantly, these proteins exert their biological functions (in cell migration, inflammation, angiogenesis etc.) primarily at the organism level, therefore their cell-essentiality scores may have little to do with their overall essentiality for tumor growth and metastasis. Inspection of the data of <xref ref-type="bibr" rid="bib53">De Kegel and Ryan, 2019</xref> shows that <italic>ACKR3, CX3CR1, TBXA2R</italic> were not assigned to the essential category in any of the 558 tumor cell lines tested.</p><p>Negatively selected, TEGs identified in the present study do include proteins involved in cell-level processes: they promote cell proliferation (<italic>FOXG1, MAPK13, PNCK</italic>, and <italic>TRIB2</italic>), evasion of cell death (<italic>MAPK13, PNCK</italic>, and <italic>TP73</italic>), replicative immortality (e.g. <italic>NOVA1</italic>), or they are crucial for the reprogramming of energy metabolism in cancer cells (e.g. <italic>GAPD, SLC16A3, SLC2A1</italic>, and <italic>SLC2A8</italic>). Nevertheless, their negative selection is unlikely to be a mere reflection of their basic cellular functions. Rather, it reflects the exceptional role of the corresponding cancer hallmarks (evasion of cell death, replicative immortality, reprogramming of metabolism) in carcinogenesis (<xref ref-type="fig" rid="fig1">Figure 1</xref>). In harmony with this conclusion <italic>NOVA1</italic>, <italic>SLC16A3, SLC2A8,</italic> and <italic>TP73</italic> were assigned to the essential category by <xref ref-type="bibr" rid="bib53">De Kegel and Ryan, 2019</xref> in less than 10% of the 558 tumor cell lines tested. <italic>SLC2A1</italic> (glucose transporter 1) is an exception in as much as it was found to be cell-essential in 41% of the cell lines. Significantly, several nutrient transporter genes (<italic>SLC16A3, SLC2A1</italic>, and <italic>SLC2A8)</italic> were found among the genes showing the strongest signs of purifying selection. It must be mentioned here that <xref ref-type="bibr" rid="bib307">Zapata et al., 2018</xref> have also noted that the glucose transporters <italic>SLC2A1</italic> and <italic>SLC2A8</italic> and the lactate transporter <italic>SLC16A3</italic> show signs of purifying selection, although they did not list these genes among the 25 genes with significant negative selection.</p><p>The most likely explanation for the tumor essentiality of transporter protein genes <italic>SLC16A3, SLC2A1</italic>, and <italic>SLC2A8</italic> is that tumor cells have an increased demand for nutrients and this demand is met by enhanced cellular entry of nutrients through upregulation of specific transporters (<xref ref-type="bibr" rid="bib71">Ganapathy et al., 2009</xref>). The uncontrolled cell proliferation of tumor cells involves major adjustments of energy metabolism in order to support cell growth and division in the hypoxic microenvironments in which they reside. Otto Warburg was the first to observe an anomalous characteristic of cancer-cell energy metabolism: even in the presence of oxygen, cancer cells limit their energy metabolism largely to glycolysis, leading to a state that has been termed ‘aerobic glycolysis’ (<xref ref-type="bibr" rid="bib275">Warburg, 1956a</xref>; <xref ref-type="bibr" rid="bib276">Warburg, 1956b</xref>). Cancer cells are known to compensate for the lower efficiency of ATP production through glycolysis than oxidative phosphorylation by upregulating glucose transporters, such as facilitated glucose transporter member 1, GLUT1 (encoded by the <italic>SLC2A1</italic> gene), thus increasing glucose import into the cytoplasm (<xref ref-type="bibr" rid="bib114">Jones and Thompson, 2009</xref>; <xref ref-type="bibr" rid="bib56">DeBerardinis et al., 2008</xref>; <xref ref-type="bibr" rid="bib102">Hsu and Sabatini, 2008</xref>).</p><p>The markedly increased uptake of glucose has been documented in many human tumor types, by visualizing glucose uptake through positron emission tomography. The reliance of tumor cells on glycolysis is also supported by the hypoxia response system: under hypoxic conditions, not only glucose transporters but also multiple enzymes of the glycolytic pathway are upregulated (<xref ref-type="bibr" rid="bib114">Jones and Thompson, 2009</xref>; <xref ref-type="bibr" rid="bib56">DeBerardinis et al., 2008</xref>; <xref ref-type="bibr" rid="bib211">Semenza, 2010a</xref>; <xref ref-type="bibr" rid="bib212">Semenza, 2010b</xref>; <xref ref-type="bibr" rid="bib127">Kroemer and Pouyssegur, 2008</xref>).</p><p>In our view, the central role of GLUT1 in cancer metabolism is reflected by the fact that the <italic>SLC2A1</italic> gene encoding this glucose transporter is among the genes that show the strongest signals of purifying selection. The key importance of GLUT1 in cancer may be illustrated by the fact that high levels of GLUT1 expression correlates with a poor overall survival and is associated with increased malignant potential, invasiveness, and poor prognosis (<xref ref-type="bibr" rid="bib267">Wang et al., 2017a</xref>; <xref ref-type="bibr" rid="bib58">Deng et al., 2018</xref>; <xref ref-type="bibr" rid="bib52">de Castro et al., 2019</xref>). The strict requirement for GLUT1 in the early stages of mammary tumorigenesis highlights the potential for glucose restriction as a breast cancer preventive strategy (<xref ref-type="bibr" rid="bib281">Wellberg et al., 2016</xref>). The tumor essentiality of GLUT1 may also be illustrated by the fact that knockdown of GLUT1 inhibits cell glycolysis and proliferation and inhibits the growth of tumors (<xref ref-type="bibr" rid="bib289">Xiao et al., 2018</xref>). In view of its essentiality for tumor growth, GLUT1 is a promising target for cancer therapy (<xref ref-type="bibr" rid="bib220">Shibuya et al., 2015</xref>; <xref ref-type="bibr" rid="bib169">Noguchi et al., 2016</xref>; <xref ref-type="bibr" rid="bib41">Chen et al., 2017d</xref>).</p><p>Recent studies suggest that the <italic>YAP1-TEAD1-GLUT1</italic> axis plays a major role in reprogramming of cancer energy metabolism by modulating glycolysis (<xref ref-type="bibr" rid="bib143">Lin and Xu, 2017</xref>). These authors have shown that <italic>YAP1</italic> and <italic>TEAD1</italic> are involved in transcriptional control of the glucose transporter <italic>GLUT1</italic>, whereas knockdown of <italic>YAP1</italic> inhibited glucose consumption, and lactate production of breast cancer cells, overexpression of GLUT1 restored glucose consumption and lactate production.</p><p>Besides GLUT1 another glucose transporter, GLUT8 (encoded by the <italic>SLC2A8</italic> gene) also shows strong signals of negative selection, arguing for its importance in tumor survival. In harmony with this interpretation, there is evidence that GLUT8 is overexpressed in and is required for proliferation and viability of tumors (<xref ref-type="bibr" rid="bib80">Goldman et al., 2006</xref>; <xref ref-type="bibr" rid="bib157">McBrayer et al., 2012</xref>).</p><p>Due to abnormal conversion of pyruvic acid to lactic acid even under normoxia, the altered metabolism of glucose consuming tumors must rapidly efflux lactic acid to the microenvironment to maintain a robust glycolytic flux and to prevent poisoning themselves (<xref ref-type="bibr" rid="bib154">Mathupala et al., 2007</xref>). Survival and maintenance of the glycolytic phenotype of tumor cells is ensured by monocarboxylate transporter 4 (MCT4, encoded by the <italic>SLC16A3</italic> gene) that efficiently transports L-lactate out of the cell (<xref ref-type="bibr" rid="bib71">Ganapathy et al., 2009</xref>). Significantly, MCT4, encoded by the <italic>SLC16A3</italic> gene also shows strong signals of negative selection, in harmony with its importance in tumor survival. As high metabolic and proliferative rates in cancer cells lead to production of large amounts of lactate, extruding transporters are essential for the survival of cancer cells as illustrated by the fact that knockdown of MCT4 increased tumor-free survival and decreased in vitro proliferation rate of tumor cells (<xref ref-type="bibr" rid="bib11">Andersen et al., 2018</xref>). Using a functional screen <xref ref-type="bibr" rid="bib15">Baenke et al., 2015</xref> have also demonstrated that monocarboxylate transporter four is an important regulator of breast cancer cell survival: MCT4 depletion reduced the ability of breast cancer cells to grow, suggesting that it might be a valuable therapeutic target. In harmony with the essentiality of MCT4 for tumor growth, several studies indicate that expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in tumors and its expression correlates with clinical outcome, thus it may serve as a valuable prognostic factor (<xref ref-type="bibr" rid="bib283">Witkiewicz et al., 2012</xref>; <xref ref-type="bibr" rid="bib64">Doyen et al., 2014</xref>; <xref ref-type="bibr" rid="bib14">Baek et al., 2014</xref>). Consistent with the key importance of MCT4 for the survival of tumor cells, its selective inhibition to block lactic acid efflux appears to be a promising therapeutic strategy against highly glycolytic malignant tumors (<xref ref-type="bibr" rid="bib48">Choi et al., 2016</xref>; <xref ref-type="bibr" rid="bib245">Todenhöfer et al., 2018</xref>; <xref ref-type="bibr" rid="bib49">Choi et al., 2018</xref>; <xref ref-type="bibr" rid="bib315">Zhao et al., 2019b</xref>).</p><p>Interestingly, the thromboxane A2 receptor gene (<italic>TBXA2R</italic>) as well as several chemokine receptor protein genes (<italic>CCR2, CCR5, CX3CR1)</italic> were also found among the genes showing strong signs of purifying selection (see Appendix 1). (Note that <xref ref-type="bibr" rid="bib192">Pyatnitskiy et al., 2015</xref> have also identified <italic>CCR5</italic> as a negatively selected gene). The most likely explanation for their essentiality for tumor growth is that tumor cells rely on these receptors in various steps of invasion and metastasis (see Appendix 1). It is noteworthy in this respect that another member of the family of chemokine receptors, the atypical chemokine receptor 3, <italic>ACKR3</italic> is also among the genes showing very high values of rSMN, suggesting negative selection of missense and nonsense mutations (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). (Note that <xref ref-type="bibr" rid="bib318">Zhou et al., 2017</xref> have also identified <italic>ACKR3</italic> as a negatively selected gene). Significantly, <italic>ACKR3</italic> is a well-known OG, present in Tier 1 of the Cancer Gene Census. Several studies support the key role of <italic>ACKR3</italic> in tumor invasion and metastasis (<xref ref-type="bibr" rid="bib132">Li et al., 2014</xref>; <xref ref-type="bibr" rid="bib226">Stacer et al., 2016</xref>; <xref ref-type="bibr" rid="bib313">Zhao et al., 2017</xref>; <xref ref-type="bibr" rid="bib190">Puddinu et al., 2017</xref>; <xref ref-type="bibr" rid="bib159">Melo et al., 2018</xref>; <xref ref-type="bibr" rid="bib193">Qian et al., 2018</xref>). Since knock-down or pharmacological inhibition of <italic>ACKR3</italic> has been shown to reduce tumor invasion and metastasis, ACKR3 is a promising therapeutic target for the control of tumor dissemination (for further details see Appendix 1).</p></sec><sec id="s2-7"><title>Negative selection of germline mutations in the human population versus negative selection of somatic mutations in cancer</title><p>The data discussed in the previous section indicate that the importance (‘essentiality’) of a given gene is a question of perspective. Cell-essential genes may be non-essential for tumor growth, whereas TEGs with tumor-specific functions do not necessarily have cell-essential functions. Similarly, we may assume that the importance of a gene might be quite different from the perspective of tumor cells and from the perspective of the entire organism. One could speculate that somatic mutations of genes with functions that have no relevance for tumor growth (PGs) experience neutral evolution during tumor growth, whereas germline mutations of the same genes may be subject to purifying selection at the level of organismal evolution, as is true for the majority of genes (<xref ref-type="bibr" rid="bib82">Gorlov et al., 2006</xref>). One may also assume that genes with tumor essential, tumor-specific functions may be subject to purifying selection during both tumor evolution and organism evolution, but the strength of purifying selection of these genes is increased in tumors relative to those of genes that do not have tumor-specific functions.</p><p>To test these assumptions, we have determined the signals of selection of germline mutations (<xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>) and compared them with those determined for the same genes in the case of somatic mutations of cancer. Comparison of the patterns of germline and somatic mutations of human transcripts (<xref ref-type="supplementary-material" rid="supp7">Supplementary file 7</xref>) has revealed that the proportion of silent substitutions is significantly higher for germline mutations than for somatic mutations of tumors (fS<sup>g</sup>: 0.33900 versus fS<sup>s</sup>: 0.24604, p&lt;0.05). Conversely, the proportions of nonsense and missense mutations are significantly lower for germline mutations than for somatic mutations of tumors (fN<sup>g</sup>: 0.02329 versus fN<sup>s</sup>: 0.04669, p&lt;0.05; fM<sup>g</sup>: 0.63771 versus fM<sup>s</sup>: 0.70727, p&lt;0.05). These observations are in harmony with the dominance of purifying selection in the human population (<xref ref-type="bibr" rid="bib82">Gorlov et al., 2006</xref>).</p><p>As shown in <xref ref-type="fig" rid="fig9">Figure 9</xref>, the pattern of the distribution of transcripts in 3D scatter plots of fM, fN, and fS parameters for germline mutations are strikingly different from those observed in the case of fM, fN, and fS parameters of somatic mutations in cancer (compare <xref ref-type="fig" rid="fig9">Figure 9A and B</xref>). In addition to a general shift of germline mutations to lower fN and fM and higher fS values, in the case of germline mutations the fN, fM, and fS parameters of transcripts of TSGs, OGs, and TEGs do not separate from those of the central cluster of genes. Similarly, the distribution of transcripts in 3D scatter plots of rS**, rM**, and rN** parameters for germline mutations are different from those observed in the case of rS*, rM*, and rN* parameters of somatic mutations in cancer (compare <xref ref-type="fig" rid="fig9">Figure 9C and D</xref>): cancer genes do not separate from the central cluster of genes.</p><fig id="fig9" position="float"><label>Figure 9.</label><caption><title>Comparison of the patterns of germline mutations of genes with those of somatic mutations observed during tumor evolution.</title><p>Panel A: fS, fM, and fN scores of somatic mutations in cancer, Panel B: fS, fM, and fN scores of germline mutations. Panel C: rS*, rM*, and rN* scores of somatic mutations in cancer, Panel D: rS**, rM**, and rN** scores of germline mutations. Each ball represents a human transcript. The positions of transcripts of the genes identified by <xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref> as oncogenes (OGs, large red balls) or tumor suppressor genes (TSGs, large blue balls) are highlighted. Novel proto-oncogenes, tumor suppressors and tumor essential genes identified in the present work are highlighted in magenta, cyan, and green, respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59629-fig9-v2.tif"/></fig><p>Comparison of the fS, rSM, and rSMN parameters of germline and somatic mutations of transcripts (<xref ref-type="fig" rid="fig10">Figure 10</xref>, <xref ref-type="supplementary-material" rid="supp7">Supplementary file 7</xref>) has shown that there is only weak correlation between the strength of purifying selection of genes during tumor evolution and organismal evolution. The Pearson's r values for the correlations of the fS, rSM, and rSMN parameters of germline and somatic mutations are 0.1127, 0.05757, and 0.02635, p&lt;0.05, respectively.</p><fig id="fig10" position="float"><label>Figure 10.</label><caption><title>Comparison of fS, rSM, and rSMN scores of genes determined for somatic mutations in tumors with those determined for germline mutations.</title><p>The abscissas indicate the fS<sup>g</sup> (panel A), rSM<sup>g</sup> (panel B), and rSMN<sup>g</sup> (panel C) scores of germline mutations of human genes and the ordinates shows the corresponding fS<sup>s</sup>, rSM<sup>s</sup>, and rSMN<sup>s</sup> scores of somatic mutations of tumors for the same genes. Each ball represents a human gene. Transcripts showing the strongest signals of negative selection during tumor evolution (CG_SO<sup>2SD</sup> rSMN &gt;0.5) are represented by dark orange balls.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59629-fig10-v2.tif"/></fig><p>These comparisons have also revealed that – relative to other genes – the candidate TEGs identified in the present study (CG_SO2SD_rSMN &gt;0.5) display significantly stronger signals of purifying selection during tumor evolution than during organismal evolution (<xref ref-type="fig" rid="fig10">Figure 10</xref>, <xref ref-type="supplementary-material" rid="supp7">Supplementary file 7</xref>). The fS, rSM, and rSMN parameters of somatic mutations of candidate TEGs are significantly higher than those of other genes (fS<sup>s</sup>: 0.38322 versus 0.24045, p&lt;0.05; rSM<sup>s</sup>: 0.66013 versus 0.34375, p&lt;0.05; rSMN<sup>s</sup>: 0.62774 versus 0.32356, p&lt;0.05). The fS, rSM, and rSMN parameters of the germline mutations of candidate TEGs, however, differ much less from the corresponding parameters of other genes (fS<sup>g</sup>: 0.36487 versus 0.33831, p&lt;0.05; rSM<sup>g</sup>: 0.64054 versus 0.56394, p&lt;0.05; rSMN<sup>g</sup>: 0.61264 versus 0.56178, p&lt;0.05). These observations indicate that the negative selection of candidate TEGs during tumor evolution is not a simple reflection of their essentiality at the organism level; it is more likely that they serve tumor-specific functions.</p><p>In order to assess the contribution of cell-essentiality to purifying selection during organismal evolution we have plotted rSMN<sup>g</sup>, a measure of negative selection of germline mutations of human genes, as a function of their cell-essentiality scores determined by <xref ref-type="bibr" rid="bib53">De Kegel and Ryan, 2019</xref>. These analyses have shown that there is a very weak negative correlation (Pearson's r = −0.03662, p&lt;0.05) between the strength of purifying selection of transcripts (rSMN<sup>g</sup>) and their cell-essentiality scores (<xref ref-type="fig" rid="fig11">Figure 11</xref>, <xref ref-type="supplementary-material" rid="supp7">Supplementary file 7</xref>). This observation also indicates that essentiality of cell-level functions measured by cell-essentiality scores contribute to, but do not explain the strength of purifying selection observed during organismal evolution.</p><fig id="fig11" position="float"><label>Figure 11.</label><caption><title>Cell-essentiality scores of human genes and negative selection on single-nucleotide polymorphisms (SNPs).</title><p>The figure shows the results of the analysis of transcripts containing at least 100 polymorphic mutations. The abscissa indicates the cell-essentiality score of the genes, the ordinate shows the rSMN<sup>g</sup> parameters of the transcripts. Each ball represents a human transcript. Note that there is a weak negative correlation (Pearson's r = −0.03662, p&lt;0.05) between the strength of purifying selection of transcripts (rSMN<sup>g</sup>) and their cell-essentiality scores.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59629-fig11-v2.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>One of the major goals of cancer research is to identify all ‘cancer genes’, that is genes that play a role in carcinogenesis. In the last two decades, several types of approaches have been developed to achieve this goal, but the implicit assumption of most of these studies was that a distinguishing feature of cancer genes is that they are positively selected for mutations that drive carcinogenesis. As a result of combined efforts, the PCAWG driver list identifies a total of 722 protein-coding genes as cancer driver genes and 22 non-coding driver mutations (<xref ref-type="bibr" rid="bib197">Rheinbay et al., 2020</xref>; <xref ref-type="bibr" rid="bib30">Campbell et al., 2020</xref>).</p><p>In a recent editorial, commenting on a suite of papers on the genetic causes of cancer, Nature has expressed the view that the core of the mission of cancer-genome sequencing projects—to provide a catalogue of driver mutations that could give rise to cancer—has been achieved (<xref ref-type="bibr" rid="bib66">Editorial, 2020</xref>). It is noteworthy, however, that, although on average, cancer genomes were shown to contain four to five driver mutations, in around 5% of cases no drivers were identified in tumors (<xref ref-type="bibr" rid="bib30">Campbell et al., 2020</xref>). As pointed out by the authors, this observation suggests that cancer driver discovery is not yet complete, possibly due to failure of the available bioinformatic algorithms. The authors have also suggested that tumors lacking driver mutations may be driven by mutations affecting cancer-associated genes that are not yet described for that tumor type, however, using driver discovery algorithms on tumors with no known drivers, no individual genes reached significance for point mutations (<xref ref-type="bibr" rid="bib30">Campbell et al., 2020</xref>).</p><p>In our view, these observations actually suggest that a rather large fraction of cancer genes remains to be identified. Assuming that tumors, on average, must have driver mutations affecting at least four or five cancer genes and that known and unknown cancer genes play similar roles in carcinogenesis, the observation that a 0.05 fraction of tumors has no known drivers (i.e. they are driven by four to five unknown cancer drivers) indicates that about half of the drivers is still unknown. If we assume that ~50% of cancer genes is still unknown 3–6% (0.5<sup>5</sup>–0.5<sup>4</sup>, i.e. 0.03125–0.0625 fraction) of tumors is expected to lack any of the known driver genes, and to be driven by four or five unknown driver mutations. Since the list of known drivers used in the study of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium (<xref ref-type="bibr" rid="bib30">Campbell et al., 2020</xref>) comprises 722 driver genes, these observations suggest that hundreds of cancer driver genes remain to be identified.</p><p>In the present work, we have used analyses that combined multiple types of signals of selection, permitting improved detection of positive and negative selection. Our analyses have identified a large number of novel positively selected cancer gene candidates, many of which could be shown to play significant roles in carcinogenesis as tumor suppressors and OGs. Significantly, our analyses have identified a major group of human genes that show signs of negative selection during tumor evolution, suggesting that the integrity of their function is essential for the growth and survival of tumor cells. Our analyses of representative members of negatively selected genes have confirmed that they play crucial pro-oncogenic roles in various cancer hallmarks (<xref ref-type="table" rid="table1">Table 1</xref>). It is important to emphasize that a survey of the group of OGs and pro-oncogenic TEGs reveals that they form a continuum in as much as there are numerous known OGs where negative selection also dominates (e.g. <italic>ACKR3, BCL2</italic>).</p><p>Although several groups have investigated the role of negative selection in tumor evolution earlier (<xref ref-type="bibr" rid="bib318">Zhou et al., 2017</xref>; <xref ref-type="bibr" rid="bib192">Pyatnitskiy et al., 2015</xref>; <xref ref-type="bibr" rid="bib278">Weghorn and Sunyaev, 2017</xref>; <xref ref-type="bibr" rid="bib153">Martincorena et al., 2017</xref>; <xref ref-type="bibr" rid="bib307">Zapata et al., 2018</xref>; <xref ref-type="bibr" rid="bib146">López et al., 2020</xref>; <xref ref-type="bibr" rid="bib244">Tilk et al., 2020</xref>; <xref ref-type="bibr" rid="bib249">Van den Eynden and Larsson, 2017</xref>), the study that received the greatest attention has reached the conclusion that negative selection has no role in tumor evolution (<xref ref-type="bibr" rid="bib153">Martincorena et al., 2017</xref>; <xref ref-type="bibr" rid="bib17">Bakhoum and Landau, 2017</xref>; <xref ref-type="bibr" rid="bib124">Koch, 2017</xref>; <xref ref-type="bibr" rid="bib254">Vitale and Galluzzi, 2018</xref>). The data presented here contradict the latter conclusion.</p><p>We believe that the approach reported here will promote the identification of numerous novel OGs, TSGs, and pro-oncogenic TEGs that may serve as therapeutic targets.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Somatic mutation data</title><p>Cancer somatic mutation data were extracted from COSMIC v88, the Catalogue Of Somatic Mutations In Cancer (<ext-link ext-link-type="uri" xlink:href="https://cancer.sanger.ac.uk/cosmic/download">https://cancer.sanger.ac.uk/cosmic/download</ext-link>), which includes single nucleotide substitutions and small insertions/deletions affecting the coding sequence of human genes. The downloaded file (CosmicMutantExport.tsv, release v88) contained data for 29,415 transcripts (<xref ref-type="supplementary-material" rid="supp8">Supplementary file 8</xref>). For all subsequent analyses we have retained only transcripts containing mutations that were annotated under’ Mutation description’ as substitution or subtle insertion/deletion. This dataset contained data for 29,405 transcripts containing 6,449,721 mutations (substitution and short indels, SSI) and 29,399 transcripts containing 6,141,650 substitutions only (SO). <xref ref-type="supplementary-material" rid="supp9">Supplementary file 9</xref> contains the metadata for these SO and SSI datasets.</p><p>Since we were interested in the selection forces that operate during tumor evolution, only confirmed somatic mutations were included in our analyses. In COSMIC such mutations are annotated under’ Mutation somatic status’ as Confirmed Somatic, that is confirmed to be somatic in the experiment by sequencing both the tumor and a matched normal tissue from the same patient. <xref ref-type="supplementary-material" rid="supp10">Supplementary file 10</xref> indicates the contribution of major tumor types (‘Tumor Primary site’) to the somatic mutations of the dataset. As to’ Sample Type, Tumor origin’: we have excluded mutation data from cell-lines, organoid-cultures, xenografts since they do not properly represent human tumor evolution at the organism level. We have found that by excluding cell lines we have eliminated many artifacts of spurious recurrent mutations caused by repeated deposition of samples taken from the same cell-line at different time-points. To eliminate the influence of polymorphisms on the conclusions we retained only somatic mutations flagged 'n' for SNPs. (<xref ref-type="supplementary-material" rid="supp8">Supplementary file 8</xref>).</p><p>To increase the statistical power of our analyses, we have limited our work to transcripts that have at least 100 somatic mutations; <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref> contains the metadata for transcripts containing at least 100 confirmed somatic, non polymorphic mutations identified in tumor tissues. Hereafter, unless otherwise indicated, our analyses refer to datasets containing transcripts with at least 100 somatic mutations. This limitation eliminated ~38% of the transcripts that contain very few mutations but reduced the number of total mutations only by 9% (<xref ref-type="supplementary-material" rid="supp8">Supplementary file 8</xref>).</p><p>It should be noted that requiring a higher minimum number of somatic mutations increases the statistical power of the analyses but may disfavor the identification of negatively selected genes that tend to be undermutated. To assess the influence of the cut-off value of the minimum number of mutations on the robustness of the conclusions about negatively or positively selected genes, we have compared the results of analyses in which the minimum number of somatic mutation per gene was set as 0, 50, 100, or 500 (<xref ref-type="supplementary-material" rid="supp11">Supplementary files 11</xref>–<xref ref-type="supplementary-material" rid="supp13">13</xref>, <xref ref-type="fig" rid="fig12">Figure 12</xref>).</p><fig id="fig12" position="float"><label>Figure 12.</label><caption><title>Analyses of fS, fM, and fN parameters of datasets N0, N50, N100, and N500 containing transcripts of human protein-coding genes with at least 0, 50, 100, or 500 somatic substitutions in tumors.</title><p>The figure shows the results of the analysis of 29,333, 21,307, 13,803, and 997 transcripts present in datasets N0 (panel A), N50 (panel B), N100 (panel C), and N500 (panel D), respectively. Axes x, y, and z represent the fractions of somatic single nucleotide substitutions that are assigned to the synonymous (fS), nonsynonymous (fM), and nonsense (fN) categories. Each gray ball represents a human transcript. The positions of transcripts of the genes identified by <xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref> as oncogenes (OGs, large red balls) or tumor suppressor genes (TSGs, large blue balls) are highlighted; novel proto-oncogenes, TSGs, and negatively selected tumor essential genes validated in the present work are represented by large magenta, cyan, and green balls, respectively. It is noteworthy that the requirement of at least 50 somatic mutations per transcript eliminates transcripts where the signal-to-noise ratio is too low to permit detection of signals of selection through the analysis of fS, fM, and fN parameters (compare panel A and panel B). It should also be noted that the requirement of at least 500 somatic mutations per transcript eliminates transcripts of negatively selected genes (compare panel C and panel D), consistent with the view that they tend to be undermutated.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59629-fig12-v2.tif"/></fig><p>The choice of the minimum number of somatic mutations was found to have a strong influence on the pattern of observed fN, fS, and fM scores (<xref ref-type="supplementary-material" rid="supp11">Supplementary files 11</xref>–<xref ref-type="supplementary-material" rid="supp13">13</xref>, <xref ref-type="fig" rid="fig12">Figure 12</xref>). In the case of dataset N0 (no requirement for a minimum number of mutations), a large number of transcripts with less than 50 substitutions had scores of zero for one or two of the fN, fS, and fM parameters due to the absence of somatic mutations in those categories (<xref ref-type="fig" rid="fig12">Figure 12A</xref>, <xref ref-type="supplementary-material" rid="supp11">Supplementary file 11</xref>). Increasing the minimum number of somatic mutations per transcript to 50, 100, and 500 resulted in loss of these transcripts and elimination of a diffusely scattered group of transcripts that do not cluster with PGs, known OGs, TSGs, and TEGs (compare <xref ref-type="fig" rid="fig12">Figure 12A and B,C and D</xref>, <xref ref-type="supplementary-material" rid="supp11">Supplementary file 11</xref>). These observations indicate that we cannot draw valid conclusions about the significance of selection from fN, fS, and fM scores in cases where the number of mutations of a given transcript is too low to permit meaningful analyses. Our analyses have also revealed that a large proportion (22%) of the transcripts unique to the N0<sup>2SD</sup> dataset (containing fewer than 50 substitutions), correspond to short transcript fragments encoding less than 100 amino acids (<xref ref-type="supplementary-material" rid="supp12">Supplementary file 12</xref>). This finding suggests that the requirement for a minimum number of somatic mutations would not only increase statistical power, but also increases the biological relevance of the conclusions with the elimination of fragments that do not properly represent the full-length coding sequences.</p><p>Our analyses, however, have shown that the requirement of more than 500 somatic mutations per transcript (dataset N500) is too stringent. Although the majority of the 86 transcripts of the N500<sup>2SD</sup> dataset correspond to known OGs (25) or TSGs (48), most OGs and TSGs are not represented in the N500<sup>2SD</sup> dataset (<xref ref-type="supplementary-material" rid="supp12">Supplementary file 12</xref>). Furthermore, none of the negatively selected TEGs validated in the present study is present among the 86 transcripts of the N500<sup>2SD</sup> dataset or among the 997 transcripts of the N500 dataset (<xref ref-type="fig" rid="fig12">Figure 12D</xref>, <xref ref-type="supplementary-material" rid="supp12">Supplementary file 12</xref>). This observation is consistent with the view that since negatively selected genes tend to have fewer mutations, they are less likely to pass the requirement for a high number of somatic mutations.</p><p>Our analyses suggest that the choice of 50 or 100 as the minimum number of somatic mutations per transcript represent acceptable trade-off between statistical power and loss of negatively or positively selected genes. As shown in <xref ref-type="supplementary-material" rid="supp12">Supplementary file 12</xref>, both the N50<sup>2SD</sup> dataset (1846 transcripts) and the N100<sup>2SD</sup> dataset (1060 transcripts) contained the majority of known OGs, known TSGs, and TEGs validated in the present work, but since the choice of 100 offers higher statistical power, we have used this dataset in our analyses.</p><p>Our choice of 100 as the minimum number of somatic mutation per transcript may also have some relevance for the lack of more extensive similarity of our list of negatively selected genes with those identified by others. As shown in <xref ref-type="supplementary-material" rid="supp13">Supplementary file 13</xref>, only 48%, 64%, 77%, and 89% of the negatively selected genes identified by <xref ref-type="bibr" rid="bib278">Weghorn and Sunyaev, 2017</xref>, <xref ref-type="bibr" rid="bib307">Zapata et al., 2018</xref>, <xref ref-type="bibr" rid="bib318">Zhou et al., 2017</xref>, and <xref ref-type="bibr" rid="bib192">Pyatnitskiy et al., 2015</xref>, respectively are present in dataset N100 containing 13,803 transcripts with at least 100 somatic mutations (<xref ref-type="supplementary-material" rid="supp11">Supplementary file 11</xref>). It thus appears that one of the reasons for the differences observed is that, with respect to minimum number of mutations, we have used rather stringent criteria to increase the robustness of our estimates. We wish to point out that, in order to obtain more reliable estimates of purifying selection, <xref ref-type="bibr" rid="bib192">Pyatnitskiy et al., 2015</xref> have also excluded genes from their analysis that carried a low number of mutations but they excluded only those with less than 11 mutations.</p><p>The COSMIC database of somatic mutations used in the present study contains data obtained by three main types of sequencing: whole-genome sequencing (WGS), whole-exome sequencing (WES) and targeted sequencing. As shown in <xref ref-type="supplementary-material" rid="supp8">Supplementary file 8</xref>, targeted screens provided substitution mutation data for only 13,120 transcripts of human genes, whereas genome wide screens covered 29,407 human transcripts as opposed to 29,415 transcripts covered by targeted plus genome wide screens. The contribution of targeted screens to somatic point mutations is even more restricted: only 508,124 (8.3%) of the 6,141,650 somatic point mutations of the entire COSMIC database were identified by targeted sequencing (<xref ref-type="supplementary-material" rid="supp8">Supplementary file 8</xref>). To check the impact of targeted sequencing on the dataset, in some analyzes we have used somatic mutation data only from genome-wide screens, excluding those obtained by targeted sequencing. We have found that omission of the data from targeted screens had no significant effect on the conclusions drawn from our analyses. Several factors may explain this observation. First, targeted screens usually focus on known cancer genes and they usually just reinforce the ‘known cancer gene’ status of the targeted genes. Second, since only a small fraction of the somatic mutations originates from targeted screens their impact is limited even in the case of the targeted genes. Finally, inclusion or omission of data from targeted screens has no impact on the number and pattern of mutations of non-targeted genes identified in genome wide screens.</p></sec><sec id="s4-2"><title>Germline mutation data</title><p>Information on SNPs affecting the coding regions of human genes was downloaded from the dbSNP database (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/snp/">https://www.ncbi.nlm.nih.gov/snp/</ext-link>). For each SNP, we extracted nucleotide and amino acid variants from the original dbSNP file. In cases where two or three mutant variant was reported for a specific rsID, each variant was treated as an independent polymorphism. The retrieved SNPs were assigned to three functional categories: (i) Nonsense or Stop_gained mutations (N), which change an amino acid-encoding codon into a stop codon, (ii) Missense mutations (M), which change an amino acid into a mutant amino acid, and (iii) Synonymous or silent mutations (S), which do not change the amino acid. We have focused only on SNPs of genes that were also found to contain at least 100 confirmed somatic, non polymorphic mutations in the COSMIC database (<xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>). <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref> shows the numbers and fractions of SNPs affecting the coding sequences of the various human genes, according to the functional categories of the point mutations.</p></sec><sec id="s4-3"><title>Substitution metrics</title><p>The 61 sense codons can undergo 549 single base substitutions and, depending on the wild type and mutant codon, each substitution can be assigned to the silent, missense or nonsense mutation category. Out of the 549 single-base substitutions, 392 result in missense mutation, 134 lead to silent mutation, and 23 generate nonsense mutation, thus – assuming equal codon frequency, equal probability of the different types of substitutions and neutrality – the expected fractions of nonsense, missense and silent substituions are fN = 0.04189, fM = 0.71403, and fS = 0.24408, respectively.</p><p>Codons, however, differ significantly in the probability that their mutation would lead to nonsense (N), missense (M), or silent (S) mutation (<xref ref-type="supplementary-material" rid="supp14">Supplementary files 14</xref>, <xref ref-type="supplementary-material" rid="supp15">15</xref>, <xref ref-type="supplementary-material" rid="supp16">16</xref>) and since the 61 sense codons (amino acids) do not occur with the same frequency in the coding region of human genes this may have a significant influence on the expected fN, fM, and fS values. We have calculated the probability that a substitution would lead to nonsense, missense or silent mutation taking into account the codon frequency of the proteome of <italic>Homo sapiens</italic> (<ext-link ext-link-type="uri" xlink:href="https://www.kazusa.or.jp/codon/cgi-bin/showcodon.cgi?species=9606">https://www.kazusa.or.jp/codon/cgi-bin/showcodon.cgi?species=9606</ext-link>). This calculation yielded values of fN = 0.0419, fM = 0.7299, fS = 0.2282 for the proteome, slightly different from the values of fN = 0.0419, fM = 0.7140, fS = 0.2441, assuming equal frequency of codons.</p><p>The amino acid composition and codon usage of some individual proteins (especially short fragments) may deviate significantly from average, therefore we have calculated the expected proportion of silent, missense, and nonsense mutations for all transcripts, assuming equal probability of different substitutions classes (<xref ref-type="supplementary-material" rid="supp17">Supplementary file 17</xref>). For these calculations, we have downloaded the coding sequences of 53,190 transcripts of human protein coding genes (All_COSMIC_Genes.fasta.gz) from the COSMIC database (<ext-link ext-link-type="uri" xlink:href="https://cancer.sanger.ac.uk/cosmic">https://cancer.sanger.ac.uk/cosmic</ext-link>) and their codon usage and amino acid composition were determined using the SMS server (<ext-link ext-link-type="uri" xlink:href="https://www.bioinformatics.org/sms2/codon_usage.html">https://www.bioinformatics.org/sms2/codon_usage.html</ext-link>, <xref ref-type="bibr" rid="bib229">Stothard, 2000</xref>).</p><p>Different classes of substitutions, however, do not occur with equal probability, moreover the various normal and tumor tissues show characteristic differences in the spectrum of substitutions classes (<xref ref-type="bibr" rid="bib6">Alexandrov et al., 2013</xref>; <xref ref-type="bibr" rid="bib8">Alexandrov et al., 2020</xref>). Substitutions are assigned to six classes (C&gt;A, C&gt;G, C&gt;T, T&gt;A, T&gt;C, and T&gt;G) referred to by the pyrimidine of the mutated Watson–Crick base pair. It is of crucial importance to take differences in the probability of the six mutation classes into account since—due to the unique structure of the genetic code—the six types of substitutions differ markedly in the probability that they would lead to nonsense (N), missense (M), or silent (S) mutation of the coding region of protein-coding genes. As shown in <xref ref-type="supplementary-material" rid="supp18">Supplementary files 18</xref>–<xref ref-type="supplementary-material" rid="supp25">25</xref>, there are significant differences in the impact of different substitution classes on the expected proportion of missense, silent, and nonsense mutations of codons (assuming equal codon frequency). For example, the dominance of C&gt;G increases the proportion of missense substitutions, whereas higher rates of C&gt;T and T&gt;C substitutions increase the proportion of silent substitutions. Since mutation bias favoring C&gt;T substitutions is expected to decrease the ratio of missense to silent mutations, decreased dN/dS values may not be taken as evidence for negative selection in the case of tumors, such as malignant melanoma, where the vast majority of all somatic mutations is C&gt;T substitution (<xref ref-type="bibr" rid="bib249">Van den Eynden and Larsson, 2017</xref>).</p><p>To take into account differences in mutation bias, we have calculated the contribution of the C&gt;A, C&gt;G, C&gt;T, T&gt;A, T&gt;C, and T&gt;G mutations to the pattern of single base substitutions in tumors. We have downloaded the files containing ‘Mutational Signatures v3.1’ and ‘Attributions of the SBS Signatures to Mutations in Tumors’ from the COSMIC website (<ext-link ext-link-type="uri" xlink:href="https://cancer.sanger.ac.uk/cosmic/signatures/SBS/index.tt">https://cancer.sanger.ac.uk/cosmic/signatures/SBS/index.tt</ext-link>). The contributions of C&gt;A, C&gt;G, C&gt;T, T&gt;A, T&gt;C, and T&gt;G mutations to the pattern of Single Base Substitutions in the tumors listed in the PCAWG_sigProfiler_SBS_signatures_in_samples file are summarized in <xref ref-type="supplementary-material" rid="supp26">Supplementary file 26</xref>. The C&gt;T substitution accounts for the largest fraction of substitutions in most tumors (0.3726), followed by T&gt;C (0.1842), C&gt;A (0.1583), C&gt;G (0.1162), T&gt;G (0.0891), and T&gt;A (0.0796). There are, however, differences in the relative contribution of the six mutation classes to different tumors. For example, the contribution of C&gt;A mutation is higher than average for colon cancer and lung cancer, the role of C&gt;G mutation is above average for bladder cancer and some breast cancers. The contribution of C&gt;T mutation is very high in the case of skin-melanoma, whereas the T&gt;A mutation contributes significantly to some kidney cancers. The T&gt;C mutation plays a significant role in biliary and liver cancer, whereas the T&gt;G mutation is more significant in colon cancer and esophageal cancer than in other tumors (see <xref ref-type="supplementary-material" rid="supp26">Supplementary file 26</xref>).</p><p>In order to correct for the influence of mutation bias on fN, fM, and fS values of transcripts in tumor tissues, we have calculated the expected fN*, fM*, and fS* values for all human transcripts using the average values of the six substitution types observed across tumors (<xref ref-type="supplementary-material" rid="supp27">Supplementary file 27</xref>). It is noteworthy that the average values of expected fN*, fM*, and fS* (fN*=0.04483, fM*=0.69114, and fS*=0.26402) are similar to those (fN = 0.04189, fM = 0.71403, and fS = 0.24408) assuming equal codon frequency and equal probability of the different types of substitutions.</p><p>In the case of germline cells, we have also calculated the expected fN**, fM**, and fS** values for all human transcripts using the mutation probabilities characteristic of these cells (<xref ref-type="supplementary-material" rid="supp28">Supplementary file 28</xref>). It has been shown earlier that the human germline mutation spectrum can be recapitulated by a combination of the cancer signatures SBS1 and SBS5 (<xref ref-type="bibr" rid="bib7">Alexandrov et al., 2015</xref>; <xref ref-type="bibr" rid="bib194">Rahbari et al., 2016</xref>; <xref ref-type="bibr" rid="bib95">Heredia-Genestar et al., 2020</xref>). In the present work, we have combined the effect of mutation signatures SBS1 and SBS5 on the germline mutation spectrum of proteins according to the formula (0.1 × SBS1 + 0.9 × SBS5) recommended by <xref ref-type="bibr" rid="bib95">Heredia-Genestar et al., 2020</xref>. It is noteworthy that the average values of expected fN**, fM**, and fS** (fN**=0.03791, fM**=0.68653, and fS**=0.27556) are similar to those expected for tumor tissues (fN*=0.04483, fM*=0.69114, and fS*=0.26402).</p></sec><sec id="s4-4"><title>Per-gene detection of selection signals in tumor tissues</title><p>We have used two approaches to determine the observed fM, fS, and fN values of transcripts: one in which we have restricted our analyses to single nucleotide substitutions (hereafter referred to as SO for 'substitution only') and a version in which we have also taken into account subtle indels (hereafter referred to as SSI for 'substitutions and subtle indels').</p><p>In the first case, we have calculated for each transcript the fraction of somatic substitutions that could be assigned to the synonymous (fS), nonsynonymous (fM), and nonsense mutation (fN) category (<xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref> and <xref ref-type="supplementary-material" rid="supp9">9</xref>). In the version that also included data for subtle indels, we have calculated the fraction of mutations corresponding to synonymous substitutions (indel_fS), but have merged nonsynonymous substitutions and short inframe indels in the category of mutations that lead to changes in the amino acid sequence (indel_fM). Nonsense substitutions and short frame-shift indels were included in the third category of mutations (indel_fN) as both types of mutation lead eventually to stop codons that truncate the protein (<xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref> and <xref ref-type="supplementary-material" rid="supp9">9</xref>).</p><p>Analyses of datasets (<xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>) containing substitutions only have shown that in 3D scatter plots transcripts form a cluster (<xref ref-type="fig" rid="fig2">Figure 2A</xref>) characterized by values of 0.2436 ± 0.0619, 0.7090 ± 0.0556, and 0.0475 ± 0.0322 for fractions of silent, missense, and nonsense substitutions, respectively. The mean fS, fM, and fN values of the transcripts in this cluster are close to those expected if we assume that the structure of the genetic code has the most important role in determining the probability of somatic substitutions during tumor evolution of human genes (<xref ref-type="supplementary-material" rid="supp29">Supplementary file 29</xref>). Based on the structure of the genetic code, assuming equal usage of the codons and equal probability of different point mutations, in the absence of selection one would expect that a fraction of 0.24408 would be silent, 0.71403 of the single-base substitutions would be missense and 0.04189 would be nonsense mutations.</p><p>It is noteworthy, however, that the fS, fM, and fN values of the best known cancer genes (<xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref>) deviate from those characteristic of the majority of human genes (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). The genes in the central cluster, deviating from mean fM, fS, and fN values by ≤1 SD, are characterized by fraction values of 0.24548 ± 0.03079, 0.71084 ± 0.0274, and 0.04368 ± 0.01572 for synonymous, nonsynonymous and nonsense substitutions, respectively. Note that these values are very close to those expected from the structure of the genetic code in the absence of selection, assuming equal frequency of codons and equal probability of the different classes of mutations (<xref ref-type="supplementary-material" rid="supp29">Supplementary file 29</xref>). This central cluster of genes (<xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>) is hereafter referred to as PG_SO<sup>f_1SD</sup> (for Passenger Gene_Substitution Only deviating from mean fM, fS, and fN values by ≤1 SD) because it is likely to be enriched in genes that play no major role in carcinogenesis.</p><p>In harmony with earlier observations, the values for OGs show a significant (p&lt;0.05) shift of fM to higher values (0.8563 ± 0.08224) relative to those of PGs (0.71084 ± 0.0274), reflecting positive selection for missense mutations (<xref ref-type="supplementary-material" rid="supp29">Supplementary file 29</xref>). On the other hand, the fN values of TSGs are significantly (p&lt;0.05) higher (0.1964 ± 0.11063) than those of PGs (0.04368 ± 0.01572), reflecting positive selection for truncating nonsense mutations (<xref ref-type="supplementary-material" rid="supp29">Supplementary file 29</xref>).</p><p>The genes (1060 transcripts) with values that deviate from mean values of fS, fM, and fN by more than 2SD, however, are likely to be subject to selection. In harmony with this expectation, this group contains transcripts of the majority of known driver genes (62 OG and 119 TSG driver gene transcripts). This gene set, defined by 2SD cut-off value, is hereafter referred to as CG_SO<sup>f_2SD</sup> (for Cancer Gene_Substitution Only deviating from mean fM, fS, and fN values by more than 2SD) because it is likely to be enriched in cancer genes (<xref ref-type="supplementary-material" rid="supp29">Supplementary file 29</xref>). Out of the 1060 transcripts present in CG_SO<sup>f_2SD</sup>, 737 transcripts are derived from genes that are not included in the OG, TSG, and CGC cancer gene lists (<xref ref-type="supplementary-material" rid="supp5">Supplementary files 5</xref> and <xref ref-type="supplementary-material" rid="supp29">29</xref>). Since the majority of these 737 transcripts have parameters that cluster them with known OGs or TSGs, we assume that they qualify as candidate OGs or TSGs. However, a group of genes deviates from both the central PG cluster and the clusters of OGs and TSGs (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). The high fS and low fM and fN values of the genes in this cluster suggest that they experience purifying selection during tumor evolution, raising the possibility that they may correspond to TEGs important for the growth and survival of tumors.</p><p>Known cancer genes (OGs and TSGs) also separate from the majority of human genes in 3D scatter plots of parameters rSM, rNM, rNS defined as the ratio of fS/fM, fN/fM, fN/fS, respectively (<xref ref-type="fig" rid="fig3">Figure 3</xref>). The central cluster of genes that deviate from mean rSM, rNM and rNS values by ≤1 SD is hereafter referred to as PG_SO<sup>r2_1SD</sup> (Passenger Gene_Substitution Only deviating from mean rSM, rNM, and rNS values by ≤1 SD) since it is likely to be enriched in PGs. Conversely, the group of transcripts that deviate from mean rSM, rNM, and rNS values by more than 2SD is referred to as CG_SO<sup>r2_2SD</sup> (Cancer Gene_Substitution Only deviating from mean rSM, rNM, rNS values by more than 2SD) because it is likely to be enriched in cancer genes (<xref ref-type="supplementary-material" rid="supp29">Supplementary file 29</xref>). The CG_SOr2_2SD gene set (780 transcripts) contains the majority of driver gene transcripts (40 transcripts of OGs, 103 transcripts of TSGs genes), 79 transcripts of CGC genes and 558 transcripts derived from 468 genes that are not found in the OG, TSG, and CGC cancer gene lists (<xref ref-type="supplementary-material" rid="supp29">Supplementary file 29</xref>).</p><p>In these scatter plots OGs separate from the central cluster in having significantly (p&lt;0.05) lower rSM (0.13971 ± 0.10621) and rNM (0.03936 ± 0.0313) values than those of the central cluster of PGs (rSM: 0.34523 ± 0.06137; rNM: 0.0607 ± 0.02595, <xref ref-type="supplementary-material" rid="supp29">Supplementary file 29</xref>), reflecting positive selection for missense mutations and negative selection of nonsense mutations. Interestingly, in these plots some OGs (e.g. BCL2) have unusually high values of rSM and low values of rNM (e.g. <xref ref-type="fig" rid="fig3">Figure 3A1, A2</xref> and <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>) suggesting that in the case of these OGs purifying selection may dominate over positive selection for amino acid changing mutations.</p><p>TSGs also separate from the central cluster: they have significantly (p&lt;0.05) higher rNS (3.92588 ± 5.66261) and rNM (0.31524 ± 0.31575) values than those of PGs (rNS: 0.18403 ± 0.09138; rNM: 0.0607 ± 0.02595; <xref ref-type="fig" rid="fig3">Figure 3A1, A2</xref>. <xref ref-type="supplementary-material" rid="supp29">Supplementary file 29</xref>), reflecting the dominance of positive selection for inactivating mutations.</p><p>As mentioned above, the candidate cancer gene set defined by a cut-off value of 2SD also contains 558 transcripts derived from 468 genes that are not found in the OG, TSG, or CGC lists.</p><p>Since the majority of these 558 transcripts have parameters that cluster them with known OGs or TSGs, they can be regarded as candidate OGs or TSGs. There is, however, a group of genes that deviate from the clusters of PGs, OGs, and TSGs in that they have unusually high rSM values and low rNM and rNS values. Since these values may be indicative of purifying selection, we assumed that they might correspond to TEGs important for the growth and survival of tumors.</p><p>The separation of known cancer genes from the majority of human genes is even more obvious in 3D scatter plots of parameters rSMN, rMSN, and rNSM defined as the ratio of fS/(fM+fN), fM/(fS+fN), and fN/(fS+fM), respectively (<xref ref-type="fig" rid="fig4">Figure 4 A1, A2</xref>). In these plots, the gene transcripts are present in a three-pronged cluster, with OGs and TSG being present on separate spikes of this cluster (<xref ref-type="fig" rid="fig4">Figure 4</xref>).</p><p>We refer to the central cluster of genes, deviating from mean rSMN, rMSN, and rNSM values by ≤1 SD as PG_SO<sup>r3_1SD</sup> (Passenger Gene_Substitution Only deviating from mean rSMN, rMSN, and rNSM values by ≤1 SD) as they are likely to be enriched in PGs. Similarly, we refer to the gene set defined by 2SD cut-off value (<xref ref-type="supplementary-material" rid="supp5">Supplementary files 5</xref> and <xref ref-type="supplementary-material" rid="supp29">29</xref>) as CG_SO<sup>r3_2SD</sup> (Cancer Gene_Substitution Only deviating from mean rSMN, rMSN, and rNSM values by more than 2SD) as it is likely to be enriched in candidate cancer genes. This gene set has 751 transcripts, containing the majority of transcripts of known driver genes (35 OGs, 103 TSGs), 80 transcripts of CGC genes and 533 transcripts (derived from 448 genes) not found in the OG, TSG, and CGC cancer gene lists (<xref ref-type="supplementary-material" rid="supp5">Supplementary files 5</xref> and <xref ref-type="supplementary-material" rid="supp29">29</xref>).</p><p>The mean parameters of TSGs differ significantly (p&lt;0.05) from those of PGs in as much as rNSM values of TSGs are higher (0.27937 ± 0.2783) but rSMN (0.10865 ± 0.06128) values are lower than those of PGs (rNSM: 0.04812 ± 0.02561; rSMN: 0.3259 ± 0.09265, <xref ref-type="supplementary-material" rid="supp29">Supplementary file 29</xref>), reflecting the dominance of positive selection for inactivating nonsense mutations.</p><p>In the case of OGs the rMSN values are significantly (p&lt;0.05) higher (15.35971 ± 30.07472) and the rSMN values are significantly lower (0.13363 ± 0.10266) than those of PGs (rMSN: 2.58911 ± 0.68355; rSMN: 0.3259±0.09265 <xref ref-type="supplementary-material" rid="supp29">Supplementary file 29</xref>), reflecting positive selection for missense mutations. The rNSM values of OGs (0.03394 ± 0.02621) are also significantly (p&lt;0.05) lower than those of PGs (0.04812 ± 0.02561), reflecting purifying selection avoiding nonsense mutations. Interestingly, some OGs have unusually high scores of rSMN (<xref ref-type="fig" rid="fig4">Figure 4 A1, A2</xref>, <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>) suggesting that in these cases (e.g. <italic>BCL2</italic>) purifying selection dominates over positive selection for amino acid changing mutations.</p><p>As mentioned above, the candidate cancer gene set defined by a cut-off value of 2SD contains 533 transcripts (derived from 448 genes) not found in the OG, TSG, or CGC lists. Since the majority of these genes have parameters that assign them to the clusters containing OGs or TSGs, they can be regarded as candidate OGs or TSGs. There is, however, a group of genes that deviates from the clusters of PGs, OGs, and TSGs (<xref ref-type="fig" rid="fig4">Figure 4</xref>). Their high rSMN and low rMSN and rNSM values suggest that they experience purifying selection during tumor evolution, raising the possibility that this group may be enriched in genes essential for the survival of tumors as pro-oncogenes or TEGs.</p><p>The three types of analyses described for Substitutions Only (illustrated in <xref ref-type="fig" rid="fig2">Figures 2</xref>–<xref ref-type="fig" rid="fig4">4</xref>) were also carried out for datasets in which both substitutions and subtle indels (Substitutions and Subtle Indels, SSI) were used (for details of these analyzes see Appendix 2).</p><p>Comparison of the data obtained by SO and SSI analyses (<xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>) revealed that inclusion of indels has only minor influence on the separation of the clusters of PGs and CGs. The lists of PGs identified with 1SD cut-off values for SO analyes (PG_SO<sup>f_1SD</sup>, PG_SO<sup>r2_1SD</sup>, PG_SO<sup>r3_1SD</sup>) and SSI analyses (PG_SSI<sup>f_1SD</sup>, PG_SSI<sup>r2_1SD</sup>, PG_SSI<sup>r3_1SD</sup>) show more than 90% identity in the case of the relevant SO/SSI pairs (<xref ref-type="supplementary-material" rid="supp30">Supplementary file 30</xref>). Similarly, the lists of CGs identified with 2SD cut-off values for SO analyses (CG_SO<sup>f_2SD</sup>, CG_SO<sup>r2_2SD</sup>, CG_SO<sup>r3_2SD</sup>) and SSI analyses (CG_SSI<sup>f_2SD</sup>, CG_SSI<sup>r2_2SD</sup>, CG_SSI<sup>r3_2SD</sup>) show 78%, 87%, and 92% identity, respectively, for the relevant SO/SSI pairs (<xref ref-type="supplementary-material" rid="supp30">Supplementary file 30</xref>).</p><p>The parameters of the 1158 transcripts present in at least one of the various CG_SO<sup>2SD</sup> lists and the 1333 transcripts present in at least one of the various CG_SSI<sup>2SD</sup> lists (<xref ref-type="supplementary-material" rid="supp31">Supplementary file 31</xref>) were used to assign them to three distinct clusters. (1) Cluster of genes positively selected for missense mutations and negatively selected for nonsense mutations; (2) Cluster of genes positively selected for nonsense mutations; (3) Clusters of negatively selected genes (see <xref ref-type="fig" rid="fig2">Figure 2C</xref>, <xref ref-type="fig" rid="fig3">Figure 3 B1, B2</xref> and <xref ref-type="fig" rid="fig4">Figure 4 B1, B2</xref>). To check the validity and predictive value of the assumption that the genes assigned to these clusters play significant roles in carcinogenesis, we have selected a number of genes for further analyses from the 1457 transcripts present in the combined list (CG_SO<sup>2SD</sup>_SSI<sup>2SD</sup>) of candidate cancer genes (<xref ref-type="supplementary-material" rid="supp31">Supplementary file 31</xref>). The results of these analyses are summarized in the Results section.</p><p>As outlined in the section on Substitution metrics, a limitation of the analyses discussed above is that they did not take into account the impact of differences in mutation probability on the fN, fM, and fS values of transcripts. In order to eliminate this source of error, we have calculated the expected fN*, fM*, and fS* values for all human transcripts using the probability of the six substitution types observed across tumors (<xref ref-type="supplementary-material" rid="supp27">Supplementary file 27</xref>). The various types of observed/expected ratios (rN*, rM*, rS*; rSM*, rNM*, rNS*; rSMN*, rMSN*, and rNSM*) of somatic mutations were calculated for all transcripts (<xref ref-type="supplementary-material" rid="supp32">Supplementary file 32</xref>) and the data were analyzed in 3D scatter plots as described above for the observed values.</p><p>As shown in <xref ref-type="fig" rid="fig5">Figures 5</xref>–<xref ref-type="fig" rid="fig7">7</xref>, the distribution of transcripts in these 3D scatter plots are similar to those observed in the corresponding <xref ref-type="fig" rid="fig2">Figures 2</xref>–<xref ref-type="fig" rid="fig4">4</xref>, in that known OGs, TSGs, and TEGs are separated from the central cluster of PGs as well as from each other (<xref ref-type="supplementary-material" rid="supp32">Supplementary file 32</xref>).</p></sec><sec id="s4-5"><title>Per-gene detection of selection signals in the database of human single-nucleotide polymorphisms</title><p>As a reference, we have carried out similar analyses of the fN, fM, and fS parameters of germline mutations, through the analysis of the human database of human single-nucleotide polymorphisms (SNPs; <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>). <xref ref-type="supplementary-material" rid="supp33">Supplementary file 33</xref> contains the various types of observed/expected ratios (rN**, rM**, rS**; rSM**, rNM**, rNS**; rSMN**, rMSN**, and rNSM**) of germline mutations calculated for all transcripts. Data were analyzed in 3D scatter plots as described for somatic mutations. Details of these analyses are presented in the Results section.</p></sec><sec id="s4-6"><title>Cancer gene list</title><p>As the gold standard of 'known' cancer genes we have used the lists of OG and TSGs identified by <xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref>. As another list of known cancer genes we have also used the genes of the Cancer Gene Census (<xref ref-type="bibr" rid="bib224">Sondka et al., 2018</xref>).</p></sec><sec id="s4-7"><title>Statistical analyses</title><p>The statistical package of Origin 2018 was used for all data processing and statistical analysis. We report details of statistical tests in the Supplementary files of the respective sections. Statistical significance was set as a p value of &lt; 0.05.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>LB, KK, MT, and LP are supported by the GINOP-2.3.2-15-2016-00001 grant of the Hungarian National Research, Development and Innovation Office (NKFIH), OC is supported by the NVKP_16-1-2016-0005 grant of the Hungarian National Research, Development and Innovation Office (NKFIH).</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Formal analysis, Validation, Investigation, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Validation, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Validation, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Funding acquisition, Validation, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Supervision, Funding acquisition, Validation, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Comparison of the lists of genes in datasets CG_SSI<sup>2SD</sup>_rNSM &gt; 0.125 and CG_SO<sup>2SD</sup>_rMSN &gt; 3.00 with the lists of cancer genes identified by others (VOG, <xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref>; TAM, <xref ref-type="bibr" rid="bib238">Tamborero et al., 2013</xref>; LAW, <xref ref-type="bibr" rid="bib129">Lawrence et al., 2014</xref>; ABB, <xref ref-type="bibr" rid="bib1">Abbott et al., 2015</xref>; TOR, <xref ref-type="bibr" rid="bib246">Torrente et al., 2016</xref>; ZHO, <xref ref-type="bibr" rid="bib318">Zhou et al., 2017</xref>; MAR, <xref ref-type="bibr" rid="bib153">Martincorena et al., 2017</xref>; BAI, <xref ref-type="bibr" rid="bib16">Bailey et al., 2018</xref>; SON, <xref ref-type="bibr" rid="bib224">Sondka et al., 2018</xref>; ZHA, <xref ref-type="bibr" rid="bib314">Zhao et al., 2019a</xref>).</title><p>Transcripts of OGs (oncogenes) and TSGs (tumor suppressor genes) of the cancer gene list of <xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref> are highlighted by brick red and blue backgrounds, respectively. Transcripts of CGC genes (SON, <xref ref-type="bibr" rid="bib224">Sondka et al., 2018</xref>) that do not correspond to OGs or TSGs of the cancer gene list of <xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref> are highlighted by yellow background. Novel positively or negatively selected cancer genes validated in the present work are highlighted in dark green background.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59629-supp1-v2.xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Comparison of the lists of genes in datasets CG_SSI<sup>2SD</sup>_rNSM &gt; 0.125 and CG_SO<sup>2SD</sup>_rMSN &gt; 3.00 with the lists of genes in datasets CG_SO*<sup>2SD</sup>_rNSM &gt; 3 and CG_SO*<sup>2SD</sup>_rMSN &gt; 1.50, respectively.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59629-supp2-v2.xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Comparison of the list of negatively selected genes, CG<sup>2SD</sup>_rSMN &gt; 0.5 with the lists of negatively selected genes (WEG, ZHOU, ZAPATA, PYATNITSKIY), defined by <xref ref-type="bibr" rid="bib318">Zhou et al., 2017</xref>, <xref ref-type="bibr" rid="bib278">Weghorn and Sunyaev, 2017</xref>, <xref ref-type="bibr" rid="bib307">Zapata et al., 2018</xref>, <xref ref-type="bibr" rid="bib192">Pyatnitskiy et al., 2015</xref>, respectively as well as the list of genes (De Kegel) identified by <xref ref-type="bibr" rid="bib53">De Kegel and Ryan, 2019</xref> as broadly essential genes.</title><p>Negatively selected genes discussed in detail in the present work are highlighted in dark green background.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59629-supp3-v2.xlsx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>Comparison of the list of genes in dataset CG<sup>2SD</sup>_rSMN &gt; 0.5 with the list of genes in dataset CG_SO*<sup>2SD</sup>_rSMN &gt; 1.50.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59629-supp4-v2.xlsx"/></supplementary-material><supplementary-material id="supp5"><label>Supplementary file 5.</label><caption><title>SO (Substitution Only) and SSI (Substitutions and Subtle Indel) analyses of somatic mutations of transcripts of human protein coding genes that have at least 100 confirmed somatic, non-polymorphic mutations identified in tumor tissues.</title><p>The table also contains lists of passenger genes (PG_SO<sup>f_1SD</sup>, PG_SO<sup>r2_1SD</sup>, PG_SO<sup>r3_1SD</sup>, PG_SSI<sup>f_1SD</sup>, PG_SSI<sup>r2_1SD</sup>, PG_SSI<sup>r3_1SD</sup>) whose parameters deviate from the mean values by ≤1 SD as well as lists of candidate cancer genes (CG_SO<sup>f_1SD</sup>, CG_SO<sup>r2_1SD</sup>, CG_SO<sup>r3_1SD</sup>, CG_SSI<sup>f_1SD</sup>, CG_SSI<sup>r2_1SD</sup>, CG_SSI<sup>r3_1SD</sup>) whose parameters deviate from the mean values by &gt;1 SD. Table also contains lists of candidate cancer genes (CG_SO<sup>f_2SD</sup>, CG_SO<sup>r2_2SD</sup>, CG_SO<sup>r3_2SD</sup>, CG_SSI<sup>f_2SD</sup>, CG_SSI<sup>r2_2SD</sup>, CG_SSI<sup>r3_2SD</sup>) whose parameters deviate from the mean values by &gt;2 SD as well as lists of passenger genes (PG_SO<sup>f_2SD</sup>, PG_SO<sup>r2_2SD</sup>, PG_SO<sup>r3_2SD</sup>, PG_SSI<sup>f_2SD</sup>, PG_SSI<sup>r2_2SD</sup>, PG_SSI<sup>r3_2SD</sup>) whose parameters deviate from the mean values by &lt;2 SD. Transcripts of OGs (oncogenes) and TSGs (tumor suppressor genes) of the cancer gene list of <xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref> are highlighted by brick red and blue backgrounds, respectively. Transcripts of CGC (Cancer Gene Census) genes (<xref ref-type="bibr" rid="bib224">Sondka et al., 2018</xref>) that do not correspond to OGs or TSGs of the cancer gene list of <xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref> are highlighted by yellow background.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59629-supp5-v2.xlsx"/></supplementary-material><supplementary-material id="supp6"><label>Supplementary file 6.</label><caption><title>Numbers and fractions of missense, nonsense, and silent single-nucleotide polymorphisms (SNPs) affecting the coding sequences of the human genes.</title><p>Transcripts of OGs (oncogenes) and TSGs (tumor suppressor genes) of the cancer gene list of <xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref> are highlighted by brick red and blue backgrounds, respectively. Transcripts of CGC genes (SON, <xref ref-type="bibr" rid="bib224">Sondka et al., 2018</xref>) that do not correspond to OGs or TSGs of the cancer gene list of <xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref> are highlighted by yellow background. Novel positively or negatively selected cancer genes validated in the present work are highlighted in dark green background.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59629-supp6-v2.xlsx"/></supplementary-material><supplementary-material id="supp7"><label>Supplementary file 7.</label><caption><title>Comparison of fS, rSM, and rSMN scores of genes determined for somatic mutations in tumors with those determined for germline mutations.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59629-supp7-v2.xlsx"/></supplementary-material><supplementary-material id="supp8"><label>Supplementary file 8.</label><caption><title>Statistics of transcripts and subtle somatic mutations of human protein coding genes of the different datasets analyzed.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59629-supp8-v2.xlsx"/></supplementary-material><supplementary-material id="supp9"><label>Supplementary file 9.</label><caption><title>SO (Substitution Only) and SSI (Substitutions and Subtle Indel) analyses of somatic mutations of transcripts of human protein coding genes.</title><p>Transcripts of OGs (oncogenes) and TSGs (tumor suppressor genes) of the cancer gene list of <xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref> are highlighted by brick red and blue backgrounds, respectively. Transcripts of CGC (Cancer Gene Census) genes (<xref ref-type="bibr" rid="bib224">Sondka et al., 2018</xref>) that do not correspond to OGs or TSGs of the cancer gene list of <xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref> are highlighted by yellow background.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59629-supp9-v2.xlsx"/></supplementary-material><supplementary-material id="supp10"><label>Supplementary file 10.</label><caption><title>Contribution of major types of tumors (‘Tumor Primary site’) to subtle somatic substitutions of the human protein coding genes analyzed.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59629-supp10-v2.xlsx"/></supplementary-material><supplementary-material id="supp11"><label>Supplementary file 11.</label><caption><title>Analyses of fS, fM, and fN parameters of transcripts of human protein coding genes that have at least 0 (N0), 50 (N50), 100 (N100), or 500 (N500) somatic substitutions in tumors, respectively.</title><p>Transcripts of OGs (oncogenes) and TSGs (tumor suppressor genes) of the cancer gene list of <xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref> are highlighted by brick red and light blue backgrounds, respectively. Transcripts of CGC (Cancer Gene Census) genes (<xref ref-type="bibr" rid="bib224">Sondka et al., 2018</xref>) that do not correspond to OGs or TSGs of the cancer gene list of <xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref> are highlighted by yellow background. Novel proto-oncogenes, TSGs and negatively selected tumor essential genes validated in the present work are shown in brown, dark blue, and green colors, respectively. For 3D representations of the data, see <xref ref-type="fig" rid="fig12">Figure 12</xref>.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59629-supp11-v2.xlsx"/></supplementary-material><supplementary-material id="supp12"><label>Supplementary file 12.</label><caption><title>Analyses of fS, fM, and fN parameters of transcripts of human protein coding genes that have at least 0 (N0<sup>2SD</sup>), 50 (N50<sup>2SD</sup>), 100 (N100<sup>2SD</sup>), or 500 (N500<sup>2SD</sup>) somatic substitutions in tumors and deviate from average values of fS, fM, and fN by more than 2SD (Sheet ‘CG_SOf_2SD’).</title><p>Transcripts of OGs (oncogenes) and TSGs (tumor suppressor genes) of the cancer gene list of <xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref> are highlighted by brick red and light blue backgrounds, respectively. Transcripts of CGC (Cancer Gene Census) genes (SON, <xref ref-type="bibr" rid="bib224">Sondka et al., 2018</xref>) that do not correspond to OGs or TSGs of the cancer gene list of <xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref> are highlighted by yellow background. Novel proto-oncogenes, TSGs and negatively selected tumor essential genes (TEGs) validated in the present work are shown in brown, dark blue, and green colors, respectively. Sheet ‘statistics’ contains a summary of the fS, fM, and fN parameters of datasets N0, N50, N100, N500, N0<sup>2SD</sup>, N50<sup>2SD</sup>, N100<sup>2SD</sup>, N500<sup>2SD</sup> and indicates the number of known and novel OGs, TSGs and TEGs that are present in the different datasets.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59629-supp12-v2.xlsx"/></supplementary-material><supplementary-material id="supp13"><label>Supplementary file 13.</label><caption><title>Negatively selected genes in datasets N0, N50, N100, and N500.</title><p>Sheet ‘SO’ lists the genes/transcripts in datasets N0, N50, N100, and N500 that contain transcripts of human protein coding genes with at least 0, 50, 100, or 500 somatic substitutions in tumors, respectively. The lists of negatively selected genes identified by others were taken from the publications of <xref ref-type="bibr" rid="bib278">Weghorn and Sunyaev, 2017</xref>, <xref ref-type="bibr" rid="bib307">Zapata et al., 2018</xref>, <xref ref-type="bibr" rid="bib318">Zhou et al., 2017</xref> and <xref ref-type="bibr" rid="bib192">Pyatnitskiy et al., 2015</xref>. Sheet ‘statistics’ indicates the number of negatively selected genes identified by others that are present in the N0, N50, N100, and N500 datasets. Note that only 48%, 64%, 77%, and 89% of the negatively selected genes identified by <xref ref-type="bibr" rid="bib278">Weghorn and Sunyaev, 2017</xref>, <xref ref-type="bibr" rid="bib307">Zapata et al., 2018</xref>, <xref ref-type="bibr" rid="bib318">Zhou et al., 2017</xref> and <xref ref-type="bibr" rid="bib192">Pyatnitskiy et al., 2015</xref>, respectively, are present in the dataset N100 that we have analyzed in the present work.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59629-supp13-v2.xlsx"/></supplementary-material><supplementary-material id="supp14"><label>Supplementary file 14.</label><caption><title>Expected fractions of nonsense, missense, and silent substitutions of various codons in the absence of selection assuming that there is no difference in the probability of the substitution classes C&gt;A, C&gt;G, C&gt;T, T&gt;A, T&gt;C, and T&gt;G.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-59629-supp14-v2.docx"/></supplementary-material><supplementary-material id="supp15"><label>Supplementary file 15.</label><caption><title>Expected fractions of nonsense, missense, and silent substitutions of various codons in the absence of selection assuming that there is no difference in the probability of the substitution classes C&gt;A, C&gt;G, C&gt;T, T&gt;A, T&gt;C, and T&gt;G.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59629-supp15-v2.xlsx"/></supplementary-material><supplementary-material id="supp16"><label>Supplementary file 16.</label><caption><title>Expected fractions of nonsense, missense, and silent substitutions of various codons in the absence of selection assuming that there is no difference in the probability of the substitution classes C&gt;A, C&gt;G, C&gt;T, T&gt;A, T&gt;C, and T&gt;G.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-59629-supp16-v2.docx"/></supplementary-material><supplementary-material id="supp17"><label>Supplementary file 17.</label><caption><title>Expected fraction of silent, missense, and nonsense mutations of coding sequences of human protein-coding genes, assuming equal probability of different substitutions classes.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59629-supp17-v2.xlsx"/></supplementary-material><supplementary-material id="supp18"><label>Supplementary file 18.</label><caption><title>Expected fractions of nonsense, missense, and silent substitutions of various codons in the absence of selection assuming that only C&gt;A and G&gt;T mutations occur.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-59629-supp18-v2.docx"/></supplementary-material><supplementary-material id="supp19"><label>Supplementary file 19.</label><caption><title>Expected fractions of nonsense, missense, and silent substitutions of various codons in the absence of selection assuming that only C&gt;G and G&gt;C mutations occur.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-59629-supp19-v2.docx"/></supplementary-material><supplementary-material id="supp20"><label>Supplementary file 20.</label><caption><title>Expected fractions of nonsense, missense, and silent substitutions of various codons in the absence of selection assuming that only C&gt;T and G&gt;A mutations occur.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-59629-supp20-v2.docx"/></supplementary-material><supplementary-material id="supp21"><label>Supplementary file 21.</label><caption><title>Expected fractions of nonsense, missense, and silent substitutions of various codons in the absence of selection assuming that only T&gt;A and A&gt;T mutations occur.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-59629-supp21-v2.docx"/></supplementary-material><supplementary-material id="supp22"><label>Supplementary file 22.</label><caption><title>Expected fractions of nonsense, missense, and silent substitutions of various codons in the absence of selection assuming that only T&gt;C and A&gt;G mutations occur.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-59629-supp22-v2.docx"/></supplementary-material><supplementary-material id="supp23"><label>Supplementary file 23.</label><caption><title>Expected fractions of nonsense, missense, and silent substitutions of various codons in the absence of selection assuming that only T&gt;G and A&gt;C mutations occur.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-59629-supp23-v2.docx"/></supplementary-material><supplementary-material id="supp24"><label>Supplementary file 24.</label><caption><title>Expected fractions of nonsense, missense and silent substitutions of various codons in the absence of selection assuming that only C&gt;A or C&gt;G or C&gt;T or T&gt;A or T&gt;C or T&gt;G mutations occur.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59629-supp24-v2.xlsx"/></supplementary-material><supplementary-material id="supp25"><label>Supplementary file 25.</label><caption><title>Expected fractions of nonsense, missense, and silent substitutions in the absence of selection assuming equal codon frequency and that only C&gt;A or C&gt;G or C&gt;T or T&gt;A or T&gt;C or T&gt;G mutations occur.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-59629-supp25-v2.docx"/></supplementary-material><supplementary-material id="supp26"><label>Supplementary file 26.</label><caption><title>Contributions of C&gt;A, C&gt;G, C&gt;T, T&gt;A, T&gt;C, and T&gt;G mutations to the pattern of Single Base Substitutions in tumors.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59629-supp26-v2.xlsx"/></supplementary-material><supplementary-material id="supp27"><label>Supplementary file 27.</label><caption><title>Expected fractions of nonsense (fN*), missense (fM*), and silent (fS*) mutations of human protein-coding genes taking into account the probability of different substitutions classes in tumors.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59629-supp27-v2.xlsx"/></supplementary-material><supplementary-material id="supp28"><label>Supplementary file 28.</label><caption><title>Expected fractions of nonsense (fN**), missense (fM**), and silent (fS**) mutations of human protein-coding genes taking into account the probability of different substitutions classes in germline cells.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59629-supp28-v2.xlsx"/></supplementary-material><supplementary-material id="supp29"><label>Supplementary file 29.</label><caption><title>Statistics of the results of SO (Substitution Only) and SSI (Substitutions and Subtle Indel) analyses of the data presented in <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>.</title><p>The column marked 'Expected' indicates the parameters expected if we assume that the structure of the genetic code determines the probability of somatic substitutions.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59629-supp29-v2.xlsx"/></supplementary-material><supplementary-material id="supp30"><label>Supplementary file 30.</label><caption><title>Comparison of the results of SO (Substitution Only) and SSI (Substitutions and Subtle Indel) analyses.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59629-supp30-v2.xlsx"/></supplementary-material><supplementary-material id="supp31"><label>Supplementary file 31.</label><caption><title>Lists of genes (CG_SO<sup>f_2SD</sup>, CG_SO<sup>r2_2SD</sup>, CG_SO<sup>r3_2SD</sup>, CG_SSI<sup>f_2SD</sup>, CG_SSI<sup>r2_2SD</sup>, CG_SSI<sup>r3_2SD</sup>) whose parameters deviate from the mean values by &gt;2 SD.</title><p>Transcripts of OGs (oncogenes) and TSGs (tumor suppressor genes) of the cancer gene list of <xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref> are highlighted by brick red and blue backgrounds, respectively. Transcripts of CGC (Cancer Gene Census) genes (<xref ref-type="bibr" rid="bib224">Sondka et al., 2018</xref>) that do not correspond to OGs or TSGs of the cancer gene list of <xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref> are highlighted by yellow background.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59629-supp31-v2.xlsx"/></supplementary-material><supplementary-material id="supp32"><label>Supplementary file 32.</label><caption><title>Observed/expected parameters (rN*, rM*, rS*; rSM*, rNM*, rNS*; rSMN*, rMSN*, and rNSM*) of somatic mutations affecting the coding sequences of the human genes in cancer.</title><p>Transcripts of OGs (oncogenes) and TSGs (tumor suppressor genes) of the cancer gene list of <xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref> are highlighted by brick red and blue backgrounds, respectively.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59629-supp32-v2.xlsx"/></supplementary-material><supplementary-material id="supp33"><label>Supplementary file 33.</label><caption><title>Observed/expected parameters (rN**, rM**, rS**; rSM**, rNM**, rNS**; rSMN**, rMSN**, and rNSM**) of single-nucleotide polymorphisms (SNPs) affecting the coding sequences of the human genes.</title><p>Transcripts of OGs (oncogenes) and TSGs (tumor suppressor genes) of the cancer gene list of <xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref> are highlighted by brick red and blue backgrounds, respectively.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-59629-supp33-v2.xlsx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-59629-transrepform-v2.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files.</p><p>The following datasets were generated:</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbott</surname> <given-names>KL</given-names></name><name><surname>Nyre</surname> <given-names>ET</given-names></name><name><surname>Abrahante</surname> <given-names>J</given-names></name><name><surname>Ho</surname> <given-names>YY</given-names></name><name><surname>Isaksson Vogel</surname> <given-names>R</given-names></name><name><surname>Starr</surname> <given-names>TK</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The candidate Cancer gene database: a database of Cancer driver genes from forward genetic screens in mice</article-title><source>Nucleic Acids Research</source><volume>43</volume><fpage>D844</fpage><lpage>D848</lpage><pub-id pub-id-type="doi">10.1093/nar/gku770</pub-id><pub-id pub-id-type="pmid">25190456</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ablain</surname> <given-names>J</given-names></name><name><surname>Xu</surname> <given-names>M</given-names></name><name><surname>Rothschild</surname> <given-names>H</given-names></name><name><surname>Jordan</surname> <given-names>RC</given-names></name><name><surname>Mito</surname> <given-names>JK</given-names></name><name><surname>Daniels</surname> <given-names>BH</given-names></name><name><surname>Bell</surname> <given-names>CF</given-names></name><name><surname>Joseph</surname> <given-names>NM</given-names></name><name><surname>Wu</surname> <given-names>H</given-names></name><name><surname>Bastian</surname> <given-names>BC</given-names></name><name><surname>Zon</surname> <given-names>LI</given-names></name><name><surname>Yeh</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Human tumor genomics and zebrafish modeling identify <italic>SPRED1</italic> loss as a driver of mucosal melanoma</article-title><source>Science</source><volume>362</volume><fpage>1055</fpage><lpage>1060</lpage><pub-id pub-id-type="doi">10.1126/science.aau6509</pub-id><pub-id pub-id-type="pmid">30385465</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adesina</surname> <given-names>AM</given-names></name><name><surname>Nguyen</surname> <given-names>Y</given-names></name><name><surname>Mehta</surname> <given-names>V</given-names></name><name><surname>Takei</surname> <given-names>H</given-names></name><name><surname>Stangeby</surname> <given-names>P</given-names></name><name><surname>Crabtree</surname> <given-names>S</given-names></name><name><surname>Chintagumpala</surname> <given-names>M</given-names></name><name><surname>Gumerlock</surname> <given-names>MK</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>FOXG1 dysregulation is a frequent event in medulloblastoma</article-title><source>Journal of Neuro-Oncology</source><volume>85</volume><fpage>111</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1007/s11060-007-9394-3</pub-id><pub-id pub-id-type="pmid">17522785</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adesina</surname> <given-names>AM</given-names></name><name><surname>Veo</surname> <given-names>BL</given-names></name><name><surname>Courteau</surname> <given-names>G</given-names></name><name><surname>Mehta</surname> <given-names>V</given-names></name><name><surname>Wu</surname> <given-names>X</given-names></name><name><surname>Pang</surname> <given-names>K</given-names></name><name><surname>Liu</surname> <given-names>Z</given-names></name><name><surname>Li</surname> <given-names>XN</given-names></name><name><surname>Peters</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>FOXG1 expression shows correlation with neuronal differentiation in cerebellar development, aggressive phenotype in Medulloblastomas, and survival in a xenograft model of medulloblastoma</article-title><source>Human Pathology</source><volume>46</volume><fpage>1859</fpage><lpage>1871</lpage><pub-id pub-id-type="doi">10.1016/j.humpath.2015.08.003</pub-id><pub-id pub-id-type="pmid">26433703</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aldinucci</surname> <given-names>D</given-names></name><name><surname>Casagrande</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Inhibition of the CCL5/CCR5 Axis against the progression of gastric Cancer</article-title><source>International Journal of Molecular Sciences</source><volume>19</volume><elocation-id>1477</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19051477</pub-id><pub-id pub-id-type="pmid">29772686</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexandrov</surname> <given-names>LB</given-names></name><name><surname>Nik-Zainal</surname> <given-names>S</given-names></name><name><surname>Wedge</surname> <given-names>DC</given-names></name><name><surname>Aparicio</surname> <given-names>SA</given-names></name><name><surname>Behjati</surname> <given-names>S</given-names></name><name><surname>Biankin</surname> <given-names>AV</given-names></name><name><surname>Bignell</surname> <given-names>GR</given-names></name><name><surname>Bolli</surname> <given-names>N</given-names></name><name><surname>Borg</surname> <given-names>A</given-names></name><name><surname>Børresen-Dale</surname> <given-names>AL</given-names></name><name><surname>Boyault</surname> <given-names>S</given-names></name><name><surname>Burkhardt</surname> <given-names>B</given-names></name><name><surname>Butler</surname> <given-names>AP</given-names></name><name><surname>Caldas</surname> <given-names>C</given-names></name><name><surname>Davies</surname> <given-names>HR</given-names></name><name><surname>Desmedt</surname> <given-names>C</given-names></name><name><surname>Eils</surname> <given-names>R</given-names></name><name><surname>Eyfjörd</surname> <given-names>JE</given-names></name><name><surname>Foekens</surname> <given-names>JA</given-names></name><name><surname>Greaves</surname> <given-names>M</given-names></name><name><surname>Hosoda</surname> <given-names>F</given-names></name><name><surname>Hutter</surname> <given-names>B</given-names></name><name><surname>Ilicic</surname> <given-names>T</given-names></name><name><surname>Imbeaud</surname> <given-names>S</given-names></name><name><surname>Imielinski</surname> <given-names>M</given-names></name><name><surname>Imielinsk</surname> <given-names>M</given-names></name><name><surname>Jäger</surname> <given-names>N</given-names></name><name><surname>Jones</surname> <given-names>DT</given-names></name><name><surname>Jones</surname> <given-names>D</given-names></name><name><surname>Knappskog</surname> <given-names>S</given-names></name><name><surname>Kool</surname> <given-names>M</given-names></name><name><surname>Lakhani</surname> <given-names>SR</given-names></name><name><surname>López-Otín</surname> <given-names>C</given-names></name><name><surname>Martin</surname> <given-names>S</given-names></name><name><surname>Munshi</surname> <given-names>NC</given-names></name><name><surname>Nakamura</surname> <given-names>H</given-names></name><name><surname>Northcott</surname> <given-names>PA</given-names></name><name><surname>Pajic</surname> <given-names>M</given-names></name><name><surname>Papaemmanuil</surname> <given-names>E</given-names></name><name><surname>Paradiso</surname> <given-names>A</given-names></name><name><surname>Pearson</surname> <given-names>JV</given-names></name><name><surname>Puente</surname> <given-names>XS</given-names></name><name><surname>Raine</surname> <given-names>K</given-names></name><name><surname>Ramakrishna</surname> <given-names>M</given-names></name><name><surname>Richardson</surname> <given-names>AL</given-names></name><name><surname>Richter</surname> <given-names>J</given-names></name><name><surname>Rosenstiel</surname> <given-names>P</given-names></name><name><surname>Schlesner</surname> <given-names>M</given-names></name><name><surname>Schumacher</surname> <given-names>TN</given-names></name><name><surname>Span</surname> <given-names>PN</given-names></name><name><surname>Teague</surname> <given-names>JW</given-names></name><name><surname>Totoki</surname> <given-names>Y</given-names></name><name><surname>Tutt</surname> <given-names>AN</given-names></name><name><surname>Valdés-Mas</surname> <given-names>R</given-names></name><name><surname>van Buuren</surname> <given-names>MM</given-names></name><name><surname>van 't Veer</surname> <given-names>L</given-names></name><name><surname>Vincent-Salomon</surname> <given-names>A</given-names></name><name><surname>Waddell</surname> <given-names>N</given-names></name><name><surname>Yates</surname> <given-names>LR</given-names></name><name><surname>Zucman-Rossi</surname> <given-names>J</given-names></name><name><surname>Futreal</surname> <given-names>PA</given-names></name><name><surname>McDermott</surname> <given-names>U</given-names></name><name><surname>Lichter</surname> <given-names>P</given-names></name><name><surname>Meyerson</surname> <given-names>M</given-names></name><name><surname>Grimmond</surname> <given-names>SM</given-names></name><name><surname>Siebert</surname> <given-names>R</given-names></name><name><surname>Campo</surname> <given-names>E</given-names></name><name><surname>Shibata</surname> <given-names>T</given-names></name><name><surname>Pfister</surname> <given-names>SM</given-names></name><name><surname>Campbell</surname> <given-names>PJ</given-names></name><name><surname>Stratton</surname> <given-names>MR</given-names></name><collab>Australian Pancreatic Cancer Genome Initiative</collab><collab>ICGC Breast Cancer Consortium</collab><collab>ICGC MMML-Seq Consortium</collab><collab>ICGC PedBrain</collab></person-group><year iso-8601-date="2013">2013</year><article-title>Signatures of mutational processes in human Cancer</article-title><source>Nature</source><volume>500</volume><fpage>415</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1038/nature12477</pub-id><pub-id pub-id-type="pmid">23945592</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexandrov</surname> <given-names>LB</given-names></name><name><surname>Jones</surname> <given-names>PH</given-names></name><name><surname>Wedge</surname> <given-names>DC</given-names></name><name><surname>Sale</surname> <given-names>JE</given-names></name><name><surname>Campbell</surname> <given-names>PJ</given-names></name><name><surname>Nik-Zainal</surname> <given-names>S</given-names></name><name><surname>Stratton</surname> <given-names>MR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Clock-like mutational processes in human somatic cells</article-title><source>Nature Genetics</source><volume>47</volume><fpage>1402</fpage><lpage>1407</lpage><pub-id pub-id-type="doi">10.1038/ng.3441</pub-id><pub-id pub-id-type="pmid">26551669</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexandrov</surname> <given-names>LB</given-names></name><name><surname>Kim</surname> <given-names>J</given-names></name><name><surname>Haradhvala</surname> <given-names>NJ</given-names></name><name><surname>Huang</surname> <given-names>MN</given-names></name><name><surname>Tian Ng</surname> <given-names>AW</given-names></name><name><surname>Wu</surname> <given-names>Y</given-names></name><name><surname>Boot</surname> <given-names>A</given-names></name><name><surname>Covington</surname> <given-names>KR</given-names></name><name><surname>Gordenin</surname> <given-names>DA</given-names></name><name><surname>Bergstrom</surname> <given-names>EN</given-names></name><name><surname>Islam</surname> <given-names>SMA</given-names></name><name><surname>Lopez-Bigas</surname> <given-names>N</given-names></name><name><surname>Klimczak</surname> <given-names>LJ</given-names></name><name><surname>McPherson</surname> <given-names>JR</given-names></name><name><surname>Morganella</surname> <given-names>S</given-names></name><name><surname>Sabarinathan</surname> <given-names>R</given-names></name><name><surname>Wheeler</surname> <given-names>DA</given-names></name><name><surname>Mustonen</surname> <given-names>V</given-names></name><name><surname>Getz</surname> <given-names>G</given-names></name><name><surname>Rozen</surname> <given-names>SG</given-names></name><name><surname>Stratton</surname> <given-names>MR</given-names></name><collab>PCAWG Mutational Signatures Working Group</collab><collab>PCAWG Consortium</collab></person-group><year iso-8601-date="2020">2020</year><article-title>The repertoire of mutational signatures in human Cancer</article-title><source>Nature</source><volume>578</volume><fpage>94</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-1943-3</pub-id><pub-id pub-id-type="pmid">32025018</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alves</surname> <given-names>IT</given-names></name><name><surname>Cano</surname> <given-names>D</given-names></name><name><surname>Böttcher</surname> <given-names>R</given-names></name><name><surname>van der Korput</surname> <given-names>H</given-names></name><name><surname>Dinjens</surname> <given-names>W</given-names></name><name><surname>Jenster</surname> <given-names>G</given-names></name><name><surname>Trapman</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A mononucleotide repeat in PRRT2 is an important, frequent target of mismatch repair deficiency in Cancer</article-title><source>Oncotarget</source><volume>8</volume><fpage>6043</fpage><lpage>6056</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.13464</pub-id><pub-id pub-id-type="pmid">27907910</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anandakrishnan</surname> <given-names>R</given-names></name><name><surname>Varghese</surname> <given-names>RT</given-names></name><name><surname>Kinney</surname> <given-names>NA</given-names></name><name><surname>Garner</surname> <given-names>HR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Estimating the number of genetic mutations (hits) required for carcinogenesis based on the distribution of somatic mutations</article-title><source>PLOS Computational Biology</source><volume>15</volume><elocation-id>e1006881</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1006881</pub-id><pub-id pub-id-type="pmid">30845172</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname> <given-names>AP</given-names></name><name><surname>Samsøe-Petersen</surname> <given-names>J</given-names></name><name><surname>Oernbo</surname> <given-names>EK</given-names></name><name><surname>Boedtkjer</surname> <given-names>E</given-names></name><name><surname>Moreira</surname> <given-names>JMA</given-names></name><name><surname>Kveiborg</surname> <given-names>M</given-names></name><name><surname>Pedersen</surname> <given-names>SF</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The net acid extruders NHE1, NBCn1 and MCT4 promote mammary tumor growth through distinct but overlapping mechanisms</article-title><source>International Journal of Cancer</source><volume>142</volume><fpage>2529</fpage><lpage>2542</lpage><pub-id pub-id-type="doi">10.1002/ijc.31276</pub-id><pub-id pub-id-type="pmid">29363134</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aoki</surname> <given-names>Y</given-names></name><name><surname>Niihori</surname> <given-names>T</given-names></name><name><surname>Banjo</surname> <given-names>T</given-names></name><name><surname>Okamoto</surname> <given-names>N</given-names></name><name><surname>Mizuno</surname> <given-names>S</given-names></name><name><surname>Kurosawa</surname> <given-names>K</given-names></name><name><surname>Ogata</surname> <given-names>T</given-names></name><name><surname>Takada</surname> <given-names>F</given-names></name><name><surname>Yano</surname> <given-names>M</given-names></name><name><surname>Ando</surname> <given-names>T</given-names></name><name><surname>Hoshika</surname> <given-names>T</given-names></name><name><surname>Barnett</surname> <given-names>C</given-names></name><name><surname>Ohashi</surname> <given-names>H</given-names></name><name><surname>Kawame</surname> <given-names>H</given-names></name><name><surname>Hasegawa</surname> <given-names>T</given-names></name><name><surname>Okutani</surname> <given-names>T</given-names></name><name><surname>Nagashima</surname> <given-names>T</given-names></name><name><surname>Hasegawa</surname> <given-names>S</given-names></name><name><surname>Funayama</surname> <given-names>R</given-names></name><name><surname>Nagashima</surname> <given-names>T</given-names></name><name><surname>Nakayama</surname> <given-names>K</given-names></name><name><surname>Inoue</surname> <given-names>S</given-names></name><name><surname>Watanabe</surname> <given-names>Y</given-names></name><name><surname>Ogura</surname> <given-names>T</given-names></name><name><surname>Matsubara</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome</article-title><source>The American Journal of Human Genetics</source><volume>93</volume><fpage>173</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2013.05.021</pub-id><pub-id pub-id-type="pmid">23791108</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avitabile</surname> <given-names>M</given-names></name><name><surname>Succoio</surname> <given-names>M</given-names></name><name><surname>Testori</surname> <given-names>A</given-names></name><name><surname>Cardinale</surname> <given-names>A</given-names></name><name><surname>Vaksman</surname> <given-names>Z</given-names></name><name><surname>Lasorsa</surname> <given-names>VA</given-names></name><name><surname>Cantalupo</surname> <given-names>S</given-names></name><name><surname>Esposito</surname> <given-names>M</given-names></name><name><surname>Cimmino</surname> <given-names>F</given-names></name><name><surname>Montella</surname> <given-names>A</given-names></name><name><surname>Formicola</surname> <given-names>D</given-names></name><name><surname>Koster</surname> <given-names>J</given-names></name><name><surname>Andreotti</surname> <given-names>V</given-names></name><name><surname>Ghiorzo</surname> <given-names>P</given-names></name><name><surname>Romano</surname> <given-names>MF</given-names></name><name><surname>Staibano</surname> <given-names>S</given-names></name><name><surname>Scalvenzi</surname> <given-names>M</given-names></name><name><surname>Ayala</surname> <given-names>F</given-names></name><name><surname>Hakonarson</surname> <given-names>H</given-names></name><name><surname>Corrias</surname> <given-names>MV</given-names></name><name><surname>Devoto</surname> <given-names>M</given-names></name><name><surname>Law</surname> <given-names>MH</given-names></name><name><surname>Iles</surname> <given-names>MM</given-names></name><name><surname>Brown</surname> <given-names>K</given-names></name><name><surname>Diskin</surname> <given-names>S</given-names></name><name><surname>Zambrano</surname> <given-names>N</given-names></name><name><surname>Iolascon</surname> <given-names>A</given-names></name><name><surname>Capasso</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Neural crest-derived tumor neuroblastoma and melanoma share 1p13.2 as susceptibility locus that shows a long-range interaction with the SLC16A1 gene</article-title><source>Carcinogenesis</source><volume>41</volume><fpage>284</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgz153</pub-id><pub-id pub-id-type="pmid">31605138</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baek</surname> <given-names>G</given-names></name><name><surname>Tse</surname> <given-names>YF</given-names></name><name><surname>Hu</surname> <given-names>Z</given-names></name><name><surname>Cox</surname> <given-names>D</given-names></name><name><surname>Buboltz</surname> <given-names>N</given-names></name><name><surname>McCue</surname> <given-names>P</given-names></name><name><surname>Yeo</surname> <given-names>CJ</given-names></name><name><surname>White</surname> <given-names>MA</given-names></name><name><surname>DeBerardinis</surname> <given-names>RJ</given-names></name><name><surname>Knudsen</surname> <given-names>ES</given-names></name><name><surname>Witkiewicz</surname> <given-names>AK</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>MCT4 defines a glycolytic subtype of pancreatic Cancer with poor prognosis and unique metabolic dependencies</article-title><source>Cell Reports</source><volume>9</volume><fpage>2233</fpage><lpage>2249</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2014.11.025</pub-id><pub-id pub-id-type="pmid">25497091</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baenke</surname> <given-names>F</given-names></name><name><surname>Dubuis</surname> <given-names>S</given-names></name><name><surname>Brault</surname> <given-names>C</given-names></name><name><surname>Weigelt</surname> <given-names>B</given-names></name><name><surname>Dankworth</surname> <given-names>B</given-names></name><name><surname>Griffiths</surname> <given-names>B</given-names></name><name><surname>Jiang</surname> <given-names>M</given-names></name><name><surname>Mackay</surname> <given-names>A</given-names></name><name><surname>Saunders</surname> <given-names>B</given-names></name><name><surname>Spencer-Dene</surname> <given-names>B</given-names></name><name><surname>Ros</surname> <given-names>S</given-names></name><name><surname>Stamp</surname> <given-names>G</given-names></name><name><surname>Reis-Filho</surname> <given-names>JS</given-names></name><name><surname>Howell</surname> <given-names>M</given-names></name><name><surname>Zamboni</surname> <given-names>N</given-names></name><name><surname>Schulze</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Functional screening identifies MCT4 as a key regulator of breast Cancer cell metabolism and survival</article-title><source>The Journal of Pathology</source><volume>237</volume><fpage>152</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1002/path.4562</pub-id><pub-id pub-id-type="pmid">25965974</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname> <given-names>MH</given-names></name><name><surname>Tokheim</surname> <given-names>C</given-names></name><name><surname>Porta-Pardo</surname> <given-names>E</given-names></name><name><surname>Sengupta</surname> <given-names>S</given-names></name><name><surname>Bertrand</surname> <given-names>D</given-names></name><name><surname>Weerasinghe</surname> <given-names>A</given-names></name><name><surname>Colaprico</surname> <given-names>A</given-names></name><name><surname>Wendl</surname> <given-names>MC</given-names></name><name><surname>Kim</surname> <given-names>J</given-names></name><name><surname>Reardon</surname> <given-names>B</given-names></name><name><surname>Kwok-Shing Ng</surname> <given-names>P</given-names></name><name><surname>Jeong</surname> <given-names>KJ</given-names></name><name><surname>Cao</surname> <given-names>S</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Gao</surname> <given-names>J</given-names></name><name><surname>Gao</surname> <given-names>Q</given-names></name><name><surname>Wang</surname> <given-names>F</given-names></name><name><surname>Liu</surname> <given-names>EM</given-names></name><name><surname>Mularoni</surname> <given-names>L</given-names></name><name><surname>Rubio-Perez</surname> <given-names>C</given-names></name><name><surname>Nagarajan</surname> <given-names>N</given-names></name><name><surname>Cortés-Ciriano</surname> <given-names>I</given-names></name><name><surname>Zhou</surname> <given-names>DC</given-names></name><name><surname>Liang</surname> <given-names>WW</given-names></name><name><surname>Hess</surname> <given-names>JM</given-names></name><name><surname>Yellapantula</surname> <given-names>VD</given-names></name><name><surname>Tamborero</surname> <given-names>D</given-names></name><name><surname>Gonzalez-Perez</surname> <given-names>A</given-names></name><name><surname>Suphavilai</surname> <given-names>C</given-names></name><name><surname>Ko</surname> <given-names>JY</given-names></name><name><surname>Khurana</surname> <given-names>E</given-names></name><name><surname>Park</surname> <given-names>PJ</given-names></name><name><surname>Van Allen</surname> <given-names>EM</given-names></name><name><surname>Liang</surname> <given-names>H</given-names></name><name><surname>Lawrence</surname> <given-names>MS</given-names></name><name><surname>Godzik</surname> <given-names>A</given-names></name><name><surname>Lopez-Bigas</surname> <given-names>N</given-names></name><name><surname>Stuart</surname> <given-names>J</given-names></name><name><surname>Wheeler</surname> <given-names>D</given-names></name><name><surname>Getz</surname> <given-names>G</given-names></name><name><surname>Chen</surname> <given-names>K</given-names></name><name><surname>Lazar</surname> <given-names>AJ</given-names></name><name><surname>Mills</surname> <given-names>GB</given-names></name><name><surname>Karchin</surname> <given-names>R</given-names></name><name><surname>Ding</surname> <given-names>L</given-names></name><collab>MC3 Working Group</collab><collab>Cancer Genome Atlas Research Network</collab></person-group><year iso-8601-date="2018">2018</year><article-title>Comprehensive characterization of Cancer driver genes and mutations</article-title><source>Cell</source><volume>174</volume><fpage>1034</fpage><lpage>1035</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.07.034</pub-id><pub-id pub-id-type="pmid">30096302</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakhoum</surname> <given-names>SF</given-names></name><name><surname>Landau</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cancer evolution: no room for negative selection</article-title><source>Cell</source><volume>171</volume><fpage>987</fpage><lpage>989</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.10.039</pub-id><pub-id pub-id-type="pmid">29149612</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barajas</surname> <given-names>JM</given-names></name><name><surname>Reyes</surname> <given-names>R</given-names></name><name><surname>Guerrero</surname> <given-names>MJ</given-names></name><name><surname>Jacob</surname> <given-names>ST</given-names></name><name><surname>Motiwala</surname> <given-names>T</given-names></name><name><surname>Ghoshal</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The role of miR-122 in the dysregulation of glucose-6-phosphate dehydrogenase (G6PD) expression in hepatocellular Cancer</article-title><source>Scientific Reports</source><volume>8</volume><elocation-id>9105</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-27358-5</pub-id><pub-id pub-id-type="pmid">29904144</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bashashati</surname> <given-names>A</given-names></name><name><surname>Ha</surname> <given-names>G</given-names></name><name><surname>Tone</surname> <given-names>A</given-names></name><name><surname>Ding</surname> <given-names>J</given-names></name><name><surname>Prentice</surname> <given-names>LM</given-names></name><name><surname>Roth</surname> <given-names>A</given-names></name><name><surname>Rosner</surname> <given-names>J</given-names></name><name><surname>Shumansky</surname> <given-names>K</given-names></name><name><surname>Kalloger</surname> <given-names>S</given-names></name><name><surname>Senz</surname> <given-names>J</given-names></name><name><surname>Yang</surname> <given-names>W</given-names></name><name><surname>McConechy</surname> <given-names>M</given-names></name><name><surname>Melnyk</surname> <given-names>N</given-names></name><name><surname>Anglesio</surname> <given-names>M</given-names></name><name><surname>Luk</surname> <given-names>MT</given-names></name><name><surname>Tse</surname> <given-names>K</given-names></name><name><surname>Zeng</surname> <given-names>T</given-names></name><name><surname>Moore</surname> <given-names>R</given-names></name><name><surname>Zhao</surname> <given-names>Y</given-names></name><name><surname>Marra</surname> <given-names>MA</given-names></name><name><surname>Gilks</surname> <given-names>B</given-names></name><name><surname>Yip</surname> <given-names>S</given-names></name><name><surname>Huntsman</surname> <given-names>DG</given-names></name><name><surname>McAlpine</surname> <given-names>JN</given-names></name><name><surname>Shah</surname> <given-names>SP</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling</article-title><source>The Journal of Pathology</source><volume>231</volume><fpage>21</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1002/path.4230</pub-id><pub-id pub-id-type="pmid">23780408</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benachenhou</surname> <given-names>N</given-names></name><name><surname>Labuda</surname> <given-names>D</given-names></name><name><surname>Sinnett</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Allelic instability of TBP gene in replication error positive tumors</article-title><source>International Journal of Cancer</source><volume>78</volume><fpage>525</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0215(19981109)78:4&lt;525::AID-IJC21&gt;3.0.CO;2-3</pub-id><pub-id pub-id-type="pmid">9797144</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname> <given-names>AH</given-names></name><name><surname>Imielinski</surname> <given-names>M</given-names></name><name><surname>Duke</surname> <given-names>F</given-names></name><name><surname>Wala</surname> <given-names>J</given-names></name><name><surname>Kaplan</surname> <given-names>N</given-names></name><name><surname>Shi</surname> <given-names>GX</given-names></name><name><surname>Andres</surname> <given-names>DA</given-names></name><name><surname>Meyerson</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Oncogenic RIT1 mutations in lung adenocarcinoma</article-title><source>Oncogene</source><volume>33</volume><fpage>4418</fpage><lpage>4423</lpage><pub-id pub-id-type="doi">10.1038/onc.2013.581</pub-id><pub-id pub-id-type="pmid">24469055</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernassola</surname> <given-names>F</given-names></name><name><surname>Chillemi</surname> <given-names>G</given-names></name><name><surname>Melino</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>HECT-Type E3 Ubiquitin Ligases in Cancer</article-title><source>Trends in Biochemical Sciences</source><volume>44</volume><fpage>1057</fpage><lpage>1075</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2019.08.004</pub-id><pub-id pub-id-type="pmid">31610939</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beroukhim</surname> <given-names>R</given-names></name><name><surname>Mermel</surname> <given-names>CH</given-names></name><name><surname>Porter</surname> <given-names>D</given-names></name><name><surname>Wei</surname> <given-names>G</given-names></name><name><surname>Raychaudhuri</surname> <given-names>S</given-names></name><name><surname>Donovan</surname> <given-names>J</given-names></name><name><surname>Barretina</surname> <given-names>J</given-names></name><name><surname>Boehm</surname> <given-names>JS</given-names></name><name><surname>Dobson</surname> <given-names>J</given-names></name><name><surname>Urashima</surname> <given-names>M</given-names></name><name><surname>Mc Henry</surname> <given-names>KT</given-names></name><name><surname>Pinchback</surname> <given-names>RM</given-names></name><name><surname>Ligon</surname> <given-names>AH</given-names></name><name><surname>Cho</surname> <given-names>YJ</given-names></name><name><surname>Haery</surname> <given-names>L</given-names></name><name><surname>Greulich</surname> <given-names>H</given-names></name><name><surname>Reich</surname> <given-names>M</given-names></name><name><surname>Winckler</surname> <given-names>W</given-names></name><name><surname>Lawrence</surname> <given-names>MS</given-names></name><name><surname>Weir</surname> <given-names>BA</given-names></name><name><surname>Tanaka</surname> <given-names>KE</given-names></name><name><surname>Chiang</surname> <given-names>DY</given-names></name><name><surname>Bass</surname> <given-names>AJ</given-names></name><name><surname>Loo</surname> <given-names>A</given-names></name><name><surname>Hoffman</surname> <given-names>C</given-names></name><name><surname>Prensner</surname> <given-names>J</given-names></name><name><surname>Liefeld</surname> <given-names>T</given-names></name><name><surname>Gao</surname> <given-names>Q</given-names></name><name><surname>Yecies</surname> <given-names>D</given-names></name><name><surname>Signoretti</surname> <given-names>S</given-names></name><name><surname>Maher</surname> <given-names>E</given-names></name><name><surname>Kaye</surname> <given-names>FJ</given-names></name><name><surname>Sasaki</surname> <given-names>H</given-names></name><name><surname>Tepper</surname> <given-names>JE</given-names></name><name><surname>Fletcher</surname> <given-names>JA</given-names></name><name><surname>Tabernero</surname> <given-names>J</given-names></name><name><surname>Baselga</surname> <given-names>J</given-names></name><name><surname>Tsao</surname> <given-names>MS</given-names></name><name><surname>Demichelis</surname> <given-names>F</given-names></name><name><surname>Rubin</surname> <given-names>MA</given-names></name><name><surname>Janne</surname> <given-names>PA</given-names></name><name><surname>Daly</surname> <given-names>MJ</given-names></name><name><surname>Nucera</surname> <given-names>C</given-names></name><name><surname>Levine</surname> <given-names>RL</given-names></name><name><surname>Ebert</surname> <given-names>BL</given-names></name><name><surname>Gabriel</surname> <given-names>S</given-names></name><name><surname>Rustgi</surname> <given-names>AK</given-names></name><name><surname>Antonescu</surname> <given-names>CR</given-names></name><name><surname>Ladanyi</surname> <given-names>M</given-names></name><name><surname>Letai</surname> <given-names>A</given-names></name><name><surname>Garraway</surname> <given-names>LA</given-names></name><name><surname>Loda</surname> <given-names>M</given-names></name><name><surname>Beer</surname> <given-names>DG</given-names></name><name><surname>True</surname> <given-names>LD</given-names></name><name><surname>Okamoto</surname> <given-names>A</given-names></name><name><surname>Pomeroy</surname> <given-names>SL</given-names></name><name><surname>Singer</surname> <given-names>S</given-names></name><name><surname>Golub</surname> <given-names>TR</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Getz</surname> <given-names>G</given-names></name><name><surname>Sellers</surname> <given-names>WR</given-names></name><name><surname>Meyerson</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The landscape of somatic copy-number alteration across human cancers</article-title><source>Nature</source><volume>463</volume><fpage>899</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1038/nature08822</pub-id><pub-id pub-id-type="pmid">20164920</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bi</surname> <given-names>G</given-names></name><name><surname>Yan</surname> <given-names>J</given-names></name><name><surname>Sun</surname> <given-names>S</given-names></name><name><surname>Qu</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>PRRT2 inhibits the proliferation of glioma cells by modulating unfolded protein response pathway</article-title><source>Biochemical and Biophysical Research Communications</source><volume>485</volume><fpage>454</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2017.02.052</pub-id><pub-id pub-id-type="pmid">28192116</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bisso</surname> <given-names>A</given-names></name><name><surname>Collavin</surname> <given-names>L</given-names></name><name><surname>Del Sal</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>p73 as a pharmaceutical target for Cancer therapy</article-title><source>Current Pharmaceutical Design</source><volume>17</volume><fpage>578</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.2174/138161211795222667</pub-id><pub-id pub-id-type="pmid">21391908</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bose</surname> <given-names>P</given-names></name><name><surname>Thakur</surname> <given-names>SS</given-names></name><name><surname>Brockton</surname> <given-names>NT</given-names></name><name><surname>Klimowicz</surname> <given-names>AC</given-names></name><name><surname>Kornaga</surname> <given-names>E</given-names></name><name><surname>Nakoneshny</surname> <given-names>SC</given-names></name><name><surname>Riabowol</surname> <given-names>KT</given-names></name><name><surname>Dort</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Tumor cell apoptosis mediated by cytoplasmic <italic>ING1</italic> is associated with improved survival in oral squamous cell carcinoma patients</article-title><source>Oncotarget</source><volume>5</volume><fpage>3210</fpage><lpage>3219</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.1907</pub-id><pub-id pub-id-type="pmid">24912621</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buisson</surname> <given-names>R</given-names></name><name><surname>Langenbucher</surname> <given-names>A</given-names></name><name><surname>Bowen</surname> <given-names>D</given-names></name><name><surname>Kwan</surname> <given-names>EE</given-names></name><name><surname>Benes</surname> <given-names>CH</given-names></name><name><surname>Zou</surname> <given-names>L</given-names></name><name><surname>Lawrence</surname> <given-names>MS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Passenger hotspot mutations in Cancer driven by APOBEC3A and mesoscale genomic features</article-title><source>Science</source><volume>364</volume><elocation-id>eaaw2872</elocation-id><pub-id pub-id-type="doi">10.1126/science.aaw2872</pub-id><pub-id pub-id-type="pmid">31249028</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calabrese</surname> <given-names>C</given-names></name><name><surname>Davidson</surname> <given-names>NR</given-names></name><name><surname>Demircioğlu</surname> <given-names>D</given-names></name><name><surname>Fonseca</surname> <given-names>NA</given-names></name><name><surname>He</surname> <given-names>Y</given-names></name><name><surname>Kahles</surname> <given-names>A</given-names></name><name><surname>Lehmann</surname> <given-names>KV</given-names></name><name><surname>Liu</surname> <given-names>F</given-names></name><name><surname>Shiraishi</surname> <given-names>Y</given-names></name><name><surname>Soulette</surname> <given-names>CM</given-names></name><name><surname>Urban</surname> <given-names>L</given-names></name><name><surname>Greger</surname> <given-names>L</given-names></name><name><surname>Li</surname> <given-names>S</given-names></name><name><surname>Liu</surname> <given-names>D</given-names></name><name><surname>Perry</surname> <given-names>MD</given-names></name><name><surname>Xiang</surname> <given-names>Q</given-names></name><name><surname>Zhang</surname> <given-names>F</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Bailey</surname> <given-names>P</given-names></name><name><surname>Erkek</surname> <given-names>S</given-names></name><name><surname>Hoadley</surname> <given-names>KA</given-names></name><name><surname>Hou</surname> <given-names>Y</given-names></name><name><surname>Huska</surname> <given-names>MR</given-names></name><name><surname>Kilpinen</surname> <given-names>H</given-names></name><name><surname>Korbel</surname> <given-names>JO</given-names></name><name><surname>Marin</surname> <given-names>MG</given-names></name><name><surname>Markowski</surname> <given-names>J</given-names></name><name><surname>Nandi</surname> <given-names>T</given-names></name><name><surname>Pan-Hammarström</surname> <given-names>Q</given-names></name><name><surname>Pedamallu</surname> <given-names>CS</given-names></name><name><surname>Siebert</surname> <given-names>R</given-names></name><name><surname>Stark</surname> <given-names>SG</given-names></name><name><surname>Su</surname> <given-names>H</given-names></name><name><surname>Tan</surname> <given-names>P</given-names></name><name><surname>Waszak</surname> <given-names>SM</given-names></name><name><surname>Yung</surname> <given-names>C</given-names></name><name><surname>Zhu</surname> <given-names>S</given-names></name><name><surname>Awadalla</surname> <given-names>P</given-names></name><name><surname>Creighton</surname> <given-names>CJ</given-names></name><name><surname>Meyerson</surname> <given-names>M</given-names></name><name><surname>Ouellette</surname> <given-names>BFF</given-names></name><name><surname>Wu</surname> <given-names>K</given-names></name><name><surname>Yang</surname> <given-names>H</given-names></name><name><surname>Brazma</surname> <given-names>A</given-names></name><name><surname>Brooks</surname> <given-names>AN</given-names></name><name><surname>Göke</surname> <given-names>J</given-names></name><name><surname>Rätsch</surname> <given-names>G</given-names></name><name><surname>Schwarz</surname> <given-names>RF</given-names></name><name><surname>Stegle</surname> <given-names>O</given-names></name><name><surname>Zhang</surname> <given-names>Z</given-names></name><collab>PCAWG Transcriptome Core Group</collab><collab>PCAWG Transcriptome Working Group</collab><collab>PCAWG Consortium</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Genomic basis for RNA alterations in Cancer</article-title><source>Nature</source><volume>578</volume><fpage>129</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-1970-0</pub-id><pub-id pub-id-type="pmid">32025019</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname> <given-names>AJ</given-names></name><name><surname>Lyne</surname> <given-names>L</given-names></name><name><surname>Brown</surname> <given-names>PJ</given-names></name><name><surname>Launchbury</surname> <given-names>RJ</given-names></name><name><surname>Bignone</surname> <given-names>P</given-names></name><name><surname>Chi</surname> <given-names>J</given-names></name><name><surname>Roncador</surname> <given-names>G</given-names></name><name><surname>Lawrie</surname> <given-names>CH</given-names></name><name><surname>Gatter</surname> <given-names>KC</given-names></name><name><surname>Kusec</surname> <given-names>R</given-names></name><name><surname>Banham</surname> <given-names>AH</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Aberrant expression of the neuronal transcription factor <italic>FOXP2</italic> in neoplastic plasma cells</article-title><source>British Journal of Haematology</source><volume>149</volume><fpage>221</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2141.2009.08070.x</pub-id><pub-id pub-id-type="pmid">20096010</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname> <given-names>PJ</given-names></name><name><surname>Getz</surname> <given-names>G</given-names></name><name><surname>Korbel</surname> <given-names>JO</given-names></name><collab>ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Pan-cancer analysis of whole genomes</article-title><source>Nature</source><volume>578</volume><fpage>82</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-1969-6</pub-id><pub-id pub-id-type="pmid">32025007</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campos</surname> <given-names>EI</given-names></name><name><surname>Martinka</surname> <given-names>M</given-names></name><name><surname>Mitchell</surname> <given-names>DL</given-names></name><name><surname>Dai</surname> <given-names>DL</given-names></name><name><surname>Li</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Mutations of the <italic>ING1</italic> tumor suppressor gene detected in human melanoma abrogate nucleotide excision repair</article-title><source>International Journal of Oncology</source><volume>25</volume><fpage>73</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.3892/ijo.25.1.73</pub-id><pub-id pub-id-type="pmid">15201991</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname> <given-names>H</given-names></name><name><surname>Chen</surname> <given-names>S</given-names></name><name><surname>Isik</surname> <given-names>L</given-names></name><name><surname>Tyekucheva</surname> <given-names>S</given-names></name><name><surname>Velculescu</surname> <given-names>VE</given-names></name><name><surname>Kinzler</surname> <given-names>KW</given-names></name><name><surname>Vogelstein</surname> <given-names>B</given-names></name><name><surname>Karchin</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations</article-title><source>Cancer Research</source><volume>69</volume><fpage>6660</fpage><lpage>6667</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-1133</pub-id><pub-id pub-id-type="pmid">19654296</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mutation hotspots may not be drug targets</article-title><source>Science</source><volume>364</volume><fpage>1228</fpage><lpage>1229</lpage><pub-id pub-id-type="doi">10.1126/science.aax9108</pub-id><pub-id pub-id-type="pmid">31249043</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaplet</surname> <given-names>M</given-names></name><name><surname>Waltregny</surname> <given-names>D</given-names></name><name><surname>Detry</surname> <given-names>C</given-names></name><name><surname>Fisher</surname> <given-names>LW</given-names></name><name><surname>Castronovo</surname> <given-names>V</given-names></name><name><surname>Bellahcène</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Expression of dentin sialophosphoprotein in human prostate Cancer and its correlation with tumor aggressiveness</article-title><source>International Journal of Cancer</source><volume>118</volume><fpage>850</fpage><lpage>856</lpage><pub-id pub-id-type="doi">10.1002/ijc.21442</pub-id><pub-id pub-id-type="pmid">16108038</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chatterjee</surname> <given-names>A</given-names></name><name><surname>Rodger</surname> <given-names>EJ</given-names></name><name><surname>Eccles</surname> <given-names>MR</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Epigenetic drivers of tumourigenesis and Cancer metastasis</article-title><source>Seminars in Cancer Biology</source><volume>51</volume><fpage>149</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2017.08.004</pub-id><pub-id pub-id-type="pmid">28807546</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>L</given-names></name><name><surname>Matsubara</surname> <given-names>N</given-names></name><name><surname>Yoshino</surname> <given-names>T</given-names></name><name><surname>Nagasaka</surname> <given-names>T</given-names></name><name><surname>Hoshizima</surname> <given-names>N</given-names></name><name><surname>Shirakawa</surname> <given-names>Y</given-names></name><name><surname>Naomoto</surname> <given-names>Y</given-names></name><name><surname>Isozaki</surname> <given-names>H</given-names></name><name><surname>Riabowol</surname> <given-names>K</given-names></name><name><surname>Tanaka</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Genetic alterations of candidate tumor suppressor <italic>ING1</italic> in human esophageal squamous cell Cancer</article-title><source>Cancer Research</source><volume>61</volume><fpage>4345</fpage><lpage>4349</lpage><pub-id pub-id-type="pmid">11389058</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>CL</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Pan</surname> <given-names>QZ</given-names></name><name><surname>Tang</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>QJ</given-names></name><name><surname>Pan</surname> <given-names>K</given-names></name><name><surname>Huang</surname> <given-names>LX</given-names></name><name><surname>He</surname> <given-names>J</given-names></name><name><surname>Zhao</surname> <given-names>JJ</given-names></name><name><surname>Jiang</surname> <given-names>SS</given-names></name><name><surname>Zhang</surname> <given-names>XF</given-names></name><name><surname>Zhang</surname> <given-names>HX</given-names></name><name><surname>Zhou</surname> <given-names>ZQ</given-names></name><name><surname>Weng</surname> <given-names>deS</given-names></name><name><surname>Xia</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Bromodomain-containing protein 7 (BRD7) as a potential tumor suppressor in hepatocellular carcinoma</article-title><source>Oncotarget</source><volume>7</volume><fpage>16248</fpage><lpage>16261</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.7637</pub-id><pub-id pub-id-type="pmid">26919247</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>YL</given-names></name><name><surname>Huang</surname> <given-names>WC</given-names></name><name><surname>Yao</surname> <given-names>HL</given-names></name><name><surname>Chen</surname> <given-names>PM</given-names></name><name><surname>Lin</surname> <given-names>PY</given-names></name><name><surname>Feng</surname> <given-names>FY</given-names></name><name><surname>Chu</surname> <given-names>PY</given-names></name></person-group><year iso-8601-date="2017">2017a</year><article-title>Down-regulation of RASA1 is associated with poor prognosis in human hepatocellular carcinoma</article-title><source>Anticancer Research</source><volume>37</volume><fpage>781</fpage><lpage>786</lpage><pub-id pub-id-type="doi">10.21873/anticanres.11377</pub-id><pub-id pub-id-type="pmid">28179330</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>YC</given-names></name><name><surname>Gotea</surname> <given-names>V</given-names></name><name><surname>Margolin</surname> <given-names>G</given-names></name><name><surname>Elnitski</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2017">2017b</year><article-title>Significant associations between driver gene mutations and DNA methylation alterations across many Cancer types</article-title><source>PLOS Computational Biology</source><volume>13</volume><elocation-id>e1005840</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1005840</pub-id><pub-id pub-id-type="pmid">29125844</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Guo</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2017">2017c</year><article-title>Proteasome dysregulation in human Cancer: implications for clinical therapies</article-title><source>Cancer and Metastasis Reviews</source><volume>36</volume><fpage>703</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1007/s10555-017-9704-y</pub-id><pub-id pub-id-type="pmid">29039081</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>Q</given-names></name><name><surname>Meng</surname> <given-names>YQ</given-names></name><name><surname>Xu</surname> <given-names>XF</given-names></name><name><surname>Gu</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017d</year><article-title>Blockade of GLUT1 by WZB117 resensitizes breast Cancer cells to adriamycin</article-title><source>Anti-Cancer Drugs</source><volume>28</volume><fpage>880</fpage><lpage>887</lpage><pub-id pub-id-type="doi">10.1097/CAD.0000000000000529</pub-id><pub-id pub-id-type="pmid">28609310</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Wu</surname> <given-names>X</given-names></name><name><surname>Xing</surname> <given-names>Z</given-names></name><name><surname>Ma</surname> <given-names>C</given-names></name><name><surname>Xiong</surname> <given-names>W</given-names></name><name><surname>Zhu</surname> <given-names>X</given-names></name><name><surname>He</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2018">2018a</year><article-title>FOXG1 expression is elevated in glioma and inhibits glioma cell apoptosis</article-title><source>Journal of Cancer</source><volume>9</volume><fpage>778</fpage><lpage>783</lpage><pub-id pub-id-type="doi">10.7150/jca.22282</pub-id><pub-id pub-id-type="pmid">29581755</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>MT</given-names></name><name><surname>Sun</surname> <given-names>HF</given-names></name><name><surname>Li</surname> <given-names>LD</given-names></name><name><surname>Zhao</surname> <given-names>Y</given-names></name><name><surname>Yang</surname> <given-names>LP</given-names></name><name><surname>Gao</surname> <given-names>SP</given-names></name><name><surname>Jin</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2018">2018b</year><article-title>Downregulation of FOXP2 promotes breast Cancer migration and invasion through TGFβ/SMAD signaling pathway</article-title><source>Oncology Letters</source><volume>15</volume><fpage>8582</fpage><lpage>8588</lpage><pub-id pub-id-type="doi">10.3892/ol.2018.8402</pub-id><pub-id pub-id-type="pmid">29805593</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Xu</surname> <given-names>Z</given-names></name><name><surname>Zhu</surname> <given-names>Z</given-names></name><name><surname>Chen</surname> <given-names>A</given-names></name><name><surname>Fu</surname> <given-names>G</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Pan</surname> <given-names>H</given-names></name><name><surname>Jin</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2018">2018c</year><article-title>Modulation of G6PD affects bladder Cancer via ROS accumulation and the AKT pathway in vitro</article-title><source>International Journal of Oncology</source><volume>53</volume><fpage>1703</fpage><lpage>1712</lpage><pub-id pub-id-type="doi">10.3892/ijo.2018.4501</pub-id><pub-id pub-id-type="pmid">30066842</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Yu</surname> <given-names>C</given-names></name><name><surname>Gao</surname> <given-names>J</given-names></name><name><surname>Zhu</surname> <given-names>H</given-names></name><name><surname>Cui</surname> <given-names>B</given-names></name><name><surname>Zhang</surname> <given-names>T</given-names></name><name><surname>Zhou</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>Q</given-names></name><name><surname>He</surname> <given-names>H</given-names></name><name><surname>Xiao</surname> <given-names>R</given-names></name><name><surname>Huang</surname> <given-names>R</given-names></name><name><surname>Xie</surname> <given-names>H</given-names></name><name><surname>Gao</surname> <given-names>D</given-names></name><name><surname>Zhou</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018d</year><article-title>A novel USP9X substrate TTK contributes to tumorigenesis in non-small-cell lung Cancer</article-title><source>Theranostics</source><volume>8</volume><fpage>2348</fpage><lpage>2360</lpage><pub-id pub-id-type="doi">10.7150/thno.22901</pub-id><pub-id pub-id-type="pmid">29721084</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Liu</surname> <given-names>F</given-names></name><name><surname>Yuan</surname> <given-names>Q</given-names></name><name><surname>Zhang</surname> <given-names>K</given-names></name><name><surname>Zhou</surname> <given-names>W</given-names></name><name><surname>Guan</surname> <given-names>S</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Mi</surname> <given-names>S</given-names></name><name><surname>Cheng</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Monocarboxylate transporter 1 is an independent prognostic factor in esophageal squamous cell carcinoma</article-title><source>Oncology Reports</source><volume>41</volume><fpage>2529</fpage><lpage>2539</lpage><pub-id pub-id-type="doi">10.3892/or.2019.6992</pub-id><pub-id pub-id-type="pmid">30720131</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname> <given-names>J</given-names></name><name><surname>Demeulemeester</surname> <given-names>J</given-names></name><name><surname>Wedge</surname> <given-names>DC</given-names></name><name><surname>Vollan</surname> <given-names>HKM</given-names></name><name><surname>Pitt</surname> <given-names>JJ</given-names></name><name><surname>Russnes</surname> <given-names>HG</given-names></name><name><surname>Pandey</surname> <given-names>BP</given-names></name><name><surname>Nilsen</surname> <given-names>G</given-names></name><name><surname>Nord</surname> <given-names>S</given-names></name><name><surname>Bignell</surname> <given-names>GR</given-names></name><name><surname>White</surname> <given-names>KP</given-names></name><name><surname>Børresen-Dale</surname> <given-names>AL</given-names></name><name><surname>Campbell</surname> <given-names>PJ</given-names></name><name><surname>Kristensen</surname> <given-names>VN</given-names></name><name><surname>Stratton</surname> <given-names>MR</given-names></name><name><surname>Lingjærde</surname> <given-names>OC</given-names></name><name><surname>Moreau</surname> <given-names>Y</given-names></name><name><surname>Van Loo</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>1221</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-017-01355-0</pub-id><pub-id pub-id-type="pmid">29089486</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname> <given-names>SY</given-names></name><name><surname>Xue</surname> <given-names>H</given-names></name><name><surname>Wu</surname> <given-names>R</given-names></name><name><surname>Fazli</surname> <given-names>L</given-names></name><name><surname>Lin</surname> <given-names>D</given-names></name><name><surname>Collins</surname> <given-names>CC</given-names></name><name><surname>Gleave</surname> <given-names>ME</given-names></name><name><surname>Gout</surname> <given-names>PW</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The <italic>MCT4</italic> gene: a novel, potential target for therapy of advanced prostate Cancer</article-title><source>Clinical Cancer Research</source><volume>22</volume><fpage>2721</fpage><lpage>2733</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-1624</pub-id><pub-id pub-id-type="pmid">26755530</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname> <given-names>SYC</given-names></name><name><surname>Ettinger</surname> <given-names>SL</given-names></name><name><surname>Lin</surname> <given-names>D</given-names></name><name><surname>Xue</surname> <given-names>H</given-names></name><name><surname>Ci</surname> <given-names>X</given-names></name><name><surname>Nabavi</surname> <given-names>N</given-names></name><name><surname>Bell</surname> <given-names>RH</given-names></name><name><surname>Mo</surname> <given-names>F</given-names></name><name><surname>Gout</surname> <given-names>PW</given-names></name><name><surname>Fleshner</surname> <given-names>NE</given-names></name><name><surname>Gleave</surname> <given-names>ME</given-names></name><name><surname>Collins</surname> <given-names>CC</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Targeting MCT4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine prostate Cancer</article-title><source>Cancer Medicine</source><volume>7</volume><fpage>3385</fpage><lpage>3392</lpage><pub-id pub-id-type="doi">10.1002/cam4.1587</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuiffo</surname> <given-names>BG</given-names></name><name><surname>Campagne</surname> <given-names>A</given-names></name><name><surname>Bell</surname> <given-names>GW</given-names></name><name><surname>Lembo</surname> <given-names>A</given-names></name><name><surname>Orso</surname> <given-names>F</given-names></name><name><surname>Lien</surname> <given-names>EC</given-names></name><name><surname>Bhasin</surname> <given-names>MK</given-names></name><name><surname>Raimo</surname> <given-names>M</given-names></name><name><surname>Hanson</surname> <given-names>SE</given-names></name><name><surname>Marusyk</surname> <given-names>A</given-names></name><name><surname>El-Ashry</surname> <given-names>D</given-names></name><name><surname>Hematti</surname> <given-names>P</given-names></name><name><surname>Polyak</surname> <given-names>K</given-names></name><name><surname>Mechta-Grigoriou</surname> <given-names>F</given-names></name><name><surname>Mariani</surname> <given-names>O</given-names></name><name><surname>Volinia</surname> <given-names>S</given-names></name><name><surname>Vincent-Salomon</surname> <given-names>A</given-names></name><name><surname>Taverna</surname> <given-names>D</given-names></name><name><surname>Karnoub</surname> <given-names>AE</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>MSC-regulated microRNAs converge on the transcription factor FOXP2 and promote breast Cancer metastasis</article-title><source>Cell Stem Cell</source><volume>15</volume><fpage>762</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2014.10.001</pub-id><pub-id pub-id-type="pmid">25515522</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dali</surname> <given-names>R</given-names></name><name><surname>Verginelli</surname> <given-names>F</given-names></name><name><surname>Pramatarova</surname> <given-names>A</given-names></name><name><surname>Sladek</surname> <given-names>R</given-names></name><name><surname>Stifani</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Characterization of a FOXG1:tle1 transcriptional network in glioblastoma-initiating cells</article-title><source>Molecular Oncology</source><volume>12</volume><fpage>775</fpage><lpage>787</lpage><pub-id pub-id-type="doi">10.1002/1878-0261.12168</pub-id><pub-id pub-id-type="pmid">29316219</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Castro</surname> <given-names>TB</given-names></name><name><surname>Mota</surname> <given-names>AL</given-names></name><name><surname>Bordin-Junior</surname> <given-names>NA</given-names></name><name><surname>Neto</surname> <given-names>DS</given-names></name><name><surname>Zuccari</surname> <given-names>DAPC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Immunohistochemical expression of melatonin receptor MT1 and glucose transporter GLUT1 in human breast Cancer</article-title><source>Anti-Cancer Agents in Medicinal Chemistry</source><volume>18</volume><fpage>2110</fpage><lpage>2116</lpage><pub-id pub-id-type="doi">10.2174/1871520618666181025125532</pub-id><pub-id pub-id-type="pmid">30360728</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Kegel</surname> <given-names>B</given-names></name><name><surname>Ryan</surname> <given-names>CJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Paralog buffering contributes to the variable essentiality of genes in Cancer cell lines</article-title><source>PLOS Genetics</source><volume>15</volume><elocation-id>e1008466</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1008466</pub-id><pub-id pub-id-type="pmid">31652272</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Paoli</surname> <given-names>L</given-names></name><name><surname>Cerri</surname> <given-names>M</given-names></name><name><surname>Monti</surname> <given-names>S</given-names></name><name><surname>Rasi</surname> <given-names>S</given-names></name><name><surname>Spina</surname> <given-names>V</given-names></name><name><surname>Bruscaggin</surname> <given-names>A</given-names></name><name><surname>Greco</surname> <given-names>M</given-names></name><name><surname>Ciardullo</surname> <given-names>C</given-names></name><name><surname>Famà</surname> <given-names>R</given-names></name><name><surname>Cresta</surname> <given-names>S</given-names></name><name><surname>Maffei</surname> <given-names>R</given-names></name><name><surname>Ladetto</surname> <given-names>M</given-names></name><name><surname>Martini</surname> <given-names>M</given-names></name><name><surname>Laurenti</surname> <given-names>L</given-names></name><name><surname>Forconi</surname> <given-names>F</given-names></name><name><surname>Marasca</surname> <given-names>R</given-names></name><name><surname>Larocca</surname> <given-names>LM</given-names></name><name><surname>Bertoni</surname> <given-names>F</given-names></name><name><surname>Gaidano</surname> <given-names>G</given-names></name><name><surname>Rossi</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title><italic>MGA</italic>, a suppressor of <italic>MYC</italic>, is recurrently inactivated in high risk chronic lymphocytic leukemia</article-title><source>Leukemia &amp; Lymphoma</source><volume>54</volume><fpage>1087</fpage><lpage>1090</lpage><pub-id pub-id-type="doi">10.3109/10428194.2012.723706</pub-id><pub-id pub-id-type="pmid">23039309</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deb</surname> <given-names>TB</given-names></name><name><surname>Zuo</surname> <given-names>AH</given-names></name><name><surname>Barndt</surname> <given-names>RJ</given-names></name><name><surname>Sengupta</surname> <given-names>S</given-names></name><name><surname>Jankovic</surname> <given-names>R</given-names></name><name><surname>Johnson</surname> <given-names>MD</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Pnck overexpression in HER-2 gene-amplified breast Cancer causes trastuzumab resistance through a paradoxical PTEN-mediated process</article-title><source>Breast Cancer Research and Treatment</source><volume>150</volume><fpage>347</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1007/s10549-015-3337-z</pub-id><pub-id pub-id-type="pmid">25773930</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeBerardinis</surname> <given-names>RJ</given-names></name><name><surname>Lum</surname> <given-names>JJ</given-names></name><name><surname>Hatzivassiliou</surname> <given-names>G</given-names></name><name><surname>Thompson</surname> <given-names>CB</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The biology of Cancer: metabolic reprogramming fuels cell growth and proliferation</article-title><source>Cell Metabolism</source><volume>7</volume><fpage>11</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2007.10.002</pub-id><pub-id pub-id-type="pmid">18177721</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Del Reino</surname> <given-names>P</given-names></name><name><surname>Alsina-Beauchamp</surname> <given-names>D</given-names></name><name><surname>Escós</surname> <given-names>A</given-names></name><name><surname>Cerezo-Guisado</surname> <given-names>MI</given-names></name><name><surname>Risco</surname> <given-names>A</given-names></name><name><surname>Aparicio</surname> <given-names>N</given-names></name><name><surname>Zur</surname> <given-names>R</given-names></name><name><surname>Fernandez-Estévez</surname> <given-names>M</given-names></name><name><surname>Collantes</surname> <given-names>E</given-names></name><name><surname>Montans</surname> <given-names>J</given-names></name><name><surname>Cuenda</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Pro-oncogenic role of alternative p38 mitogen-activated protein kinases p38γ and p38δ, linking inflammation and Cancer in colitis-associated Colon cancer</article-title><source>Cancer Research</source><volume>74</volume><fpage>6150</fpage><lpage>6160</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-0870</pub-id><pub-id pub-id-type="pmid">25217523</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname> <given-names>Y</given-names></name><name><surname>Zou</surname> <given-names>J</given-names></name><name><surname>Deng</surname> <given-names>T</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Clinicopathological and prognostic significance of GLUT1 in breast Cancer: a meta-analysis</article-title><source>Medicine</source><volume>97</volume><elocation-id>e12961</elocation-id><pub-id pub-id-type="doi">10.1097/MD.0000000000012961</pub-id><pub-id pub-id-type="pmid">30508885</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Domenico</surname> <given-names>A</given-names></name><name><surname>Wiedmer</surname> <given-names>T</given-names></name><name><surname>Marinoni</surname> <given-names>I</given-names></name><name><surname>Perren</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Genetic and epigenetic drivers of neuroendocrine tumours (NET)</article-title><source>Endocrine-Related Cancer</source><volume>24</volume><fpage>R315</fpage><lpage>R334</lpage><pub-id pub-id-type="doi">10.1530/ERC-17-0012</pub-id><pub-id pub-id-type="pmid">28710117</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diao</surname> <given-names>H</given-names></name><name><surname>Ye</surname> <given-names>Z</given-names></name><name><surname>Qin</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>miR-23a acts as an oncogene in pancreatic carcinoma by targeting FOXP2</article-title><source>Journal of Investigative Medicine</source><volume>66</volume><fpage>676</fpage><lpage>683</lpage><pub-id pub-id-type="doi">10.1136/jim-2017-000598</pub-id><pub-id pub-id-type="pmid">29141872</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diederichs</surname> <given-names>S</given-names></name><name><surname>Bartsch</surname> <given-names>L</given-names></name><name><surname>Berkmann</surname> <given-names>JC</given-names></name><name><surname>Fröse</surname> <given-names>K</given-names></name><name><surname>Heitmann</surname> <given-names>J</given-names></name><name><surname>Hoppe</surname> <given-names>C</given-names></name><name><surname>Iggena</surname> <given-names>D</given-names></name><name><surname>Jazmati</surname> <given-names>D</given-names></name><name><surname>Karschnia</surname> <given-names>P</given-names></name><name><surname>Linsenmeier</surname> <given-names>M</given-names></name><name><surname>Maulhardt</surname> <given-names>T</given-names></name><name><surname>Möhrmann</surname> <given-names>L</given-names></name><name><surname>Morstein</surname> <given-names>J</given-names></name><name><surname>Paffenholz</surname> <given-names>SV</given-names></name><name><surname>Röpenack</surname> <given-names>P</given-names></name><name><surname>Rückert</surname> <given-names>T</given-names></name><name><surname>Sandig</surname> <given-names>L</given-names></name><name><surname>Schell</surname> <given-names>M</given-names></name><name><surname>Steinmann</surname> <given-names>A</given-names></name><name><surname>Voss</surname> <given-names>G</given-names></name><name><surname>Wasmuth</surname> <given-names>J</given-names></name><name><surname>Weinberger</surname> <given-names>ME</given-names></name><name><surname>Wullenkord</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The dark matter of the Cancer genome: aberrations in regulatory elements, untranslated regions, splice sites, non-coding RNA and synonymous mutations</article-title><source>EMBO Molecular Medicine</source><volume>8</volume><fpage>442</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.15252/emmm.201506055</pub-id><pub-id pub-id-type="pmid">26992833</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doherty</surname> <given-names>JR</given-names></name><name><surname>Yang</surname> <given-names>C</given-names></name><name><surname>Scott</surname> <given-names>KE</given-names></name><name><surname>Cameron</surname> <given-names>MD</given-names></name><name><surname>Fallahi</surname> <given-names>M</given-names></name><name><surname>Li</surname> <given-names>W</given-names></name><name><surname>Hall</surname> <given-names>MA</given-names></name><name><surname>Amelio</surname> <given-names>AL</given-names></name><name><surname>Mishra</surname> <given-names>JK</given-names></name><name><surname>Li</surname> <given-names>F</given-names></name><name><surname>Tortosa</surname> <given-names>M</given-names></name><name><surname>Genau</surname> <given-names>HM</given-names></name><name><surname>Rounbehler</surname> <given-names>RJ</given-names></name><name><surname>Lu</surname> <given-names>Y</given-names></name><name><surname>Dang</surname> <given-names>CV</given-names></name><name><surname>Kumar</surname> <given-names>KG</given-names></name><name><surname>Butler</surname> <given-names>AA</given-names></name><name><surname>Bannister</surname> <given-names>TD</given-names></name><name><surname>Hooper</surname> <given-names>AT</given-names></name><name><surname>Unsal-Kacmaz</surname> <given-names>K</given-names></name><name><surname>Roush</surname> <given-names>WR</given-names></name><name><surname>Cleveland</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Blocking lactate export by inhibiting the myc target MCT1 disables glycolysis and glutathione synthesis</article-title><source>Cancer Research</source><volume>74</volume><fpage>908</fpage><lpage>920</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-2034</pub-id><pub-id pub-id-type="pmid">24285728</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Domínguez</surname> <given-names>G</given-names></name><name><surname>García</surname> <given-names>JM</given-names></name><name><surname>Peña</surname> <given-names>C</given-names></name><name><surname>Silva</surname> <given-names>J</given-names></name><name><surname>García</surname> <given-names>V</given-names></name><name><surname>Martínez</surname> <given-names>L</given-names></name><name><surname>Maximiano</surname> <given-names>C</given-names></name><name><surname>Gómez</surname> <given-names>ME</given-names></name><name><surname>Rivera</surname> <given-names>JA</given-names></name><name><surname>García-Andrade</surname> <given-names>C</given-names></name><name><surname>Bonilla</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1</article-title><source>Journal of Clinical Oncology</source><volume>24</volume><fpage>805</fpage><lpage>815</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.02.2350</pub-id><pub-id pub-id-type="pmid">16380414</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doyen</surname> <given-names>J</given-names></name><name><surname>Trastour</surname> <given-names>C</given-names></name><name><surname>Ettore</surname> <given-names>F</given-names></name><name><surname>Peyrottes</surname> <given-names>I</given-names></name><name><surname>Toussant</surname> <given-names>N</given-names></name><name><surname>Gal</surname> <given-names>J</given-names></name><name><surname>Ilc</surname> <given-names>K</given-names></name><name><surname>Roux</surname> <given-names>D</given-names></name><name><surname>Parks</surname> <given-names>SK</given-names></name><name><surname>Ferrero</surname> <given-names>JM</given-names></name><name><surname>Pouysségur</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast Cancer and correlates independently with clinical outcome</article-title><source>Biochemical and Biophysical Research Communications</source><volume>451</volume><fpage>54</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2014.07.050</pub-id><pub-id pub-id-type="pmid">25058459</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dvinge</surname> <given-names>H</given-names></name><name><surname>Kim</surname> <given-names>E</given-names></name><name><surname>Abdel-Wahab</surname> <given-names>O</given-names></name><name><surname>Bradley</surname> <given-names>RK</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>RNA splicing factors as oncoproteins and tumour suppressors</article-title><source>Nature Reviews Cancer</source><volume>16</volume><fpage>413</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1038/nrc.2016.51</pub-id><pub-id pub-id-type="pmid">27282250</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Editorial</collab></person-group><year iso-8601-date="2020">2020</year><article-title>The era of massive Cancer sequencing projects has reached a turning point</article-title><source>Nature</source><volume>578</volume><fpage>7</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/d41586-020-00308-w</pub-id><pub-id pub-id-type="pmid">32025026</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname> <given-names>PD</given-names></name><name><surname>Narzisi</surname> <given-names>G</given-names></name><name><surname>Jayaprakash</surname> <given-names>AD</given-names></name><name><surname>Venturini</surname> <given-names>E</given-names></name><name><surname>Robine</surname> <given-names>N</given-names></name><name><surname>Smibert</surname> <given-names>P</given-names></name><name><surname>Germer</surname> <given-names>S</given-names></name><name><surname>Yu</surname> <given-names>HA</given-names></name><name><surname>Jordan</surname> <given-names>EJ</given-names></name><name><surname>Paik</surname> <given-names>PK</given-names></name><name><surname>Janjigian</surname> <given-names>YY</given-names></name><name><surname>Chaft</surname> <given-names>JE</given-names></name><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Jungbluth</surname> <given-names>AA</given-names></name><name><surname>Middha</surname> <given-names>S</given-names></name><name><surname>Spraggon</surname> <given-names>L</given-names></name><name><surname>Qiao</surname> <given-names>H</given-names></name><name><surname>Lovly</surname> <given-names>CM</given-names></name><name><surname>Kris</surname> <given-names>MG</given-names></name><name><surname>Riely</surname> <given-names>GJ</given-names></name><name><surname>Politi</surname> <given-names>K</given-names></name><name><surname>Varmus</surname> <given-names>H</given-names></name><name><surname>Ladanyi</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title><italic>YES1</italic> amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics</article-title><source>PNAS</source><volume>115</volume><fpage>E6030</fpage><lpage>E6038</lpage><pub-id pub-id-type="doi">10.1073/pnas.1717782115</pub-id><pub-id pub-id-type="pmid">29875142</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>G</given-names></name><name><surname>Zhou</surname> <given-names>C</given-names></name><name><surname>Wang</surname> <given-names>P</given-names></name><name><surname>Zhao</surname> <given-names>S</given-names></name><name><surname>Zhao</surname> <given-names>S</given-names></name><name><surname>Huang</surname> <given-names>S</given-names></name><name><surname>Su</surname> <given-names>W</given-names></name><name><surname>Jiang</surname> <given-names>P</given-names></name><name><surname>Chang</surname> <given-names>A</given-names></name><name><surname>Xiang</surname> <given-names>R</given-names></name><name><surname>Sun</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Inactivation of p38 MAPK contributes to stem cell-like properties of non-small cell lung Cancer</article-title><source>Oncotarget</source><volume>8</volume><fpage>26702</fpage><lpage>26717</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.15804</pub-id><pub-id pub-id-type="pmid">28460458</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Firestein</surname> <given-names>R</given-names></name><name><surname>Bass</surname> <given-names>AJ</given-names></name><name><surname>Kim</surname> <given-names>SY</given-names></name><name><surname>Dunn</surname> <given-names>IF</given-names></name><name><surname>Silver</surname> <given-names>SJ</given-names></name><name><surname>Guney</surname> <given-names>I</given-names></name><name><surname>Freed</surname> <given-names>E</given-names></name><name><surname>Ligon</surname> <given-names>AH</given-names></name><name><surname>Vena</surname> <given-names>N</given-names></name><name><surname>Ogino</surname> <given-names>S</given-names></name><name><surname>Chheda</surname> <given-names>MG</given-names></name><name><surname>Tamayo</surname> <given-names>P</given-names></name><name><surname>Finn</surname> <given-names>S</given-names></name><name><surname>Shrestha</surname> <given-names>Y</given-names></name><name><surname>Boehm</surname> <given-names>JS</given-names></name><name><surname>Jain</surname> <given-names>S</given-names></name><name><surname>Bojarski</surname> <given-names>E</given-names></name><name><surname>Mermel</surname> <given-names>C</given-names></name><name><surname>Barretina</surname> <given-names>J</given-names></name><name><surname>Chan</surname> <given-names>JA</given-names></name><name><surname>Baselga</surname> <given-names>J</given-names></name><name><surname>Tabernero</surname> <given-names>J</given-names></name><name><surname>Root</surname> <given-names>DE</given-names></name><name><surname>Fuchs</surname> <given-names>CS</given-names></name><name><surname>Loda</surname> <given-names>M</given-names></name><name><surname>Shivdasani</surname> <given-names>RA</given-names></name><name><surname>Meyerson</surname> <given-names>M</given-names></name><name><surname>Hahn</surname> <given-names>WC</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>CDK8 is a colorectal Cancer oncogene that regulates beta-catenin activity</article-title><source>Nature</source><volume>455</volume><fpage>547</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1038/nature07179</pub-id><pub-id pub-id-type="pmid">18794900</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Futreal</surname> <given-names>PA</given-names></name><name><surname>Coin</surname> <given-names>L</given-names></name><name><surname>Marshall</surname> <given-names>M</given-names></name><name><surname>Down</surname> <given-names>T</given-names></name><name><surname>Hubbard</surname> <given-names>T</given-names></name><name><surname>Wooster</surname> <given-names>R</given-names></name><name><surname>Rahman</surname> <given-names>N</given-names></name><name><surname>Stratton</surname> <given-names>MR</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>A census of human Cancer genes</article-title><source>Nature Reviews Cancer</source><volume>4</volume><fpage>177</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1038/nrc1299</pub-id><pub-id pub-id-type="pmid">14993899</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganapathy</surname> <given-names>V</given-names></name><name><surname>Thangaraju</surname> <given-names>M</given-names></name><name><surname>Prasad</surname> <given-names>PD</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Nutrient transporters in Cancer: relevance to warburg hypothesis and beyond</article-title><source>Pharmacology &amp; Therapeutics</source><volume>121</volume><fpage>29</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2008.09.005</pub-id><pub-id pub-id-type="pmid">18992769</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname> <given-names>L</given-names></name><name><surname>Smit</surname> <given-names>MA</given-names></name><name><surname>van den Oord</surname> <given-names>JJ</given-names></name><name><surname>Goeman</surname> <given-names>JJ</given-names></name><name><surname>Verdegaal</surname> <given-names>EM</given-names></name><name><surname>van der Burg</surname> <given-names>SH</given-names></name><name><surname>Stas</surname> <given-names>M</given-names></name><name><surname>Beck</surname> <given-names>S</given-names></name><name><surname>Gruis</surname> <given-names>NA</given-names></name><name><surname>Tensen</surname> <given-names>CP</given-names></name><name><surname>Willemze</surname> <given-names>R</given-names></name><name><surname>Peeper</surname> <given-names>DS</given-names></name><name><surname>van Doorn</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Genome-wide promoter methylation analysis identifies epigenetic silencing of MAPK13 in primary cutaneous melanoma</article-title><source>Pigment Cell &amp; Melanoma Research</source><volume>26</volume><fpage>542</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1111/pcmr.12096</pub-id><pub-id pub-id-type="pmid">23590314</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>B</given-names></name><name><surname>Gao</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title><italic>BRD7</italic> acts as a tumor suppressor gene in lung adenocarcinoma</article-title><source>PLOS ONE</source><volume>11</volume><elocation-id>e0156701</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0156701</pub-id><pub-id pub-id-type="pmid">27580131</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gardner</surname> <given-names>HP</given-names></name><name><surname>Ha</surname> <given-names>SI</given-names></name><name><surname>Reynolds</surname> <given-names>C</given-names></name><name><surname>Chodosh</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The caM kinase, pnck, is spatially and temporally regulated during murine mammary gland development and may identify an epithelial cell subtype involved in breast Cancer</article-title><source>Cancer Research</source><volume>60</volume><fpage>5571</fpage><lpage>5577</lpage><pub-id pub-id-type="pmid">11034105</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garmendia</surname> <given-names>I</given-names></name><name><surname>Pajares</surname> <given-names>MJ</given-names></name><name><surname>Hermida-Prado</surname> <given-names>F</given-names></name><name><surname>Ajona</surname> <given-names>D</given-names></name><name><surname>Bértolo</surname> <given-names>C</given-names></name><name><surname>Sainz</surname> <given-names>C</given-names></name><name><surname>Lavín</surname> <given-names>A</given-names></name><name><surname>Remírez</surname> <given-names>AB</given-names></name><name><surname>Valencia</surname> <given-names>K</given-names></name><name><surname>Moreno</surname> <given-names>H</given-names></name><name><surname>Ferrer</surname> <given-names>I</given-names></name><name><surname>Behrens</surname> <given-names>C</given-names></name><name><surname>Cuadrado</surname> <given-names>M</given-names></name><name><surname>Paz-Ares</surname> <given-names>L</given-names></name><name><surname>Bustelo</surname> <given-names>XR</given-names></name><name><surname>Gil-Bazo</surname> <given-names>I</given-names></name><name><surname>Alameda</surname> <given-names>D</given-names></name><name><surname>Lecanda</surname> <given-names>F</given-names></name><name><surname>Calvo</surname> <given-names>A</given-names></name><name><surname>Felip</surname> <given-names>E</given-names></name><name><surname>Sánchez-Céspedes</surname> <given-names>M</given-names></name><name><surname>Wistuba</surname> <given-names>II</given-names></name><name><surname>Granda-Diaz</surname> <given-names>R</given-names></name><name><surname>Rodrigo</surname> <given-names>JP</given-names></name><name><surname>García-Pedrero</surname> <given-names>JM</given-names></name><name><surname>Pio</surname> <given-names>R</given-names></name><name><surname>Montuenga</surname> <given-names>LM</given-names></name><name><surname>Agorreta</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>YES1 drives lung Cancer growth and progression and predicts sensitivity to dasatinib</article-title><source>American Journal of Respiratory and Critical Care Medicine</source><volume>200</volume><fpage>888</fpage><lpage>899</lpage><pub-id pub-id-type="doi">10.1164/rccm.201807-1292OC</pub-id><pub-id pub-id-type="pmid">31166114</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ge</surname> <given-names>Z</given-names></name><name><surname>Leighton</surname> <given-names>JS</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Peng</surname> <given-names>X</given-names></name><name><surname>Chen</surname> <given-names>Z</given-names></name><name><surname>Chen</surname> <given-names>H</given-names></name><name><surname>Sun</surname> <given-names>Y</given-names></name><name><surname>Yao</surname> <given-names>F</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Shriver</surname> <given-names>CD</given-names></name><name><surname>Hu</surname> <given-names>H</given-names></name><name><surname>Piwnica-Worms</surname> <given-names>H</given-names></name><name><surname>Ma</surname> <given-names>L</given-names></name><name><surname>Liang</surname> <given-names>H</given-names></name><collab>Cancer Genome Atlas Research Network</collab></person-group><year iso-8601-date="2018">2018</year><article-title>Integrated genomic analysis of the ubiquitin pathway across Cancer types</article-title><source>Cell Reports</source><volume>23</volume><fpage>213</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.03.047</pub-id><pub-id pub-id-type="pmid">29617661</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerstung</surname> <given-names>M</given-names></name><name><surname>Eriksson</surname> <given-names>N</given-names></name><name><surname>Lin</surname> <given-names>J</given-names></name><name><surname>Vogelstein</surname> <given-names>B</given-names></name><name><surname>Beerenwinkel</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The temporal order of genetic and pathway alterations in tumorigenesis</article-title><source>PLOS ONE</source><volume>6</volume><elocation-id>e27136</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0027136</pub-id><pub-id pub-id-type="pmid">22069497</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerstung</surname> <given-names>M</given-names></name><name><surname>Jolly</surname> <given-names>C</given-names></name><name><surname>Leshchiner</surname> <given-names>I</given-names></name><name><surname>Dentro</surname> <given-names>SC</given-names></name><name><surname>Gonzalez</surname> <given-names>S</given-names></name><name><surname>Rosebrock</surname> <given-names>D</given-names></name><name><surname>Mitchell</surname> <given-names>TJ</given-names></name><name><surname>Rubanova</surname> <given-names>Y</given-names></name><name><surname>Anur</surname> <given-names>P</given-names></name><name><surname>Yu</surname> <given-names>K</given-names></name><name><surname>Tarabichi</surname> <given-names>M</given-names></name><name><surname>Deshwar</surname> <given-names>A</given-names></name><name><surname>Wintersinger</surname> <given-names>J</given-names></name><name><surname>Kleinheinz</surname> <given-names>K</given-names></name><name><surname>Vázquez-García</surname> <given-names>I</given-names></name><name><surname>Haase</surname> <given-names>K</given-names></name><name><surname>Jerman</surname> <given-names>L</given-names></name><name><surname>Sengupta</surname> <given-names>S</given-names></name><name><surname>Macintyre</surname> <given-names>G</given-names></name><name><surname>Malikic</surname> <given-names>S</given-names></name><name><surname>Donmez</surname> <given-names>N</given-names></name><name><surname>Livitz</surname> <given-names>DG</given-names></name><name><surname>Cmero</surname> <given-names>M</given-names></name><name><surname>Demeulemeester</surname> <given-names>J</given-names></name><name><surname>Schumacher</surname> <given-names>S</given-names></name><name><surname>Fan</surname> <given-names>Y</given-names></name><name><surname>Yao</surname> <given-names>X</given-names></name><name><surname>Lee</surname> <given-names>J</given-names></name><name><surname>Schlesner</surname> <given-names>M</given-names></name><name><surname>Boutros</surname> <given-names>PC</given-names></name><name><surname>Bowtell</surname> <given-names>DD</given-names></name><name><surname>Zhu</surname> <given-names>H</given-names></name><name><surname>Getz</surname> <given-names>G</given-names></name><name><surname>Imielinski</surname> <given-names>M</given-names></name><name><surname>Beroukhim</surname> <given-names>R</given-names></name><name><surname>Sahinalp</surname> <given-names>SC</given-names></name><name><surname>Ji</surname> <given-names>Y</given-names></name><name><surname>Peifer</surname> <given-names>M</given-names></name><name><surname>Markowetz</surname> <given-names>F</given-names></name><name><surname>Mustonen</surname> <given-names>V</given-names></name><name><surname>Yuan</surname> <given-names>K</given-names></name><name><surname>Wang</surname> <given-names>W</given-names></name><name><surname>Morris</surname> <given-names>QD</given-names></name><name><surname>Spellman</surname> <given-names>PT</given-names></name><name><surname>Wedge</surname> <given-names>DC</given-names></name><name><surname>Van Loo</surname> <given-names>P</given-names></name><collab>PCAWG Evolution &amp; Heterogeneity Working Group</collab><collab>PCAWG Consortium</collab></person-group><year iso-8601-date="2020">2020</year><article-title>The evolutionary history of 2,658 cancers</article-title><source>Nature</source><volume>578</volume><fpage>122</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1907-7</pub-id><pub-id pub-id-type="pmid">32025013</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gkouveris</surname> <given-names>I</given-names></name><name><surname>Nikitakis</surname> <given-names>NG</given-names></name><name><surname>Aseervatham</surname> <given-names>J</given-names></name><name><surname>Ogbureke</surname> <given-names>KUE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The tumorigenic role of DSPP and its potential regulation of the unfolded protein response and ER stress in oral Cancer cells</article-title><source>International Journal of Oncology</source><volume>53</volume><fpage>1743</fpage><lpage>1751</lpage><pub-id pub-id-type="doi">10.3892/ijo.2018.4484</pub-id><pub-id pub-id-type="pmid">30015841</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldman</surname> <given-names>NA</given-names></name><name><surname>Katz</surname> <given-names>EB</given-names></name><name><surname>Glenn</surname> <given-names>AS</given-names></name><name><surname>Weldon</surname> <given-names>RH</given-names></name><name><surname>Jones</surname> <given-names>JG</given-names></name><name><surname>Lynch</surname> <given-names>U</given-names></name><name><surname>Fezzari</surname> <given-names>MJ</given-names></name><name><surname>Runowicz</surname> <given-names>CD</given-names></name><name><surname>Goldberg</surname> <given-names>GL</given-names></name><name><surname>Charron</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>GLUT1 and GLUT8 in endometrium and endometrial adenocarcinoma</article-title><source>Modern Pathology</source><volume>19</volume><fpage>1429</fpage><lpage>1436</lpage><pub-id pub-id-type="doi">10.1038/modpathol.3800656</pub-id><pub-id pub-id-type="pmid">16892013</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez-Perez</surname> <given-names>A</given-names></name><name><surname>Sabarinathan</surname> <given-names>R</given-names></name><name><surname>Lopez-Bigas</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Local determinants of the mutational landscape of the human genome</article-title><source>Cell</source><volume>177</volume><fpage>101</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.02.051</pub-id><pub-id pub-id-type="pmid">30901533</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorlov</surname> <given-names>IP</given-names></name><name><surname>Kimmel</surname> <given-names>M</given-names></name><name><surname>Amos</surname> <given-names>CI</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Strength of the purifying selection against different categories of the point mutations in the coding regions of the human genome</article-title><source>Human Molecular Genetics</source><volume>15</volume><fpage>1143</fpage><lpage>1150</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddl029</pub-id><pub-id pub-id-type="pmid">16500998</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grandinetti</surname> <given-names>KB</given-names></name><name><surname>Stevens</surname> <given-names>TA</given-names></name><name><surname>Ha</surname> <given-names>S</given-names></name><name><surname>Salamone</surname> <given-names>RJ</given-names></name><name><surname>Walker</surname> <given-names>JR</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Agarwalla</surname> <given-names>S</given-names></name><name><surname>Tenen</surname> <given-names>DG</given-names></name><name><surname>Peters</surname> <given-names>EC</given-names></name><name><surname>Reddy</surname> <given-names>VA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Overexpression of TRIB2 in human lung cancers contributes to tumorigenesis through downregulation of C/EBPα</article-title><source>Oncogene</source><volume>30</volume><fpage>3328</fpage><lpage>3335</lpage><pub-id pub-id-type="doi">10.1038/onc.2011.57</pub-id><pub-id pub-id-type="pmid">21399661</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guérillon</surname> <given-names>C</given-names></name><name><surname>Larrieu</surname> <given-names>D</given-names></name><name><surname>Pedeux</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>ING<italic>1</italic> and <italic>ING2</italic>: multifaceted tumor suppressor genes</article-title><source>Cellular and Molecular Life Sciences</source><volume>70</volume><fpage>3753</fpage><lpage>3772</lpage><pub-id pub-id-type="doi">10.1007/s00018-013-1270-z</pub-id><pub-id pub-id-type="pmid">23412501</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haller</surname> <given-names>F</given-names></name><name><surname>Bieg</surname> <given-names>M</given-names></name><name><surname>Will</surname> <given-names>R</given-names></name><name><surname>Körner</surname> <given-names>C</given-names></name><name><surname>Weichenhan</surname> <given-names>D</given-names></name><name><surname>Bott</surname> <given-names>A</given-names></name><name><surname>Ishaque</surname> <given-names>N</given-names></name><name><surname>Lutsik</surname> <given-names>P</given-names></name><name><surname>Moskalev</surname> <given-names>EA</given-names></name><name><surname>Mueller</surname> <given-names>SK</given-names></name><name><surname>Bähr</surname> <given-names>M</given-names></name><name><surname>Woerner</surname> <given-names>A</given-names></name><name><surname>Kaiser</surname> <given-names>B</given-names></name><name><surname>Scherl</surname> <given-names>C</given-names></name><name><surname>Haderlein</surname> <given-names>M</given-names></name><name><surname>Kleinheinz</surname> <given-names>K</given-names></name><name><surname>Fietkau</surname> <given-names>R</given-names></name><name><surname>Iro</surname> <given-names>H</given-names></name><name><surname>Eils</surname> <given-names>R</given-names></name><name><surname>Hartmann</surname> <given-names>A</given-names></name><name><surname>Plass</surname> <given-names>C</given-names></name><name><surname>Wiemann</surname> <given-names>S</given-names></name><name><surname>Agaimy</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Enhancer hijacking activates oncogenic transcription factor NR4A3 in acinic cell carcinomas of the salivary glands</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>368</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-08069-x</pub-id><pub-id pub-id-type="pmid">30664630</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamanaka</surname> <given-names>N</given-names></name><name><surname>Nakanishi</surname> <given-names>Y</given-names></name><name><surname>Mizuno</surname> <given-names>T</given-names></name><name><surname>Horiguchi-Takei</surname> <given-names>K</given-names></name><name><surname>Akiyama</surname> <given-names>N</given-names></name><name><surname>Tanimura</surname> <given-names>H</given-names></name><name><surname>Hasegawa</surname> <given-names>M</given-names></name><name><surname>Satoh</surname> <given-names>Y</given-names></name><name><surname>Tachibana</surname> <given-names>Y</given-names></name><name><surname>Fujii</surname> <given-names>T</given-names></name><name><surname>Sakata</surname> <given-names>K</given-names></name><name><surname>Ogasawara</surname> <given-names>K</given-names></name><name><surname>Ebiike</surname> <given-names>H</given-names></name><name><surname>Koyano</surname> <given-names>H</given-names></name><name><surname>Sato</surname> <given-names>H</given-names></name><name><surname>Ishii</surname> <given-names>N</given-names></name><name><surname>Mio</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title><italic>YES1</italic> is a targetable oncogene in cancers harboring <italic>YES1</italic> Gene Amplification</article-title><source>Cancer Research</source><volume>79</volume><fpage>5734</fpage><lpage>5745</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-18-3376</pub-id><pub-id pub-id-type="pmid">31391186</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname> <given-names>D</given-names></name><name><surname>Weinberg</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Hallmarks of Cancer: the next generation</article-title><source>Cell</source><volume>144</volume><fpage>646</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id><pub-id pub-id-type="pmid">21376230</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hannon</surname> <given-names>MM</given-names></name><name><surname>Lohan</surname> <given-names>F</given-names></name><name><surname>Erbilgin</surname> <given-names>Y</given-names></name><name><surname>Sayitoglu</surname> <given-names>M</given-names></name><name><surname>O'Hagan</surname> <given-names>K</given-names></name><name><surname>Mills</surname> <given-names>K</given-names></name><name><surname>Ozbek</surname> <given-names>U</given-names></name><name><surname>Keeshan</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Elevated TRIB2 with NOTCH1 activation in paediatric/adult T-ALL</article-title><source>British Journal of Haematology</source><volume>158</volume><fpage>626</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2141.2012.09222.x</pub-id><pub-id pub-id-type="pmid">22775572</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname> <given-names>JJ</given-names></name><name><surname>Lin</surname> <given-names>DC</given-names></name><name><surname>Dinh</surname> <given-names>HQ</given-names></name><name><surname>Mayakonda</surname> <given-names>A</given-names></name><name><surname>Jiang</surname> <given-names>YY</given-names></name><name><surname>Chang</surname> <given-names>C</given-names></name><name><surname>Jiang</surname> <given-names>Y</given-names></name><name><surname>Lu</surname> <given-names>CC</given-names></name><name><surname>Shi</surname> <given-names>ZZ</given-names></name><name><surname>Xu</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Cai</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>JW</given-names></name><name><surname>Zhan</surname> <given-names>QM</given-names></name><name><surname>Wei</surname> <given-names>WQ</given-names></name><name><surname>Berman</surname> <given-names>BP</given-names></name><name><surname>Wang</surname> <given-names>MR</given-names></name><name><surname>Koeffler</surname> <given-names>HP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Spatial intratumoral heterogeneity and temporal clonal evolution in esophageal squamous cell carcinoma</article-title><source>Nature Genetics</source><volume>48</volume><fpage>1500</fpage><lpage>1507</lpage><pub-id pub-id-type="doi">10.1038/ng.3683</pub-id><pub-id pub-id-type="pmid">27749841</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassan</surname> <given-names>HM</given-names></name><name><surname>Dave</surname> <given-names>BJ</given-names></name><name><surname>Singh</surname> <given-names>RK</given-names></name></person-group><year iso-8601-date="2014">2014a</year><article-title>TP73, an under-appreciated player in non-Hodgkin lymphoma pathogenesis and management</article-title><source>Current Molecular Medicine</source><volume>14</volume><fpage>432</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.2174/1566524014666140414204458</pub-id><pub-id pub-id-type="pmid">24730526</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassan</surname> <given-names>HM</given-names></name><name><surname>Varney</surname> <given-names>ML</given-names></name><name><surname>Jain</surname> <given-names>S</given-names></name><name><surname>Weisenburger</surname> <given-names>DD</given-names></name><name><surname>Singh</surname> <given-names>RK</given-names></name><name><surname>Dave</surname> <given-names>BJ</given-names></name></person-group><year iso-8601-date="2014">2014b</year><article-title>Disruption of chromosomal locus 1p36 differentially modulates TAp73 and δnp73 expression in follicular lymphoma</article-title><source>Leukemia &amp; Lymphoma</source><volume>55</volume><fpage>2924</fpage><lpage>2931</lpage><pub-id pub-id-type="doi">10.3109/10428194.2014.900759</pub-id><pub-id pub-id-type="pmid">24660851</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hata</surname> <given-names>T</given-names></name><name><surname>Furukawa</surname> <given-names>T</given-names></name><name><surname>Sunamura</surname> <given-names>M</given-names></name><name><surname>Egawa</surname> <given-names>S</given-names></name><name><surname>Motoi</surname> <given-names>F</given-names></name><name><surname>Ohmura</surname> <given-names>N</given-names></name><name><surname>Marumoto</surname> <given-names>T</given-names></name><name><surname>Saya</surname> <given-names>H</given-names></name><name><surname>Horii</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>RNA interference targeting Aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic Cancer cells</article-title><source>Cancer Research</source><volume>65</volume><fpage>2899</fpage><lpage>2905</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-3981</pub-id><pub-id pub-id-type="pmid">15805292</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hazawa</surname> <given-names>M</given-names></name><name><surname>Lin</surname> <given-names>DC</given-names></name><name><surname>Handral</surname> <given-names>H</given-names></name><name><surname>Xu</surname> <given-names>L</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Jiang</surname> <given-names>YY</given-names></name><name><surname>Mayakonda</surname> <given-names>A</given-names></name><name><surname>Ding</surname> <given-names>LW</given-names></name><name><surname>Meng</surname> <given-names>X</given-names></name><name><surname>Sharma</surname> <given-names>A</given-names></name><name><surname>Samuel</surname> <given-names>S</given-names></name><name><surname>Movahednia</surname> <given-names>MM</given-names></name><name><surname>Wong</surname> <given-names>RW</given-names></name><name><surname>Yang</surname> <given-names>H</given-names></name><name><surname>Tong</surname> <given-names>C</given-names></name><name><surname>Koeffler</surname> <given-names>HP</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>ZNF750 is a lineage-specific tumour suppressor in squamous cell carcinoma</article-title><source>Oncogene</source><volume>36</volume><fpage>2243</fpage><lpage>2254</lpage><pub-id pub-id-type="doi">10.1038/onc.2016.377</pub-id><pub-id pub-id-type="pmid">27819679</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heidenreich</surname> <given-names>B</given-names></name><name><surname>Rachakonda</surname> <given-names>PS</given-names></name><name><surname>Hemminki</surname> <given-names>K</given-names></name><name><surname>Kumar</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>TERT promoter mutations in Cancer development</article-title><source>Current Opinion in Genetics &amp; Development</source><volume>24</volume><fpage>30</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.gde.2013.11.005</pub-id><pub-id pub-id-type="pmid">24657534</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heredia-Genestar</surname> <given-names>JM</given-names></name><name><surname>Marquès-Bonet</surname> <given-names>T</given-names></name><name><surname>Juan</surname> <given-names>D</given-names></name><name><surname>Navarro</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Extreme differences between human germline and tumor mutation densities are driven by ancestral human-specific deviations</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>2512</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-16296-4</pub-id><pub-id pub-id-type="pmid">32427823</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herreño</surname> <given-names>AM</given-names></name><name><surname>Ramírez</surname> <given-names>AC</given-names></name><name><surname>Chaparro</surname> <given-names>VP</given-names></name><name><surname>Fernandez</surname> <given-names>MJ</given-names></name><name><surname>Cañas</surname> <given-names>A</given-names></name><name><surname>Morantes</surname> <given-names>CF</given-names></name><name><surname>Moreno</surname> <given-names>OM</given-names></name><name><surname>Brugés</surname> <given-names>RE</given-names></name><name><surname>Mejía</surname> <given-names>JA</given-names></name><name><surname>Bustos</surname> <given-names>FJ</given-names></name><name><surname>Montecino</surname> <given-names>M</given-names></name><name><surname>Rojas</surname> <given-names>AP</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Role of <italic>RUNX2</italic> transcription factor in epithelial mesenchymal transition in non-small cell lung Cancer lung Cancer: epigenetic control of the <italic>RUNX2</italic> P1 promoter</article-title><source>Tumor Biology</source><volume>41</volume><elocation-id>1010428319851014</elocation-id><pub-id pub-id-type="doi">10.1177/1010428319851014</pub-id><pub-id pub-id-type="pmid">31109257</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrero</surname> <given-names>MJ</given-names></name><name><surname>Gitton</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The untold stories of the speech gene, the <italic>FOXP2</italic> Cancer gene</article-title><source>Genes &amp; Cancer</source><volume>9</volume><fpage>11</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.18632/genesandcancer.169</pub-id><pub-id pub-id-type="pmid">29725501</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname> <given-names>R</given-names></name><name><surname>Madureira</surname> <given-names>PA</given-names></name><name><surname>Ferreira</surname> <given-names>B</given-names></name><name><surname>Baptista</surname> <given-names>I</given-names></name><name><surname>Machado</surname> <given-names>S</given-names></name><name><surname>Colaço</surname> <given-names>L</given-names></name><name><surname>Dos Santos</surname> <given-names>M</given-names></name><name><surname>Liu</surname> <given-names>N</given-names></name><name><surname>Dopazo</surname> <given-names>A</given-names></name><name><surname>Ugurel</surname> <given-names>S</given-names></name><name><surname>Adrienn</surname> <given-names>A</given-names></name><name><surname>Kiss-Toth</surname> <given-names>E</given-names></name><name><surname>Isbilen</surname> <given-names>M</given-names></name><name><surname>Gure</surname> <given-names>AO</given-names></name><name><surname>Link</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>14687</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms14687</pub-id><pub-id pub-id-type="pmid">28276427</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodson</surname> <given-names>DJ</given-names></name><name><surname>Janas</surname> <given-names>ML</given-names></name><name><surname>Galloway</surname> <given-names>A</given-names></name><name><surname>Bell</surname> <given-names>SE</given-names></name><name><surname>Andrews</surname> <given-names>S</given-names></name><name><surname>Li</surname> <given-names>CM</given-names></name><name><surname>Pannell</surname> <given-names>R</given-names></name><name><surname>Siebel</surname> <given-names>CW</given-names></name><name><surname>MacDonald</surname> <given-names>HR</given-names></name><name><surname>De Keersmaecker</surname> <given-names>K</given-names></name><name><surname>Ferrando</surname> <given-names>AA</given-names></name><name><surname>Grutz</surname> <given-names>G</given-names></name><name><surname>Turner</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Deletion of the RNA-binding proteins ZFP36L1 and ZFP36L2 leads to perturbed thymic development and T lymphoblastic leukemia</article-title><source>Nature Immunology</source><volume>11</volume><fpage>717</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1038/ni.1901</pub-id><pub-id pub-id-type="pmid">20622884</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname> <given-names>CS</given-names></name><name><surname>Graham</surname> <given-names>NA</given-names></name><name><surname>Gu</surname> <given-names>W</given-names></name><name><surname>Espindola Camacho</surname> <given-names>C</given-names></name><name><surname>Mah</surname> <given-names>V</given-names></name><name><surname>Maresh</surname> <given-names>EL</given-names></name><name><surname>Alavi</surname> <given-names>M</given-names></name><name><surname>Bagryanova</surname> <given-names>L</given-names></name><name><surname>Krotee</surname> <given-names>PAL</given-names></name><name><surname>Gardner</surname> <given-names>BK</given-names></name><name><surname>Behbahan</surname> <given-names>IS</given-names></name><name><surname>Horvath</surname> <given-names>S</given-names></name><name><surname>Chia</surname> <given-names>D</given-names></name><name><surname>Mellinghoff</surname> <given-names>IK</given-names></name><name><surname>Hurvitz</surname> <given-names>SA</given-names></name><name><surname>Dubinett</surname> <given-names>SM</given-names></name><name><surname>Critchlow</surname> <given-names>SE</given-names></name><name><surname>Kurdistani</surname> <given-names>SK</given-names></name><name><surname>Goodglick</surname> <given-names>L</given-names></name><name><surname>Braas</surname> <given-names>D</given-names></name><name><surname>Graeber</surname> <given-names>TG</given-names></name><name><surname>Christofk</surname> <given-names>HR</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>MCT1 modulates Cancer cell pyruvate export and growth of tumors that Co-express MCT1 and MCT4</article-title><source>Cell Reports</source><volume>14</volume><fpage>1590</fpage><lpage>1601</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.01.057</pub-id><pub-id pub-id-type="pmid">26876179</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname> <given-names>Z</given-names></name><name><surname>Guo</surname> <given-names>K</given-names></name><name><surname>Sun</surname> <given-names>X</given-names></name><name><surname>Hu</surname> <given-names>F</given-names></name><name><surname>Chen</surname> <given-names>Q</given-names></name><name><surname>Luo</surname> <given-names>X</given-names></name><name><surname>Wang</surname> <given-names>G</given-names></name><name><surname>Hu</surname> <given-names>J</given-names></name><name><surname>Sun</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>TRIB2 functions as novel oncogene in colorectal Cancer by blocking cellular senescence through AP4/p21 signaling</article-title><source>Molecular Cancer</source><volume>17</volume><elocation-id>172</elocation-id><pub-id pub-id-type="doi">10.1186/s12943-018-0922-x</pub-id><pub-id pub-id-type="pmid">30541550</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname> <given-names>PP</given-names></name><name><surname>Sabatini</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Cancer cell metabolism: warburg and beyond</article-title><source>Cell</source><volume>134</volume><fpage>703</fpage><lpage>707</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2008.08.021</pub-id><pub-id pub-id-type="pmid">18775299</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname> <given-names>J</given-names></name><name><surname>Meng</surname> <given-names>Y</given-names></name><name><surname>Yu</surname> <given-names>T</given-names></name><name><surname>Hu</surname> <given-names>L</given-names></name><name><surname>Mao</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Ubiquitin E3 ligase MARCH7 promotes ovarian tumor growth</article-title><source>Oncotarget</source><volume>6</volume><fpage>12174</fpage><lpage>12187</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.3650</pub-id><pub-id pub-id-type="pmid">25895127</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Gao</surname> <given-names>H</given-names></name><name><surname>Zhao</surname> <given-names>W</given-names></name><name><surname>Huang</surname> <given-names>Y</given-names></name><name><surname>Jiang</surname> <given-names>T</given-names></name><name><surname>Zhou</surname> <given-names>J</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2018">2018a</year><article-title>The circular RNA circ-ITCH suppresses ovarian carcinoma progression through targeting miR-145/RASA1 signaling</article-title><source>Biochemical and Biophysical Research Communications</source><volume>505</volume><fpage>222</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2018.09.060</pub-id><pub-id pub-id-type="pmid">30243714</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname> <given-names>J</given-names></name><name><surname>Meng</surname> <given-names>Y</given-names></name><name><surname>Zeng</surname> <given-names>J</given-names></name><name><surname>Zeng</surname> <given-names>B</given-names></name><name><surname>Jiang</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2018">2018b</year><article-title>Ubiquitin E3 ligase MARCH7 promotes proliferation and invasion of cervical Cancer cells through VAV2-RAC1-CDC42 pathway</article-title><source>Oncology Letters</source><volume>16</volume><fpage>2312</fpage><lpage>2318</lpage><pub-id pub-id-type="doi">10.3892/ol.2018.8908</pub-id><pub-id pub-id-type="pmid">30008934</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurst</surname> <given-names>LD</given-names></name><name><surname>Batada</surname> <given-names>NN</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Depletion of somatic mutations in splicing-associated sequences in Cancer genomes</article-title><source>Genome Biology</source><volume>18</volume><elocation-id>213</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-017-1337-5</pub-id><pub-id pub-id-type="pmid">29115978</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname> <given-names>Q</given-names></name><name><surname>Cai</surname> <given-names>G</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Zhou</surname> <given-names>L</given-names></name><name><surname>Sui</surname> <given-names>H</given-names></name><name><surname>Li</surname> <given-names>Q</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>MALAT1 regulates the transcriptional and translational levels of proto-oncogene RUNX2 in colorectal Cancer metastasis</article-title><source>Cell Death &amp; Disease</source><volume>10</volume><elocation-id>378</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-019-1598-x</pub-id><pub-id pub-id-type="pmid">31097689</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname> <given-names>N</given-names></name><name><surname>Ke</surname> <given-names>B</given-names></name><name><surname>Hjort-Jensen</surname> <given-names>K</given-names></name><name><surname>Iglesias-Gato</surname> <given-names>D</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Chang</surname> <given-names>P</given-names></name><name><surname>Zhao</surname> <given-names>Y</given-names></name><name><surname>Niu</surname> <given-names>X</given-names></name><name><surname>Wu</surname> <given-names>T</given-names></name><name><surname>Peng</surname> <given-names>B</given-names></name><name><surname>Jiang</surname> <given-names>M</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Shang</surname> <given-names>Z</given-names></name><name><surname>Wang</surname> <given-names>Q</given-names></name><name><surname>Chang</surname> <given-names>C</given-names></name><name><surname>Flores-Morales</surname> <given-names>A</given-names></name><name><surname>Niu</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>YAP1 regulates prostate Cancer stem cell-like characteristics to promote castration resistant growth</article-title><source>Oncotarget</source><volume>8</volume><fpage>115054</fpage><lpage>115067</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.23014</pub-id><pub-id pub-id-type="pmid">29383141</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiao</surname> <given-names>X</given-names></name><name><surname>Nawab</surname> <given-names>O</given-names></name><name><surname>Patel</surname> <given-names>T</given-names></name><name><surname>Kossenkov</surname> <given-names>AV</given-names></name><name><surname>Halama</surname> <given-names>N</given-names></name><name><surname>Jaeger</surname> <given-names>D</given-names></name><name><surname>Pestell</surname> <given-names>RG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Recent advances targeting CCR5 for Cancer and its role in Immuno-Oncology</article-title><source>Cancer Research</source><volume>79</volume><fpage>4801</fpage><lpage>4807</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-19-1167</pub-id><pub-id pub-id-type="pmid">31292161</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jo</surname> <given-names>YS</given-names></name><name><surname>Kim</surname> <given-names>MS</given-names></name><name><surname>Yoo</surname> <given-names>NJ</given-names></name><name><surname>Lee</surname> <given-names>SH</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Somatic mutation of a candidate tumour suppressor <italic>MGA</italic> gene and its mutational heterogeneity in colorectal cancers</article-title><source>Pathology</source><volume>48</volume><fpage>525</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1016/j.pathol.2016.04.010</pub-id><pub-id pub-id-type="pmid">27306572</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname> <given-names>SA</given-names></name><name><surname>Dubeau</surname> <given-names>L</given-names></name><name><surname>Kawalek</surname> <given-names>M</given-names></name><name><surname>Dervan</surname> <given-names>A</given-names></name><name><surname>Schönthal</surname> <given-names>AH</given-names></name><name><surname>Dang</surname> <given-names>CV</given-names></name><name><surname>Johnson</surname> <given-names>DL</given-names></name></person-group><year iso-8601-date="2003">2003a</year><article-title>Increased expression of TATA-binding protein, the central transcription factor, can contribute to oncogenesis</article-title><source>Molecular and Cellular Biology</source><volume>23</volume><fpage>3043</fpage><lpage>3051</lpage><pub-id pub-id-type="doi">10.1128/MCB.23.9.3043-3051.2003</pub-id><pub-id pub-id-type="pmid">12697807</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname> <given-names>SA</given-names></name><name><surname>Dubeau</surname> <given-names>L</given-names></name><name><surname>White</surname> <given-names>RJ</given-names></name><name><surname>Johnson</surname> <given-names>DL</given-names></name></person-group><year iso-8601-date="2003">2003b</year><article-title>The TATA-binding protein as a regulator of cellular transformation</article-title><source>Cell Cycle</source><volume>2</volume><fpage>440</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.4161/cc.2.5.493</pub-id><pub-id pub-id-type="pmid">12963838</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname> <given-names>SAS</given-names></name><name><surname>Lin</surname> <given-names>JJ</given-names></name><name><surname>Walkey</surname> <given-names>CJ</given-names></name><name><surname>Leathers</surname> <given-names>MP</given-names></name><name><surname>Coarfa</surname> <given-names>C</given-names></name><name><surname>Johnson</surname> <given-names>DL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Elevated TATA-binding protein expression drives vascular endothelial growth factor expression in Colon cancer</article-title><source>Oncotarget</source><volume>8</volume><fpage>48832</fpage><lpage>48845</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.16384</pub-id><pub-id pub-id-type="pmid">28415573</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname> <given-names>RG</given-names></name><name><surname>Thompson</surname> <given-names>CB</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Tumor suppressors and cell metabolism: a recipe for Cancer growth</article-title><source>Genes &amp; Development</source><volume>23</volume><fpage>537</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1101/gad.1756509</pub-id><pub-id pub-id-type="pmid">19270154</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joshi</surname> <given-names>R</given-names></name><name><surname>Tawfik</surname> <given-names>A</given-names></name><name><surname>Edeh</surname> <given-names>N</given-names></name><name><surname>McCloud</surname> <given-names>V</given-names></name><name><surname>Looney</surname> <given-names>S</given-names></name><name><surname>Lewis</surname> <given-names>J</given-names></name><name><surname>Hsu</surname> <given-names>S</given-names></name><name><surname>Ogbureke</surname> <given-names>KU</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Dentin sialophosphoprotein (DSPP) gene-silencing inhibits key tumorigenic activities in human oral Cancer cell line, OSC2</article-title><source>PLOS ONE</source><volume>5</volume><elocation-id>e13974</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0013974</pub-id><pub-id pub-id-type="pmid">21103065</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joyce</surname> <given-names>BT</given-names></name><name><surname>Zheng</surname> <given-names>Y</given-names></name><name><surname>Zhang</surname> <given-names>Z</given-names></name><name><surname>Liu</surname> <given-names>L</given-names></name><name><surname>Kocherginsky</surname> <given-names>M</given-names></name><name><surname>Murphy</surname> <given-names>R</given-names></name><name><surname>Achenbach</surname> <given-names>CJ</given-names></name><name><surname>Musa</surname> <given-names>J</given-names></name><name><surname>Wehbe</surname> <given-names>F</given-names></name><name><surname>Just</surname> <given-names>A</given-names></name><name><surname>Shen</surname> <given-names>J</given-names></name><name><surname>Vokonas</surname> <given-names>P</given-names></name><name><surname>Schwartz</surname> <given-names>J</given-names></name><name><surname>Baccarelli</surname> <given-names>AA</given-names></name><name><surname>Hou</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>miRNA-Processing gene methylation and Cancer risk</article-title><source>Cancer Epidemiology Biomarkers &amp; Prevention</source><volume>27</volume><fpage>550</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-17-0849</pub-id><pub-id pub-id-type="pmid">29475968</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaistha</surname> <given-names>BP</given-names></name><name><surname>Honstein</surname> <given-names>T</given-names></name><name><surname>Müller</surname> <given-names>V</given-names></name><name><surname>Bielak</surname> <given-names>S</given-names></name><name><surname>Sauer</surname> <given-names>M</given-names></name><name><surname>Kreider</surname> <given-names>R</given-names></name><name><surname>Fassan</surname> <given-names>M</given-names></name><name><surname>Scarpa</surname> <given-names>A</given-names></name><name><surname>Schmees</surname> <given-names>C</given-names></name><name><surname>Volkmer</surname> <given-names>H</given-names></name><name><surname>Gress</surname> <given-names>TM</given-names></name><name><surname>Buchholz</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Key role of dual specificity kinase TTK in proliferation and survival of pancreatic Cancer cells</article-title><source>British Journal of Cancer</source><volume>111</volume><fpage>1780</fpage><lpage>1787</lpage><pub-id pub-id-type="doi">10.1038/bjc.2014.460</pub-id><pub-id pub-id-type="pmid">25137017</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaminker</surname> <given-names>JS</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Watanabe</surname> <given-names>C</given-names></name><name><surname>Zhang</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>CanPredict: a computational tool for predicting cancer-associated missense mutations</article-title><source>Nucleic Acids Research</source><volume>35</volume><fpage>W595</fpage><lpage>W598</lpage><pub-id pub-id-type="doi">10.1093/nar/gkm405</pub-id><pub-id pub-id-type="pmid">17537827</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kent</surname> <given-names>OA</given-names></name><name><surname>Mendell</surname> <given-names>JT</given-names></name><name><surname>Rottapel</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Transcriptional regulation of miR-31 by oncogenic KRAS mediates metastatic phenotypes by repressing RASA1</article-title><source>Molecular Cancer Research</source><volume>14</volume><fpage>267</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-15-0456</pub-id><pub-id pub-id-type="pmid">26747707</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>IY</given-names></name><name><surname>Lee</surname> <given-names>DH</given-names></name><name><surname>Lee</surname> <given-names>DK</given-names></name><name><surname>Ahn</surname> <given-names>HJ</given-names></name><name><surname>Kim</surname> <given-names>MM</given-names></name><name><surname>Kim</surname> <given-names>SJ</given-names></name><name><surname>Morton</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Loss of expression of bone morphogenetic protein receptor type II in human prostate Cancer cells</article-title><source>Oncogene</source><volume>23</volume><fpage>7651</fpage><lpage>7659</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1207924</pub-id><pub-id pub-id-type="pmid">15354178</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>HS</given-names></name><name><surname>Oh</surname> <given-names>SH</given-names></name><name><surname>Kim</surname> <given-names>JH</given-names></name><name><surname>Sohn</surname> <given-names>WJ</given-names></name><name><surname>Kim</surname> <given-names>JY</given-names></name><name><surname>Kim</surname> <given-names>DH</given-names></name><name><surname>Choi</surname> <given-names>SU</given-names></name><name><surname>Park</surname> <given-names>KM</given-names></name><name><surname>Ryoo</surname> <given-names>ZY</given-names></name><name><surname>Park</surname> <given-names>TS</given-names></name><name><surname>Lee</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>TRIB2 regulates the differentiation of MLL-TET1 transduced myeloid progenitor cells</article-title><source>Journal of Molecular Medicine</source><volume>96</volume><fpage>1267</fpage><lpage>1277</lpage><pub-id pub-id-type="doi">10.1007/s00109-018-1700-3</pub-id><pub-id pub-id-type="pmid">30324339</pub-id></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiss</surname> <given-names>A</given-names></name><name><surname>Koppel</surname> <given-names>AC</given-names></name><name><surname>Anders</surname> <given-names>J</given-names></name><name><surname>Cataisson</surname> <given-names>C</given-names></name><name><surname>Yuspa</surname> <given-names>SH</given-names></name><name><surname>Blumenberg</surname> <given-names>M</given-names></name><name><surname>Efimova</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Keratinocyte p38δ loss inhibits Ras-induced tumor formation, while systemic p38δ loss enhances skin inflammation in the early phase of chemical carcinogenesis in mouse skin</article-title><source>Molecular Carcinogenesis</source><volume>55</volume><fpage>563</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1002/mc.22303</pub-id><pub-id pub-id-type="pmid">25753147</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiss</surname> <given-names>A</given-names></name><name><surname>Koppel</surname> <given-names>A</given-names></name><name><surname>Murphy</surname> <given-names>E</given-names></name><name><surname>Sall</surname> <given-names>M</given-names></name><name><surname>Barlas</surname> <given-names>M</given-names></name><name><surname>Kissling</surname> <given-names>G</given-names></name><name><surname>Efimova</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cell Type-Specific p38δ targeting reveals a context-, Stage-, and Sex-Dependent regulation of skin carcinogenesis</article-title><source>International Journal of Molecular Sciences</source><volume>20</volume><elocation-id>1532</elocation-id><pub-id pub-id-type="doi">10.3390/ijms20071532</pub-id></element-citation></ref><ref id="bib124"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koch</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cancer genomics: the driving force of Cancer evolution</article-title><source>Nature Reviews. Genetics</source><volume>18</volume><elocation-id>703</elocation-id><pub-id pub-id-type="doi">10.1038/nrg.2017.95</pub-id><pub-id pub-id-type="pmid">29109522</pub-id></element-citation></ref><ref id="bib125"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kodach</surname> <given-names>LL</given-names></name><name><surname>Wiercinska</surname> <given-names>E</given-names></name><name><surname>de Miranda</surname> <given-names>NF</given-names></name><name><surname>Bleuming</surname> <given-names>SA</given-names></name><name><surname>Musler</surname> <given-names>AR</given-names></name><name><surname>Peppelenbosch</surname> <given-names>MP</given-names></name><name><surname>Dekker</surname> <given-names>E</given-names></name><name><surname>van den Brink</surname> <given-names>GR</given-names></name><name><surname>van Noesel</surname> <given-names>CJ</given-names></name><name><surname>Morreau</surname> <given-names>H</given-names></name><name><surname>Hommes</surname> <given-names>DW</given-names></name><name><surname>Ten Dijke</surname> <given-names>P</given-names></name><name><surname>Offerhaus</surname> <given-names>GJ</given-names></name><name><surname>Hardwick</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The bone morphogenetic protein pathway is inactivated in the majority of sporadic colorectal cancers</article-title><source>Gastroenterology</source><volume>134</volume><fpage>1332</fpage><lpage>1341</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2008.02.059</pub-id><pub-id pub-id-type="pmid">18471510</pub-id></element-citation></ref><ref id="bib126"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koenighofer</surname> <given-names>M</given-names></name><name><surname>Hung</surname> <given-names>CY</given-names></name><name><surname>McCauley</surname> <given-names>JL</given-names></name><name><surname>Dallman</surname> <given-names>J</given-names></name><name><surname>Back</surname> <given-names>EJ</given-names></name><name><surname>Mihalek</surname> <given-names>I</given-names></name><name><surname>Gripp</surname> <given-names>KW</given-names></name><name><surname>Sol-Church</surname> <given-names>K</given-names></name><name><surname>Rusconi</surname> <given-names>P</given-names></name><name><surname>Zhang</surname> <given-names>Z</given-names></name><name><surname>Shi</surname> <given-names>GX</given-names></name><name><surname>Andres</surname> <given-names>DA</given-names></name><name><surname>Bodamer</surname> <given-names>OA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Mutations in <italic>RIT1</italic> cause Noonan syndrome - additional functional evidence and expanding the clinical phenotype</article-title><source>Clinical Genetics</source><volume>89</volume><fpage>359</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1111/cge.12608</pub-id><pub-id pub-id-type="pmid">25959749</pub-id></element-citation></ref><ref id="bib127"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kroemer</surname> <given-names>G</given-names></name><name><surname>Pouyssegur</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Tumor cell metabolism: cancer's Achilles' heel</article-title><source>Cancer Cell</source><volume>13</volume><fpage>472</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2008.05.005</pub-id><pub-id pub-id-type="pmid">18538731</pub-id></element-citation></ref><ref id="bib128"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawrence</surname> <given-names>MS</given-names></name><name><surname>Stojanov</surname> <given-names>P</given-names></name><name><surname>Polak</surname> <given-names>P</given-names></name><name><surname>Kryukov</surname> <given-names>GV</given-names></name><name><surname>Cibulskis</surname> <given-names>K</given-names></name><name><surname>Sivachenko</surname> <given-names>A</given-names></name><name><surname>Carter</surname> <given-names>SL</given-names></name><name><surname>Stewart</surname> <given-names>C</given-names></name><name><surname>Mermel</surname> <given-names>CH</given-names></name><name><surname>Roberts</surname> <given-names>SA</given-names></name><name><surname>Kiezun</surname> <given-names>A</given-names></name><name><surname>Hammerman</surname> <given-names>PS</given-names></name><name><surname>McKenna</surname> <given-names>A</given-names></name><name><surname>Drier</surname> <given-names>Y</given-names></name><name><surname>Zou</surname> <given-names>L</given-names></name><name><surname>Ramos</surname> <given-names>AH</given-names></name><name><surname>Pugh</surname> <given-names>TJ</given-names></name><name><surname>Stransky</surname> <given-names>N</given-names></name><name><surname>Helman</surname> <given-names>E</given-names></name><name><surname>Kim</surname> <given-names>J</given-names></name><name><surname>Sougnez</surname> <given-names>C</given-names></name><name><surname>Ambrogio</surname> <given-names>L</given-names></name><name><surname>Nickerson</surname> <given-names>E</given-names></name><name><surname>Shefler</surname> <given-names>E</given-names></name><name><surname>Cortés</surname> <given-names>ML</given-names></name><name><surname>Auclair</surname> <given-names>D</given-names></name><name><surname>Saksena</surname> <given-names>G</given-names></name><name><surname>Voet</surname> <given-names>D</given-names></name><name><surname>Noble</surname> <given-names>M</given-names></name><name><surname>DiCara</surname> <given-names>D</given-names></name><name><surname>Lin</surname> <given-names>P</given-names></name><name><surname>Lichtenstein</surname> <given-names>L</given-names></name><name><surname>Heiman</surname> <given-names>DI</given-names></name><name><surname>Fennell</surname> <given-names>T</given-names></name><name><surname>Imielinski</surname> <given-names>M</given-names></name><name><surname>Hernandez</surname> <given-names>B</given-names></name><name><surname>Hodis</surname> <given-names>E</given-names></name><name><surname>Baca</surname> <given-names>S</given-names></name><name><surname>Dulak</surname> <given-names>AM</given-names></name><name><surname>Lohr</surname> <given-names>J</given-names></name><name><surname>Landau</surname> <given-names>DA</given-names></name><name><surname>Wu</surname> <given-names>CJ</given-names></name><name><surname>Melendez-Zajgla</surname> <given-names>J</given-names></name><name><surname>Hidalgo-Miranda</surname> <given-names>A</given-names></name><name><surname>Koren</surname> <given-names>A</given-names></name><name><surname>McCarroll</surname> <given-names>SA</given-names></name><name><surname>Mora</surname> <given-names>J</given-names></name><name><surname>Crompton</surname> <given-names>B</given-names></name><name><surname>Onofrio</surname> <given-names>R</given-names></name><name><surname>Parkin</surname> <given-names>M</given-names></name><name><surname>Winckler</surname> <given-names>W</given-names></name><name><surname>Ardlie</surname> <given-names>K</given-names></name><name><surname>Gabriel</surname> <given-names>SB</given-names></name><name><surname>Roberts</surname> <given-names>CWM</given-names></name><name><surname>Biegel</surname> <given-names>JA</given-names></name><name><surname>Stegmaier</surname> <given-names>K</given-names></name><name><surname>Bass</surname> <given-names>AJ</given-names></name><name><surname>Garraway</surname> <given-names>LA</given-names></name><name><surname>Meyerson</surname> <given-names>M</given-names></name><name><surname>Golub</surname> <given-names>TR</given-names></name><name><surname>Gordenin</surname> <given-names>DA</given-names></name><name><surname>Sunyaev</surname> <given-names>S</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Getz</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mutational heterogeneity in Cancer and the search for new cancer-associated genes</article-title><source>Nature</source><volume>499</volume><fpage>214</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1038/nature12213</pub-id><pub-id pub-id-type="pmid">23770567</pub-id></element-citation></ref><ref id="bib129"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawrence</surname> <given-names>MS</given-names></name><name><surname>Stojanov</surname> <given-names>P</given-names></name><name><surname>Mermel</surname> <given-names>CH</given-names></name><name><surname>Robinson</surname> <given-names>JT</given-names></name><name><surname>Garraway</surname> <given-names>LA</given-names></name><name><surname>Golub</surname> <given-names>TR</given-names></name><name><surname>Meyerson</surname> <given-names>M</given-names></name><name><surname>Gabriel</surname> <given-names>SB</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Getz</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Discovery and saturation analysis of Cancer genes across 21 tumour types</article-title><source>Nature</source><volume>505</volume><fpage>495</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1038/nature12912</pub-id><pub-id pub-id-type="pmid">24390350</pub-id></element-citation></ref><ref id="bib130"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>YY</given-names></name><name><surname>Wang</surname> <given-names>CT</given-names></name><name><surname>Huang</surname> <given-names>SK</given-names></name><name><surname>Wu</surname> <given-names>WJ</given-names></name><name><surname>Huang</surname> <given-names>CN</given-names></name><name><surname>Li</surname> <given-names>CC</given-names></name><name><surname>Chan</surname> <given-names>TC</given-names></name><name><surname>Liang</surname> <given-names>PI</given-names></name><name><surname>Hsing</surname> <given-names>CH</given-names></name><name><surname>Li</surname> <given-names>CF</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Downregulation of <italic>RNF128</italic> predicts progression and poor prognosis in patients with urothelial carcinoma of the upper tract and urinary bladder</article-title><source>Journal of Cancer</source><volume>7</volume><fpage>2187</fpage><lpage>2196</lpage><pub-id pub-id-type="doi">10.7150/jca.16798</pub-id><pub-id pub-id-type="pmid">27994654</pub-id></element-citation></ref><ref id="bib131"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lengauer</surname> <given-names>C</given-names></name><name><surname>Kinzler</surname> <given-names>KW</given-names></name><name><surname>Vogelstein</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Genetic instabilities in human cancers</article-title><source>Nature</source><volume>396</volume><fpage>643</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1038/25292</pub-id><pub-id pub-id-type="pmid">9872311</pub-id></element-citation></ref><ref id="bib132"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>XX</given-names></name><name><surname>Zheng</surname> <given-names>HT</given-names></name><name><surname>Huang</surname> <given-names>LY</given-names></name><name><surname>Shi</surname> <given-names>DB</given-names></name><name><surname>Peng</surname> <given-names>JJ</given-names></name><name><surname>Liang</surname> <given-names>L</given-names></name><name><surname>Cai</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Silencing of CXCR7 gene represses growth and invasion and induces apoptosis in colorectal Cancer through ERK and β-arrestin pathways</article-title><source>International Journal of Oncology</source><volume>45</volume><fpage>1649</fpage><lpage>5167</lpage><pub-id pub-id-type="doi">10.3892/ijo.2014.2547</pub-id><pub-id pub-id-type="pmid">25051350</pub-id></element-citation></ref><ref id="bib133"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>D</given-names></name><name><surname>Yang</surname> <given-names>Y</given-names></name><name><surname>Zhu</surname> <given-names>G</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Zhao</surname> <given-names>M</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Yang</surname> <given-names>Q</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>MicroRNA-410 promotes cell proliferation by targeting <italic>BRD7</italic> in non-small cell lung Cancer</article-title><source>FEBS Letters</source><volume>589</volume><fpage>2218</fpage><lpage>2223</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2015.06.031</pub-id><pub-id pub-id-type="pmid">26149213</pub-id></element-citation></ref><ref id="bib134"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>XQ</given-names></name><name><surname>Lu</surname> <given-names>JT</given-names></name><name><surname>Tan</surname> <given-names>CC</given-names></name><name><surname>Wang</surname> <given-names>QS</given-names></name><name><surname>Feng</surname> <given-names>YM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>RUNX2 promotes breast Cancer bone metastasis by increasing integrin α5-mediated colonization</article-title><source>Cancer Letters</source><volume>380</volume><fpage>78</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2016.06.007</pub-id><pub-id pub-id-type="pmid">27317874</pub-id></element-citation></ref><ref id="bib135"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Xu</surname> <given-names>W</given-names></name><name><surname>Kang</surname> <given-names>W</given-names></name><name><surname>Wong</surname> <given-names>SH</given-names></name><name><surname>Wang</surname> <given-names>M</given-names></name><name><surname>Zhou</surname> <given-names>Y</given-names></name><name><surname>Fang</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Yang</surname> <given-names>H</given-names></name><name><surname>Wong</surname> <given-names>CH</given-names></name><name><surname>To</surname> <given-names>KF</given-names></name><name><surname>Chan</surname> <given-names>SL</given-names></name><name><surname>Chan</surname> <given-names>MTV</given-names></name><name><surname>Sung</surname> <given-names>JJY</given-names></name><name><surname>Wu</surname> <given-names>WKK</given-names></name><name><surname>Yu</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018a</year><article-title>Genomic analysis of liver Cancer unveils novel driver genes and distinct prognostic features</article-title><source>Theranostics</source><volume>8</volume><fpage>1740</fpage><lpage>1751</lpage><pub-id pub-id-type="doi">10.7150/thno.22010</pub-id><pub-id pub-id-type="pmid">29556353</pub-id></element-citation></ref><ref id="bib136"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>Z</given-names></name><name><surname>Guo</surname> <given-names>J</given-names></name><name><surname>Ma</surname> <given-names>Y</given-names></name><name><surname>Zhang</surname> <given-names>L</given-names></name><name><surname>Lin</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2018">2018b</year><article-title>Oncogenic role of MicroRNA-30b-5p in glioblastoma through targeting Proline-Rich transmembrane protein 2</article-title><source>Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics</source><volume>26</volume><fpage>219</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.3727/096504017X14944585873659</pub-id><pub-id pub-id-type="pmid">28550683</pub-id></element-citation></ref><ref id="bib137"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>ZY</given-names></name><name><surname>Zhang</surname> <given-names>ZZ</given-names></name><name><surname>Bi</surname> <given-names>H</given-names></name><name><surname>Zhang</surname> <given-names>QD</given-names></name><name><surname>Zhang</surname> <given-names>SJ</given-names></name><name><surname>Zhou</surname> <given-names>L</given-names></name><name><surname>Zhu</surname> <given-names>XQ</given-names></name><name><surname>Zhou</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Upregulated microRNA–671–3p promotes tumor progression by suppressing forkhead box P2 expression in non–small–cell lung cancer</article-title><source>Molecular Medicine Reports</source><volume>20</volume><fpage>3149</fpage><lpage>3159</lpage><pub-id pub-id-type="doi">10.3892/mmr.2019.10563</pub-id><pub-id pub-id-type="pmid">31432170</pub-id></element-citation></ref><ref id="bib138"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Roberts</surname> <given-names>ND</given-names></name><name><surname>Wala</surname> <given-names>JA</given-names></name><name><surname>Shapira</surname> <given-names>O</given-names></name><name><surname>Schumacher</surname> <given-names>SE</given-names></name><name><surname>Kumar</surname> <given-names>K</given-names></name><name><surname>Khurana</surname> <given-names>E</given-names></name><name><surname>Waszak</surname> <given-names>S</given-names></name><name><surname>Korbel</surname> <given-names>JO</given-names></name><name><surname>Haber</surname> <given-names>JE</given-names></name><name><surname>Imielinski</surname> <given-names>M</given-names></name><name><surname>Weischenfeldt</surname> <given-names>J</given-names></name><name><surname>Beroukhim</surname> <given-names>R</given-names></name><name><surname>Campbell</surname> <given-names>PJ</given-names></name><collab>PCAWG Structural Variation Working Group</collab><collab>PCAWG Consortium</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Patterns of somatic structural variation in human Cancer genomes</article-title><source>Nature</source><volume>578</volume><fpage>112</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1913-9</pub-id><pub-id pub-id-type="pmid">32025012</pub-id></element-citation></ref><ref id="bib139"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Tai</surname> <given-names>HH</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Activation of thromboxane A2 receptor (TP) increases the expression of monocyte chemoattractant protein -1 (MCP-1)/chemokine (C-C motif) ligand 2 (CCL2) and recruits macrophages to promote invasion of lung Cancer cells</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e54073</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0054073</pub-id><pub-id pub-id-type="pmid">23349788</pub-id></element-citation></ref><ref id="bib140"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname> <given-names>J</given-names></name><name><surname>Chen</surname> <given-names>M</given-names></name><name><surname>Hughes</surname> <given-names>D</given-names></name><name><surname>Chumanevich</surname> <given-names>AA</given-names></name><name><surname>Altilia</surname> <given-names>S</given-names></name><name><surname>Kaza</surname> <given-names>V</given-names></name><name><surname>Lim</surname> <given-names>CU</given-names></name><name><surname>Kiaris</surname> <given-names>H</given-names></name><name><surname>Mythreye</surname> <given-names>K</given-names></name><name><surname>Pena</surname> <given-names>MM</given-names></name><name><surname>Broude</surname> <given-names>EV</given-names></name><name><surname>Roninson</surname> <given-names>IB</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>CDK8 selectively promotes the growth of Colon cancer metastases in the liver by regulating gene expression of TIMP3 and matrix metalloproteinases</article-title><source>Cancer Research</source><volume>78</volume><fpage>6594</fpage><lpage>6606</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-18-1583</pub-id><pub-id pub-id-type="pmid">30185549</pub-id></element-citation></ref><ref id="bib141"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname> <given-names>SY</given-names></name><name><surname>Yuzhalin</surname> <given-names>AE</given-names></name><name><surname>Gordon-Weeks</surname> <given-names>AN</given-names></name><name><surname>Muschel</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Targeting the CCL2-CCR2 signaling Axis in Cancer metastasis</article-title><source>Oncotarget</source><volume>7</volume><fpage>28697</fpage><lpage>28710</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.7376</pub-id><pub-id pub-id-type="pmid">26885690</pub-id></element-citation></ref><ref id="bib142"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>DC</given-names></name><name><surname>Dinh</surname> <given-names>HQ</given-names></name><name><surname>Xie</surname> <given-names>JJ</given-names></name><name><surname>Mayakonda</surname> <given-names>A</given-names></name><name><surname>Silva</surname> <given-names>TC</given-names></name><name><surname>Jiang</surname> <given-names>YY</given-names></name><name><surname>Ding</surname> <given-names>LW</given-names></name><name><surname>He</surname> <given-names>JZ</given-names></name><name><surname>Xu</surname> <given-names>XE</given-names></name><name><surname>Hao</surname> <given-names>JJ</given-names></name><name><surname>Wang</surname> <given-names>MR</given-names></name><name><surname>Li</surname> <given-names>C</given-names></name><name><surname>Xu</surname> <given-names>LY</given-names></name><name><surname>Li</surname> <given-names>EM</given-names></name><name><surname>Berman</surname> <given-names>BP</given-names></name><name><surname>Phillip Koeffler</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Identification of distinct mutational patterns and new driver genes in oesophageal squamous cell carcinomas and adenocarcinomas</article-title><source>Gut</source><volume>67</volume><fpage>1769</fpage><lpage>1779</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2017-314607</pub-id><pub-id pub-id-type="pmid">28860350</pub-id></element-citation></ref><ref id="bib143"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>C</given-names></name><name><surname>Xu</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>YAP1-TEAD1-Glut1 Axis dictates the oncogenic phenotypes of breast Cancer cells by modulating glycolysis</article-title><source>Biomedicine &amp; Pharmacotherapy</source><volume>95</volume><fpage>789</fpage><lpage>794</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2017.08.091</pub-id><pub-id pub-id-type="pmid">28892790</pub-id></element-citation></ref><ref id="bib144"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>T</given-names></name><name><surname>Sun</surname> <given-names>Q</given-names></name><name><surname>Niu</surname> <given-names>M</given-names></name><name><surname>Jiang</surname> <given-names>Y</given-names></name><name><surname>Pang</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Downregulation of ras gtpase‑activating protein 1 is associated with poor survival of breast invasive ductal carcinoma patients</article-title><source>Oncology Reports</source><volume>33</volume><fpage>119</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.3892/or.2014.3604</pub-id><pub-id pub-id-type="pmid">25394563</pub-id></element-citation></ref><ref id="bib145"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>L</given-names></name><name><surname>Hu</surname> <given-names>J</given-names></name><name><surname>Yu</surname> <given-names>T</given-names></name><name><surname>You</surname> <given-names>S</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Hu</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>miR-27b-3p/MARCH7 regulates invasion and metastasis of endometrial Cancer cells through Snail-mediated pathway</article-title><source>Acta Biochimica Et Biophysica Sinica</source><volume>51</volume><fpage>492</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1093/abbs/gmz030</pub-id><pub-id pub-id-type="pmid">31006800</pub-id></element-citation></ref><ref id="bib146"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>López</surname> <given-names>S</given-names></name><name><surname>Lim</surname> <given-names>EL</given-names></name><name><surname>Horswell</surname> <given-names>S</given-names></name><name><surname>Haase</surname> <given-names>K</given-names></name><name><surname>Huebner</surname> <given-names>A</given-names></name><name><surname>Dietzen</surname> <given-names>M</given-names></name><name><surname>Mourikis</surname> <given-names>TP</given-names></name><name><surname>Watkins</surname> <given-names>TBK</given-names></name><name><surname>Rowan</surname> <given-names>A</given-names></name><name><surname>Dewhurst</surname> <given-names>SM</given-names></name><name><surname>Birkbak</surname> <given-names>NJ</given-names></name><name><surname>Wilson</surname> <given-names>GA</given-names></name><name><surname>Van Loo</surname> <given-names>P</given-names></name><name><surname>Jamal-Hanjani</surname> <given-names>M</given-names></name><name><surname>Swanton</surname> <given-names>C</given-names></name><name><surname>McGranahan</surname> <given-names>N</given-names></name><collab>TRACERx Consortium</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Interplay between whole-genome doubling and the accumulation of deleterious alterations in Cancer evolution</article-title><source>Nature Genetics</source><volume>52</volume><fpage>283</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1038/s41588-020-0584-7</pub-id><pub-id pub-id-type="pmid">32139907</pub-id></element-citation></ref><ref id="bib147"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lorenzetto</surname> <given-names>E</given-names></name><name><surname>Brenca</surname> <given-names>M</given-names></name><name><surname>Boeri</surname> <given-names>M</given-names></name><name><surname>Verri</surname> <given-names>C</given-names></name><name><surname>Piccinin</surname> <given-names>E</given-names></name><name><surname>Gasparini</surname> <given-names>P</given-names></name><name><surname>Facchinetti</surname> <given-names>F</given-names></name><name><surname>Rossi</surname> <given-names>S</given-names></name><name><surname>Salvatore</surname> <given-names>G</given-names></name><name><surname>Massimino</surname> <given-names>M</given-names></name><name><surname>Sozzi</surname> <given-names>G</given-names></name><name><surname>Maestro</surname> <given-names>R</given-names></name><name><surname>Modena</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title><italic>YAP1</italic> acts as oncogenic target of 11q22 amplification in multiple Cancer subtypes</article-title><source>Oncotarget</source><volume>5</volume><fpage>2608</fpage><lpage>2621</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.1844</pub-id><pub-id pub-id-type="pmid">24810989</pub-id></element-citation></ref><ref id="bib148"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname> <given-names>H</given-names></name><name><surname>Jiang</surname> <given-names>T</given-names></name><name><surname>Ren</surname> <given-names>K</given-names></name><name><surname>Li</surname> <given-names>ZL</given-names></name><name><surname>Ren</surname> <given-names>J</given-names></name><name><surname>Wu</surname> <given-names>G</given-names></name><name><surname>Han</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>RUNX2 plays an oncogenic role in esophageal carcinoma by activating the PI3K/AKT and ERK signaling pathways</article-title><source>Cellular Physiology and Biochemistry</source><volume>49</volume><fpage>217</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1159/000492872</pub-id><pub-id pub-id-type="pmid">30138923</pub-id></element-citation></ref><ref id="bib149"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lucena-Araujo</surname> <given-names>AR</given-names></name><name><surname>Kim</surname> <given-names>HT</given-names></name><name><surname>Thomé</surname> <given-names>C</given-names></name><name><surname>Jacomo</surname> <given-names>RH</given-names></name><name><surname>Melo</surname> <given-names>RA</given-names></name><name><surname>Bittencourt</surname> <given-names>R</given-names></name><name><surname>Pasquini</surname> <given-names>R</given-names></name><name><surname>Pagnano</surname> <given-names>K</given-names></name><name><surname>Glória</surname> <given-names>AB</given-names></name><name><surname>Chauffaille</surname> <given-names>ML</given-names></name><name><surname>Athayde</surname> <given-names>M</given-names></name><name><surname>Chiattone</surname> <given-names>CS</given-names></name><name><surname>Mito</surname> <given-names>I</given-names></name><name><surname>Bendlin</surname> <given-names>R</given-names></name><name><surname>Souza</surname> <given-names>C</given-names></name><name><surname>Bortolheiro</surname> <given-names>C</given-names></name><name><surname>Coelho-Silva</surname> <given-names>JL</given-names></name><name><surname>Schrier</surname> <given-names>SL</given-names></name><name><surname>Tallman</surname> <given-names>MS</given-names></name><name><surname>Grimwade</surname> <given-names>D</given-names></name><name><surname>Ganser</surname> <given-names>A</given-names></name><name><surname>Berliner</surname> <given-names>N</given-names></name><name><surname>Ribeiro</surname> <given-names>RC</given-names></name><name><surname>Lo-Coco</surname> <given-names>F</given-names></name><name><surname>Löwenberg</surname> <given-names>B</given-names></name><name><surname>Sanz</surname> <given-names>MA</given-names></name><name><surname>Rego</surname> <given-names>EM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>High δnp73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia</article-title><source>Blood</source><volume>126</volume><fpage>2302</fpage><lpage>2306</lpage><pub-id pub-id-type="doi">10.1182/blood-2015-01-623330</pub-id><pub-id pub-id-type="pmid">26429976</pub-id></element-citation></ref><ref id="bib150"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname> <given-names>ZG</given-names></name><name><surname>Tang</surname> <given-names>H</given-names></name><name><surname>Li</surname> <given-names>B</given-names></name><name><surname>Zhu</surname> <given-names>Z</given-names></name><name><surname>Ni</surname> <given-names>CR</given-names></name><name><surname>Zhu</surname> <given-names>MH</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Genetic alterations of tumor suppressor <italic>ING1</italic> in human non-small cell lung Cancer</article-title><source>Oncology Reports</source><volume>25</volume><fpage>1073</fpage><lpage>1081</lpage><pub-id pub-id-type="doi">10.3892/or.2011.1172</pub-id><pub-id pub-id-type="pmid">21286670</pub-id></element-citation></ref><ref id="bib151"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname> <given-names>Y</given-names></name><name><surname>Hao</surname> <given-names>T</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>M</given-names></name><name><surname>Sun</surname> <given-names>P</given-names></name><name><surname>Wu</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>MicroRNA-592 suppresses the malignant phenotypes of thyroid Cancer by regulating lncRNA NEAT1 and downregulating NOVA1</article-title><source>International Journal of Molecular Medicine</source><volume>44</volume><fpage>1172</fpage><lpage>1182</lpage><pub-id pub-id-type="doi">10.3892/ijmm.2019.4278</pub-id><pub-id pub-id-type="pmid">31524231</pub-id></element-citation></ref><ref id="bib152"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maas</surname> <given-names>AM</given-names></name><name><surname>Bretz</surname> <given-names>AC</given-names></name><name><surname>Mack</surname> <given-names>E</given-names></name><name><surname>Stiewe</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Targeting p73 in cancer</article-title><source>Cancer Letters</source><volume>332</volume><fpage>229</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2011.07.030</pub-id><pub-id pub-id-type="pmid">21903324</pub-id></element-citation></ref><ref id="bib153"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martincorena</surname> <given-names>I</given-names></name><name><surname>Raine</surname> <given-names>KM</given-names></name><name><surname>Gerstung</surname> <given-names>M</given-names></name><name><surname>Dawson</surname> <given-names>KJ</given-names></name><name><surname>Haase</surname> <given-names>K</given-names></name><name><surname>Van Loo</surname> <given-names>P</given-names></name><name><surname>Davies</surname> <given-names>H</given-names></name><name><surname>Stratton</surname> <given-names>MR</given-names></name><name><surname>Campbell</surname> <given-names>PJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Universal patterns of selection in Cancer and somatic tissues</article-title><source>Cell</source><volume>171</volume><fpage>1029</fpage><lpage>1041</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.09.042</pub-id><pub-id pub-id-type="pmid">29056346</pub-id></element-citation></ref><ref id="bib154"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathupala</surname> <given-names>SP</given-names></name><name><surname>Colen</surname> <given-names>CB</given-names></name><name><surname>Parajuli</surname> <given-names>P</given-names></name><name><surname>Sloan</surname> <given-names>AE</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Lactate and malignant tumors: a therapeutic target at the end stage of glycolysis</article-title><source>Journal of Bioenergetics and Biomembranes</source><volume>39</volume><fpage>73</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1007/s10863-006-9062-x</pub-id><pub-id pub-id-type="pmid">17354062</pub-id></element-citation></ref><ref id="bib155"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsui</surname> <given-names>Y</given-names></name><name><surname>Amano</surname> <given-names>H</given-names></name><name><surname>Ito</surname> <given-names>Y</given-names></name><name><surname>Eshima</surname> <given-names>K</given-names></name><name><surname>Suzuki</surname> <given-names>T</given-names></name><name><surname>Ogawa</surname> <given-names>F</given-names></name><name><surname>Iyoda</surname> <given-names>A</given-names></name><name><surname>Satoh</surname> <given-names>Y</given-names></name><name><surname>Kato</surname> <given-names>S</given-names></name><name><surname>Nakamura</surname> <given-names>M</given-names></name><name><surname>Kitasato</surname> <given-names>H</given-names></name><name><surname>Narumiya</surname> <given-names>S</given-names></name><name><surname>Majima</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Thromboxane A₂ receptor signaling facilitates tumor colonization through P-selectin-mediated interaction of tumor cells with platelets and endothelial cells</article-title><source>Cancer Science</source><volume>103</volume><fpage>700</fpage><lpage>707</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2012.02200.x</pub-id><pub-id pub-id-type="pmid">22296266</pub-id></element-citation></ref><ref id="bib156"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maura</surname> <given-names>F</given-names></name><name><surname>Bolli</surname> <given-names>N</given-names></name><name><surname>Angelopoulos</surname> <given-names>N</given-names></name><name><surname>Dawson</surname> <given-names>KJ</given-names></name><name><surname>Leongamornlert</surname> <given-names>D</given-names></name><name><surname>Martincorena</surname> <given-names>I</given-names></name><name><surname>Mitchell</surname> <given-names>TJ</given-names></name><name><surname>Fullam</surname> <given-names>A</given-names></name><name><surname>Gonzalez</surname> <given-names>S</given-names></name><name><surname>Szalat</surname> <given-names>R</given-names></name><name><surname>Abascal</surname> <given-names>F</given-names></name><name><surname>Rodriguez-Martin</surname> <given-names>B</given-names></name><name><surname>Samur</surname> <given-names>MK</given-names></name><name><surname>Glodzik</surname> <given-names>D</given-names></name><name><surname>Roncador</surname> <given-names>M</given-names></name><name><surname>Fulciniti</surname> <given-names>M</given-names></name><name><surname>Tai</surname> <given-names>YT</given-names></name><name><surname>Minvielle</surname> <given-names>S</given-names></name><name><surname>Magrangeas</surname> <given-names>F</given-names></name><name><surname>Moreau</surname> <given-names>P</given-names></name><name><surname>Corradini</surname> <given-names>P</given-names></name><name><surname>Anderson</surname> <given-names>KC</given-names></name><name><surname>Tubio</surname> <given-names>JMC</given-names></name><name><surname>Wedge</surname> <given-names>DC</given-names></name><name><surname>Gerstung</surname> <given-names>M</given-names></name><name><surname>Avet-Loiseau</surname> <given-names>H</given-names></name><name><surname>Munshi</surname> <given-names>N</given-names></name><name><surname>Campbell</surname> <given-names>PJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Genomic landscape and chronological reconstruction of driver events in multiple myeloma</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>3835</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-11680-1</pub-id><pub-id pub-id-type="pmid">31444325</pub-id></element-citation></ref><ref id="bib157"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McBrayer</surname> <given-names>SK</given-names></name><name><surname>Cheng</surname> <given-names>JC</given-names></name><name><surname>Singhal</surname> <given-names>S</given-names></name><name><surname>Krett</surname> <given-names>NL</given-names></name><name><surname>Rosen</surname> <given-names>ST</given-names></name><name><surname>Shanmugam</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy</article-title><source>Blood</source><volume>119</volume><fpage>4686</fpage><lpage>4697</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-09-377846</pub-id><pub-id pub-id-type="pmid">22452979</pub-id></element-citation></ref><ref id="bib158"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKnight</surname> <given-names>DA</given-names></name><name><surname>Suzanne Hart</surname> <given-names>P</given-names></name><name><surname>Hart</surname> <given-names>TC</given-names></name><name><surname>Hartsfield</surname> <given-names>JK</given-names></name><name><surname>Wilson</surname> <given-names>A</given-names></name><name><surname>Wright</surname> <given-names>JT</given-names></name><name><surname>Fisher</surname> <given-names>LW</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>A comprehensive analysis of normal variation and disease-causing mutations in the human <italic>DSPP</italic> gene</article-title><source>Human Mutation</source><volume>29</volume><fpage>1392</fpage><lpage>1404</lpage><pub-id pub-id-type="doi">10.1002/humu.20783</pub-id><pub-id pub-id-type="pmid">18521831</pub-id></element-citation></ref><ref id="bib159"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melo</surname> <given-names>RCC</given-names></name><name><surname>Ferro</surname> <given-names>KPV</given-names></name><name><surname>Duarte</surname> <given-names>A</given-names></name><name><surname>Olalla Saad</surname> <given-names>ST</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>CXCR7 participates in CXCL12-mediated migration and homing of leukemic and normal hematopoietic cells</article-title><source>Stem Cell Research &amp; Therapy</source><volume>9</volume><elocation-id>34</elocation-id><pub-id pub-id-type="doi">10.1186/s13287-017-0765-1</pub-id><pub-id pub-id-type="pmid">29433559</pub-id></element-citation></ref><ref id="bib160"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname> <given-names>FJ</given-names></name><name><surname>Meng</surname> <given-names>FM</given-names></name><name><surname>Wu</surname> <given-names>HX</given-names></name><name><surname>Cao</surname> <given-names>XF</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>miR-564 inhibited metastasis and proliferation of prostate Cancer by targeting MLLT3</article-title><source>European Review for Medical and Pharmacological Sciences</source><volume>21</volume><fpage>4828</fpage><lpage>4834</lpage><pub-id pub-id-type="pmid">29164580</pub-id></element-citation></ref><ref id="bib161"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyerson</surname> <given-names>M</given-names></name><name><surname>Gabriel</surname> <given-names>S</given-names></name><name><surname>Getz</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Advances in understanding Cancer genomes through second-generation sequencing</article-title><source>Nature Reviews Genetics</source><volume>11</volume><fpage>685</fpage><lpage>696</lpage><pub-id pub-id-type="doi">10.1038/nrg2841</pub-id><pub-id pub-id-type="pmid">20847746</pub-id></element-citation></ref><ref id="bib162"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miao</surname> <given-names>R</given-names></name><name><surname>Wu</surname> <given-names>Y</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Zhou</surname> <given-names>H</given-names></name><name><surname>Sun</surname> <given-names>X</given-names></name><name><surname>Csizmadia</surname> <given-names>E</given-names></name><name><surname>He</surname> <given-names>L</given-names></name><name><surname>Zhao</surname> <given-names>Y</given-names></name><name><surname>Jiang</surname> <given-names>C</given-names></name><name><surname>Miksad</surname> <given-names>RA</given-names></name><name><surname>Ghaziani</surname> <given-names>T</given-names></name><name><surname>Robson</surname> <given-names>SC</given-names></name><name><surname>Zhao</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Utility of the dual-specificity protein kinase TTK as a therapeutic target for intrahepatic spread of liver Cancer</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>33121</elocation-id><pub-id pub-id-type="doi">10.1038/srep33121</pub-id><pub-id pub-id-type="pmid">27618777</pub-id></element-citation></ref><ref id="bib163"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michaelson</surname> <given-names>JJ</given-names></name><name><surname>Shi</surname> <given-names>Y</given-names></name><name><surname>Gujral</surname> <given-names>M</given-names></name><name><surname>Zheng</surname> <given-names>H</given-names></name><name><surname>Malhotra</surname> <given-names>D</given-names></name><name><surname>Jin</surname> <given-names>X</given-names></name><name><surname>Jian</surname> <given-names>M</given-names></name><name><surname>Liu</surname> <given-names>G</given-names></name><name><surname>Greer</surname> <given-names>D</given-names></name><name><surname>Bhandari</surname> <given-names>A</given-names></name><name><surname>Wu</surname> <given-names>W</given-names></name><name><surname>Corominas</surname> <given-names>R</given-names></name><name><surname>Peoples</surname> <given-names>A</given-names></name><name><surname>Koren</surname> <given-names>A</given-names></name><name><surname>Gore</surname> <given-names>A</given-names></name><name><surname>Kang</surname> <given-names>S</given-names></name><name><surname>Lin</surname> <given-names>GN</given-names></name><name><surname>Estabillo</surname> <given-names>J</given-names></name><name><surname>Gadomski</surname> <given-names>T</given-names></name><name><surname>Singh</surname> <given-names>B</given-names></name><name><surname>Zhang</surname> <given-names>K</given-names></name><name><surname>Akshoomoff</surname> <given-names>N</given-names></name><name><surname>Corsello</surname> <given-names>C</given-names></name><name><surname>McCarroll</surname> <given-names>S</given-names></name><name><surname>Iakoucheva</surname> <given-names>LM</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Sebat</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Whole-genome sequencing in autism identifies hot spots for de novo germline mutation</article-title><source>Cell</source><volume>151</volume><fpage>1431</fpage><lpage>1442</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.11.019</pub-id><pub-id pub-id-type="pmid">23260136</pub-id></element-citation></ref><ref id="bib164"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mikheev</surname> <given-names>AM</given-names></name><name><surname>Mikheeva</surname> <given-names>SA</given-names></name><name><surname>Severs</surname> <given-names>LJ</given-names></name><name><surname>Funk</surname> <given-names>CC</given-names></name><name><surname>Huang</surname> <given-names>L</given-names></name><name><surname>McFaline-Figueroa</surname> <given-names>JL</given-names></name><name><surname>Schwensen</surname> <given-names>J</given-names></name><name><surname>Trapnell</surname> <given-names>C</given-names></name><name><surname>Price</surname> <given-names>ND</given-names></name><name><surname>Wong</surname> <given-names>S</given-names></name><name><surname>Rostomily</surname> <given-names>RC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Targeting TWIST1 through loss of function inhibits tumorigenicity of human glioblastoma</article-title><source>Molecular Oncology</source><volume>12</volume><fpage>1188</fpage><lpage>1202</lpage><pub-id pub-id-type="doi">10.1002/1878-0261.12320</pub-id><pub-id pub-id-type="pmid">29754406</pub-id></element-citation></ref><ref id="bib165"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mofers</surname> <given-names>A</given-names></name><name><surname>Pellegrini</surname> <given-names>P</given-names></name><name><surname>Linder</surname> <given-names>S</given-names></name><name><surname>D'Arcy</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Proteasome-associated deubiquitinases and cancer</article-title><source>Cancer and Metastasis Reviews</source><volume>36</volume><fpage>635</fpage><lpage>653</lpage><pub-id pub-id-type="doi">10.1007/s10555-017-9697-6</pub-id><pub-id pub-id-type="pmid">29134486</pub-id></element-citation></ref><ref id="bib166"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nambara</surname> <given-names>S</given-names></name><name><surname>Masuda</surname> <given-names>T</given-names></name><name><surname>Tobo</surname> <given-names>T</given-names></name><name><surname>Kidogami</surname> <given-names>S</given-names></name><name><surname>Komatsu</surname> <given-names>H</given-names></name><name><surname>Sugimachi</surname> <given-names>K</given-names></name><name><surname>Saeki</surname> <given-names>H</given-names></name><name><surname>Oki</surname> <given-names>E</given-names></name><name><surname>Maehara</surname> <given-names>Y</given-names></name><name><surname>Mimori</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Clinical significance of <italic>ZNF750</italic> gene expression, a novel tumor suppressor gene, in esophageal squamous cell carcinoma</article-title><source>Oncology Letters</source><volume>14</volume><fpage>1795</fpage><lpage>1801</lpage><pub-id pub-id-type="doi">10.3892/ol.2017.6341</pub-id><pub-id pub-id-type="pmid">28789412</pub-id></element-citation></ref><ref id="bib167"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikitakis</surname> <given-names>NG</given-names></name><name><surname>Gkouveris</surname> <given-names>I</given-names></name><name><surname>Aseervatham</surname> <given-names>J</given-names></name><name><surname>Barahona</surname> <given-names>K</given-names></name><name><surname>Ogbureke</surname> <given-names>KUE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>DSPP-MMP20 gene silencing downregulates Cancer stem cell markers in human oral Cancer cells</article-title><source>Cellular &amp; Molecular Biology Letters</source><volume>23</volume><elocation-id>30</elocation-id><pub-id pub-id-type="doi">10.1186/s11658-018-0096-y</pub-id><pub-id pub-id-type="pmid">30002682</pub-id></element-citation></ref><ref id="bib168"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niu</surname> <given-names>W</given-names></name><name><surname>Luo</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Zhou</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Fu</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>S</given-names></name><name><surname>Yin</surname> <given-names>S</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Zhao</surname> <given-names>R</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Fan</surname> <given-names>S</given-names></name><name><surname>Li</surname> <given-names>Z</given-names></name><name><surname>Xiong</surname> <given-names>W</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Li</surname> <given-names>G</given-names></name><name><surname>Ren</surname> <given-names>C</given-names></name><name><surname>Tan</surname> <given-names>M</given-names></name><name><surname>Zhou</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>BRD7 inhibits the warburg effect and tumor progression through inactivation of HIF1α/LDHA Axis in breast Cancer</article-title><source>Cell Death &amp; Disease</source><volume>9</volume><elocation-id>519</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-018-0536-7</pub-id><pub-id pub-id-type="pmid">29725006</pub-id></element-citation></ref><ref id="bib169"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noguchi</surname> <given-names>C</given-names></name><name><surname>Kamitori</surname> <given-names>K</given-names></name><name><surname>Hossain</surname> <given-names>A</given-names></name><name><surname>Hoshikawa</surname> <given-names>H</given-names></name><name><surname>Katagi</surname> <given-names>A</given-names></name><name><surname>Dong</surname> <given-names>Y</given-names></name><name><surname>Sui</surname> <given-names>L</given-names></name><name><surname>Tokuda</surname> <given-names>M</given-names></name><name><surname>Yamaguchi</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>D-Allose inhibits Cancer cell growth by reducing GLUT1 expression</article-title><source>The Tohoku Journal of Experimental Medicine</source><volume>238</volume><fpage>131</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1620/tjem.238.131</pub-id><pub-id pub-id-type="pmid">26829886</pub-id></element-citation></ref><ref id="bib170"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nussinov</surname> <given-names>R</given-names></name><name><surname>Jang</surname> <given-names>H</given-names></name><name><surname>Tsai</surname> <given-names>CJ</given-names></name><name><surname>Cheng</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Review: precision medicine and driver mutations: computational methods, functional assays and conformational principles for interpreting Cancer drivers</article-title><source>PLOS Computational Biology</source><volume>15</volume><elocation-id>e1006658</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1006658</pub-id><pub-id pub-id-type="pmid">30921324</pub-id></element-citation></ref><ref id="bib171"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Callaghan</surname> <given-names>C</given-names></name><name><surname>Fanning</surname> <given-names>LJ</given-names></name><name><surname>Houston</surname> <given-names>A</given-names></name><name><surname>Barry</surname> <given-names>OP</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Loss of p38δ mitogen-activated protein kinase expression promotes oesophageal squamous cell carcinoma proliferation, migration and anchorage-independent growth</article-title><source>International Journal of Oncology</source><volume>43</volume><fpage>405</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.3892/ijo.2013.1968</pub-id><pub-id pub-id-type="pmid">23722928</pub-id></element-citation></ref><ref id="bib172"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orr</surname> <given-names>K</given-names></name><name><surname>Buckley</surname> <given-names>NE</given-names></name><name><surname>Haddock</surname> <given-names>P</given-names></name><name><surname>James</surname> <given-names>C</given-names></name><name><surname>Parent</surname> <given-names>JL</given-names></name><name><surname>McQuaid</surname> <given-names>S</given-names></name><name><surname>Mullan</surname> <given-names>PB</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Thromboxane A2 receptor (TBXA2R) is a potent survival factor for triple negative breast cancers (TNBCs)</article-title><source>Oncotarget</source><volume>7</volume><fpage>55458</fpage><lpage>55472</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.10969</pub-id><pub-id pub-id-type="pmid">27487152</pub-id></element-citation></ref><ref id="bib173"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otsuka</surname> <given-names>R</given-names></name><name><surname>Akutsu</surname> <given-names>Y</given-names></name><name><surname>Sakata</surname> <given-names>H</given-names></name><name><surname>Hanari</surname> <given-names>N</given-names></name><name><surname>Murakami</surname> <given-names>K</given-names></name><name><surname>Kano</surname> <given-names>M</given-names></name><name><surname>Toyozumi</surname> <given-names>T</given-names></name><name><surname>Takahashi</surname> <given-names>M</given-names></name><name><surname>Matsumoto</surname> <given-names>Y</given-names></name><name><surname>Sekino</surname> <given-names>N</given-names></name><name><surname>Yokoyama</surname> <given-names>M</given-names></name><name><surname>Okada</surname> <given-names>K</given-names></name><name><surname>Shiraishi</surname> <given-names>T</given-names></name><name><surname>Komatsu</surname> <given-names>A</given-names></name><name><surname>Iida</surname> <given-names>K</given-names></name><name><surname>Matsubara</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>ZNF750 expression is a potential prognostic biomarker in esophageal squamous cell carcinoma</article-title><source>Oncology</source><volume>94</volume><fpage>142</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1159/000484932</pub-id><pub-id pub-id-type="pmid">29216641</pub-id></element-citation></ref><ref id="bib174"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owens</surname> <given-names>P</given-names></name><name><surname>Pickup</surname> <given-names>MW</given-names></name><name><surname>Novitskiy</surname> <given-names>SV</given-names></name><name><surname>Chytil</surname> <given-names>A</given-names></name><name><surname>Gorska</surname> <given-names>AE</given-names></name><name><surname>Aakre</surname> <given-names>ME</given-names></name><name><surname>West</surname> <given-names>J</given-names></name><name><surname>Moses</surname> <given-names>HL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Disruption of bone morphogenetic protein receptor 2 (BMPR2) in mammary tumors promotes metastases through cell autonomous and paracrine mediators</article-title><source>PNAS</source><volume>109</volume><fpage>2814</fpage><lpage>2819</lpage><pub-id pub-id-type="doi">10.1073/pnas.1101139108</pub-id><pub-id pub-id-type="pmid">21576484</pub-id></element-citation></ref><ref id="bib175"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pancrazi</surname> <given-names>L</given-names></name><name><surname>Di Benedetto</surname> <given-names>G</given-names></name><name><surname>Colombaioni</surname> <given-names>L</given-names></name><name><surname>Della Sala</surname> <given-names>G</given-names></name><name><surname>Testa</surname> <given-names>G</given-names></name><name><surname>Olimpico</surname> <given-names>F</given-names></name><name><surname>Reyes</surname> <given-names>A</given-names></name><name><surname>Zeviani</surname> <given-names>M</given-names></name><name><surname>Pozzan</surname> <given-names>T</given-names></name><name><surname>Costa</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Foxg1 localizes to mitochondria and coordinates cell differentiation and bioenergetics</article-title><source>PNAS</source><volume>112</volume><fpage>13910</fpage><lpage>13915</lpage><pub-id pub-id-type="doi">10.1073/pnas.1515190112</pub-id><pub-id pub-id-type="pmid">26508630</pub-id></element-citation></ref><ref id="bib176"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parajuli</surname> <given-names>P</given-names></name><name><surname>Singh</surname> <given-names>P</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Eragamreddi</surname> <given-names>S</given-names></name><name><surname>Ozkan</surname> <given-names>S</given-names></name><name><surname>Ferrigno</surname> <given-names>O</given-names></name><name><surname>Prunier</surname> <given-names>C</given-names></name><name><surname>Razzaque</surname> <given-names>MS</given-names></name><name><surname>Xu</surname> <given-names>K</given-names></name><name><surname>Atfi</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>TGIF1 functions as a tumor suppressor in pancreatic ductal adenocarcinoma</article-title><source>The EMBO Journal</source><volume>38</volume><elocation-id>e101067</elocation-id><pub-id pub-id-type="doi">10.15252/embj.2018101067</pub-id><pub-id pub-id-type="pmid">31268604</pub-id></element-citation></ref><ref id="bib177"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname> <given-names>SW</given-names></name><name><surname>Hur</surname> <given-names>SY</given-names></name><name><surname>Yoo</surname> <given-names>NJ</given-names></name><name><surname>Lee</surname> <given-names>SH</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Somatic frameshift mutations of bone morphogenic protein receptor 2 gene in gastric and colorectal cancers with microsatellite instability</article-title><source>Apmis</source><volume>118</volume><fpage>824</fpage><lpage>829</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0463.2010.02670.x</pub-id><pub-id pub-id-type="pmid">20955454</pub-id></element-citation></ref><ref id="bib178"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parmigiani</surname> <given-names>G</given-names></name><name><surname>Boca</surname> <given-names>S</given-names></name><name><surname>Lin</surname> <given-names>J</given-names></name><name><surname>Kinzler</surname> <given-names>KW</given-names></name><name><surname>Velculescu</surname> <given-names>V</given-names></name><name><surname>Vogelstein</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Design and analysis issues in genome-wide somatic mutation studies of Cancer</article-title><source>Genomics</source><volume>93</volume><fpage>17</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.ygeno.2008.07.005</pub-id><pub-id pub-id-type="pmid">18692126</pub-id></element-citation></ref><ref id="bib179"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasmant</surname> <given-names>E</given-names></name><name><surname>Gilbert-Dussardier</surname> <given-names>B</given-names></name><name><surname>Petit</surname> <given-names>A</given-names></name><name><surname>de Laval</surname> <given-names>B</given-names></name><name><surname>Luscan</surname> <given-names>A</given-names></name><name><surname>Gruber</surname> <given-names>A</given-names></name><name><surname>Lapillonne</surname> <given-names>H</given-names></name><name><surname>Deswarte</surname> <given-names>C</given-names></name><name><surname>Goussard</surname> <given-names>P</given-names></name><name><surname>Laurendeau</surname> <given-names>I</given-names></name><name><surname>Uzan</surname> <given-names>B</given-names></name><name><surname>Pflumio</surname> <given-names>F</given-names></name><name><surname>Brizard</surname> <given-names>F</given-names></name><name><surname>Vabres</surname> <given-names>P</given-names></name><name><surname>Naguibvena</surname> <given-names>I</given-names></name><name><surname>Fasola</surname> <given-names>S</given-names></name><name><surname>Millot</surname> <given-names>F</given-names></name><name><surname>Porteu</surname> <given-names>F</given-names></name><name><surname>Vidaud</surname> <given-names>D</given-names></name><name><surname>Landman-Parker</surname> <given-names>J</given-names></name><name><surname>Ballerini</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>SPRED1, a RAS MAPK pathway inhibitor that causes legius syndrome, is a tumour suppressor downregulated in paediatric acute myeloblastic leukaemia</article-title><source>Oncogene</source><volume>34</volume><fpage>631</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.1038/onc.2013.587</pub-id><pub-id pub-id-type="pmid">24469042</pub-id></element-citation></ref><ref id="bib180"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Patthy</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="1999">1999</year><edition>2nd ed</edition><source>Protein Evolution</source><publisher-name>Blackwell Publishing Ltd</publisher-name></element-citation></ref><ref id="bib181"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peña</surname> <given-names>PV</given-names></name><name><surname>Hom</surname> <given-names>RA</given-names></name><name><surname>Hung</surname> <given-names>T</given-names></name><name><surname>Lin</surname> <given-names>H</given-names></name><name><surname>Kuo</surname> <given-names>AJ</given-names></name><name><surname>Wong</surname> <given-names>RP</given-names></name><name><surname>Subach</surname> <given-names>OM</given-names></name><name><surname>Champagne</surname> <given-names>KS</given-names></name><name><surname>Zhao</surname> <given-names>R</given-names></name><name><surname>Verkhusha</surname> <given-names>VV</given-names></name><name><surname>Li</surname> <given-names>G</given-names></name><name><surname>Gozani</surname> <given-names>O</given-names></name><name><surname>Kutateladze</surname> <given-names>TG</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Histone H3K4me3 binding is required for the DNA repair and apoptotic activities of ING1 tumor suppressor</article-title><source>Journal of Molecular Biology</source><volume>380</volume><fpage>303</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2008.04.061</pub-id><pub-id pub-id-type="pmid">18533182</pub-id></element-citation></ref><ref id="bib182"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrenko</surname> <given-names>O</given-names></name><name><surname>Zaika</surname> <given-names>A</given-names></name><name><surname>Moll</surname> <given-names>UM</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>deltaNp73 facilitates cell immortalization and cooperates with oncogenic ras in cellular transformation in vivo</article-title><source>Molecular and Cellular Biology</source><volume>23</volume><fpage>5540</fpage><lpage>5555</lpage><pub-id pub-id-type="doi">10.1128/MCB.23.16.5540-5555.2003</pub-id><pub-id pub-id-type="pmid">12897129</pub-id></element-citation></ref><ref id="bib183"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfeifer</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Defining driver DNA methylation changes in human Cancer</article-title><source>International Journal of Molecular Sciences</source><volume>19</volume><elocation-id>1166</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19041166</pub-id><pub-id pub-id-type="pmid">29649096</pub-id></element-citation></ref><ref id="bib184"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Philip</surname> <given-names>S</given-names></name><name><surname>Kumarasiri</surname> <given-names>M</given-names></name><name><surname>Teo</surname> <given-names>T</given-names></name><name><surname>Yu</surname> <given-names>M</given-names></name><name><surname>Wang</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cyclin-Dependent kinase 8: a new hope in targeted Cancer therapy?</article-title><source>Journal of Medicinal Chemistry</source><volume>61</volume><fpage>5073</fpage><lpage>5092</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.7b00901</pub-id><pub-id pub-id-type="pmid">29266937</pub-id></element-citation></ref><ref id="bib185"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pickup</surname> <given-names>MW</given-names></name><name><surname>Hover</surname> <given-names>LD</given-names></name><name><surname>Polikowsky</surname> <given-names>ER</given-names></name><name><surname>Chytil</surname> <given-names>A</given-names></name><name><surname>Gorska</surname> <given-names>AE</given-names></name><name><surname>Novitskiy</surname> <given-names>SV</given-names></name><name><surname>Moses</surname> <given-names>HL</given-names></name><name><surname>Owens</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title><italic>BMPR2</italic> loss in fibroblasts promotes mammary carcinoma metastasis via increased inflammation</article-title><source>Molecular Oncology</source><volume>9</volume><fpage>179</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1016/j.molonc.2014.08.004</pub-id><pub-id pub-id-type="pmid">25205038</pub-id></element-citation></ref><ref id="bib186"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polak</surname> <given-names>P</given-names></name><name><surname>Karlić</surname> <given-names>R</given-names></name><name><surname>Koren</surname> <given-names>A</given-names></name><name><surname>Thurman</surname> <given-names>R</given-names></name><name><surname>Sandstrom</surname> <given-names>R</given-names></name><name><surname>Lawrence</surname> <given-names>M</given-names></name><name><surname>Reynolds</surname> <given-names>A</given-names></name><name><surname>Rynes</surname> <given-names>E</given-names></name><name><surname>Vlahoviček</surname> <given-names>K</given-names></name><name><surname>Stamatoyannopoulos</surname> <given-names>JA</given-names></name><name><surname>Sunyaev</surname> <given-names>SR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cell-of-origin chromatin organization shapes the mutational landscape of Cancer</article-title><source>Nature</source><volume>518</volume><fpage>360</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1038/nature14221</pub-id><pub-id pub-id-type="pmid">25693567</pub-id></element-citation></ref><ref id="bib187"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poulain</surname> <given-names>L</given-names></name><name><surname>Sujobert</surname> <given-names>P</given-names></name><name><surname>Zylbersztejn</surname> <given-names>F</given-names></name><name><surname>Barreau</surname> <given-names>S</given-names></name><name><surname>Stuani</surname> <given-names>L</given-names></name><name><surname>Lambert</surname> <given-names>M</given-names></name><name><surname>Palama</surname> <given-names>TL</given-names></name><name><surname>Chesnais</surname> <given-names>V</given-names></name><name><surname>Birsen</surname> <given-names>R</given-names></name><name><surname>Vergez</surname> <given-names>F</given-names></name><name><surname>Farge</surname> <given-names>T</given-names></name><name><surname>Chenevier-Gobeaux</surname> <given-names>C</given-names></name><name><surname>Fraisse</surname> <given-names>M</given-names></name><name><surname>Bouillaud</surname> <given-names>F</given-names></name><name><surname>Debeissat</surname> <given-names>C</given-names></name><name><surname>Herault</surname> <given-names>O</given-names></name><name><surname>Récher</surname> <given-names>C</given-names></name><name><surname>Lacombe</surname> <given-names>C</given-names></name><name><surname>Fontenay</surname> <given-names>M</given-names></name><name><surname>Mayeux</surname> <given-names>P</given-names></name><name><surname>Maciel</surname> <given-names>TT</given-names></name><name><surname>Portais</surname> <given-names>JC</given-names></name><name><surname>Sarry</surname> <given-names>JE</given-names></name><name><surname>Tamburini</surname> <given-names>J</given-names></name><name><surname>Bouscary</surname> <given-names>D</given-names></name><name><surname>Chapuis</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells</article-title><source>Leukemia</source><volume>31</volume><fpage>2326</fpage><lpage>2335</lpage><pub-id pub-id-type="doi">10.1038/leu.2017.81</pub-id><pub-id pub-id-type="pmid">28280275</pub-id></element-citation></ref><ref id="bib188"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poulos</surname> <given-names>RC</given-names></name><name><surname>Wong</surname> <given-names>YT</given-names></name><name><surname>Ryan</surname> <given-names>R</given-names></name><name><surname>Pang</surname> <given-names>H</given-names></name><name><surname>Wong</surname> <given-names>JWH</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Analysis of 7,815 Cancer exomes reveals associations between mutational processes and somatic driver mutations</article-title><source>PLOS Genetics</source><volume>14</volume><elocation-id>e1007779</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1007779</pub-id><pub-id pub-id-type="pmid">30412573</pub-id></element-citation></ref><ref id="bib189"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pu</surname> <given-names>H</given-names></name><name><surname>Zhang</surname> <given-names>Q</given-names></name><name><surname>Zhao</surname> <given-names>C</given-names></name><name><surname>Shi</surname> <given-names>L</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Overexpression of G6PD is associated with high risks of recurrent metastasis and poor progression-free survival in primary breast carcinoma</article-title><source>World Journal of Surgical Oncology</source><volume>13</volume><elocation-id>323</elocation-id><pub-id pub-id-type="doi">10.1186/s12957-015-0733-0</pub-id><pub-id pub-id-type="pmid">26607846</pub-id></element-citation></ref><ref id="bib190"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puddinu</surname> <given-names>V</given-names></name><name><surname>Casella</surname> <given-names>S</given-names></name><name><surname>Radice</surname> <given-names>E</given-names></name><name><surname>Thelen</surname> <given-names>S</given-names></name><name><surname>Dirnhofer</surname> <given-names>S</given-names></name><name><surname>Bertoni</surname> <given-names>F</given-names></name><name><surname>Thelen</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>ACKR3 expression on diffuse large B cell lymphoma is required for tumor spreading and tissue infiltration</article-title><source>Oncotarget</source><volume>8</volume><fpage>85068</fpage><lpage>85084</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.18844</pub-id><pub-id pub-id-type="pmid">29156704</pub-id></element-citation></ref><ref id="bib191"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pulley</surname> <given-names>JM</given-names></name><name><surname>Jerome</surname> <given-names>RN</given-names></name><name><surname>Ogletree</surname> <given-names>ML</given-names></name><name><surname>Bernard</surname> <given-names>GR</given-names></name><name><surname>Lavieri</surname> <given-names>RR</given-names></name><name><surname>Zaleski</surname> <given-names>NM</given-names></name><name><surname>Hong</surname> <given-names>CC</given-names></name><name><surname>Shirey-Rice</surname> <given-names>JK</given-names></name><name><surname>Arteaga</surname> <given-names>CL</given-names></name><name><surname>Mayer</surname> <given-names>IA</given-names></name><name><surname>Holroyd</surname> <given-names>KJ</given-names></name><name><surname>Cook</surname> <given-names>RS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Motivation for launching a Cancer metastasis inhibition (CMI) Program</article-title><source>Targeted Oncology</source><volume>13</volume><fpage>61</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1007/s11523-017-0542-1</pub-id><pub-id pub-id-type="pmid">29218624</pub-id></element-citation></ref><ref id="bib192"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pyatnitskiy</surname> <given-names>M</given-names></name><name><surname>Karpov</surname> <given-names>D</given-names></name><name><surname>Poverennaya</surname> <given-names>E</given-names></name><name><surname>Lisitsa</surname> <given-names>A</given-names></name><name><surname>Moshkovskii</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Bringing down Cancer aircraft: searching for essential hypomutated proteins in skin melanoma</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e0142819</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0142819</pub-id><pub-id pub-id-type="pmid">26565620</pub-id></element-citation></ref><ref id="bib193"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qian</surname> <given-names>T</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Dong</surname> <given-names>Y</given-names></name><name><surname>Zhang</surname> <given-names>L</given-names></name><name><surname>Dong</surname> <given-names>Y</given-names></name><name><surname>Sun</surname> <given-names>Y</given-names></name><name><surname>Sun</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>CXCR7 regulates breast tumor metastasis and angiogenesis in vivo and in vitro</article-title><source>Molecular Medicine Reports</source><volume>17</volume><fpage>3633</fpage><lpage>3639</lpage><pub-id pub-id-type="doi">10.3892/mmr.2017.8286</pub-id><pub-id pub-id-type="pmid">29257351</pub-id></element-citation></ref><ref id="bib194"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahbari</surname> <given-names>R</given-names></name><name><surname>Wuster</surname> <given-names>A</given-names></name><name><surname>Lindsay</surname> <given-names>SJ</given-names></name><name><surname>Hardwick</surname> <given-names>RJ</given-names></name><name><surname>Alexandrov</surname> <given-names>LB</given-names></name><name><surname>Turki</surname> <given-names>SA</given-names></name><name><surname>Dominiczak</surname> <given-names>A</given-names></name><name><surname>Morris</surname> <given-names>A</given-names></name><name><surname>Porteous</surname> <given-names>D</given-names></name><name><surname>Smith</surname> <given-names>B</given-names></name><name><surname>Stratton</surname> <given-names>MR</given-names></name><name><surname>Hurles</surname> <given-names>ME</given-names></name><collab>UK10K Consortium</collab></person-group><year iso-8601-date="2016">2016</year><article-title>Timing, rates and spectra of human germline mutation</article-title><source>Nature Genetics</source><volume>48</volume><fpage>126</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1038/ng.3469</pub-id><pub-id pub-id-type="pmid">26656846</pub-id></element-citation></ref><ref id="bib195"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rai</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Personalized Cancer therapy: yes1 is the new kid on the block</article-title><source>Cancer Research</source><volume>79</volume><fpage>5702</fpage><lpage>5703</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-19-2995</pub-id><pub-id pub-id-type="pmid">31772072</pub-id></element-citation></ref><ref id="bib196"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Razzaque</surname> <given-names>MS</given-names></name><name><surname>Atfi</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>TGIF function in Oncogenic wnt signaling</article-title><source>Biochimica Et Biophysica Acta (BBA) - Reviews on Cancer</source><volume>1865</volume><fpage>101</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1016/j.bbcan.2015.10.003</pub-id><pub-id pub-id-type="pmid">26522669</pub-id></element-citation></ref><ref id="bib197"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rheinbay</surname> <given-names>E</given-names></name><name><surname>Nielsen</surname> <given-names>MM</given-names></name><name><surname>Abascal</surname> <given-names>F</given-names></name><name><surname>Wala</surname> <given-names>JA</given-names></name><name><surname>Shapira</surname> <given-names>O</given-names></name><name><surname>Tiao</surname> <given-names>G</given-names></name><name><surname>Hornshøj</surname> <given-names>H</given-names></name><name><surname>Hess</surname> <given-names>JM</given-names></name><name><surname>Juul</surname> <given-names>RI</given-names></name><name><surname>Lin</surname> <given-names>Z</given-names></name><name><surname>Feuerbach</surname> <given-names>L</given-names></name><name><surname>Sabarinathan</surname> <given-names>R</given-names></name><name><surname>Madsen</surname> <given-names>T</given-names></name><name><surname>Kim</surname> <given-names>J</given-names></name><name><surname>Mularoni</surname> <given-names>L</given-names></name><name><surname>Shuai</surname> <given-names>S</given-names></name><name><surname>Lanzós</surname> <given-names>A</given-names></name><name><surname>Herrmann</surname> <given-names>C</given-names></name><name><surname>Maruvka</surname> <given-names>YE</given-names></name><name><surname>Shen</surname> <given-names>C</given-names></name><name><surname>Amin</surname> <given-names>SB</given-names></name><name><surname>Bandopadhayay</surname> <given-names>P</given-names></name><name><surname>Bertl</surname> <given-names>J</given-names></name><name><surname>Boroevich</surname> <given-names>KA</given-names></name><name><surname>Busanovich</surname> <given-names>J</given-names></name><name><surname>Carlevaro-Fita</surname> <given-names>J</given-names></name><name><surname>Chakravarty</surname> <given-names>D</given-names></name><name><surname>Chan</surname> <given-names>CWY</given-names></name><name><surname>Craft</surname> <given-names>D</given-names></name><name><surname>Dhingra</surname> <given-names>P</given-names></name><name><surname>Diamanti</surname> <given-names>K</given-names></name><name><surname>Fonseca</surname> <given-names>NA</given-names></name><name><surname>Gonzalez-Perez</surname> <given-names>A</given-names></name><name><surname>Guo</surname> <given-names>Q</given-names></name><name><surname>Hamilton</surname> <given-names>MP</given-names></name><name><surname>Haradhvala</surname> <given-names>NJ</given-names></name><name><surname>Hong</surname> <given-names>C</given-names></name><name><surname>Isaev</surname> <given-names>K</given-names></name><name><surname>Johnson</surname> <given-names>TA</given-names></name><name><surname>Juul</surname> <given-names>M</given-names></name><name><surname>Kahles</surname> <given-names>A</given-names></name><name><surname>Kahraman</surname> <given-names>A</given-names></name><name><surname>Kim</surname> <given-names>Y</given-names></name><name><surname>Komorowski</surname> <given-names>J</given-names></name><name><surname>Kumar</surname> <given-names>K</given-names></name><name><surname>Kumar</surname> <given-names>S</given-names></name><name><surname>Lee</surname> <given-names>D</given-names></name><name><surname>Lehmann</surname> <given-names>KV</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>EM</given-names></name><name><surname>Lochovsky</surname> <given-names>L</given-names></name><name><surname>Park</surname> <given-names>K</given-names></name><name><surname>Pich</surname> <given-names>O</given-names></name><name><surname>Roberts</surname> <given-names>ND</given-names></name><name><surname>Saksena</surname> <given-names>G</given-names></name><name><surname>Schumacher</surname> <given-names>SE</given-names></name><name><surname>Sidiropoulos</surname> <given-names>N</given-names></name><name><surname>Sieverling</surname> <given-names>L</given-names></name><name><surname>Sinnott-Armstrong</surname> <given-names>N</given-names></name><name><surname>Stewart</surname> <given-names>C</given-names></name><name><surname>Tamborero</surname> <given-names>D</given-names></name><name><surname>Tubio</surname> <given-names>JMC</given-names></name><name><surname>Umer</surname> <given-names>HM</given-names></name><name><surname>Uusküla-Reimand</surname> <given-names>L</given-names></name><name><surname>Wadelius</surname> <given-names>C</given-names></name><name><surname>Wadi</surname> <given-names>L</given-names></name><name><surname>Yao</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>CZ</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Haber</surname> <given-names>JE</given-names></name><name><surname>Hobolth</surname> <given-names>A</given-names></name><name><surname>Imielinski</surname> <given-names>M</given-names></name><name><surname>Kellis</surname> <given-names>M</given-names></name><name><surname>Lawrence</surname> <given-names>MS</given-names></name><name><surname>von Mering</surname> <given-names>C</given-names></name><name><surname>Nakagawa</surname> <given-names>H</given-names></name><name><surname>Raphael</surname> <given-names>BJ</given-names></name><name><surname>Rubin</surname> <given-names>MA</given-names></name><name><surname>Sander</surname> <given-names>C</given-names></name><name><surname>Stein</surname> <given-names>LD</given-names></name><name><surname>Stuart</surname> <given-names>JM</given-names></name><name><surname>Tsunoda</surname> <given-names>T</given-names></name><name><surname>Wheeler</surname> <given-names>DA</given-names></name><name><surname>Johnson</surname> <given-names>R</given-names></name><name><surname>Reimand</surname> <given-names>J</given-names></name><name><surname>Gerstein</surname> <given-names>M</given-names></name><name><surname>Khurana</surname> <given-names>E</given-names></name><name><surname>Campbell</surname> <given-names>PJ</given-names></name><name><surname>López-Bigas</surname> <given-names>N</given-names></name><name><surname>Weischenfeldt</surname> <given-names>J</given-names></name><name><surname>Beroukhim</surname> <given-names>R</given-names></name><name><surname>Martincorena</surname> <given-names>I</given-names></name><name><surname>Pedersen</surname> <given-names>JS</given-names></name><name><surname>Getz</surname> <given-names>G</given-names></name><collab>PCAWG Drivers and Functional Interpretation Working Group</collab><collab>PCAWG Structural Variation Working Group</collab><collab>PCAWG Consortium</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Analyses of non-coding somatic drivers in 2,658 cancer whole genomes</article-title><source>Nature</source><volume>578</volume><fpage>102</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-1965-x</pub-id><pub-id pub-id-type="pmid">32025015</pub-id></element-citation></ref><ref id="bib198"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rishi</surname> <given-names>L</given-names></name><name><surname>Hannon</surname> <given-names>M</given-names></name><name><surname>Salomè</surname> <given-names>M</given-names></name><name><surname>Hasemann</surname> <given-names>M</given-names></name><name><surname>Frank</surname> <given-names>AK</given-names></name><name><surname>Campos</surname> <given-names>J</given-names></name><name><surname>Timoney</surname> <given-names>J</given-names></name><name><surname>O'Connor</surname> <given-names>C</given-names></name><name><surname>Cahill</surname> <given-names>MR</given-names></name><name><surname>Porse</surname> <given-names>B</given-names></name><name><surname>Keeshan</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Regulation of Trib2 by an E2F1-C/EBPα feedback loop in AML cell proliferation</article-title><source>Blood</source><volume>123</volume><fpage>2389</fpage><lpage>2400</lpage><pub-id pub-id-type="doi">10.1182/blood-2013-07-511683</pub-id><pub-id pub-id-type="pmid">24516045</pub-id></element-citation></ref><ref id="bib199"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname> <given-names>E</given-names></name><name><surname>Perry</surname> <given-names>C</given-names></name><name><surname>Doherty</surname> <given-names>R</given-names></name><name><surname>Madhusudan</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Transcriptomic profiling of forkhead box transcription factors in adult glioblastoma multiforme</article-title><source>Cancer Genomics &amp; Proteomics</source><volume>12</volume><fpage>103</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">25977169</pub-id></element-citation></ref><ref id="bib200"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogozin</surname> <given-names>IB</given-names></name><name><surname>Pavlov</surname> <given-names>YI</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Theoretical analysis of mutation hotspots and their DNA sequence context specificity</article-title><source>Mutation Research/Reviews in Mutation Research</source><volume>544</volume><fpage>65</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/S1383-5742(03)00032-2</pub-id><pub-id pub-id-type="pmid">12888108</pub-id></element-citation></ref><ref id="bib201"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romero</surname> <given-names>OA</given-names></name><name><surname>Torres-Diz</surname> <given-names>M</given-names></name><name><surname>Pros</surname> <given-names>E</given-names></name><name><surname>Savola</surname> <given-names>S</given-names></name><name><surname>Gomez</surname> <given-names>A</given-names></name><name><surname>Moran</surname> <given-names>S</given-names></name><name><surname>Saez</surname> <given-names>C</given-names></name><name><surname>Iwakawa</surname> <given-names>R</given-names></name><name><surname>Villanueva</surname> <given-names>A</given-names></name><name><surname>Montuenga</surname> <given-names>LM</given-names></name><name><surname>Kohno</surname> <given-names>T</given-names></name><name><surname>Yokota</surname> <given-names>J</given-names></name><name><surname>Sanchez-Cespedes</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title><italic>MAX</italic> inactivation in small cell lung Cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1</article-title><source>Cancer Discovery</source><volume>4</volume><fpage>292</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-13-0799</pub-id><pub-id pub-id-type="pmid">24362264</pub-id></element-citation></ref><ref id="bib202"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenbluh</surname> <given-names>J</given-names></name><name><surname>Nijhawan</surname> <given-names>D</given-names></name><name><surname>Cox</surname> <given-names>AG</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Neal</surname> <given-names>JT</given-names></name><name><surname>Schafer</surname> <given-names>EJ</given-names></name><name><surname>Zack</surname> <given-names>TI</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Tsherniak</surname> <given-names>A</given-names></name><name><surname>Schinzel</surname> <given-names>AC</given-names></name><name><surname>Shao</surname> <given-names>DD</given-names></name><name><surname>Schumacher</surname> <given-names>SE</given-names></name><name><surname>Weir</surname> <given-names>BA</given-names></name><name><surname>Vazquez</surname> <given-names>F</given-names></name><name><surname>Cowley</surname> <given-names>GS</given-names></name><name><surname>Root</surname> <given-names>DE</given-names></name><name><surname>Mesirov</surname> <given-names>JP</given-names></name><name><surname>Beroukhim</surname> <given-names>R</given-names></name><name><surname>Kuo</surname> <given-names>CJ</given-names></name><name><surname>Goessling</surname> <given-names>W</given-names></name><name><surname>Hahn</surname> <given-names>WC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis</article-title><source>Cell</source><volume>151</volume><fpage>1457</fpage><lpage>1473</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.11.026</pub-id><pub-id pub-id-type="pmid">23245941</pub-id></element-citation></ref><ref id="bib203"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roussel</surname> <given-names>MF</given-names></name><name><surname>Stripay</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Epigenetic drivers in pediatric medulloblastoma</article-title><source>The Cerebellum</source><volume>17</volume><fpage>28</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1007/s12311-017-0899-9</pub-id><pub-id pub-id-type="pmid">29178021</pub-id></element-citation></ref><ref id="bib204"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salvadores</surname> <given-names>M</given-names></name><name><surname>Mas-Ponte</surname> <given-names>D</given-names></name><name><surname>Supek</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Passenger mutations accurately classify human tumors</article-title><source>PLOS Computational Biology</source><volume>15</volume><elocation-id>e1006953</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1006953</pub-id><pub-id pub-id-type="pmid">30986244</pub-id></element-citation></ref><ref id="bib205"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sancisi</surname> <given-names>V</given-names></name><name><surname>Manzotti</surname> <given-names>G</given-names></name><name><surname>Gugnoni</surname> <given-names>M</given-names></name><name><surname>Rossi</surname> <given-names>T</given-names></name><name><surname>Gandolfi</surname> <given-names>G</given-names></name><name><surname>Gobbi</surname> <given-names>G</given-names></name><name><surname>Torricelli</surname> <given-names>F</given-names></name><name><surname>Catellani</surname> <given-names>F</given-names></name><name><surname>Faria do Valle</surname> <given-names>I</given-names></name><name><surname>Remondini</surname> <given-names>D</given-names></name><name><surname>Castellani</surname> <given-names>G</given-names></name><name><surname>Ragazzi</surname> <given-names>M</given-names></name><name><surname>Piana</surname> <given-names>S</given-names></name><name><surname>Ciarrocchi</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>RUNX2 expression in thyroid and breast Cancer requires the cooperation of three non-redundant enhancers under the control of BRD4 and c-JUN</article-title><source>Nucleic Acids Research</source><volume>45</volume><fpage>11249</fpage><lpage>11267</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx802</pub-id><pub-id pub-id-type="pmid">28981843</pub-id></element-citation></ref><ref id="bib206"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saxena</surname> <given-names>G</given-names></name><name><surname>Koli</surname> <given-names>K</given-names></name><name><surname>de la Garza</surname> <given-names>J</given-names></name><name><surname>Ogbureke</surname> <given-names>KU</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Matrix metalloproteinase 20-dentin sialophosphoprotein interaction in oral Cancer</article-title><source>Journal of Dental Research</source><volume>94</volume><fpage>584</fpage><lpage>593</lpage><pub-id pub-id-type="doi">10.1177/0022034515570156</pub-id><pub-id pub-id-type="pmid">25666817</pub-id></element-citation></ref><ref id="bib207"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sayed</surname> <given-names>ME</given-names></name><name><surname>Yuan</surname> <given-names>L</given-names></name><name><surname>Robin</surname> <given-names>JD</given-names></name><name><surname>Tedone</surname> <given-names>E</given-names></name><name><surname>Batten</surname> <given-names>K</given-names></name><name><surname>Dahlson</surname> <given-names>N</given-names></name><name><surname>Wright</surname> <given-names>WE</given-names></name><name><surname>Shay</surname> <given-names>JW</given-names></name><name><surname>Ludlow</surname> <given-names>AT</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>NOVA1 directs PTBP1 to hTERT pre-mRNA and promotes telomerase activity in Cancer cells</article-title><source>Oncogene</source><volume>38</volume><fpage>2937</fpage><lpage>2952</lpage><pub-id pub-id-type="doi">10.1038/s41388-018-0639-8</pub-id><pub-id pub-id-type="pmid">30568224</pub-id></element-citation></ref><ref id="bib208"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schindler</surname> <given-names>EM</given-names></name><name><surname>Hindes</surname> <given-names>A</given-names></name><name><surname>Gribben</surname> <given-names>EL</given-names></name><name><surname>Burns</surname> <given-names>CJ</given-names></name><name><surname>Yin</surname> <given-names>Y</given-names></name><name><surname>Lin</surname> <given-names>MH</given-names></name><name><surname>Owen</surname> <given-names>RJ</given-names></name><name><surname>Longmore</surname> <given-names>GD</given-names></name><name><surname>Kissling</surname> <given-names>GE</given-names></name><name><surname>Arthur</surname> <given-names>JS</given-names></name><name><surname>Efimova</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>p38δ Mitogen-activated protein kinase is essential for skin tumor development in mice</article-title><source>Cancer Research</source><volume>69</volume><fpage>4648</fpage><lpage>4655</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-4455</pub-id><pub-id pub-id-type="pmid">19458068</pub-id></element-citation></ref><ref id="bib209"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmall</surname> <given-names>A</given-names></name><name><surname>Al-Tamari</surname> <given-names>HM</given-names></name><name><surname>Herold</surname> <given-names>S</given-names></name><name><surname>Kampschulte</surname> <given-names>M</given-names></name><name><surname>Weigert</surname> <given-names>A</given-names></name><name><surname>Wietelmann</surname> <given-names>A</given-names></name><name><surname>Vipotnik</surname> <given-names>N</given-names></name><name><surname>Grimminger</surname> <given-names>F</given-names></name><name><surname>Seeger</surname> <given-names>W</given-names></name><name><surname>Pullamsetti</surname> <given-names>SS</given-names></name><name><surname>Savai</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Macrophage and Cancer cell cross-talk via CCR2 and CX3CR1 is a fundamental mechanism driving lung Cancer</article-title><source>American Journal of Respiratory and Critical Care Medicine</source><volume>191</volume><fpage>437</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1164/rccm.201406-1137OC</pub-id><pub-id pub-id-type="pmid">25536148</pub-id></element-citation></ref><ref id="bib210"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuster-Böckler</surname> <given-names>B</given-names></name><name><surname>Lehner</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Chromatin organization is a major influence on regional mutation rates in human Cancer cells</article-title><source>Nature</source><volume>488</volume><fpage>504</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1038/nature11273</pub-id><pub-id pub-id-type="pmid">22820252</pub-id></element-citation></ref><ref id="bib211"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Semenza</surname> <given-names>GL</given-names></name></person-group><year iso-8601-date="2010">2010a</year><article-title>HIF-1: upstream and downstream of Cancer metabolism</article-title><source>Current Opinion in Genetics &amp; Development</source><volume>20</volume><fpage>51</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.gde.2009.10.009</pub-id><pub-id pub-id-type="pmid">19942427</pub-id></element-citation></ref><ref id="bib212"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Semenza</surname> <given-names>GL</given-names></name></person-group><year iso-8601-date="2010">2010b</year><article-title>Defining the role of hypoxia-inducible factor 1 in Cancer biology and therapeutics</article-title><source>Oncogene</source><volume>29</volume><fpage>625</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1038/onc.2009.441</pub-id><pub-id pub-id-type="pmid">19946328</pub-id></element-citation></ref><ref id="bib213"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serrao</surname> <given-names>A</given-names></name><name><surname>Jenkins</surname> <given-names>LM</given-names></name><name><surname>Chumanevich</surname> <given-names>AA</given-names></name><name><surname>Horst</surname> <given-names>B</given-names></name><name><surname>Liang</surname> <given-names>J</given-names></name><name><surname>Gatza</surname> <given-names>ML</given-names></name><name><surname>Lee</surname> <given-names>NY</given-names></name><name><surname>Roninson</surname> <given-names>IB</given-names></name><name><surname>Broude</surname> <given-names>EV</given-names></name><name><surname>Mythreye</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mediator kinase CDK8/CDK19 drives YAP1-dependent BMP4-induced EMT in Cancer</article-title><source>Oncogene</source><volume>37</volume><fpage>4792</fpage><lpage>4808</lpage><pub-id pub-id-type="doi">10.1038/s41388-018-0316-y</pub-id><pub-id pub-id-type="pmid">29780169</pub-id></element-citation></ref><ref id="bib214"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname> <given-names>A</given-names></name><name><surname>Melhuish</surname> <given-names>TA</given-names></name><name><surname>Fox</surname> <given-names>TE</given-names></name><name><surname>Frierson</surname> <given-names>HF</given-names></name><name><surname>Wotton</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>TGIF transcription factors repress acetyl CoA metabolic gene expression and promote intestinal tumor growth</article-title><source>Genes &amp; Development</source><volume>33</volume><fpage>388</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1101/gad.320127.118</pub-id><pub-id pub-id-type="pmid">30808659</pub-id></element-citation></ref><ref id="bib215"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shain</surname> <given-names>AH</given-names></name><name><surname>Yeh</surname> <given-names>I</given-names></name><name><surname>Kovalyshyn</surname> <given-names>I</given-names></name><name><surname>Sriharan</surname> <given-names>A</given-names></name><name><surname>Talevich</surname> <given-names>E</given-names></name><name><surname>Gagnon</surname> <given-names>A</given-names></name><name><surname>Dummer</surname> <given-names>R</given-names></name><name><surname>North</surname> <given-names>J</given-names></name><name><surname>Pincus</surname> <given-names>L</given-names></name><name><surname>Ruben</surname> <given-names>B</given-names></name><name><surname>Rickaby</surname> <given-names>W</given-names></name><name><surname>D’Arrigo</surname> <given-names>C</given-names></name><name><surname>Robson</surname> <given-names>A</given-names></name><name><surname>Bastian</surname> <given-names>BC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The genetic evolution of melanoma from precursor lesions</article-title><source>New England Journal of Medicine</source><volume>373</volume><fpage>1926</fpage><lpage>1936</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1502583</pub-id><pub-id pub-id-type="pmid">26559571</pub-id></element-citation></ref><ref id="bib216"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname> <given-names>Y</given-names></name><name><surname>Miladi</surname> <given-names>M</given-names></name><name><surname>Dukare</surname> <given-names>S</given-names></name><name><surname>Boulay</surname> <given-names>K</given-names></name><name><surname>Caudron-Herger</surname> <given-names>M</given-names></name><name><surname>Groß</surname> <given-names>M</given-names></name><name><surname>Backofen</surname> <given-names>R</given-names></name><name><surname>Diederichs</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A pan-cancer analysis of synonymous mutations</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>2569</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-10489-2</pub-id><pub-id pub-id-type="pmid">31189880</pub-id></element-citation></ref><ref id="bib217"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname> <given-names>F</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Jernigan</surname> <given-names>DL</given-names></name><name><surname>Feng</surname> <given-names>X</given-names></name><name><surname>Yan</surname> <given-names>J</given-names></name><name><surname>Garcia</surname> <given-names>FU</given-names></name><name><surname>Meucci</surname> <given-names>O</given-names></name><name><surname>Salvino</surname> <given-names>JM</given-names></name><name><surname>Fatatis</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Novel Small-Molecule CX3CR1 antagonist impairs metastatic seeding and colonization of breast Cancer cells</article-title><source>Molecular Cancer Research</source><volume>14</volume><fpage>518</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-16-0013</pub-id><pub-id pub-id-type="pmid">27001765</pub-id></element-citation></ref><ref id="bib218"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname> <given-names>Y</given-names></name><name><surname>Chen</surname> <given-names>F</given-names></name><name><surname>Liang</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>MicroRNA-133a inhibits the proliferation of non-small cell lung Cancer by targeting <italic>YES1</italic></article-title><source>Oncology Letters</source><volume>18</volume><fpage>6759</fpage><lpage>6765</lpage><pub-id pub-id-type="doi">10.3892/ol.2019.11030</pub-id><pub-id pub-id-type="pmid">31807185</pub-id></element-citation></ref><ref id="bib219"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname> <given-names>Y</given-names></name><name><surname>Geng</surname> <given-names>D</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Zhao</surname> <given-names>M</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Jiang</surname> <given-names>Y</given-names></name><name><surname>Yu</surname> <given-names>R</given-names></name><name><surname>Zhou</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>LATS2 inhibits malignant behaviors of glioma cells via inactivating YAP</article-title><source>Journal of Molecular Neuroscience</source><volume>68</volume><fpage>38</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1007/s12031-019-1262-z</pub-id><pub-id pub-id-type="pmid">30771084</pub-id></element-citation></ref><ref id="bib220"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shibuya</surname> <given-names>K</given-names></name><name><surname>Okada</surname> <given-names>M</given-names></name><name><surname>Suzuki</surname> <given-names>S</given-names></name><name><surname>Seino</surname> <given-names>M</given-names></name><name><surname>Seino</surname> <given-names>S</given-names></name><name><surname>Takeda</surname> <given-names>H</given-names></name><name><surname>Kitanaka</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Targeting the facilitative glucose transporter GLUT1 inhibits the self-renewal and tumor-initiating capacity of Cancer stem cells</article-title><source>Oncotarget</source><volume>6</volume><fpage>651</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.2892</pub-id><pub-id pub-id-type="pmid">25528771</pub-id></element-citation></ref><ref id="bib221"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname> <given-names>MH</given-names></name><name><surname>He</surname> <given-names>Y</given-names></name><name><surname>Marrogi</surname> <given-names>E</given-names></name><name><surname>Piperdi</surname> <given-names>S</given-names></name><name><surname>Ren</surname> <given-names>L</given-names></name><name><surname>Khanna</surname> <given-names>C</given-names></name><name><surname>Gorlick</surname> <given-names>R</given-names></name><name><surname>Liu</surname> <given-names>C</given-names></name><name><surname>Huang</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A RUNX2-Mediated epigenetic regulation of the survival of p53 defective Cancer cells</article-title><source>PLOS Genetics</source><volume>12</volume><elocation-id>e1005884</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1005884</pub-id><pub-id pub-id-type="pmid">26925584</pub-id></element-citation></ref><ref id="bib222"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sillars-Hardebol</surname> <given-names>AH</given-names></name><name><surname>Carvalho</surname> <given-names>B</given-names></name><name><surname>Tijssen</surname> <given-names>M</given-names></name><name><surname>Beliën</surname> <given-names>JA</given-names></name><name><surname>de Wit</surname> <given-names>M</given-names></name><name><surname>Delis-van Diemen</surname> <given-names>PM</given-names></name><name><surname>Pontén</surname> <given-names>F</given-names></name><name><surname>van de Wiel</surname> <given-names>MA</given-names></name><name><surname>Fijneman</surname> <given-names>RJ</given-names></name><name><surname>Meijer</surname> <given-names>GA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title><italic>TPX2</italic> and <italic>AURKA</italic> promote 20q amplicon-driven colorectal adenoma to carcinoma progression</article-title><source>Gut</source><volume>61</volume><fpage>1568</fpage><lpage>1575</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2011-301153</pub-id><pub-id pub-id-type="pmid">22207630</pub-id></element-citation></ref><ref id="bib223"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slack</surname> <given-names>FJ</given-names></name><name><surname>Chinnaiyan</surname> <given-names>AM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The role of Non-coding RNAs in oncology</article-title><source>Cell</source><volume>179</volume><fpage>1033</fpage><lpage>1055</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.10.017</pub-id><pub-id pub-id-type="pmid">31730848</pub-id></element-citation></ref><ref id="bib224"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sondka</surname> <given-names>Z</given-names></name><name><surname>Bamford</surname> <given-names>S</given-names></name><name><surname>Cole</surname> <given-names>CG</given-names></name><name><surname>Ward</surname> <given-names>SA</given-names></name><name><surname>Dunham</surname> <given-names>I</given-names></name><name><surname>Forbes</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The COSMIC Cancer gene census: describing genetic dysfunction across all human cancers</article-title><source>Nature Reviews Cancer</source><volume>18</volume><fpage>696</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1038/s41568-018-0060-1</pub-id><pub-id pub-id-type="pmid">30293088</pub-id></element-citation></ref><ref id="bib225"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname> <given-names>XL</given-names></name><name><surname>Tang</surname> <given-names>Y</given-names></name><name><surname>Lei</surname> <given-names>XH</given-names></name><name><surname>Zhao</surname> <given-names>SC</given-names></name><name><surname>Wu</surname> <given-names>ZQ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>miR-618 inhibits prostate Cancer migration and invasion by targeting FOXP2</article-title><source>Journal of Cancer</source><volume>8</volume><fpage>2501</fpage><lpage>2510</lpage><pub-id pub-id-type="doi">10.7150/jca.17407</pub-id><pub-id pub-id-type="pmid">28900488</pub-id></element-citation></ref><ref id="bib226"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stacer</surname> <given-names>AC</given-names></name><name><surname>Fenner</surname> <given-names>J</given-names></name><name><surname>Cavnar</surname> <given-names>SP</given-names></name><name><surname>Xiao</surname> <given-names>A</given-names></name><name><surname>Zhao</surname> <given-names>S</given-names></name><name><surname>Chang</surname> <given-names>SL</given-names></name><name><surname>Salomonnson</surname> <given-names>A</given-names></name><name><surname>Luker</surname> <given-names>KE</given-names></name><name><surname>Luker</surname> <given-names>GD</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Endothelial CXCR7 regulates breast Cancer metastasis</article-title><source>Oncogene</source><volume>35</volume><fpage>1716</fpage><lpage>1724</lpage><pub-id pub-id-type="doi">10.1038/onc.2015.236</pub-id><pub-id pub-id-type="pmid">26119946</pub-id></element-citation></ref><ref id="bib227"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stiewe</surname> <given-names>T</given-names></name><name><surname>Zimmermann</surname> <given-names>S</given-names></name><name><surname>Frilling</surname> <given-names>A</given-names></name><name><surname>Esche</surname> <given-names>H</given-names></name><name><surname>Pützer</surname> <given-names>BM</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Transactivation-deficient DeltaTA-p73 acts as an oncogene</article-title><source>Cancer Research</source><volume>62</volume><fpage>3598</fpage><lpage>3602</lpage><pub-id pub-id-type="pmid">12097259</pub-id></element-citation></ref><ref id="bib228"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stiewe</surname> <given-names>T</given-names></name><name><surname>Pützer</surname> <given-names>BM</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Role of p73 in malignancy: tumor suppressor or oncogene?</article-title><source>Cell Death &amp; Differentiation</source><volume>9</volume><fpage>237</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1038/sj.cdd.4400995</pub-id><pub-id pub-id-type="pmid">11859406</pub-id></element-citation></ref><ref id="bib229"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stothard</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The sequence manipulation suite: javascript programs for analyzing and formatting protein and DNA sequences</article-title><source>BioTechniques</source><volume>28</volume><fpage>1102</fpage><lpage>1104</lpage><pub-id pub-id-type="doi">10.2144/00286ir01</pub-id><pub-id pub-id-type="pmid">10868275</pub-id></element-citation></ref><ref id="bib230"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname> <given-names>ZL</given-names></name><name><surname>Su</surname> <given-names>CW</given-names></name><name><surname>Huang</surname> <given-names>YL</given-names></name><name><surname>Yang</surname> <given-names>WY</given-names></name><name><surname>Sampurna</surname> <given-names>BP</given-names></name><name><surname>Ouchi</surname> <given-names>T</given-names></name><name><surname>Lee</surname> <given-names>KL</given-names></name><name><surname>Cs</surname> <given-names>W</given-names></name><name><surname>Wang</surname> <given-names>HD</given-names></name><name><surname>Yuh</surname> <given-names>CH</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A novel AURKA Mutant-Induced Early-Onset severe hepatocarcinogenesis greater than Wild-Type via activating different pathways in zebrafish</article-title><source>Cancers</source><volume>11</volume><elocation-id>927</elocation-id><pub-id pub-id-type="doi">10.3390/cancers11070927</pub-id><pub-id pub-id-type="pmid">31269749</pub-id></element-citation></ref><ref id="bib231"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suk</surname> <given-names>FM</given-names></name><name><surname>Chang</surname> <given-names>CC</given-names></name><name><surname>Lin</surname> <given-names>RJ</given-names></name><name><surname>Lin</surname> <given-names>SY</given-names></name><name><surname>Liu</surname> <given-names>SC</given-names></name><name><surname>Jau</surname> <given-names>CF</given-names></name><name><surname>Liang</surname> <given-names>YC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>ZFP36L1 and ZFP36L2 inhibit cell proliferation in a cyclin D-dependent and p53-independent manner</article-title><source>Scientific Reports</source><volume>8</volume><elocation-id>2742</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-21160-z</pub-id><pub-id pub-id-type="pmid">29426877</pub-id></element-citation></ref><ref id="bib232"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sukeda</surname> <given-names>A</given-names></name><name><surname>Nakamura</surname> <given-names>Y</given-names></name><name><surname>Nishida</surname> <given-names>Y</given-names></name><name><surname>Kojima</surname> <given-names>M</given-names></name><name><surname>Gotohda</surname> <given-names>N</given-names></name><name><surname>Akimoto</surname> <given-names>T</given-names></name><name><surname>Ochiai</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Expression of monocarboxylate transporter 1 is associated with better prognosis and reduced nodal metastasis in pancreatic ductal adenocarcinoma</article-title><source>Pancreas</source><volume>48</volume><fpage>1102</fpage><lpage>1110</lpage><pub-id pub-id-type="doi">10.1097/MPA.0000000000001369</pub-id><pub-id pub-id-type="pmid">31404019</pub-id></element-citation></ref><ref id="bib233"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname> <given-names>D</given-names></name><name><surname>Wang</surname> <given-names>C</given-names></name><name><surname>Long</surname> <given-names>S</given-names></name><name><surname>Ma</surname> <given-names>Y</given-names></name><name><surname>Guo</surname> <given-names>Y</given-names></name><name><surname>Huang</surname> <given-names>Z</given-names></name><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>C</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>C/EBP-β-activated microRNA-223 promotes tumour growth through targeting RASA1 in human colorectal Cancer</article-title><source>British Journal of Cancer</source><volume>112</volume><fpage>1491</fpage><lpage>1500</lpage><pub-id pub-id-type="doi">10.1038/bjc.2015.107</pub-id><pub-id pub-id-type="pmid">25867276</pub-id></element-citation></ref><ref id="bib234"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Zhang</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A pilot study of aberrant CpG island hypermethylation of <italic>SPRED1</italic> in Acute Myeloloid Leukemia</article-title><source>International Journal of Medical Sciences</source><volume>16</volume><fpage>324</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.7150/ijms.27757</pub-id><pub-id pub-id-type="pmid">30745814</pub-id></element-citation></ref><ref id="bib235"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname> <given-names>H</given-names></name><name><surname>Kanchi</surname> <given-names>KL</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Hill</surname> <given-names>KS</given-names></name><name><surname>Messina</surname> <given-names>JL</given-names></name><name><surname>Lee</surname> <given-names>JH</given-names></name><name><surname>Kim</surname> <given-names>Y</given-names></name><name><surname>Dees</surname> <given-names>ND</given-names></name><name><surname>Ding</surname> <given-names>L</given-names></name><name><surname>Teer</surname> <given-names>JK</given-names></name><name><surname>Yang</surname> <given-names>S</given-names></name><name><surname>Sarnaik</surname> <given-names>AA</given-names></name><name><surname>Sondak</surname> <given-names>VK</given-names></name><name><surname>Mulé</surname> <given-names>JJ</given-names></name><name><surname>Wilson</surname> <given-names>RK</given-names></name><name><surname>Weber</surname> <given-names>JS</given-names></name><name><surname>Kim</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation</article-title><source>Oncotarget</source><volume>7</volume><fpage>23885</fpage><lpage>23896</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.8127</pub-id><pub-id pub-id-type="pmid">26993606</pub-id></element-citation></ref><ref id="bib236"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Supek</surname> <given-names>F</given-names></name><name><surname>Miñana</surname> <given-names>B</given-names></name><name><surname>Valcárcel</surname> <given-names>J</given-names></name><name><surname>Gabaldón</surname> <given-names>T</given-names></name><name><surname>Lehner</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Synonymous mutations frequently act as driver mutations in human cancers</article-title><source>Cell</source><volume>156</volume><fpage>1324</fpage><lpage>1335</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.01.051</pub-id><pub-id pub-id-type="pmid">24630730</pub-id></element-citation></ref><ref id="bib237"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname> <given-names>Y</given-names></name><name><surname>Sheridan</surname> <given-names>P</given-names></name><name><surname>Niida</surname> <given-names>A</given-names></name><name><surname>Sawada</surname> <given-names>G</given-names></name><name><surname>Uchi</surname> <given-names>R</given-names></name><name><surname>Mizuno</surname> <given-names>H</given-names></name><name><surname>Kurashige</surname> <given-names>J</given-names></name><name><surname>Sugimachi</surname> <given-names>K</given-names></name><name><surname>Sasaki</surname> <given-names>S</given-names></name><name><surname>Shimada</surname> <given-names>Y</given-names></name><name><surname>Hase</surname> <given-names>K</given-names></name><name><surname>Kusunoki</surname> <given-names>M</given-names></name><name><surname>Kudo</surname> <given-names>S</given-names></name><name><surname>Watanabe</surname> <given-names>M</given-names></name><name><surname>Yamada</surname> <given-names>K</given-names></name><name><surname>Sugihara</surname> <given-names>K</given-names></name><name><surname>Yamamoto</surname> <given-names>H</given-names></name><name><surname>Suzuki</surname> <given-names>A</given-names></name><name><surname>Doki</surname> <given-names>Y</given-names></name><name><surname>Miyano</surname> <given-names>S</given-names></name><name><surname>Mori</surname> <given-names>M</given-names></name><name><surname>Mimori</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The AURKA/TPX2 Axis drives Colon tumorigenesis cooperatively with MYC</article-title><source>Annals of Oncology</source><volume>26</volume><fpage>935</fpage><lpage>942</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdv034</pub-id><pub-id pub-id-type="pmid">25632068</pub-id></element-citation></ref><ref id="bib238"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamborero</surname> <given-names>D</given-names></name><name><surname>Gonzalez-Perez</surname> <given-names>A</given-names></name><name><surname>Perez-Llamas</surname> <given-names>C</given-names></name><name><surname>Deu-Pons</surname> <given-names>J</given-names></name><name><surname>Kandoth</surname> <given-names>C</given-names></name><name><surname>Reimand</surname> <given-names>J</given-names></name><name><surname>Lawrence</surname> <given-names>MS</given-names></name><name><surname>Getz</surname> <given-names>G</given-names></name><name><surname>Bader</surname> <given-names>GD</given-names></name><name><surname>Ding</surname> <given-names>L</given-names></name><name><surname>Lopez-Bigas</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Comprehensive identification of mutational Cancer driver genes across 12 tumor types</article-title><source>Scientific Reports</source><volume>3</volume><elocation-id>2650</elocation-id><pub-id pub-id-type="doi">10.1038/srep02650</pub-id><pub-id pub-id-type="pmid">24084849</pub-id></element-citation></ref><ref id="bib239"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname> <given-names>W</given-names></name><name><surname>Lim</surname> <given-names>SG</given-names></name><name><surname>Tan</surname> <given-names>TM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Up-regulation of microRNA-210 inhibits proliferation of hepatocellular carcinoma cells by targeting YES1</article-title><source>World Journal of Gastroenterology</source><volume>21</volume><fpage>13030</fpage><lpage>13041</lpage><pub-id pub-id-type="doi">10.3748/wjg.v21.i46.13030</pub-id><pub-id pub-id-type="pmid">26676187</pub-id></element-citation></ref><ref id="bib240"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tandon</surname> <given-names>M</given-names></name><name><surname>Chen</surname> <given-names>Z</given-names></name><name><surname>Pratap</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Runx2 activates PI3K/Akt signaling via mTORC2 regulation in invasive breast Cancer cells</article-title><source>Breast Cancer Research</source><volume>16</volume><elocation-id>R16</elocation-id><pub-id pub-id-type="doi">10.1186/bcr3611</pub-id><pub-id pub-id-type="pmid">24479521</pub-id></element-citation></ref><ref id="bib241"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tandon</surname> <given-names>M</given-names></name><name><surname>Chen</surname> <given-names>Z</given-names></name><name><surname>Othman</surname> <given-names>AH</given-names></name><name><surname>Pratap</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Role of Runx2 in IGF-1Rβ/Akt- and AMPK/Erk-dependent growth, survival and sensitivity towards metformin in breast Cancer bone metastasis</article-title><source>Oncogene</source><volume>35</volume><fpage>4730</fpage><lpage>4740</lpage><pub-id pub-id-type="doi">10.1038/onc.2015.518</pub-id><pub-id pub-id-type="pmid">26804175</pub-id></element-citation></ref><ref id="bib242"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tate</surname> <given-names>JG</given-names></name><name><surname>Bamford</surname> <given-names>S</given-names></name><name><surname>Jubb</surname> <given-names>HC</given-names></name><name><surname>Sondka</surname> <given-names>Z</given-names></name><name><surname>Beare</surname> <given-names>DM</given-names></name><name><surname>Bindal</surname> <given-names>N</given-names></name><name><surname>Boutselakis</surname> <given-names>H</given-names></name><name><surname>Cole</surname> <given-names>CG</given-names></name><name><surname>Creatore</surname> <given-names>C</given-names></name><name><surname>Dawson</surname> <given-names>E</given-names></name><name><surname>Fish</surname> <given-names>P</given-names></name><name><surname>Harsha</surname> <given-names>B</given-names></name><name><surname>Hathaway</surname> <given-names>C</given-names></name><name><surname>Jupe</surname> <given-names>SC</given-names></name><name><surname>Kok</surname> <given-names>CY</given-names></name><name><surname>Noble</surname> <given-names>K</given-names></name><name><surname>Ponting</surname> <given-names>L</given-names></name><name><surname>Ramshaw</surname> <given-names>CC</given-names></name><name><surname>Rye</surname> <given-names>CE</given-names></name><name><surname>Speedy</surname> <given-names>HE</given-names></name><name><surname>Stefancsik</surname> <given-names>R</given-names></name><name><surname>Thompson</surname> <given-names>SL</given-names></name><name><surname>Wang</surname> <given-names>S</given-names></name><name><surname>Ward</surname> <given-names>S</given-names></name><name><surname>Campbell</surname> <given-names>PJ</given-names></name><name><surname>Forbes</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>COSMIC: the catalogue of somatic mutations in Cancer</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>D941</fpage><lpage>D947</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1015</pub-id><pub-id pub-id-type="pmid">30371878</pub-id></element-citation></ref><ref id="bib243"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thakur</surname> <given-names>S</given-names></name><name><surname>Singla</surname> <given-names>AK</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Tran</surname> <given-names>U</given-names></name><name><surname>Yang</surname> <given-names>Y</given-names></name><name><surname>Salazar</surname> <given-names>C</given-names></name><name><surname>Magliocco</surname> <given-names>A</given-names></name><name><surname>Klimowicz</surname> <given-names>A</given-names></name><name><surname>Jirik</surname> <given-names>F</given-names></name><name><surname>Riabowol</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Reduced ING1 levels in breast Cancer promotes metastasis</article-title><source>Oncotarget</source><volume>5</volume><fpage>4244</fpage><lpage>4256</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.1988</pub-id><pub-id pub-id-type="pmid">24962136</pub-id></element-citation></ref><ref id="bib244"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Tilk</surname> <given-names>S</given-names></name><name><surname>Curtis</surname> <given-names>C</given-names></name><name><surname>Petrov</surname> <given-names>DA</given-names></name><name><surname>McFarland</surname> <given-names>CD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Most cancers carry a substantial deleterious load due to Hill-Robertson interference</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/764340</pub-id></element-citation></ref><ref id="bib245"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Todenhöfer</surname> <given-names>T</given-names></name><name><surname>Seiler</surname> <given-names>R</given-names></name><name><surname>Stewart</surname> <given-names>C</given-names></name><name><surname>Moskalev</surname> <given-names>I</given-names></name><name><surname>Gao</surname> <given-names>J</given-names></name><name><surname>Ladhar</surname> <given-names>S</given-names></name><name><surname>Kamjabi</surname> <given-names>A</given-names></name><name><surname>Al Nakouzi</surname> <given-names>N</given-names></name><name><surname>Hayashi</surname> <given-names>T</given-names></name><name><surname>Choi</surname> <given-names>S</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Frees</surname> <given-names>S</given-names></name><name><surname>Daugaard</surname> <given-names>M</given-names></name><name><surname>Oo</surname> <given-names>HZ</given-names></name><name><surname>Fisel</surname> <given-names>P</given-names></name><name><surname>Schwab</surname> <given-names>M</given-names></name><name><surname>Schaeffeler</surname> <given-names>E</given-names></name><name><surname>Douglas</surname> <given-names>J</given-names></name><name><surname>Hennenlotter</surname> <given-names>J</given-names></name><name><surname>Bedke</surname> <given-names>J</given-names></name><name><surname>Gibb</surname> <given-names>EA</given-names></name><name><surname>Fazli</surname> <given-names>L</given-names></name><name><surname>Stenzl</surname> <given-names>A</given-names></name><name><surname>Black</surname> <given-names>PC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Selective inhibition of the lactate transporter MCT4 reduces growth of invasive bladder Cancer</article-title><source>Molecular Cancer Therapeutics</source><volume>17</volume><fpage>2746</fpage><lpage>2755</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-18-0107</pub-id><pub-id pub-id-type="pmid">30262589</pub-id></element-citation></ref><ref id="bib246"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torrente</surname> <given-names>A</given-names></name><name><surname>Lukk</surname> <given-names>M</given-names></name><name><surname>Xue</surname> <given-names>V</given-names></name><name><surname>Parkinson</surname> <given-names>H</given-names></name><name><surname>Rung</surname> <given-names>J</given-names></name><name><surname>Brazma</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Identification of Cancer related genes using a comprehensive map of human gene expression</article-title><source>PLOS ONE</source><volume>11</volume><elocation-id>e0157484</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0157484</pub-id><pub-id pub-id-type="pmid">27322383</pub-id></element-citation></ref><ref id="bib247"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toyama</surname> <given-names>T</given-names></name><name><surname>Iwase</surname> <given-names>H</given-names></name><name><surname>Watson</surname> <given-names>P</given-names></name><name><surname>Muzik</surname> <given-names>H</given-names></name><name><surname>Saettler</surname> <given-names>E</given-names></name><name><surname>Magliocco</surname> <given-names>A</given-names></name><name><surname>DiFrancesco</surname> <given-names>L</given-names></name><name><surname>Forsyth</surname> <given-names>P</given-names></name><name><surname>Garkavtsev</surname> <given-names>I</given-names></name><name><surname>Kobayashi</surname> <given-names>S</given-names></name><name><surname>Riabowol</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Suppression of <italic>ING1</italic> expression in sporadic breast Cancer</article-title><source>Oncogene</source><volume>18</volume><fpage>5187</fpage><lpage>5193</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1202905</pub-id><pub-id pub-id-type="pmid">10498868</pub-id></element-citation></ref><ref id="bib248"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Treekitkarnmongkol</surname> <given-names>W</given-names></name><name><surname>Katayama</surname> <given-names>H</given-names></name><name><surname>Kai</surname> <given-names>K</given-names></name><name><surname>Sasai</surname> <given-names>K</given-names></name><name><surname>Jones</surname> <given-names>JC</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Shen</surname> <given-names>L</given-names></name><name><surname>Sahin</surname> <given-names>AA</given-names></name><name><surname>Gagea</surname> <given-names>M</given-names></name><name><surname>Ueno</surname> <given-names>NT</given-names></name><name><surname>Creighton</surname> <given-names>CJ</given-names></name><name><surname>Sen</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Aurora kinase-A overexpression in mouse mammary epithelium induces mammary adenocarcinomas harboring genetic alterations shared with human breast Cancer</article-title><source>Carcinogenesis</source><volume>37</volume><fpage>1180</fpage><lpage>1189</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgw097</pub-id><pub-id pub-id-type="pmid">27624071</pub-id></element-citation></ref><ref id="bib249"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van den Eynden</surname> <given-names>J</given-names></name><name><surname>Larsson</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Mutational signatures are critical for proper estimation of purifying selection pressures in Cancer somatic mutation data when using the dN/dS metric</article-title><source>Frontiers in Genetics</source><volume>8</volume><elocation-id>74</elocation-id><pub-id pub-id-type="doi">10.3389/fgene.2017.00074</pub-id></element-citation></ref><ref id="bib250"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Gijn</surname> <given-names>SE</given-names></name><name><surname>Wierenga</surname> <given-names>E</given-names></name><name><surname>van den Tempel</surname> <given-names>N</given-names></name><name><surname>Kok</surname> <given-names>YP</given-names></name><name><surname>Heijink</surname> <given-names>AM</given-names></name><name><surname>Spierings</surname> <given-names>DCJ</given-names></name><name><surname>Foijer</surname> <given-names>F</given-names></name><name><surname>van Vugt</surname> <given-names>M</given-names></name><name><surname>Fehrmann</surname> <given-names>RSN</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>TPX2/Aurora kinase A signaling as a potential therapeutic target in genomically unstable cancer cells</article-title><source>Oncogene</source><volume>38</volume><fpage>852</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1038/s41388-018-0470-2</pub-id><pub-id pub-id-type="pmid">30177840</pub-id></element-citation></ref><ref id="bib251"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Tongelen</surname> <given-names>A</given-names></name><name><surname>Loriot</surname> <given-names>A</given-names></name><name><surname>De Smet</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Oncogenic roles of DNA hypomethylation through the activation of cancer-germline genes</article-title><source>Cancer Letters</source><volume>396</volume><fpage>130</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2017.03.029</pub-id><pub-id pub-id-type="pmid">28342986</pub-id></element-citation></ref><ref id="bib252"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venkitachalam</surname> <given-names>S</given-names></name><name><surname>Revoredo</surname> <given-names>L</given-names></name><name><surname>Varadan</surname> <given-names>V</given-names></name><name><surname>Fecteau</surname> <given-names>RE</given-names></name><name><surname>Ravi</surname> <given-names>L</given-names></name><name><surname>Lutterbaugh</surname> <given-names>J</given-names></name><name><surname>Markowitz</surname> <given-names>SD</given-names></name><name><surname>Willis</surname> <given-names>JE</given-names></name><name><surname>Gerken</surname> <given-names>TA</given-names></name><name><surname>Guda</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Biochemical and functional characterization of glycosylation-associated mutational landscapes in Colon cancer</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>23642</elocation-id><pub-id pub-id-type="doi">10.1038/srep23642</pub-id><pub-id pub-id-type="pmid">27004849</pub-id></element-citation></ref><ref id="bib253"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verhaak</surname> <given-names>RGW</given-names></name><name><surname>Bafna</surname> <given-names>V</given-names></name><name><surname>Mischel</surname> <given-names>PS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Extrachromosomal oncogene amplification in tumour pathogenesis and evolution</article-title><source>Nature Reviews Cancer</source><volume>19</volume><fpage>283</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1038/s41568-019-0128-6</pub-id><pub-id pub-id-type="pmid">30872802</pub-id></element-citation></ref><ref id="bib254"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vitale</surname> <given-names>I</given-names></name><name><surname>Galluzzi</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Everybody in! no bouncers at tumor gates</article-title><source>Trends in Genetics</source><volume>34</volume><fpage>85</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/j.tig.2017.12.006</pub-id><pub-id pub-id-type="pmid">29277455</pub-id></element-citation></ref><ref id="bib255"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogelstein</surname> <given-names>B</given-names></name><name><surname>Papadopoulos</surname> <given-names>N</given-names></name><name><surname>Velculescu</surname> <given-names>VE</given-names></name><name><surname>Zhou</surname> <given-names>S</given-names></name><name><surname>Diaz</surname> <given-names>LA</given-names></name><name><surname>Kinzler</surname> <given-names>KW</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Cancer genome landscapes</article-title><source>Science</source><volume>339</volume><fpage>1546</fpage><lpage>1558</lpage><pub-id pub-id-type="doi">10.1126/science.1235122</pub-id><pub-id pub-id-type="pmid">23539594</pub-id></element-citation></ref><ref id="bib256"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogelstein</surname> <given-names>B</given-names></name><name><surname>Kinzler</surname> <given-names>KW</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The path to Cancer — Three Strikes and You're Out</article-title><source>New England Journal of Medicine</source><volume>373</volume><fpage>1895</fpage><lpage>1898</lpage><pub-id pub-id-type="doi">10.1056/NEJMp1508811</pub-id></element-citation></ref><ref id="bib257"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voronina</surname> <given-names>N</given-names></name><name><surname>Wong</surname> <given-names>JKL</given-names></name><name><surname>Hübschmann</surname> <given-names>D</given-names></name><name><surname>Hlevnjak</surname> <given-names>M</given-names></name><name><surname>Uhrig</surname> <given-names>S</given-names></name><name><surname>Heilig</surname> <given-names>CE</given-names></name><name><surname>Horak</surname> <given-names>P</given-names></name><name><surname>Kreutzfeldt</surname> <given-names>S</given-names></name><name><surname>Mock</surname> <given-names>A</given-names></name><name><surname>Stenzinger</surname> <given-names>A</given-names></name><name><surname>Hutter</surname> <given-names>B</given-names></name><name><surname>Fröhlich</surname> <given-names>M</given-names></name><name><surname>Brors</surname> <given-names>B</given-names></name><name><surname>Jahn</surname> <given-names>A</given-names></name><name><surname>Klink</surname> <given-names>B</given-names></name><name><surname>Gieldon</surname> <given-names>L</given-names></name><name><surname>Sieverling</surname> <given-names>L</given-names></name><name><surname>Feuerbach</surname> <given-names>L</given-names></name><name><surname>Chudasama</surname> <given-names>P</given-names></name><name><surname>Beck</surname> <given-names>K</given-names></name><name><surname>Kroiss</surname> <given-names>M</given-names></name><name><surname>Heining</surname> <given-names>C</given-names></name><name><surname>Möhrmann</surname> <given-names>L</given-names></name><name><surname>Fischer</surname> <given-names>A</given-names></name><name><surname>Schröck</surname> <given-names>E</given-names></name><name><surname>Glimm</surname> <given-names>H</given-names></name><name><surname>Zapatka</surname> <given-names>M</given-names></name><name><surname>Lichter</surname> <given-names>P</given-names></name><name><surname>Fröhling</surname> <given-names>S</given-names></name><name><surname>Ernst</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The landscape of chromothripsis across adult Cancer types</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>2320</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-16134-7</pub-id><pub-id pub-id-type="pmid">32385320</pub-id></element-citation></ref><ref id="bib258"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voutsadakis</surname> <given-names>IA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Proteasome expression and activity in Cancer and Cancer stem cells</article-title><source>Tumor Biology</source><volume>39</volume><elocation-id>101042831769224</elocation-id><pub-id pub-id-type="doi">10.1177/1010428317692248</pub-id><pub-id pub-id-type="pmid">28345458</pub-id></element-citation></ref><ref id="bib259"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wada</surname> <given-names>M</given-names></name><name><surname>Canals</surname> <given-names>D</given-names></name><name><surname>Adada</surname> <given-names>M</given-names></name><name><surname>Coant</surname> <given-names>N</given-names></name><name><surname>Salama</surname> <given-names>MF</given-names></name><name><surname>Helke</surname> <given-names>KL</given-names></name><name><surname>Arthur</surname> <given-names>JS</given-names></name><name><surname>Shroyer</surname> <given-names>KR</given-names></name><name><surname>Kitatani</surname> <given-names>K</given-names></name><name><surname>Obeid</surname> <given-names>LM</given-names></name><name><surname>Hannun</surname> <given-names>YA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>P38 Delta MAPK promotes breast Cancer progression and lung metastasis by enhancing cell proliferation and cell detachment</article-title><source>Oncogene</source><volume>36</volume><fpage>6649</fpage><lpage>6657</lpage><pub-id pub-id-type="doi">10.1038/onc.2017.274</pub-id><pub-id pub-id-type="pmid">28783172</pub-id></element-citation></ref><ref id="bib260"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname> <given-names>GJ</given-names></name><name><surname>Walters</surname> <given-names>MK</given-names></name><name><surname>Palmer</surname> <given-names>JM</given-names></name><name><surname>Hayward</surname> <given-names>NK</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>The <italic>MLLT3</italic> gene maps between D9S156 and D9S171 and contains an unstable polymorphic trinucleotide repeat</article-title><source>Genomics</source><volume>20</volume><fpage>490</fpage><lpage>491</lpage><pub-id pub-id-type="doi">10.1006/geno.1994.1206</pub-id><pub-id pub-id-type="pmid">8034324</pub-id></element-citation></ref><ref id="bib261"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Yuan</surname> <given-names>W</given-names></name><name><surname>Chen</surname> <given-names>Z</given-names></name><name><surname>Wu</surname> <given-names>S</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Ge</surname> <given-names>J</given-names></name><name><surname>Hou</surname> <given-names>F</given-names></name><name><surname>Chen</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Overexpression of G6PD is associated with poor clinical outcome in gastric Cancer</article-title><source>Tumor Biology</source><volume>33</volume><fpage>95</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1007/s13277-011-0251-9</pub-id><pub-id pub-id-type="pmid">22012600</pub-id></element-citation></ref><ref id="bib262"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Park</surname> <given-names>JS</given-names></name><name><surname>Wei</surname> <given-names>Y</given-names></name><name><surname>Rajurkar</surname> <given-names>M</given-names></name><name><surname>Cotton</surname> <given-names>JL</given-names></name><name><surname>Fan</surname> <given-names>Q</given-names></name><name><surname>Lewis</surname> <given-names>BC</given-names></name><name><surname>Ji</surname> <given-names>H</given-names></name><name><surname>Mao</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013a</year><article-title>TRIB2 acts downstream of wnt/TCF in liver Cancer cells to regulate YAP and C/EBPα function</article-title><source>Molecular Cell</source><volume>51</volume><fpage>211</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2013.05.013</pub-id><pub-id pub-id-type="pmid">23769673</pub-id></element-citation></ref><ref id="bib263"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Weng</surname> <given-names>W</given-names></name><name><surname>Qiao</surname> <given-names>Y</given-names></name><name><surname>Ma</surname> <given-names>L</given-names></name><name><surname>Xiao</surname> <given-names>W</given-names></name><name><surname>Yu</surname> <given-names>Y</given-names></name><name><surname>Pan</surname> <given-names>Q</given-names></name><name><surname>Sun</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2013">2013b</year><article-title>Impaired phosphorylation and ubiquitination by p70 S6 kinase (p70S6K) and smad ubiquitination regulatory factor 1 (Smurf1) promote tribbles homolog 2 (TRIB2) stability and carcinogenic property in liver Cancer</article-title><source>Journal of Biological Chemistry</source><volume>288</volume><fpage>33667</fpage><lpage>33681</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.503292</pub-id><pub-id pub-id-type="pmid">24089522</pub-id></element-citation></ref><ref id="bib264"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>T</given-names></name><name><surname>Birsoy</surname> <given-names>K</given-names></name><name><surname>Hughes</surname> <given-names>NW</given-names></name><name><surname>Krupczak</surname> <given-names>KM</given-names></name><name><surname>Post</surname> <given-names>Y</given-names></name><name><surname>Wei</surname> <given-names>JJ</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Sabatini</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2015">2015a</year><article-title>Identification and characterization of essential genes in the human genome</article-title><source>Science</source><volume>350</volume><fpage>1096</fpage><lpage>1101</lpage><pub-id pub-id-type="doi">10.1126/science.aac7041</pub-id><pub-id pub-id-type="pmid">26472758</pub-id></element-citation></ref><ref id="bib265"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Fan</surname> <given-names>R</given-names></name><name><surname>Gu</surname> <given-names>H</given-names></name><name><surname>Shi</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2015">2015b</year><article-title>Glucose-6-phosphate dehydrogenase expression is correlated with poor clinical prognosis in esophageal squamous cell carcinoma</article-title><source>European Journal of Surgical Oncology</source><volume>41</volume><fpage>1293</fpage><lpage>1299</lpage><pub-id pub-id-type="doi">10.1016/j.ejso.2015.08.155</pub-id><pub-id pub-id-type="pmid">26329784</pub-id></element-citation></ref><ref id="bib266"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Wu</surname> <given-names>Y</given-names></name><name><surname>Zhang</surname> <given-names>R</given-names></name><name><surname>Zhang</surname> <given-names>M</given-names></name><name><surname>Liao</surname> <given-names>D</given-names></name><name><surname>Wang</surname> <given-names>G</given-names></name><name><surname>Qin</surname> <given-names>G</given-names></name><name><surname>Xu</surname> <given-names>RH</given-names></name><name><surname>Kang</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>CBX4 suppresses metastasis via recruitment of HDAC3 to the Runx2 promoter in colorectal carcinoma</article-title><source>Cancer Research</source><volume>76</volume><fpage>7277</fpage><lpage>7289</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-16-2100</pub-id><pub-id pub-id-type="pmid">27864346</pub-id></element-citation></ref><ref id="bib267"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Ye</surname> <given-names>C</given-names></name><name><surname>Chen</surname> <given-names>C</given-names></name><name><surname>Xiong</surname> <given-names>H</given-names></name><name><surname>Xie</surname> <given-names>B</given-names></name><name><surname>Zhou</surname> <given-names>J</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Zheng</surname> <given-names>S</given-names></name><name><surname>Wang</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2017">2017a</year><article-title>Glucose transporter GLUT1 expression and clinical outcome in solid tumors: a systematic review and meta-analysis</article-title><source>Oncotarget</source><volume>8</volume><fpage>16875</fpage><lpage>16886</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.15171</pub-id><pub-id pub-id-type="pmid">28187435</pub-id></element-citation></ref><ref id="bib268"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Nikhil</surname> <given-names>K</given-names></name><name><surname>Viccaro</surname> <given-names>K</given-names></name><name><surname>Chang</surname> <given-names>L</given-names></name><name><surname>Jacobsen</surname> <given-names>M</given-names></name><name><surname>Sandusky</surname> <given-names>G</given-names></name><name><surname>Shah</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2017">2017b</year><article-title>The Aurora-A-Twist1 Axis promotes highly aggressive phenotypes in pancreatic carcinoma</article-title><source>Journal of Cell Science</source><volume>130</volume><fpage>1078</fpage><lpage>1093</lpage><pub-id pub-id-type="doi">10.1242/jcs.196790</pub-id><pub-id pub-id-type="pmid">28167680</pub-id></element-citation></ref><ref id="bib269"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>J-L</given-names></name><name><surname>Qi</surname> <given-names>Z</given-names></name><name><surname>Li</surname> <given-names>Y-H</given-names></name><name><surname>Zhao</surname> <given-names>H-M</given-names></name><name><surname>Chen</surname> <given-names>Y-G</given-names></name><name><surname>Fu</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2017">2017c</year><article-title>TGFβ induced factor homeobox 1 promotes colorectal Cancer development through activating wnt/β-catenin signaling</article-title><source>Oncotarget</source><volume>8</volume><fpage>70214</fpage><lpage>70225</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.19603</pub-id></element-citation></ref><ref id="bib270"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Xie</surname> <given-names>Y</given-names></name><name><surname>Bai</surname> <given-names>X</given-names></name><name><surname>Wang</surname> <given-names>N</given-names></name><name><surname>Yu</surname> <given-names>H</given-names></name><name><surname>Deng</surname> <given-names>Z</given-names></name><name><surname>Lian</surname> <given-names>M</given-names></name><name><surname>Yu</surname> <given-names>S</given-names></name><name><surname>Liu</surname> <given-names>H</given-names></name><name><surname>Xie</surname> <given-names>W</given-names></name><name><surname>Wang</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018a</year><article-title>Targeting dual specificity protein kinase TTK attenuates tumorigenesis of glioblastoma</article-title><source>Oncotarget</source><volume>9</volume><fpage>3081</fpage><lpage>3088</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.23152</pub-id><pub-id pub-id-type="pmid">29423030</pub-id></element-citation></ref><ref id="bib271"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Jin</surname> <given-names>T</given-names></name><name><surname>Zhou</surname> <given-names>Y</given-names></name><name><surname>Chen</surname> <given-names>Q</given-names></name></person-group><year iso-8601-date="2018">2018b</year><article-title>FoxG1 facilitates proliferation and inhibits differentiation by downregulating FoxO/Smad signaling in glioblastoma</article-title><source>Biochemical and Biophysical Research Communications</source><volume>504</volume><fpage>46</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2018.08.118</pub-id><pub-id pub-id-type="pmid">30172378</pub-id></element-citation></ref><ref id="bib272"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Yang</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018c</year><article-title>Silencing <italic>TGIF</italic> suppresses migration, invasion and metastasis of MDA–MB–231 human breast cancer cells</article-title><source>Oncology Reports</source><volume>39</volume><fpage>802</fpage><lpage>808</lpage><pub-id pub-id-type="doi">10.3892/or.2017.6133</pub-id><pub-id pub-id-type="pmid">29207164</pub-id></element-citation></ref><ref id="bib273"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>WX</given-names></name><name><surname>Yu</surname> <given-names>HL</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>MiR-9-5p suppresses cell metastasis and epithelial-mesenchymal transition through targeting FOXP2 and predicts prognosis of colorectal carcinoma</article-title><source>European Review for Medical and Pharmacological Sciences</source><volume>23</volume><fpage>6467</fpage><lpage>6477</lpage><pub-id pub-id-type="doi">10.26355/eurrev_201908_18530</pub-id><pub-id pub-id-type="pmid">31378886</pub-id></element-citation></ref><ref id="bib274"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Zuo</surname> <given-names>J</given-names></name><name><surname>Wahafu</surname> <given-names>A</given-names></name><name><surname>Wang</surname> <given-names>MD</given-names></name><name><surname>Li</surname> <given-names>RC</given-names></name><name><surname>Xie</surname> <given-names>WF</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Combined elevation of TRIB2 and MAP3K1 indicates poor prognosis and chemoresistance to temozolomide in glioblastoma</article-title><source>CNS Neuroscience &amp; Therapeutics</source><volume>26</volume><fpage>297</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1111/cns.13197</pub-id><pub-id pub-id-type="pmid">31318172</pub-id></element-citation></ref><ref id="bib275"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warburg</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="1956">1956a</year><article-title>On respiratory impairment in Cancer cells</article-title><source>Science</source><volume>124</volume><fpage>269</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1126/science.124.3215.267</pub-id><pub-id pub-id-type="pmid">13351639</pub-id></element-citation></ref><ref id="bib276"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warburg</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="1956">1956b</year><article-title>On the origin of Cancer cells</article-title><source>Science</source><volume>123</volume><fpage>309</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1126/science.123.3191.309</pub-id><pub-id pub-id-type="pmid">13298683</pub-id></element-citation></ref><ref id="bib277"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watkins</surname> <given-names>G</given-names></name><name><surname>Douglas-Jones</surname> <given-names>A</given-names></name><name><surname>Mansel</surname> <given-names>RE</given-names></name><name><surname>Jiang</surname> <given-names>WG</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Expression of thromboxane synthase, TBXAS1 and the thromboxane A2 receptor, TBXA2R, in human breast Cancer</article-title><source>International Seminars in Surgical Oncology : ISSO</source><volume>2</volume><elocation-id>23</elocation-id><pub-id pub-id-type="doi">10.1186/1477-7800-2-23</pub-id><pub-id pub-id-type="pmid">16250911</pub-id></element-citation></ref><ref id="bib278"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weghorn</surname> <given-names>D</given-names></name><name><surname>Sunyaev</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Bayesian inference of negative and positive selection in human cancers</article-title><source>Nature Genetics</source><volume>49</volume><fpage>1785</fpage><lpage>1788</lpage><pub-id pub-id-type="doi">10.1038/ng.3987</pub-id><pub-id pub-id-type="pmid">29106416</pub-id></element-citation></ref><ref id="bib279"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname> <given-names>LM</given-names></name><name><surname>Cao</surname> <given-names>S</given-names></name><name><surname>Yu</surname> <given-names>WD</given-names></name><name><surname>Liu</surname> <given-names>YL</given-names></name><name><surname>Wang</surname> <given-names>JT</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Overexpression of CX3CR1 is associated with cellular metastasis, proliferation and survival in gastric Cancer</article-title><source>Oncology Reports</source><volume>33</volume><fpage>615</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.3892/or.2014.3645</pub-id><pub-id pub-id-type="pmid">25482732</pub-id></element-citation></ref><ref id="bib280"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname> <given-names>CY</given-names></name><name><surname>Zhu</surname> <given-names>MX</given-names></name><name><surname>Yang</surname> <given-names>YW</given-names></name><name><surname>Zhang</surname> <given-names>PF</given-names></name><name><surname>Yang</surname> <given-names>X</given-names></name><name><surname>Peng</surname> <given-names>R</given-names></name><name><surname>Gao</surname> <given-names>C</given-names></name><name><surname>Lu</surname> <given-names>JC</given-names></name><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Deng</surname> <given-names>XY</given-names></name><name><surname>Lu</surname> <given-names>NH</given-names></name><name><surname>Qi</surname> <given-names>FZ</given-names></name><name><surname>Gu</surname> <given-names>JY</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Downregulation of <italic>RNF128</italic> activates wnt/β-catenin signaling to induce cellular EMT and stemness via CD44 and CTTN ubiquitination in melanoma</article-title><source>Journal of Hematology &amp; Oncology</source><volume>12</volume><elocation-id>21</elocation-id><pub-id pub-id-type="doi">10.1186/s13045-019-0711-z</pub-id><pub-id pub-id-type="pmid">30832692</pub-id></element-citation></ref><ref id="bib281"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wellberg</surname> <given-names>EA</given-names></name><name><surname>Johnson</surname> <given-names>S</given-names></name><name><surname>Finlay-Schultz</surname> <given-names>J</given-names></name><name><surname>Lewis</surname> <given-names>AS</given-names></name><name><surname>Terrell</surname> <given-names>KL</given-names></name><name><surname>Sartorius</surname> <given-names>CA</given-names></name><name><surname>Abel</surname> <given-names>ED</given-names></name><name><surname>Muller</surname> <given-names>WJ</given-names></name><name><surname>Anderson</surname> <given-names>SM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The glucose transporter GLUT1 is required for ErbB2-induced mammary tumorigenesis</article-title><source>Breast Cancer Research</source><volume>18</volume><elocation-id>131</elocation-id><pub-id pub-id-type="doi">10.1186/s13058-016-0795-0</pub-id><pub-id pub-id-type="pmid">27998284</pub-id></element-citation></ref><ref id="bib282"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weng</surname> <given-names>CC</given-names></name><name><surname>Hsieh</surname> <given-names>MJ</given-names></name><name><surname>Wu</surname> <given-names>CC</given-names></name><name><surname>Lin</surname> <given-names>YC</given-names></name><name><surname>Shan</surname> <given-names>YS</given-names></name><name><surname>Hung</surname> <given-names>WC</given-names></name><name><surname>Chen</surname> <given-names>LT</given-names></name><name><surname>Cheng</surname> <given-names>KH</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Loss of the transcriptional repressor TGIF1 results in enhanced Kras-driven development of pancreatic Cancer</article-title><source>Molecular Cancer</source><volume>18</volume><elocation-id>96</elocation-id><pub-id pub-id-type="doi">10.1186/s12943-019-1023-1</pub-id><pub-id pub-id-type="pmid">31109321</pub-id></element-citation></ref><ref id="bib283"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witkiewicz</surname> <given-names>AK</given-names></name><name><surname>Whitaker-Menezes</surname> <given-names>D</given-names></name><name><surname>Dasgupta</surname> <given-names>A</given-names></name><name><surname>Philp</surname> <given-names>NJ</given-names></name><name><surname>Lin</surname> <given-names>Z</given-names></name><name><surname>Gandara</surname> <given-names>R</given-names></name><name><surname>Sneddon</surname> <given-names>S</given-names></name><name><surname>Martinez-Outschoorn</surname> <given-names>UE</given-names></name><name><surname>Sotgia</surname> <given-names>F</given-names></name><name><surname>Lisanti</surname> <given-names>MP</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Using the &quot;reverse Warburg effect&quot; to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers</article-title><source>Cell Cycle</source><volume>11</volume><fpage>1108</fpage><lpage>1117</lpage><pub-id pub-id-type="doi">10.4161/cc.11.6.19530</pub-id><pub-id pub-id-type="pmid">22313602</pub-id></element-citation></ref><ref id="bib284"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname> <given-names>JCY</given-names></name><name><surname>Gokgoz</surname> <given-names>N</given-names></name><name><surname>Alon</surname> <given-names>N</given-names></name><name><surname>Andrulis</surname> <given-names>IL</given-names></name><name><surname>Buchwald</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Cloning and mutation analysis of ZFP276 as a candidate tumor suppressor in breast Cancer</article-title><source>Journal of Human Genetics</source><volume>48</volume><fpage>668</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.1007/s10038-003-0088-1</pub-id><pub-id pub-id-type="pmid">14605947</pub-id></element-citation></ref><ref id="bib285"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>S</given-names></name><name><surname>Lv</surname> <given-names>Z</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Sun</surname> <given-names>L</given-names></name><name><surname>Jiang</surname> <given-names>Z</given-names></name><name><surname>Xu</surname> <given-names>C</given-names></name><name><surname>Zhao</surname> <given-names>J</given-names></name><name><surname>Sun</surname> <given-names>X</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Hu</surname> <given-names>L</given-names></name><name><surname>Tang</surname> <given-names>A</given-names></name><name><surname>Gui</surname> <given-names>Y</given-names></name><name><surname>Zhou</surname> <given-names>F</given-names></name><name><surname>Cai</surname> <given-names>Z</given-names></name><name><surname>Wang</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Increased expression of pregnancy up-regulated non-ubiquitous calmodulin kinase is associated with poor prognosis in clear cell renal cell carcinoma</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e59936</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0059936</pub-id><pub-id pub-id-type="pmid">23634203</pub-id></element-citation></ref><ref id="bib286"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>J</given-names></name><name><surname>Liu</surname> <given-names>P</given-names></name><name><surname>Tang</surname> <given-names>H</given-names></name><name><surname>Shuang</surname> <given-names>Z</given-names></name><name><surname>Qiu</surname> <given-names>Q</given-names></name><name><surname>Zhang</surname> <given-names>L</given-names></name><name><surname>Song</surname> <given-names>C</given-names></name><name><surname>Liu</surname> <given-names>L</given-names></name><name><surname>Xie</surname> <given-names>X</given-names></name><name><surname>Xiao</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>FOXP2 promotes tumor proliferation and metastasis by targeting GRP78 in Triple-negative breast Cancer</article-title><source>Current Cancer Drug Targets</source><volume>18</volume><fpage>382</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.2174/1568009618666180131115356</pub-id><pub-id pub-id-type="pmid">29484998</pub-id></element-citation></ref><ref id="bib287"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wushou</surname> <given-names>A</given-names></name><name><surname>Hou</surname> <given-names>J</given-names></name><name><surname>Zhao</surname> <given-names>Y-J</given-names></name><name><surname>Shao</surname> <given-names>Z-M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Twist-1 Up-Regulation in carcinoma correlates to poor survival</article-title><source>International Journal of Molecular Sciences</source><volume>15</volume><fpage>21621</fpage><lpage>21630</lpage><pub-id pub-id-type="doi">10.3390/ijms151221621</pub-id><pub-id pub-id-type="pmid">25429425</pub-id></element-citation></ref><ref id="bib288"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiang</surname> <given-names>G</given-names></name><name><surname>Yi</surname> <given-names>Y</given-names></name><name><surname>Weiwei</surname> <given-names>H</given-names></name><name><surname>Weiming</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>TGIF1 promoted the growth and migration of Cancer cells in nonsmall cell lung Cancer</article-title><source>Tumor Biology</source><volume>36</volume><fpage>9303</fpage><lpage>9310</lpage><pub-id pub-id-type="doi">10.1007/s13277-015-3676-8</pub-id><pub-id pub-id-type="pmid">26104768</pub-id></element-citation></ref><ref id="bib289"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname> <given-names>H</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Yan</surname> <given-names>W</given-names></name><name><surname>Cui</surname> <given-names>Y</given-names></name><name><surname>Chen</surname> <given-names>Z</given-names></name><name><surname>Gao</surname> <given-names>X</given-names></name><name><surname>Wen</surname> <given-names>X</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>GLUT1 regulates cell glycolysis and proliferation in prostate cancer</article-title><source>The Prostate</source><volume>78</volume><fpage>86</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1002/pros.23448</pub-id><pub-id pub-id-type="pmid">29105798</pub-id></element-citation></ref><ref id="bib290"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>F</given-names></name><name><surname>Sun</surname> <given-names>S</given-names></name><name><surname>Yan</surname> <given-names>S</given-names></name><name><surname>Guo</surname> <given-names>H</given-names></name><name><surname>Dai</surname> <given-names>M</given-names></name><name><surname>Teng</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Elevated expression of RIT1 correlates with poor prognosis in endometrial Cancer</article-title><source>International Journal of Clinical and Experimental Pathology</source><volume>8</volume><fpage>10315</fpage><lpage>10324</lpage><pub-id pub-id-type="pmid">26617739</pub-id></element-citation></ref><ref id="bib291"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>Y</given-names></name><name><surname>Lee</surname> <given-names>DK</given-names></name><name><surname>Feng</surname> <given-names>Z</given-names></name><name><surname>Xu</surname> <given-names>Y</given-names></name><name><surname>Bu</surname> <given-names>W</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Liao</surname> <given-names>L</given-names></name><name><surname>Xu</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017a</year><article-title>Breast tumor cell-specific knockout of <italic>Twist1</italic> inhibits cancer cell plasticity, dissemination, and lung metastasis in mice</article-title><source>PNAS</source><volume>114</volume><fpage>11494</fpage><lpage>11499</lpage><pub-id pub-id-type="doi">10.1073/pnas.1618091114</pub-id><pub-id pub-id-type="pmid">29073077</pub-id></element-citation></ref><ref id="bib292"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>Y</given-names></name><name><surname>Qin</surname> <given-names>L</given-names></name><name><surname>Sun</surname> <given-names>T</given-names></name><name><surname>Wu</surname> <given-names>H</given-names></name><name><surname>He</surname> <given-names>T</given-names></name><name><surname>Yang</surname> <given-names>Z</given-names></name><name><surname>Mo</surname> <given-names>Q</given-names></name><name><surname>Liao</surname> <given-names>L</given-names></name><name><surname>Xu</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017b</year><article-title>Twist1 promotes breast cancer invasion and metastasis by silencing Foxa1 expression</article-title><source>Oncogene</source><volume>36</volume><fpage>1157</fpage><lpage>1166</lpage><pub-id pub-id-type="doi">10.1038/onc.2016.286</pub-id><pub-id pub-id-type="pmid">27524420</pub-id></element-citation></ref><ref id="bib293"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Cai</surname> <given-names>S</given-names></name><name><surname>Chen</surname> <given-names>G</given-names></name><name><surname>Xiao</surname> <given-names>N</given-names></name><name><surname>Fu</surname> <given-names>Y</given-names></name><name><surname>Chen</surname> <given-names>Q</given-names></name><name><surname>Qiu</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>PNCK depletion inhibits proliferation and induces apoptosis of human nasopharyngeal carcinoma cells <italic>in vitro</italic> and <italic>in vivo</italic></article-title><source>Journal of Cancer</source><volume>10</volume><fpage>6925</fpage><lpage>6932</lpage><pub-id pub-id-type="doi">10.7150/jca.33698</pub-id><pub-id pub-id-type="pmid">31839828</pub-id></element-citation></ref><ref id="bib294"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yachida</surname> <given-names>S</given-names></name><name><surname>Wood</surname> <given-names>LD</given-names></name><name><surname>Suzuki</surname> <given-names>M</given-names></name><name><surname>Takai</surname> <given-names>E</given-names></name><name><surname>Totoki</surname> <given-names>Y</given-names></name><name><surname>Kato</surname> <given-names>M</given-names></name><name><surname>Luchini</surname> <given-names>C</given-names></name><name><surname>Arai</surname> <given-names>Y</given-names></name><name><surname>Nakamura</surname> <given-names>H</given-names></name><name><surname>Hama</surname> <given-names>N</given-names></name><name><surname>Elzawahry</surname> <given-names>A</given-names></name><name><surname>Hosoda</surname> <given-names>F</given-names></name><name><surname>Shirota</surname> <given-names>T</given-names></name><name><surname>Morimoto</surname> <given-names>N</given-names></name><name><surname>Hori</surname> <given-names>K</given-names></name><name><surname>Funazaki</surname> <given-names>J</given-names></name><name><surname>Tanaka</surname> <given-names>H</given-names></name><name><surname>Morizane</surname> <given-names>C</given-names></name><name><surname>Okusaka</surname> <given-names>T</given-names></name><name><surname>Nara</surname> <given-names>S</given-names></name><name><surname>Shimada</surname> <given-names>K</given-names></name><name><surname>Hiraoka</surname> <given-names>N</given-names></name><name><surname>Taniguchi</surname> <given-names>H</given-names></name><name><surname>Higuchi</surname> <given-names>R</given-names></name><name><surname>Oshima</surname> <given-names>M</given-names></name><name><surname>Okano</surname> <given-names>K</given-names></name><name><surname>Hirono</surname> <given-names>S</given-names></name><name><surname>Mizuma</surname> <given-names>M</given-names></name><name><surname>Arihiro</surname> <given-names>K</given-names></name><name><surname>Yamamoto</surname> <given-names>M</given-names></name><name><surname>Unno</surname> <given-names>M</given-names></name><name><surname>Yamaue</surname> <given-names>H</given-names></name><name><surname>Weiss</surname> <given-names>MJ</given-names></name><name><surname>Wolfgang</surname> <given-names>CL</given-names></name><name><surname>Furukawa</surname> <given-names>T</given-names></name><name><surname>Nakagama</surname> <given-names>H</given-names></name><name><surname>Vogelstein</surname> <given-names>B</given-names></name><name><surname>Kiyono</surname> <given-names>T</given-names></name><name><surname>Hruban</surname> <given-names>RH</given-names></name><name><surname>Shibata</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Genomic sequencing identifies ELF3 as a driver of ampullary carcinoma</article-title><source>Cancer Cell</source><volume>29</volume><fpage>229</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2015.12.012</pub-id><pub-id pub-id-type="pmid">26806338</pub-id></element-citation></ref><ref id="bib295"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname> <given-names>X</given-names></name><name><surname>Zhou</surname> <given-names>H</given-names></name><name><surname>Zhang</surname> <given-names>T</given-names></name><name><surname>Xu</surname> <given-names>P</given-names></name><name><surname>Zhang</surname> <given-names>S</given-names></name><name><surname>Huang</surname> <given-names>W</given-names></name><name><surname>Yang</surname> <given-names>L</given-names></name><name><surname>Gu</surname> <given-names>X</given-names></name><name><surname>Ni</surname> <given-names>R</given-names></name><name><surname>Zhang</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Downregulation of FOXP2 promoter human hepatocellular carcinoma cell invasion</article-title><source>Tumor Biology</source><volume>36</volume><fpage>9611</fpage><lpage>9619</lpage><pub-id pub-id-type="doi">10.1007/s13277-015-3701-y</pub-id><pub-id pub-id-type="pmid">26142732</pub-id></element-citation></ref><ref id="bib296"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>H</given-names></name><name><surname>Pan</surname> <given-names>L</given-names></name><name><surname>Xu</surname> <given-names>C</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>K</given-names></name><name><surname>Chen</surname> <given-names>S</given-names></name><name><surname>Zhang</surname> <given-names>B</given-names></name><name><surname>Liu</surname> <given-names>Z</given-names></name><name><surname>Wang</surname> <given-names>LX</given-names></name><name><surname>Chen</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Overexpression of tumor suppressor gene <italic>ZNF750</italic> inhibits oral squamous cell carcinoma metastasis</article-title><source>Oncology Letters</source><volume>14</volume><fpage>5591</fpage><lpage>5596</lpage><pub-id pub-id-type="doi">10.3892/ol.2017.6908</pub-id><pub-id pub-id-type="pmid">29113187</pub-id></element-citation></ref><ref id="bib297"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>CA</given-names></name><name><surname>Huang</surname> <given-names>HY</given-names></name><name><surname>Lin</surname> <given-names>CL</given-names></name><name><surname>Chang</surname> <given-names>JG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>G6PD as a predictive marker for glioma risk, prognosis and chemosensitivity</article-title><source>Journal of Neuro-Oncology</source><volume>139</volume><fpage>661</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1007/s11060-018-2911-8</pub-id><pub-id pub-id-type="pmid">29845423</pub-id></element-citation></ref><ref id="bib298"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>HC</given-names></name><name><surname>Wu</surname> <given-names>Y-H</given-names></name><name><surname>Yen</surname> <given-names>W-C</given-names></name><name><surname>Liu</surname> <given-names>H-Y</given-names></name><name><surname>Hwang</surname> <given-names>T-L</given-names></name><name><surname>Stern</surname> <given-names>A</given-names></name><name><surname>Chiu</surname> <given-names>DT-Y</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The redox role of G6PD in cell growth, cell death, and Cancer</article-title><source>Cells</source><volume>8</volume><elocation-id>1055</elocation-id><pub-id pub-id-type="doi">10.3390/cells8091055</pub-id><pub-id pub-id-type="pmid">31500396</pub-id></element-citation></ref><ref id="bib299"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>YA</given-names></name><name><surname>Yu</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>EZH2, an epigenetic driver of prostate Cancer</article-title><source>Protein &amp; Cell</source><volume>4</volume><fpage>331</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1007/s13238-013-2093-2</pub-id><pub-id pub-id-type="pmid">23636686</pub-id></element-citation></ref><ref id="bib300"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname> <given-names>X</given-names></name><name><surname>Qi</surname> <given-names>L</given-names></name><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Du</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>Z</given-names></name><name><surname>Liu</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Expression of CX3CR1 associates with cellular migration, metastasis, and prognosis in human clear cell renal cell carcinoma</article-title><source>Urologic Oncology: Seminars and Original Investigations</source><volume>32</volume><fpage>162</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1016/j.urolonc.2012.12.006</pub-id><pub-id pub-id-type="pmid">23570708</pub-id></element-citation></ref><ref id="bib301"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yasuda</surname> <given-names>K</given-names></name><name><surname>Hirohashi</surname> <given-names>Y</given-names></name><name><surname>Kuroda</surname> <given-names>T</given-names></name><name><surname>Takaya</surname> <given-names>A</given-names></name><name><surname>Kubo</surname> <given-names>T</given-names></name><name><surname>Kanaseki</surname> <given-names>T</given-names></name><name><surname>Tsukahara</surname> <given-names>T</given-names></name><name><surname>Hasegawa</surname> <given-names>T</given-names></name><name><surname>Saito</surname> <given-names>T</given-names></name><name><surname>Sato</surname> <given-names>N</given-names></name><name><surname>Torigoe</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>MAPK13 is preferentially expressed in gynecological Cancer stem cells and has a role in the tumor-initiation</article-title><source>Biochemical and Biophysical Research Communications</source><volume>472</volume><fpage>643</fpage><lpage>647</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2016.03.004</pub-id><pub-id pub-id-type="pmid">26969274</pub-id></element-citation></ref><ref id="bib302"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Youn</surname> <given-names>A</given-names></name><name><surname>Simon</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Identifying cancer driver genes in tumor genome sequencing studies</article-title><source>Bioinformatics</source><volume>27</volume><fpage>175</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btq630</pub-id><pub-id pub-id-type="pmid">21169372</pub-id></element-citation></ref><ref id="bib303"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>X</given-names></name><name><surname>Li</surname> <given-names>Z</given-names></name><name><surname>Shen</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title><italic>BRD7</italic>: a novel tumor suppressor gene in different cancers</article-title><source>American Journal of Translational Research</source><volume>8</volume><fpage>742</fpage><lpage>748</lpage><pub-id pub-id-type="pmid">27158366</pub-id></element-citation></ref><ref id="bib304"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>X</given-names></name><name><surname>Zheng</surname> <given-names>H</given-names></name><name><surname>Chan</surname> <given-names>MTV</given-names></name><name><surname>Wu</surname> <given-names>WKK</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>NOVA1 acts as an oncogene in melanoma via regulating FOXO3a expression</article-title><source>Journal of Cellular and Molecular Medicine</source><volume>22</volume><fpage>2622</fpage><lpage>2630</lpage><pub-id pub-id-type="doi">10.1111/jcmm.13527</pub-id><pub-id pub-id-type="pmid">29498217</pub-id></element-citation></ref><ref id="bib305"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaika</surname> <given-names>AI</given-names></name><name><surname>Slade</surname> <given-names>N</given-names></name><name><surname>Erster</surname> <given-names>SH</given-names></name><name><surname>Sansome</surname> <given-names>C</given-names></name><name><surname>Joseph</surname> <given-names>TW</given-names></name><name><surname>Pearl</surname> <given-names>M</given-names></name><name><surname>Chalas</surname> <given-names>E</given-names></name><name><surname>Moll</surname> <given-names>UM</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>DeltaNp73, A Dominant-Negative inhibitor of Wild-type p53 and TAp73, is Up-regulated in human tumors</article-title><source>Journal of Experimental Medicine</source><volume>196</volume><fpage>765</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.1084/jem.20020179</pub-id></element-citation></ref><ref id="bib306"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zanella</surname> <given-names>F</given-names></name><name><surname>Renner</surname> <given-names>O</given-names></name><name><surname>García</surname> <given-names>B</given-names></name><name><surname>Callejas</surname> <given-names>S</given-names></name><name><surname>Dopazo</surname> <given-names>A</given-names></name><name><surname>Peregrina</surname> <given-names>S</given-names></name><name><surname>Carnero</surname> <given-names>A</given-names></name><name><surname>Link</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Human TRIB2 is a repressor of FOXO that contributes to the malignant phenotype of melanoma cells</article-title><source>Oncogene</source><volume>29</volume><fpage>2973</fpage><lpage>2982</lpage><pub-id pub-id-type="doi">10.1038/onc.2010.58</pub-id><pub-id pub-id-type="pmid">20208562</pub-id></element-citation></ref><ref id="bib307"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zapata</surname> <given-names>L</given-names></name><name><surname>Pich</surname> <given-names>O</given-names></name><name><surname>Serrano</surname> <given-names>L</given-names></name><name><surname>Kondrashov</surname> <given-names>FA</given-names></name><name><surname>Ossowski</surname> <given-names>S</given-names></name><name><surname>Schaefer</surname> <given-names>MH</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Negative selection in tumor genome evolution acts on essential cellular functions and the immunopeptidome</article-title><source>Genome Biology</source><volume>19</volume><elocation-id>67</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-018-1434-0</pub-id><pub-id pub-id-type="pmid">29855388</pub-id></element-citation></ref><ref id="bib308"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>T</given-names></name><name><surname>Luo</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>T</given-names></name><name><surname>Yang</surname> <given-names>JY</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>MicroRNA-297b-5p/3p target Mllt3/Af9 to suppress lymphoma cell proliferation, migration and invasion <italic>in vitro</italic> and tumor growth in nude mice</article-title><source>Leukemia &amp; Lymphoma</source><volume>53</volume><fpage>2033</fpage><lpage>2040</lpage><pub-id pub-id-type="doi">10.3109/10428194.2012.678005</pub-id><pub-id pub-id-type="pmid">22448917</pub-id></element-citation></ref><ref id="bib309"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>C</given-names></name><name><surname>Zhang</surname> <given-names>Z</given-names></name><name><surname>Zhu</surname> <given-names>Y</given-names></name><name><surname>Qin</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014a</year><article-title>Glucose-6-phosphate dehydrogenase: a biomarker and potential therapeutic target for Cancer</article-title><source>Anti-Cancer Agents in Medicinal Chemistry</source><volume>14</volume><fpage>280</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.2174/18715206113136660337</pub-id><pub-id pub-id-type="pmid">24066844</pub-id></element-citation></ref><ref id="bib310"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>YA</given-names></name><name><surname>Zhu</surname> <given-names>JM</given-names></name><name><surname>Yin</surname> <given-names>J</given-names></name><name><surname>Tang</surname> <given-names>WQ</given-names></name><name><surname>Guo</surname> <given-names>YM</given-names></name><name><surname>Shen</surname> <given-names>XZ</given-names></name><name><surname>Liu</surname> <given-names>TT</given-names></name></person-group><year iso-8601-date="2014">2014b</year><article-title>High expression of neuro-oncological ventral antigen 1 correlates with poor prognosis in hepatocellular carcinoma</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e90955</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0090955</pub-id><pub-id pub-id-type="pmid">24608171</pub-id></element-citation></ref><ref id="bib311"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>MZ</given-names></name><name><surname>Ferrigno</surname> <given-names>O</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Ohnishi</surname> <given-names>M</given-names></name><name><surname>Prunier</surname> <given-names>C</given-names></name><name><surname>Levy</surname> <given-names>L</given-names></name><name><surname>Razzaque</surname> <given-names>M</given-names></name><name><surname>Horne</surname> <given-names>WC</given-names></name><name><surname>Romero</surname> <given-names>D</given-names></name><name><surname>Tzivion</surname> <given-names>G</given-names></name><name><surname>Colland</surname> <given-names>F</given-names></name><name><surname>Baron</surname> <given-names>R</given-names></name><name><surname>Atfi</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>TGIF governs a feed-forward network that empowers wnt signaling to drive mammary tumorigenesis</article-title><source>Cancer Cell</source><volume>27</volume><fpage>547</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2015.03.002</pub-id><pub-id pub-id-type="pmid">25873176</pub-id></element-citation></ref><ref id="bib312"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>YX</given-names></name><name><surname>Yan</surname> <given-names>YF</given-names></name><name><surname>Liu</surname> <given-names>YM</given-names></name><name><surname>Li</surname> <given-names>YJ</given-names></name><name><surname>Zhang</surname> <given-names>HH</given-names></name><name><surname>Pang</surname> <given-names>M</given-names></name><name><surname>Hu</surname> <given-names>JX</given-names></name><name><surname>Zhao</surname> <given-names>W</given-names></name><name><surname>Xie</surname> <given-names>N</given-names></name><name><surname>Zhou</surname> <given-names>L</given-names></name><name><surname>Wang</surname> <given-names>PY</given-names></name><name><surname>Xie</surname> <given-names>SY</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Smad3-related miRNAs regulated oncogenic TRIB2 promoter activity to effectively suppress lung adenocarcinoma growth</article-title><source>Cell Death &amp; Disease</source><volume>7</volume><elocation-id>e2528</elocation-id><pub-id pub-id-type="doi">10.1038/cddis.2016.432</pub-id><pub-id pub-id-type="pmid">28005074</pub-id></element-citation></ref><ref id="bib313"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname> <given-names>ZW</given-names></name><name><surname>Fan</surname> <given-names>XX</given-names></name><name><surname>Song</surname> <given-names>JJ</given-names></name><name><surname>Xu</surname> <given-names>M</given-names></name><name><surname>Chen</surname> <given-names>MJ</given-names></name><name><surname>Tu</surname> <given-names>JF</given-names></name><name><surname>Wu</surname> <given-names>FZ</given-names></name><name><surname>Zhang</surname> <given-names>DK</given-names></name><name><surname>Liu</surname> <given-names>L</given-names></name><name><surname>Chen</surname> <given-names>L</given-names></name><name><surname>Ying</surname> <given-names>XH</given-names></name><name><surname>Ji</surname> <given-names>JS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>ShRNA knock-down of CXCR7 inhibits tumour invasion and metastasis in hepatocellular carcinoma after transcatheter arterial chemoembolization</article-title><source>Journal of Cellular and Molecular Medicine</source><volume>21</volume><fpage>1989</fpage><lpage>1999</lpage><pub-id pub-id-type="doi">10.1111/jcmm.13119</pub-id><pub-id pub-id-type="pmid">28429395</pub-id></element-citation></ref><ref id="bib314"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname> <given-names>S</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Nanga</surname> <given-names>P</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Cicek</surname> <given-names>AE</given-names></name><name><surname>Knoblauch</surname> <given-names>N</given-names></name><name><surname>He</surname> <given-names>C</given-names></name><name><surname>Stephens</surname> <given-names>M</given-names></name><name><surname>He</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2019">2019a</year><article-title>Detailed modeling of positive selection improves detection of Cancer driver genes</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>3399</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-11284-9</pub-id><pub-id pub-id-type="pmid">31363082</pub-id></element-citation></ref><ref id="bib315"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>W</given-names></name><name><surname>Li</surname> <given-names>M</given-names></name><name><surname>Hu</surname> <given-names>Y</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Song</surname> <given-names>G</given-names></name><name><surname>Yang</surname> <given-names>L</given-names></name><name><surname>Cai</surname> <given-names>K</given-names></name><name><surname>Luo</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2019">2019b</year><article-title>Targeted inhibition of MCT4 disrupts intracellular pH homeostasis and confers self-regulated apoptosis on hepatocellular carcinoma</article-title><source>Experimental Cell Research</source><volume>384</volume><elocation-id>111591</elocation-id><pub-id pub-id-type="doi">10.1016/j.yexcr.2019.111591</pub-id><pub-id pub-id-type="pmid">31479685</pub-id></element-citation></ref><ref id="bib316"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname> <given-names>S</given-names></name><name><surname>Jie</surname> <given-names>C</given-names></name><name><surname>Xu</surname> <given-names>P</given-names></name><name><surname>Diao</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>MicroRNA-140 inhibit prostate cancer cell invasion and migration by targeting YES proto-oncogene 1</article-title><source>Journal of Cellular Biochemistry</source><volume>121</volume><fpage>482</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1002/jcb.29231</pub-id><pub-id pub-id-type="pmid">31310382</pub-id></element-citation></ref><ref id="bib317"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname> <given-names>C</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Luo</surname> <given-names>J</given-names></name><name><surname>Zheng</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>MicroRNA-139 inhibits the proliferation and migration of osteosarcoma cells via targeting forkhead-box P2</article-title><source>Life Sciences</source><volume>191</volume><fpage>68</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2017.10.010</pub-id><pub-id pub-id-type="pmid">28993144</pub-id></element-citation></ref><ref id="bib318"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>Z</given-names></name><name><surname>Zou</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>G</given-names></name><name><surname>Zhou</surname> <given-names>J</given-names></name><name><surname>Wu</surname> <given-names>J</given-names></name><name><surname>Zhao</surname> <given-names>S</given-names></name><name><surname>Su</surname> <given-names>Z</given-names></name><name><surname>Gu</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Mutation-profile-based methods for understanding selection forces in cancer somatic mutations: a comparative analysis</article-title><source>Oncotarget</source><volume>8</volume><fpage>58835</fpage><lpage>58846</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.19371</pub-id><pub-id pub-id-type="pmid">28938601</pub-id></element-citation></ref><ref id="bib319"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname> <given-names>QQ</given-names></name><name><surname>Ma</surname> <given-names>C</given-names></name><name><surname>Wang</surname> <given-names>Q</given-names></name><name><surname>Song</surname> <given-names>Y</given-names></name><name><surname>Lv</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The role of TWIST1 in epithelial-mesenchymal transition and cancers</article-title><source>Tumor Biology</source><volume>37</volume><fpage>185</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1007/s13277-015-4450-7</pub-id><pub-id pub-id-type="pmid">26602382</pub-id></element-citation></ref><ref id="bib320"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname> <given-names>D</given-names></name><name><surname>Zhou</surname> <given-names>J</given-names></name><name><surname>Zhao</surname> <given-names>J</given-names></name><name><surname>Jiang</surname> <given-names>G</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Dong</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>ZC3H13 suppresses colorectal Cancer proliferation and invasion via inactivating Ras-ERK signaling</article-title><source>Journal of Cellular Physiology</source><volume>234</volume><fpage>8899</fpage><lpage>8907</lpage><pub-id pub-id-type="doi">10.1002/jcp.27551</pub-id><pub-id pub-id-type="pmid">30311220</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><boxed-text><sec id="s8" sec-type="appendix"><title>Examples of genes with strong signatures of positive and/or negative selection</title><p>The assignments of the genes to key cellular processes of carcinogenesis are summarized in <xref ref-type="table" rid="table1">Table 1</xref> of the main text.</p></sec><sec id="s9" sec-type="appendix"><title>Novel cancer genes positively selected for truncating mutations</title><sec id="s9-1"><title>Beta-1,3-galactosyltransferase 1, encoded by the <italic>B3GALT1</italic> gene</title><p>B3GALT1 belongs to the glycosyltransferase 31 family. It transfers galactose from UDP-alpha-D-galactose to substrates with a terminal beta-N-acetylglucosamine residue. B3GALT1 is involved in the biosynthesis of the carbohydrate moieties of glycolipids and glycoproteins.</p><p>It has been suggested that loss of the activity of B3GALT1 may play an important role in aberrant protein glycosylation and tumor progression in colorectal cancers (<xref ref-type="bibr" rid="bib252">Venkitachalam et al., 2016</xref>). Although such a role would be consistent with positive selection for inactivating mutations, analysis of the distribution of nonsense mutations along the protein sequence suggests that the high rNSM value is an artefact, rather than a signature of positive selection for iactivating mutations. The high rate of nonsense substitutions vs. sense substitutions is due to the fact that the majority of sequences contain nonsense substitution at a single site (p.R199*). Since there is no reason why selection would favor nonsense mutation at a single site it seems more likely that it reflects some sort of data deposition error. It is noteworthy in this respect that all the samples containing the p.R199* mutations originate from different regions of pancreatic tumor tissue samples from a single study (<xref ref-type="bibr" rid="bib294">Yachida et al., 2016</xref>).</p></sec><sec id="s9-2"><title>Bone morphogenetic protein receptor type-2, encoded by the <italic>BMPR2</italic> gene</title><p>Bone morphogenetic protein receptor type-2, a member of the TGF beta family of growth factor receptors. Upon ligand binding, it forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases and activates SMAD transcriptional regulators.</p><p>There is convincing evidence in the literature that BMPR2 is a tumor suppressor. The <italic>BMPR2</italic> gene has been shown to contain several somatic frameshift mutations and to be inactivated in gastric and colorectal cancers with microsatellite instability (<xref ref-type="bibr" rid="bib125">Kodach et al., 2008</xref>; <xref ref-type="bibr" rid="bib177">Park et al., 2010</xref>). Loss of BMPR2 function has been found to result in increased tumorigenicity in human prostate cancer cells (<xref ref-type="bibr" rid="bib120">Kim et al., 2004</xref>). More recent studies have shown that disruption of BMPR2 expression promotes mammary carcinoma metastases (<xref ref-type="bibr" rid="bib174">Owens et al., 2012</xref>; <xref ref-type="bibr" rid="bib185">Pickup et al., 2015</xref>). It was shown that loss of BMPR2 results in increased chemokine expression, which facilitates inflammation by a sustained increase in myeloid cells. The chemokines increased in <italic>BMPR2</italic> deleted cells correlated with poor outcome in human breast cancer patients, suggesting that BMPR2 has tumor suppressive functions in the stroma by regulating inflammation (<xref ref-type="bibr" rid="bib185">Pickup et al., 2015</xref>).</p></sec><sec id="s9-3"><title>Bromodomain-containing protein 7, encoded by the <italic>BRD</italic>7 gene</title><p>BRD7 is a crucial component of both functional p53 and BRCA1 pathways and recent studies have fully established BRD7 as a tumor suppressor. The expression of BRD7 was shown to be downregulated in various cancers, including breast cancer, nasopharyngeal carcinoma, gastric cancer, colorectal carcinoma, ovarian cancer, lung adenocarcinoma, NSCLC, hepatocellular carcinoma, and prostate cancer. Moreover, BRD7 inhibited cancer cell growth and metastasis and promoted apoptosis in vitro and in vivo (<xref ref-type="bibr" rid="bib303">Yu et al., 2016</xref>; <xref ref-type="bibr" rid="bib73">Gao et al., 2016</xref>; <xref ref-type="bibr" rid="bib37">Chen et al., 2016</xref>; <xref ref-type="bibr" rid="bib133">Li et al., 2015</xref>).</p><p>Recent studies suggest that BRD7 exerts it tumor suppressive role through multiple pathways, by suppressing cell proliferation, initiating cell apoptosis, and reducing aerobic glycolysis (<xref ref-type="bibr" rid="bib168">Niu et al., 2018</xref>). These studies suggest that BRD7 inhibits the Warburg effect through inactivation of the HIF1α/LDHA axis.</p></sec><sec id="s9-4"><title>Inhibitor of growth protein 1 encoded by the <italic>ING1</italic> gene</title><p><italic>ING1</italic> encodes a nuclear, cell cycle-regulated protein, overexpression of which efficiently blocks cell growth and is capable of inducing apoptosis in different experimental systems (<xref ref-type="bibr" rid="bib247">Toyama et al., 1999</xref>). ING1 is known to cooperate with p53/TP53 in the negative regulatory pathway of cell growth by modulating p53-dependent transcriptional activation.</p><p>The tumor suppressor status of <italic>ING1</italic> has been fully established since several studies have described the loss of ING1 protein expression in human tumors and <italic>ING1</italic> knockout mice were reported to have spontaneously developed tumors, B cell lymphomas, and soft tissue sarcomas (<xref ref-type="bibr" rid="bib84">Guérillon et al., 2013</xref>).</p><p>ING1 levels were found to be lower in breast tumors compared to adjacent normal breast tissue (<xref ref-type="bibr" rid="bib243">Thakur et al., 2014</xref>). Decreasing levels of ING1 increased, and increasing levels decreased migration and invasion of cancer cells in vitro. ING1 overexpression also blocked cancer cell metastasis in vivo and eliminated tumor-induced mortality in mouse models.</p><p>ING1 can inhibit the growth of lung cancer cell lines through the induction of cell cycle arrest and apoptosis by forming a complex with p53 (<xref ref-type="bibr" rid="bib150">Luo et al., 2011</xref>; <xref ref-type="bibr" rid="bib26">Bose et al., 2014</xref>)</p><p>Genetic alterations that abrogate the normal function of <italic>ING1</italic> may contribute to esophageal squamous cell carcinogenesis (<xref ref-type="bibr" rid="bib36">Chen et al., 2001</xref>). Mutations of the <italic>ING1</italic> tumor suppressor gene (TSG) detected in human melanoma abrogate nucleotide excision repair activity of the protein (<xref ref-type="bibr" rid="bib31">Campos et al., 2004</xref>). Nonsense mutations cluster in the region of residues 339–378. These mutations eliminate the Zn finger domain and polybasic region, which are involved in interaction with histone H3 trimethylated at Lys4 (H3K4me3). It is noteworthy thar histone H3K4me3 binding is required for the DNA repair and apoptotic activities of the ING1 tumor suppressor (<xref ref-type="bibr" rid="bib181">Peña et al., 2008</xref>).</p></sec><sec id="s9-5"><title>MAX gene-associated protein, encoded by the <italic>MGA</italic> gene</title><p>MGA functions as a dual-specificity transcription factor, regulating the expression of both MAX-network and T-box family target genes. Suppresses transcriptional activation by MYC and inhibits MYC-dependent cell transformation. Recurrent inactivation of <italic>MGA</italic>, a suppressor of MYC, has been shown to occur in lymphocytic leukemia, and in both NSCLC and small cell lung cancer, colorectal cancer (<xref ref-type="bibr" rid="bib54">De Paoli et al., 2013</xref>; <xref ref-type="bibr" rid="bib201">Romero et al., 2014</xref>; <xref ref-type="bibr" rid="bib110">Jo et al., 2016</xref>).</p></sec><sec id="s9-6"><title>Proline-rich transmembrane protein 2, encoded by the <italic>PRRT2</italic> gene</title><p>PPRT2, as a component of the outer core of AMPAR complex, is involved in ion channel functions. <italic>PRRT2</italic> has been shown to be significantly downregulated in glioblastoma tissues compared with normal brain tissue (<xref ref-type="bibr" rid="bib24">Bi et al., 2017</xref>; <xref ref-type="bibr" rid="bib136">Li et al., 2018b</xref>). Overexpression of PRRT2 strongly impaired the cell viability and promoted cell apoptosis. These antitumor effects indicate that PRRT2 acts as a tumor suppressor in glioma. PRRT2 has been shown to have an inhibitory effect on proliferation, consistent with the low expression level of PRRT2 in cancer versus normal samples (<xref ref-type="bibr" rid="bib9">Alves et al., 2017</xref>).</p></sec><sec id="s9-7"><title>Ras GTPase-activating protein 1, encoded by the <italic>RASA1</italic> gene</title><p>RASA1 is an inhibitory regulator of the Ras-cyclic AMP pathway. Consistent with the tumor suppressor role of RASA1, the circular RNA circ-ITCH was shown to suppress ovarian carcinoma progression through targeting miR-145/<italic>RASA1</italic> signaling, by increasing the level of RASA1 (<xref ref-type="bibr" rid="bib104">Hu et al., 2018a</xref>).</p><p>There is evidence that <italic>RASA1</italic> is a potent TSG that is frequently downregulated or inactivated in several human cancer types. RASA1 expression is frequently reduced in breast cancer tissues, and the reduced RASA1 expression is associated with breast cancer progression and poor survival and disease-free survival of patients (<xref ref-type="bibr" rid="bib144">Liu et al., 2015</xref>).</p><p>In hepatocellular carcinoma patients, low level of RASA1 expression correlated with a significantly poorer survival compared to those with high level of RASA1 expression, suggesting that RASA1 could serve as an independent prognostic marker for hepatocellular carcinoma patients (<xref ref-type="bibr" rid="bib38">Chen et al., 2017a</xref>).</p><p>Analyses of melanoma whole-genome sequencing data have led to the identification of two novel, clustered somatic missense mutations (Y472H and L481F) in RASA1 (<xref ref-type="bibr" rid="bib235">Sung et al., 2016</xref>). Unlike wild-type RASA1, these mutants, do not suppresses soft agar colony formation and tumor growth of melanoma cell lines. In addition to mutations, loss of RASA1 expression was frequently observed in metastatic melanoma samples and a low level of RASA1 mRNA expression was associated with decreased overall survival in melanoma patients. Thus, these data support that RASA1 is inactivated by mutations or by suppressed expression in melanoma and that RASA1 plays a tumor suppressive role.</p><p>The tumor suppressor role of RASA1 is also supported by the fact that knockdown or miR targeting of <italic>RASA1</italic> significantly enhanced invasion and migration of multiple pancreatic cancer cells (<xref ref-type="bibr" rid="bib233">Sun et al., 2015</xref>; <xref ref-type="bibr" rid="bib119">Kent et al., 2016</xref>).</p></sec><sec id="s9-8"><title>E3 ubiquitin-protein ligase RNF128, encoded by the <italic>RNF128</italic> gene</title><p>E3 ubiquitin-protein ligase RNF128 catalyzes 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains formation. Consistent with its suggested tumor suppressor role, downregulation of <italic>RNF128</italic> was found to predict poor prognosis in patients with urothelial carcinoma and urinary bladder. Downregulation of <italic>RNF128</italic> was correlated with cancer invasiveness and metastasis as well as reduced survival in patients (<xref ref-type="bibr" rid="bib130">Lee et al., 2016</xref>). <italic>RNF128</italic> downregulation was also shown to correlate with the malignant phenotype of melanoma (<xref ref-type="bibr" rid="bib280">Wei et al., 2019</xref>).</p></sec><sec id="s9-9"><title>Monocarboxylate transporter 1, MCT1 encoded by the <italic>SLC16A1</italic> gene</title><p>SLC16A1 is a multipass plasma membrane protein that functions as a proton-coupled monocarboxylate transporter. It catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate. Depending on the tissue and on cicumstances, mediates the import or export of lactic acid. Deficiency of this lactate transporter may result in an acidic intracellular environment created by muscle activity with consequent degeneration of muscle.</p><p>Although the high values of rNSM would suggest a tumor suppressor role for <italic>SLC16A1</italic>, several studies suggest that the protein may serve a pro-oncogenic role. For example, depletion of <italic>SLC16A1</italic> was found to decrease cellular proliferation and invasion in both neuroblastoma and malignant cutaneous melanoma cell lines, suggesting its role as an oncogene (OG; <xref ref-type="bibr" rid="bib13">Avitabile et al., 2020</xref>). The pro-oncogenic role of MCT1 is also supported by the results of studies on esophageal squamous cell carcinoma (ESCC). Kaplan-Meier survival analysis of ESCC patients in a high-MCT1 group had a lower overall survival and lower progression-free survival, whereas downregulation of MCT1 suppressed proliferation and survival of ESCC cells in vitro (<xref ref-type="bibr" rid="bib46">Chen et al., 2019</xref>). Disrupting MCT1 function leads to an accumulation of intracellular lactate that rapidly disables tumor cell growth (<xref ref-type="bibr" rid="bib62">Doherty et al., 2014</xref>).</p><p>MCT1 expression is elevated in glycolytic breast tumors, and high MCT1 expression predicts poor prognosis in breast and lung cancer patients. Similarly, the observations that MCT1 inhibition impairs proliferation of glycolytic breast cancer cells co-expressing MCT1 and MCT4 and that MCT1 loss-of-function decreases breast cancer cell proliferation and blocks growth of mammary fat pad xenograft tumors suggest a pro-oncogenic or tumor essential role for MCT1 (<xref ref-type="bibr" rid="bib100">Hong et al., 2016</xref>).</p><p>A recent study, however, has led to the conclusion that MCT1 and MCT4 have opposing roles in carcinogenesis (<xref ref-type="bibr" rid="bib232">Sukeda et al., 2019</xref>). In a retrospective survey conducted on patients who underwent surgical resection for pancreatic ductal adenocarcinoma, the expression of MCT1, MCT4, and GLUT1 was assessed in tumor cells and cancer-associated fibroblasts (CAFs) and the impact of their expression on patient outcome was also analyzed. In tumor cells, MCT1 expression was associated with extended overall and progression-free survival and decreased nodal metastasis. Conversely, MCT4 expression in CAFs was associated with shortened survival. In other words, in tumor cells, MCT1 expression is associated with better prognosis and reduced nodal metastasis in pancreatic cancer, contrary to findings of previous studies.</p><p>It is noteworthy in this respcect that based on the pattern of mutations SLC16A1/MCT1 appers to be a tumor suppressor rather than a tumor essential gene (TEG) in as much as it has a high proportion of truncating mutations. It seems possible that glycolytic tumor cells that must get rid of lactate are selected for increased efflux and decreased influx of lactate and this might be achieved by increased expression of MCT4 and decreased activity of MCT1.</p></sec><sec id="s9-10"><title>Sprouty-related, EVH1 domain-containing protein 1, encoded by the <italic>SPRED1</italic> gene</title><p>The <italic>SPRED1</italic> gene, which encodes a negative regulator of mitogen-activated protein kinase (MAPK) signaling, has been shown to function as a TSG in several types of cancer (<xref ref-type="bibr" rid="bib179">Pasmant et al., 2015</xref>; <xref ref-type="bibr" rid="bib2">Ablain et al., 2018</xref>; <xref ref-type="bibr" rid="bib234">Sun et al., 2019</xref>).</p></sec><sec id="s9-11"><title>Homeobox protein TGIF1, encoded by the <italic>TGIF1</italic> gene</title><p>TGIF binds to a retinoid X receptor (RXR)-responsive element from the cellular retinol-binding protein II promoter (CRBPII-RXRE). Inhibits the 9-cis-retinoic acid-dependent RXR alpha transcription activation of the retinoic-acid-responsive element. Active transcriptional corepressor of SMAD2.</p><p>There is evidence that TGIF1 may function as a tumor suppressor. In pancreatic ductal adenocarcinoma genetic inactivation of <italic>TGIF1</italic> in the context of oncogenic KRASG12D, culminated in the development of highly aggressive and metastatic pancreatic ductal adenocarcinoma (<xref ref-type="bibr" rid="bib176">Parajuli et al., 2019</xref>; <xref ref-type="bibr" rid="bib282">Weng et al., 2019</xref>). These authors have found that TGIF1 associates with TWIST1 and inhibits TWIST1 expression and activity, and this function is suppressed in the vast majority of human pancreatic ductal adenocarcinoma by KRASG12D /MAPK-mediated TGIF1 phosphorylation. Ablation of TWIST1 in KRASG12D;TGIF1KO mice blocked pancreatic ductal adenocarcinoma formation, providing evidence that TGIF1 restrains KRASG12D-driven pancreatic ductal adenocarcinoma through its ability to antagonize TWIST1.</p><p>The majority of available evidence, however, suggests that the protein plays a cancer promoting role. TGIF1 has been shown to promote the growth and migration of cancer cells in NSCLC (<xref ref-type="bibr" rid="bib288">Xiang et al., 2015</xref>). The authors have shown that expression of TGIF1 is elevated in NSCLC tissues, that TGIF1 promoted the growth and migration of cancer cells and that knocking down the expression of <italic>TGIF1</italic> inhibited the growth and migration of NSCLC cells. These studies have also shown that TGIF1 exerted its oncogenic role through beta-catenin/TCF signaling.</p><p>Studies on triple negative breast cancer have revealed that high levels of TGIF expression correlate with poor prognosis since TGIF promotes Wnt-driven mammary tumorigenesis. As to the molecular mechanism of the oncogenic role of TGIF: it has been shown that TGIF interacts with and sequesters Axin1 and Axin2 into the nucleus, disassembles the β-catenin-destruction complex leading to the accumulation of β-catenin that activates expression of Wnt target genes (<xref ref-type="bibr" rid="bib311">Zhang et al., 2015</xref>; <xref ref-type="bibr" rid="bib196">Razzaque and Atfi, 2016</xref>).</p><p>In harmony with an oncogenic role of TGIF in breast cancer, silencing of <italic>TGIF</italic> was found to suppress the migration, invasion and metastasis of the human breast cancer cells in both in vitro and in vivo experiments (<xref ref-type="bibr" rid="bib272">Wang et al., 2018c</xref>).</p><p><italic>TGIF1</italic> has also been found to be significantly upregulated in some colorectal cancers and to promote adenoma growth in the context of mutant Apc (<xref ref-type="bibr" rid="bib214">Shah et al., 2019</xref>). Overexpression of TGIF1 markedly promoted the proliferation of colorectal cancer cells through the activation of Wnt/β-catenin signaling (<xref ref-type="bibr" rid="bib269">Wang et al., 2017c</xref>).</p><p>In summary, the majority of data suggest that <italic>TGIF1</italic> may act as an OG, despite the fact that the high proportion of truncating indel mutations would indicate a tumor suppressor function. Since the transcription regulator TGIF1 may play both pro-oncogenic and tumor suppressor functions (in different cellular processes), our observation that during tumor evolution selection for truncating mutations appears to dominate for TGIF1 suggests that the selection pressure to eliminate the tumor suppressor activity may override the pressure to preserve it oncogenic activities.</p></sec><sec id="s9-12"><title>Trinucleotide repeat-containing gene 6B protein, encoded by the <italic>TNRC6B</italic> gene</title><p><italic>TNRC6B</italic> is a key miRNA-processing gene that plays a role in RNA-mediated gene silencing by both micro-RNAs (miRNAs) and short interfering RNAs (siRNAs). TNRC6B is required for miRNA-dependent translational repression and siRNA-dependent endonucleolytic cleavage of complementary mRNAs by argonaute family proteins.</p><p>Genomic analysis of liver cancer have identified <italic>TNRC6B</italic> as a significantly mutated gene, suggesting that it may be an important driver gene (<xref ref-type="bibr" rid="bib135">Li et al., 2018a</xref>). Consistent with its putative tumor suppressor role, DNA methylation of <italic>TNRC6B</italic> has been suggested to play a role in early carcinogenesis (<xref ref-type="bibr" rid="bib116">Joyce et al., 2018</xref>).</p></sec><sec id="s9-13"><title>Dual specificity protein kinase TTK, encoded by the <italic>TTK</italic> gene</title><p>TTK, capable of phosphorylating serine, threonine, and tyrosine residues of proteins, plays a role in cell proliferation. Although, intuitively the high rate of truncating mutations would suggest a tumor suppressor role for TTK, all the available evidence indicates that it acts as an OG.</p><p>It has been shown that dual specificity kinase TTK is strongly overexpressed in human pancreatic ductal adenocarcinoma, suggesting a cancer promoting role. In harmony with such a role, following <italic>TTK</italic> knockdown cell proliferation was significantly attenuated, whereas apoptosis and necrosis rates were significantly increased. Apoptosis was associated with increased formation of micronuclei, suggesting that loss of TTK results in chromosomal instability and mitotic catastrophe (<xref ref-type="bibr" rid="bib117">Kaistha et al., 2014</xref>).</p><p>Levels of TTK protein were also found to be significantly elevated in neoplastic tissues of liver cancer patients, when compared with adjacent hepatic tissues. In an experimental animal model, it was shown that in vitro knockdown of <italic>TTK</italic> effectively blocks intrahepatic growth of human hepatic carcinoma cell xenografts, suggesting that targeted TTK inhibition might have clinical utility in the therapy of liver cancer (<xref ref-type="bibr" rid="bib162">Miao et al., 2016</xref>).</p><p>In a recent study, dual specificity protein kinase TTK has been identified as the most upregulated and differentially expressed kinase in glioma stem-like cells that are responsible for tumorigenesis and subsequent tumor recurrence in glioblastoma. TTK expression was highly enriched in glioblastoma and was inversely correlated with a poor prognosis (<xref ref-type="bibr" rid="bib270">Wang et al., 2018a</xref>).</p><p>The deubiquitinase, USP9X has been implicated in multiple cancers and its oncogenic effects were shown to be exerted at least in part through dual specificity protein kinase TTK (<xref ref-type="bibr" rid="bib45">Chen et al., 2018d</xref>). USP9X was found to stabilize TTK by efficient deubiquitination of the kinase; levels of USP9X and TTK were significantly elevated and positively correlated in tumor tissues, suggesting that the USP9X-TTK axis plays a critical role in carcinogenesis. In harmony with the synergism of these OGs, knockdown of <italic>USP9X</italic> or <italic>TTK</italic> inhibited cell proliferation, migration, and tumorigenesis.</p><p>The explanation for the apparent contradiction of the oncogenic role of TTK and the abundance of truncating mutations in the protein probably lies in the fact that – unlike in the case of typical TSGs – mutations are not randomly distributed along the protein sequence. The truncating mutations are practically restricted to the very C-terminal end of the protein (EKKRGKK, residues 851–857), downstream of the catalytic domain and missense mutations also cluster in this C-terminal end. It seems likely that this region is involved in some negative control of the activity of TTK and missense and truncating mutations liberate TTK from this negative control. It is unclear at present whether the mutations affecting this C-terminal motif activate the TTK proto-oncogene by interfering with its ubiquitination or by affecting its subcellular localization.</p></sec><sec id="s9-14"><title>Zinc finger CCCH domain-containing protein 13, encoded by the <italic>ZC3H13</italic> gene</title><p>ZC3H13 is associated with a complex that mediates N6-methyladenosine (m6A) methylation of RNAs, a modification that plays a role in the efficiency of mRNA splicing and RNA processing. It acts as a key regulator of m6A methylation by promoting m6A methylation of mRNAs at the 3'-UTR. ZC3H13 has been shown to serve as a tumor suppressor in colorectal cancer (<xref ref-type="bibr" rid="bib320">Zhu et al., 2019</xref>).</p></sec><sec id="s9-15"><title>mRNA decay activator protein ZFP36L2, encoded by the <italic>ZFP36L2</italic> gene</title><p><italic>ZFP36L2</italic> has been selected as a gene characterized by very high values of indel_rNSM, suggesting positive selection for truncating mutations. Although the closely related <italic>ZFP36L1</italic> gene is not present in the lists defined by the CG_SO and CG_SSI lists defined by the 2SD cut-off values, it is also characterized by very high values of rNSM (<xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>).</p><p>ZFP36L1 and ZFP36L2 zinc-finger RNA-binding proteins destabilize several cytoplasmic AU-rich element (ARE)-containing mRNA transcripts by promoting their poly(A) tail removal or deadenylation, and hence provide a mechanism for attenuating protein synthesis. The proteins are necessary for thymocyte development and prevention of T-cell acute lymphoblastic leukemia transformation by promoting ARE-mediated mRNA decay of the mRNA of oncogenic factors.</p><p>Deletion of the genes <italic>ZFP36L1</italic> and <italic>ZFP36L2</italic> leads to perturbed thymic development and T lymphoblastic leukemia (<xref ref-type="bibr" rid="bib99">Hodson et al., 2010</xref>).</p><p>ZFP36L1 and ZFP36L2 play a negative role in cell proliferation. Forced expression of ZFP36L1 or ZFP36L2 inhibited cell proliferation in colorectal cancer cell lines, whereas knockdown of these genes increased cell proliferation (<xref ref-type="bibr" rid="bib231">Suk et al., 2018</xref>). ZFP36L2 has been validated as an important tumor-suppressor specific to oesophageal squamous cell carcinomas (<xref ref-type="bibr" rid="bib142">Lin et al., 2018</xref>).</p></sec><sec id="s9-16"><title>Zinc finger protein 276, encoded by the <italic>ZNF276</italic> gene</title><p>Zinc finger protein is involved in transcriptional regulation.</p><p>It has been suggested that ZNF276 may be a tumor suppressor in breast cancer progression in colorectal cancers (<xref ref-type="bibr" rid="bib284">Wong et al., 2003</xref>).</p><p>Although such a role would be consistent with positive selection for inactivating mutations, analysis of the distribution of nonsense mutations along the protein sequence suggests that the high rNSM value is an artefact, rather than a signature of positive selection for inactivating mutations. The high rate of nonsense substitutions vs. sense substitutions is due to the fact that the majority of sequences contain nonsense substitution at a single site (p.Q217*). Since there is no reason why selection would favor nonsense mutation at a single site, it seems more likely that it reflects some sort of data deposition error. It is noteworthy in this respect that all the samples containing the p.Q217* mutations originate from different regions of pancreatic tumor tissue samples from a single study (<xref ref-type="bibr" rid="bib294">Yachida et al., 2016</xref>).</p></sec><sec id="s9-17"><title>Zinc finger protein 750, encoded by the <italic>ZNF750</italic> Gene</title><p>Zinc finger protein 750 is a transcription factor required for terminal epidermal differentiation, it acts downstream of p63/TP63. Its mutations have been shown to abolish the ability to induce epidermal terminal differentiation. In harmony with its mutation pattern, numerous studies suggest a tumor suppressor role for ZNF750.</p><p>Analysis of cancer genes across 21 tumor types identified <italic>ZNF750</italic> as a gene harboring many early frameshift and nonsense mutations in head and neck cancer and as the only known gene residing in a small current focal deletion in head and neck and lung squamous cancers (<xref ref-type="bibr" rid="bib129">Lawrence et al., 2014</xref>). <italic>ZNF750</italic> has also been identified as a tumor suppressor in oral and esophageal squamous cell carcinoma (<xref ref-type="bibr" rid="bib296">Yang et al., 2017</xref>; <xref ref-type="bibr" rid="bib166">Nambara et al., 2017</xref>; <xref ref-type="bibr" rid="bib93">Hazawa et al., 2017</xref>; <xref ref-type="bibr" rid="bib173">Otsuka et al., 2018</xref>). Studies on the clonal evolution in esophageal squamous cell carcinoma revealed that the majority of driver mutations in this cancer occurred in the tumor-suppressor genes, including <italic>TP53, KMT2D</italic>, and <italic>ZNF750</italic> (<xref ref-type="bibr" rid="bib89">Hao et al., 2016</xref>).</p></sec></sec><sec id="s10" sec-type="appendix"><title>Novel cancer genes positively selected for missense mutations</title><sec id="s10-1"><title>Aurora kinase A encoded by the <italic>AURKA</italic> gene</title><p>AURKA, also known as a Breast tumor-amplified kinase, is a mitotic serine/threonine kinase that contributes to the regulation of cell cycle progression. It associates with the centrosome and the spindle microtubules during mitosis and plays a critical role in various mitotic events.</p><p>In harmony with the notion that AURKA’s mutation pattern reflects a pro-oncogenic role for the protein, elevated expression of AURKA has been shown to induce oncogenic phenotypes (<xref ref-type="bibr" rid="bib237">Takahashi et al., 2015</xref>; <xref ref-type="bibr" rid="bib248">Treekitkarnmongkol et al., 2016</xref>).</p><p>Similarly, the observation that downregulation, inhibition or depletion of AURKA reduced viability and invasiveness of cancer cells (<xref ref-type="bibr" rid="bib222">Sillars-Hardebol et al., 2012</xref>; <xref ref-type="bibr" rid="bib135">Li et al., 2018a</xref>; <xref ref-type="bibr" rid="bib250">van Gijn et al., 2019</xref>) also argues for an oncogenic role of the protein.</p><p>Significantly, specific knockdown of <italic>AURKA</italic> in cultured pancreatic cancer cells strongly suppressed in vitro cell growth and in vivo tumorigenicity (<xref ref-type="bibr" rid="bib92">Hata et al., 2005</xref>). Recently, a novel AURKA mutation (V352I) was identified from clinical specimens and it was shown that AURKA (V352I)-induced carcinogenesis was earlier and much more severe than wild-type AURKA, implying that the V352I mutation may accelerate cancer progression (<xref ref-type="bibr" rid="bib230">Su et al., 2019</xref>).</p><p>Although many <italic>AURKA</italic> mutations were identified in cancer patients, it is noteworthy that there is no evidence for the clustering or ‘recurrence’ of mutations. The most likely explanation for the lack of clustering of mutations is that since AURKA interacts with numerous proteins (e.g. PIFO, GADD45A, AUNIP, NIN, FRY, SIRT2, MYCN, HNRNPU, AAAS, KLHL18, CUL3, FOXP1) there may be multiple sites where missense mutations affecting these interactions may result in disregulation of the activity of <bold>AURKA</bold>.</p><p>In summary, although all the available experimental information argues for an oncogenic role of <italic>AURKA</italic>, there was no evidence for the clustering of its missense mutations. In our view, this observation illustrates that recurrence of missense mutations is not a <italic>sine qua non</italic> criterion of OGs.</p><p>Recent studies have also revealed that AURKA and TWIST1 are linked in a feedback loop controlling tumorigenesis and metastasis. AURKA phosphorylates TWIST1, inhibits its ubiquitylation, increases its transcriptional activity and favors its homodimerization. TWIST1 prevents AURKA degradation, thereby triggering a feedback loop. Ablation of either AURKA or TWIST1 completely inhibits epithelial-to-mesenchymal transition, suggesting that inhibition of AURKA and TWIST1 are synergistic in inhibiting tumorigenesis and metastasis (<xref ref-type="bibr" rid="bib268">Wang et al., 2017b</xref>).</p><p>Although the <italic>TWIST1</italic> gene is not present in the datasets (<xref ref-type="supplementary-material" rid="supp5">Supplementary files 5</xref> and <xref ref-type="supplementary-material" rid="supp31">31</xref>) that contain the metadata for transcripts containing at least 100 confirmed somatic, non-polymorphic mutations identified in tumor tisses, inspection of the primary dataset (<xref ref-type="supplementary-material" rid="supp9">Supplementary file 9</xref>) indicates that it is characterized by very high value of rSMN (<xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>), indicating strong signature of purifying selection (see section on Negatively selected genes) consistent with the view that – in synergism with AURKA – it plays an important role in promoting tumorigenesis.</p></sec><sec id="s10-2"><title>Cyclin-dependent kinase 8, encoded by the <italic>CDK8</italic> gene</title><p>The <italic>CDK8</italic> gene is a coactivator involved in regulated gene transcription of nearly all RNA polymerase II-dependent genes.</p><p><italic>CDK8</italic> is a colorectal cancer OG that regulates beta-catenin activity. Suppression of CDK8 expression inhibits proliferation in colon cancer cells characterized by high levels of CDK8 and beta-catenin hyperactivity (<xref ref-type="bibr" rid="bib69">Firestein et al., 2008</xref>). CDK8 has been shown to promote SMAD1-driven epithelial-to-mesenchymal transition through YAP1 recruitment (<xref ref-type="bibr" rid="bib213">Serrao et al., 2018</xref>). There is a large body of evidence that CDK8 is a key oncogenic driver in many cancers (<xref ref-type="bibr" rid="bib184">Philip et al., 2018</xref>). <italic>CDK8</italic> was found to be amplified or overexpressed in many colon cancers and CDK8 expression correlated with shorter patient survival (<xref ref-type="bibr" rid="bib140">Liang et al., 2018</xref>).</p></sec><sec id="s10-3"><title>Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial, encoded by the <italic>IDH3B</italic> gene</title><p>IDH3B plays an essential role in the activity of isocitrate dehydrogenase. The heterodimer composed of the alpha (IDH3A) and beta (IDH3B) subunits and the heterodimer composed of the alpha (IDH3A) and gamma (IDH3G) subunits, have significant activity but the full activity of the heterotetramer (containing two subunits of IDH3A, one of IDH3B and one of IDH3G) requires the assembly of both heterodimers.</p><p>Our Pubmed search failed to identify publications with major relevance for the role of <italic>IDH3B</italic> in carcinogenesis. It is noteworthy, however, that the <italic>IDH3B</italic> gene contains recurrent somatic missense mutations at residue R131 that is equevalent with R132 and R140 of the paralogous enzymes, IDH1 and IDH2, respectively, that are affected by recurrent oncogenic missense mutations. These mutations of IDH1 and IDH2 result in loss of normal enzymatic function and the abnormal production of 2-hydroxyglutarate. 2-Hydroxyglutarate has been found to inhibit enzymatic function of many alpha-ketoglutarate-dependent enzymes, including histone and DNA demethylases, causing widespread epigenetic changes in the genome thereby promoting tumorigenesis. It seems likely that the R131 mutations of IDH3B may conntribute to carcinogenesis by a similar mechanism.</p></sec><sec id="s10-4"><title>E3 ubiquitin-protein ligase MARCH7, encoded by the <italic>MARCH7</italic> gene</title><p>March7 is an E3 ubiquitin-protein ligase, an enzyme that accepts ubiquitin from an E2 ubiquitin-conjugating enzyme and then directly transfer the ubiquitin to targeted substrates.</p><p>Several studies support an oncogenic role for the ubiquitin E3 ligase MARCH7. Studies on ovarian tissues have revealed that expression of MARCH7 was higher in ovarian cancer tissues than normal ovarian tissues. Silencing <italic>MARCH7</italic> decreased, whereas ectopic expression of MARCH7 increased cell proliferation, migration and invasion, suggesting that MARCH7 is oncogenic and a potential target for ovarian cancer therapy (<xref ref-type="bibr" rid="bib103">Hu et al., 2015</xref>). The expression of MARCH7 was significantly higher in cervical cancer tissues than normal cervical tissues, suggesting that this OG may also serves as a potential target for cervical cancer therapy (<xref ref-type="bibr" rid="bib105">Hu et al., 2018b</xref>).</p><p>The expression level of MARCH7 in endometrial cancer tissues was also found to be significantly higher than that in normal endometrium tissues, suggesting that it may be an oncogenic factor in endometrial cancer (<xref ref-type="bibr" rid="bib145">Liu et al., 2019</xref>). The oncogenic role of MARCH7 is supported by the fact its knockdown inhibited the invasion and metastasis of endometrial cancer cells in vitro and in vivo, whereas the opposite effect was observed after overexpressing MARCH7.</p></sec><sec id="s10-5"><title>GTP-binding protein RIT1, encoded by the <italic>RIT1</italic> gene</title><p>The high value of rMSN reflects primarily the recurrence of substitutions (Met90Ile, Met90Val) of Met90 of RIT1 protein.</p><p>RIT1 plays a crucial role in the activation of MAPK signaling cascades that mediate a wide variety of cellular functions, including cell proliferation, survival, and differentiation.</p><p>Since the Met90Ile substitution has been shown to result in an increased MAPK-ERK signaling (<xref ref-type="bibr" rid="bib12">Aoki et al., 2013</xref>; <xref ref-type="bibr" rid="bib126">Koenighofer et al., 2016</xref>), it is plausible to assume that the high rate of missense mutations reflects positive selection of oncogenic driver mutations.</p><p>In harmony with this conclusion, studies on endometrial cancer have revealed that RIT1 mRNA and protein were significantly overexpressed in endometrial cancer cell lines and in endometrial cancer tissues compared to non-cancerous endometrial tissue samples (<xref ref-type="bibr" rid="bib290">Xu et al., 2015</xref>). Elevated expression of RIT1 was significantly correlated with pathological type, clinical stage. Kaplan-Meier survival analysis indicated that RIT1 expression was associated with poor overall survival of endometrial cancer patients, suggesting that elevated expression of RIT1 may contribute to the progression of endometrial cancer.</p><p>In a study of lung adenocarcinoma cases, several somatic mutations (including Met90Ile) were identified in the <italic>RIT1</italic> gene that were found to cluster in a hotspot near the switch II domain of the GTPase protein (<xref ref-type="bibr" rid="bib21">Berger et al., 2014</xref>). Ectopic expression of these mutated <italic>RIT1</italic> genes was found to induce cellular transformation in vitro and in vivo, confirming that these substitutions are driver mutations and that <italic>RIT1</italic> is an OG in lung adenocarcinoma.</p></sec><sec id="s10-6"><title>Yes-associated protein 1, encoded by the <italic>YAP1</italic> gene</title><p>Yes-associated protein one is known to be the critical downstream regulatory target in the Hippo signaling pathway that plays a pivotal role in tumor suppression by restricting proliferation and promoting apoptosis. This pathway is composed of a kinase cascade that eventually inactivates YAP1 since phosphorylation of YAP1 by the tumor suppressors LATS1/2 inhibits its translocation into the nucleus.</p><p>Several lines of evidence indicate that YAP1 is an OG. <italic>YAP1</italic> was found to act as oncogenic target of 11q22 amplification in multiple cancer subtypes, whereas <italic>YAP1</italic> silencing significantly decreases cell proliferation (<xref ref-type="bibr" rid="bib147">Lorenzetto et al., 2014</xref>; <xref ref-type="bibr" rid="bib86">Hamanaka et al., 2019</xref>). <italic>YAP1</italic> was shown to promote growth of prostate cancer, whereas knock down of its expression or inhibition of YAP1 function significantly suppressed tumor recurrence (<xref ref-type="bibr" rid="bib108">Jiang et al., 2017</xref>). The key role of YAP1 in carcinogenesis is also supported by the fact that the tumor suppressor LATS2 inhibits the malignant behaviors of glioma cells by inactivating of YAP1 (<xref ref-type="bibr" rid="bib219">Shi et al., 2019</xref>).</p><p>Although several <italic>YAP1</italic> mutations were identified in cancer patients, there is no evidence for the clustering or ‘recurrence’ of mutations. Similarly to the case of AURKA (see above), the most plausible explanation for the lack of clustering of mutations of this OG is that since YAP1 interacts with several proteins (e.g. YES kinase, LATS1, LATS2, TP73, RUNX1, WBP1, WBP2, TEAD1, TEAD2, TEAD3, TEAD4, HCK, MAPK8, MAPK9, CK1, ABL1) mutations at several different sites may affect these interactions and may result in disregulation of the activity of YAP1. In our view, the cases of AURKA, YAP1 and YES1 illustrate that recurrence of missense mutations is not a <italic>sine qua non</italic> criterion of OGs.</p></sec><sec id="s10-7"><title>Tyrosine-protein kinase Yes, encoded by the <italic>YES1</italic> gene</title><p>Tyrosine-protein kinase Yes (also known as proto-oncogene c-Yes) is a multidomain non-receptor protein tyrosine kinase containing an SH3 domain, an SH2 domain and a protein kinase domain. YES1 is involved in the regulation of cell growth and survival, apoptosis, cell-cell adhesion, cytoskeleton remodeling, and differentiation. It plays a role in cell cycle progression by phosphorylating the cyclin-dependent kinase 4/CDK4 thus regulating the G1 phase. YES1 has been shown to phosphorylate YAP1, leading to the localization of a YAP1-TBX-β-catenin complex to the promoters of antiapoptotic genes, thereby promoting carcinogenes (<xref ref-type="bibr" rid="bib202">Rosenbluh et al., 2012</xref>). A small-molecule inhibitor of YES1 impeded the proliferation of β-catenin-dependent cancers in both cell lines and animal models.</p><p>Several lines of evidence have established an oncogenic role for <italic>YES1</italic>.</p><p>It has been demonstrated recently that YES1 is essential for lung cancer growth and progression in NSCLC, suggesting that it is a promising therapeutic target in lung cancer. YES1 overexpression induced metastatic spread in preclinical in vivo models, whereas <italic>YES1</italic> genetic depletion by CRISPR/Cas9 technology significantly reduced tumor growth and metastasis (<xref ref-type="bibr" rid="bib75">Garmendia et al., 2019</xref>).</p><p>In harmony with an oncogenic role of <italic>YES1</italic>, several microRNAs have been shown to inhibit the proliferation of tumor cells by targeting <italic>YES1</italic> (<xref ref-type="bibr" rid="bib239">Tan et al., 2015</xref>; <xref ref-type="bibr" rid="bib218">Shen et al., 2019</xref>; <xref ref-type="bibr" rid="bib316">Zhao et al., 2020</xref>).</p><p>The oncogenic role of YES1 in cancer is also supported by the observation that it is amplified in several types of cancer, suggesting that it could be an attractive target for a cancer drug (<xref ref-type="bibr" rid="bib67">Fan et al., 2018</xref>; <xref ref-type="bibr" rid="bib86">Hamanaka et al., 2019</xref>). <xref ref-type="bibr" rid="bib86">Hamanaka et al., 2019</xref> have generated a YES1 kinase inhibitor, and have shown that YES1 kinase inhibition by this drug led to antitumor activity against <italic>YES1</italic>-amplified cancers in vitro and in vivo. The authors have also shown that Yes-associated protein 1 (YAP1) played a role downstream of YES1 and contributed to the growth of <italic>YES1</italic>-amplified cancers. indicating that the regulation of YAP1 by YES1 plays an important role in <italic>YES1</italic>-amplified cancers. These findings identify YES1 as a targetable OG of significant potential for clinical utility (<xref ref-type="bibr" rid="bib195">Rai, 2019</xref>).</p><p>Although <italic>YES1</italic> contains an increased proportion of nonsynonymous mutations there is no evidence for the clustering or ‘recurrence’ of mutations. Similarly to the cases of <italic>AURKA</italic> and <italic>YAP1</italic> (see above), the most plausible explanation for the lack of clustering of mutations of this OG is that since YES1 is a multidomain protein that interacts with several proteins, mutations at several different sites may affect these interactions and may result in disregulation of the activity of YAP1. In our view, the cases of AURKA, YAP1, and YES1 illustrate that recurrence of missense mutations is not a <italic>sine qua non</italic> criterion of OGs.</p></sec></sec><sec id="s11" sec-type="appendix"><title>Negatively selected TEGs</title><sec id="s11-1"><title>Atypical chemokine receptor 3, encoded by the <italic>ACKR3</italic> (<italic>CXCR7</italic>) gene</title><p>ACKR3 is a member of the group of chemokine receptors that acts as a receptor for chemokines CXCL11 and CXCL12/SDF1. It is activated by CXCL11 in malignant hemapoietic cells, leading to phosphorylation of ERK1/2 (MAPK3/MAPK1) and enhanced cell adhesion and migration.</p><p><italic>ACKR3</italic> is a known cancer gene, from Tier 1 of the Cancer Gene Census; it has a cancer hallmark annotation. Its importance in carcinogenesis is underlined by the fact that high expression of ACKR3 is associated with poor survival in several types of cancer.</p><p>As to the role of ACKR3 in hallmarks of cancer: it has been suggested that ACKR3 promotes proliferative signaling, angiogenesis, evasion of programmed cell death and invasion and metastasis.</p><p>Several studies support the key role of ACKR3 in tumor invasion and metastasis (<xref ref-type="bibr" rid="bib132">Li et al., 2014</xref>; <xref ref-type="bibr" rid="bib226">Stacer et al., 2016</xref>; <xref ref-type="bibr" rid="bib313">Zhao et al., 2017</xref>; <xref ref-type="bibr" rid="bib190">Puddinu et al., 2017</xref>; <xref ref-type="bibr" rid="bib159">Melo et al., 2018</xref>; <xref ref-type="bibr" rid="bib193">Qian et al., 2018</xref>). Since knock-down or pharmacological inhibition of <italic>ACKR3</italic> has been shown to reduce tumor invasion and metastasis, ACKR3 is a promising therapeutic target for the control of tumor dissemination.</p></sec><sec id="s11-2"><title>CX3C chemokine receptor 1, encoded by the <italic>CX3CR1</italic> gene</title><p>CX3CR1 is a member of the group of chemokine receptors that play a major role in tumor metastasis. The interactions of chemokines, also known as chemotactic cytokines, with their receptors regulate immune and inflammatory responses. However, recent studies have demonstrated that cancer cells subvert the normal chemokine role, transforming them into fundamental constituents of the tumor microenvironment with tumor-promoting effects. CX3CR1 is the receptor for the CX3C chemokine fractalkine (CX3CL1) that mediates both its adhesive and migratory functions.</p><p>CX3CR1 expression has been shown to be associated with the process of cellular migration in vitro and tumor metastasis of clear cell renal cell carcinoma in vivo (<xref ref-type="bibr" rid="bib300">Yao et al., 2014</xref>).</p><p>Recent studies indicate that tumor-associated macrophages MΦ can influence cancer progression and metastasis and that CCR2 and CX3CR1 play important roles in metastasis. <xref ref-type="bibr" rid="bib209">Schmall et al., 2015</xref> have shown that coculturing of tumor-associated macrophages with mouse Lewis lung carcinoma caused up-regulation of CCR2/CCL2 and CX3CR1/CX3CL1 in both the cancer cells and the macrophages. In vivo, MΦ depletion and genetic ablation of <italic>CCR2</italic> and <italic>CX3CR1</italic> all inhibited LLC1 tumor growth and metastasis, and enhanced survival. Furthermore, mice treated with CCR2 antagonist mimicked genetic ablation of CCR2, showing reduced tumor growth and metastasis. These findings indicate that tumor-associated MΦ play a central role in lung cancer growth and metastasis, with bidirectional cross-talk between MΦ and cancer cells via CCR2 and CX3CR1 signaling. These studies suggest that the therapeutic strategy of blocking CCR2 and CX3CR1 may prove beneficial for halting metastasis.</p><p>CX3CR1 is highly expressed in gastric cancer tissues and is related to lymph node metastasis and larger tumor size. CX3CR1 overexpression promoted gastric cancer cell migration, invasion, proliferation, and survival (<xref ref-type="bibr" rid="bib279">Wei et al., 2015</xref>).</p><p>CX3CR1 is overexpressed in human breast tumors and cancer cells utilize the chemokine receptor CX3CR1 to exit the blood circulation and metastize to the skeleton. To assess the clinical potential of targeting CX3CR1 in breast cancer <xref ref-type="bibr" rid="bib217">Shen et al., 2016</xref> have used neutralizing antibody for this receptor, transcriptional suppression by CRISPR interference as well as a potent and selective small-molecule antagonist of CX3CR1 in preclinical animal models of metastasis. The authors have found that inactivation of CX3CR1 impairs the lodging of circulating tumor cells to the skeleton and impairs further growth of established metastases. These data suggest that CX3CR1 has a important role in promoting metastasis activity and that CX3CR1 antagonists may valuable as drugs of tumor therapy.</p></sec></sec><sec id="s12" sec-type="appendix"><title>C-C chemokine receptor type 2, encoded by the <italic>CCR2</italic> gene</title><sec id="s12-1"><title>C-C chemokine receptor type 5, encoded by the <italic>CCR5</italic> gene</title><p>Although the <italic>CCR2</italic> gene of C-C chemokine receptor type two and the <italic>CCR5</italic> gene of C-C chemokine receptor type five are not present in the CG_SO and CG_SSI lists defined by the 2SD cut-off values they are also characterized by very high values of rSNM (<xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>), suggesting that they may also play importanct roles in tumor metastasis.</p><p>CCR2 is the key functional receptor for the chemokine ligand CCL2. Its binding with CCL2 on monocytes and macrophages mediates chemotaxis and migration induction. Recent studies indicate that CCR2 and CX3CR1 play important roles in metastasis (<xref ref-type="bibr" rid="bib209">Schmall et al., 2015</xref>). The CCL2-CCR2 signaling axis has generated increasing interest in recent years due to its association with the progression of cancer. The CCL2-CCR2, signaling pair has been shown to have multiple pro-tumorigenic roles, mediating tumor growth and angiogenesis (<xref ref-type="bibr" rid="bib141">Lim et al., 2016</xref>).</p><p>CCR5 serves as a receptor for a number of inflammatory CC-chemokines including CCL3/MIP-1-alpha, CCL4/MIP-1-beta. Recent studies have revealed that C-C chemokine receptor type 5 plays a key role in progression of tumorigenesis, Expression of CCR5 augments regulatory T cell differentiation and migration to sites of inflammation. The misexpression of CCR5 in epithelial cells, induced upon oncogenic transformation, hijacks this migratory phenotype (<xref ref-type="bibr" rid="bib5">Aldinucci and Casagrande, 2018</xref>; <xref ref-type="bibr" rid="bib109">Jiao et al., 2019</xref>).</p></sec><sec id="s12-2"><title>Dentin sialophosphoprotein, encoded by the <italic>DSPP</italic> gene</title><p>The <italic>DSPP</italic> gene has been selected as a gene showing very high values of rSMN, suggesting negative selection of missense and nonsense mutations (<xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>). It must be pointed out that based on the high silent/missense ratio <italic>DSPP</italic> has also been identified by others as a gene showing signs of strong negative selection (<xref ref-type="bibr" rid="bib318">Zhou et al., 2017</xref>).</p><p>Dentin sialophosphoprotein is a secreted protein that has been shown to play an important role in dentinogenesis. It binds high amount of calcium and facilitates initial mineralization of dentin matrix collagen as well as regulate the size and shape of the crystals, therefore it seemed surprising that its gene would qualify as a negatively selected TEG.</p><p>There is evidence in the scientific literature that the protein may have a tumorigenic role in oral cancer (<xref ref-type="bibr" rid="bib34">Chaplet et al., 2006</xref>; <xref ref-type="bibr" rid="bib115">Joshi et al., 2010</xref>; <xref ref-type="bibr" rid="bib206">Saxena et al., 2015</xref>; <xref ref-type="bibr" rid="bib79">Gkouveris et al., 2018</xref>; <xref ref-type="bibr" rid="bib167">Nikitakis et al., 2018</xref>). Nevertheless, the high silent to missense rate is not a reflection of the importance of <italic>DSPP</italic> for carcinogenesis. The <italic>DSPP</italic> gene contains a 2 kb repeat domain containing over 200 tandem copies of a nominal 9-basepair (AGC AGC GAC) repeat encoding a series of tandem Ser Ser Asp repeats and the unusully high rate of silent mutations is restricted to this region of the gene.</p><p>A study of 188 normal human chromosomes revealed that the repeat domain of <italic>DSPP</italic> is hypervariable with extraordinary rates of change including slip-replication indel events and predominantly C-to-T transition SNPs (<xref ref-type="bibr" rid="bib158">McKnight et al., 2008</xref>). In harmony with the increased rate and predominance of C-to-T transition in the AGC AGC GAC (Ser-Ser-Asp) repeats, the vast majority of substitutions in this repeat region of the <italic>DSSP</italic> gene are silent. The unusually high silent to missense mutation ratio of the <italic>DSPP</italic> gene is thus not due to purifying selection of a TEG.</p></sec><sec id="s12-3"><title>Forkhead box protein G1, encoded by the <italic>FOXG1</italic></title><p>FOXG1 is a member of the FOX (Forkhead box) protein family of transcription factors that play important roles in regulating the expression of genes involved in cell growth, proliferation, differentiation, and longevity. FOXG1 localizes to mitochondria and coordinates cell differentiation and bioenergetics (<xref ref-type="bibr" rid="bib175">Pancrazi et al., 2015</xref>).</p><p>The tumor promoting role of FOXG1 is supported by the observation that childhood medulloblastomas are characterized by 2–7-fold copy gain for <italic>FOXG1. FOXG1</italic> copy gain (&gt;2 to 21 folds) was seen in 93% of a validating set of tumors and showed a positive correlation with protein expression (<xref ref-type="bibr" rid="bib3">Adesina et al., 2007</xref>).</p><p>The oncogenic role of FOXG1 is also supported by the observation that a decrease of FOXG1 in medulloblastoma cells offers a survival advantage in mice (<xref ref-type="bibr" rid="bib4">Adesina et al., 2015</xref>), whereas high expression of FOXG1 was associated with poor survival of glioblastoma patients (<xref ref-type="bibr" rid="bib199">Robertson et al., 2015</xref>).</p><p>The carcinogenesis promoting activity of FOXG1 is supported by the observation that endogenous FOXG1 expression levels were positively correlated to the glioblastoma multiforme disease progression (<xref ref-type="bibr" rid="bib271">Wang et al., 2018b</xref>). Overexpression of FOXG1 protein resulted in increased cell viability, and it was suggested that FOXG1 functions as an onco-factor by promoting proliferation and inhibiting differentiation.</p><p>Recent studies on glioblastoma have shown that transcription factors FOXG1 and TLE1 promote glioblastoma propagation by supporting maintenance of brain tumor-initiating cells (<xref ref-type="bibr" rid="bib51">Dali et al., 2018</xref>). Since the expressions of caspase family members were significantly altered in response to change of FOXG1 expression, it has been suggested that FOXG1 also contributes to carcinogenesis as a negative regulator of glioma cell apoptosis (<xref ref-type="bibr" rid="bib42">Chen et al., 2018a</xref>).</p></sec><sec id="s12-4"><title>Forkhead box protein P2, encoded by <italic>FOXP2</italic> gene</title><sec id="s12-4-1"><title>Forkhead box protein P2 (FOXP2) is a transcriptional repressor</title><p>The role of FOXP2 in cancer is somewhat controversial, it appears to have oncogenic or tumor suppressor roles, depending on the cellular and histological features of tumors. While FOXP2 has been found to be down-regulated in breast cancer, hepatocellular carcinoma and gastric cancer biopsies, overexpressed FOXP2 has been reported in multiple myelomas, several subtypes of lymphomas, as well as in neuroblastomas and some prostate cancers (<xref ref-type="bibr" rid="bib97">Herrero and Gitton, 2018</xref>).</p><p>Numerous recent studies indicate a tumor suppressor like role for FOXP2 (<xref ref-type="bibr" rid="bib29">Campbell et al., 2010</xref>; <xref ref-type="bibr" rid="bib50">Cuiffo et al., 2014</xref>; <xref ref-type="bibr" rid="bib295">Yan et al., 2015</xref>; <xref ref-type="bibr" rid="bib60">Diao et al., 2018</xref>; <xref ref-type="bibr" rid="bib225">Song et al., 2017</xref>; <xref ref-type="bibr" rid="bib43">Chen et al., 2018b</xref>; <xref ref-type="bibr" rid="bib137">Li et al., 2019</xref>), others present evidence for an OG-like role of the protein (<xref ref-type="bibr" rid="bib29">Campbell et al., 2010</xref>; <xref ref-type="bibr" rid="bib317">Zhong et al., 2017</xref>; <xref ref-type="bibr" rid="bib286">Wu et al., 2018</xref>; <xref ref-type="bibr" rid="bib273">Wang et al., 2019</xref>).</p><p>The high silent to missense ratio of substitution mutations observed in the case of the <italic>FOXP2</italic> gene does not seem to be a reflection of purifying selection, that might be in harmony of an OG-like role, but definitely not with a tumor suppressor role.</p><p>The translated region of the <italic>FOXP2</italic> gene contains a long stretch of CAG repeats (residiues 177–216), corresponding to the polyQ segment of the protein. Silent mutations are clustered in the polyQ tract of the protein encoded by the imperfect polymorphic region, suggesting that the increased silent to missense rate of substitutions in this gene has much less to do with purifying selection than with microsatellite instability.</p></sec></sec><sec id="s12-5"><title>Glucose-6-phosphate 1-dehydrogenase, encoded by the <italic>G6PD</italic> gene</title><p>Glucose-6-phosphate 1-dehydrogenase catalyzes the rate-limiting step of the oxidative pentose-phosphate pathway, its main function is to provide reducing power (NADPH) and pentose phosphates for fatty acid and nucleic acid synthesis. There is strong support for the importance of G6PD for tumor growth. Progression of tumor cells to more aggressive phenotypes requires not only the upregulation of glygolysis but also the pentose phosphate pathway as a provider of reducing power and ribose phosphate to the cell for maintenance of redox balance and biosynthesis of nucleotides and lipids, making G6PD a promising target in cancer therapy (<xref ref-type="bibr" rid="bib309">Zhang et al., 2014a</xref>).</p><p>The key importance of G6PD for tumor growth is supported by the fact that elevated G6PD levels promote cancer progression in numerous tumor types, that high G6PD expression is a poor prognostic factor and that knockdown of G6PD suppresses cell viability and growth (<xref ref-type="bibr" rid="bib261">Wang et al., 2012</xref>; <xref ref-type="bibr" rid="bib189">Pu et al., 2015</xref>; <xref ref-type="bibr" rid="bib265">Wang et al., 2015b</xref>; <xref ref-type="bibr" rid="bib187">Poulain et al., 2017</xref>; <xref ref-type="bibr" rid="bib44">Chen et al., 2018c</xref>; <xref ref-type="bibr" rid="bib297">Yang et al., 2018</xref>; <xref ref-type="bibr" rid="bib18">Barajas et al., 2018</xref>; <xref ref-type="bibr" rid="bib298">Yang et al., 2019</xref>).</p></sec><sec id="s12-6"><title>Mitogen-activated protein kinase 13, encoded by the <italic>MAPK13</italic> gene</title><p>MAPK13 (p38δ mitogen-activated protein kinase) is a serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK13 plays an important role in the cascades of cellular responses evoked by extracellular stimuli such as proinflammatory cytokines. The protein is involved in the regulation of epidermal keratinocyte differentiation, apoptosis, and skin tumor development.</p><p>Although MAPK13 shows signatures of negative selection that would suggest a pro-oncogenioc role for the protein, expermintal data are controversial as to its role in carcinogenesis: there is evidence for both a pro-oncogenic and tumor suppressor roles of MAPK13.</p><p>The observation that p38delta promotes cell proliferation and tumor development in epidermis suggests that it has a pro-oncogenic role (<xref ref-type="bibr" rid="bib208">Schindler et al., 2009</xref>). Analyzes of the gene expression profiles have shown that MAPK13 is expressed in uterine, ovary, stomach, colon, liver, and kidney cancer tissues at higher levels compared with adjacent normal tissues. <italic>MAPK13</italic> gene knockdown has been shown to abrogate the tumor-initiating ability of cancer stem-like cells, indicating that the gene has a cancer-promoting role (<xref ref-type="bibr" rid="bib301">Yasuda et al., 2016</xref>). The protein p38δ is highly expressed in all types of human breast cancers, whereas lack of p38δ resulted in reduced primary tumor size and blocked the metastatic potential to the lungs (<xref ref-type="bibr" rid="bib259">Wada et al., 2017</xref>). The fact that mice with germline deletion of the p38δ gene are significantly protected from chemical skin carcinogenesis also suggests a cancer promoting role for the protein (<xref ref-type="bibr" rid="bib122">Kiss et al., 2016</xref>). Interestingly, cell-selective targeted ablation of p38δ in keratinocytes and in immune (myeloid) cells on skin tumor development had different effects. Conditional keratinocyte-specific p38δ ablation reduced malignant progression in males and females relative to their wild-type counterparts. In contrast, conditional myeloid cell-specific p38δ deletion inhibited skin tumorigenesis in male but not female mice. These results reveal that cell-specific p38δ targeting modifies susceptibility to skin carcinogenesis in a context-, stage-, and sex-specific manner (<xref ref-type="bibr" rid="bib123">Kiss et al., 2019</xref>).</p><p>The closely related MAPK14, MAPK12, and MAPK13 proteins are known to modulate the immune response, and since chronic inflammation is a known risk factor for tumorigenesis it seems possible that the role of MAPK13 in carcinogenesis may be associated with inflammation. <xref ref-type="bibr" rid="bib57">Del Reino et al., 2014</xref> have analyzed the role of MAPK12 and MAPK13 in colon cancer associated to colitis and have shown that the deficiency of MAPK12 and MAPK13 significantly decreased tumor formation, in parallel with a decrease in proinflammatory cytokine and chemokine production.</p><p>In contrast with the observations arguing for a pro-oncogenic role of the protein, loss of p38δ mitogen-activated protein kinase expression has been shown to promote oesophageal squamous cell carcinoma proliferation, migration, and anchorage-independent growth, suggesting that it has a tumor suppressor role (<xref ref-type="bibr" rid="bib171">O'Callaghan et al., 2013</xref>). Similarly, inactivation of the gene in lung cancer cells has been shown to lead to upregulation of the stemness proteins, thus promoting the cancer stem cell properties of these cells (<xref ref-type="bibr" rid="bib68">Fang et al., 2017</xref>). Promoter methylation of <italic>MAPK13</italic> was found to be present in the majority of primary and metastatic melanomas. Restoration of MAPK13 expression in melanoma cells exhibiting epigenetic silencing of this gene reduced proliferation, indicative of tumor suppressive functions for the protein (<xref ref-type="bibr" rid="bib72">Gao et al., 2013</xref>).</p><p>In summary, although MAPK13 plays both pro-oncogenic and tumor suppressor functions in different cellular processes our observation that during tumor evolution negative selection dominates for MAPK13 suggests that the selection pressure to preserve the tumor promoting activities of MAPK13 activity overrides the pressure to eliminate its tumor suppressor activities.</p></sec><sec id="s12-7"><title>Protein AF-9, encoded by the <italic>MLLT3</italic> gene</title><p>The <italic>MLLT3</italic> gene (present in CGC list of cancer genes) has been selected as a gene showing very high values of rSMN, suggesting negative selection of missense and nonsense mutations (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>).</p><p>It must be pointed out that based on the high silent/missense ratio <italic>MLLT3</italic> (as well as <italic>TBP</italic> and <italic>DSPP</italic>) has also been identified by others as a gene subject to negative selection (<xref ref-type="bibr" rid="bib318">Zhou et al., 2017</xref>).</p><p>Protein AF-9 is a component of a complex required to increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by the polymerase at multiple sites along the DNA.</p><p>Several studies indicate that <italic>MLLT3</italic> is a proto-oncogene, its inactivation or downregulation suppresses lymphoma cell proliferation, invasion and inhibits metastasis and proliferation of prostate cancer (<xref ref-type="bibr" rid="bib308">Zhang et al., 2012</xref>; <xref ref-type="bibr" rid="bib160">Meng et al., 2017</xref>).</p><p>Despite the tumor promoting role of <italic>MLLT3</italic>, the high silent to missense ratio of substitution mutations does not seem to be a reflection of strong negative selection. The translated region of the <italic>MLLT3</italic> gene contains a long stretch of AGC repeats (encoding the polyS segment of the protein, residues 149–194). The ‘excess’ of silent mutations are clustered in the polyS tract of the protein encoded by the imperfect polymorphic AGC microsatellite region of the <italic>MLLT3</italic> gene, that is known to be highly unstable (<xref ref-type="bibr" rid="bib260">Walker et al., 1994</xref>).</p></sec><sec id="s12-8"><title>Neuro-oncological ventral antigen 1 (Nova-1), encoded by the <italic>NOVA1</italic> gene</title><p>Nova-1 is an RNA-binding protein involved in the regulation of RNA splicing.</p><p>The importance of Nova1 for tumor growth is supported by the observation that overexpressed intratumoral NOVA1 was associated with poor survival rate and increased recurrence rate of hepatocellular carcinoma (HCC) and was an independent prognostic factor for overall survival rate and tumor recurrence. HCC cell lines over-expressing NOVA1 exhibited greater potentials in cell proliferation, invasion, and migration, while knockdown of NOVA1 had the opposite effects. All these findings indicate that NOVA1 may act as a prognostic marker for poor outcome and high recurrence in HCC (<xref ref-type="bibr" rid="bib310">Zhang et al., 2014b</xref>).</p><p>Similarly, NOVA1 expression was found to be upregulated in melanoma samples and cell lines. and knockdown of NOVA1 suppressed melanoma cell proliferation, migration and invasion in both A375 and A875 cell lines These results suggested that NOVA1 acted as an OG in the development of melanoma (<xref ref-type="bibr" rid="bib304">Yu et al., 2018</xref>).</p><p>Recent studies have shown that the tumor suppressor microRNA-592 suppresses the malignant phenotypes of thyroid cancer by downregulating NOVA1. Whereas overexpression of miR–592 resulted in decreased cell proliferation, migration, and invasion in thyroid cancer, ectopic NOVA1 expression effectively abolished the tumor-suppressing effects of miR–592 overexpression in thyroid cancer cells vitro and in vivo (<xref ref-type="bibr" rid="bib151">Luo et al., 2019</xref>).</p><p>Recent studies have provided an explanation for the role of NOVA1 in carcinogenesis. <xref ref-type="bibr" rid="bib207">Sayed et al., 2019</xref> have shown that NOVA1 as well as the polypyrimidine-tract binding protein PTBP1 acts as enhancers of full-length TERT splicing, increasing telomerase activity, promoting telomere maintenance in cancer cells, thereby favoring theit replicative immortality.</p></sec><sec id="s12-9"><title>Calcium/calmodulin-dependent protein kinase type 1B, encoded by the <italic>PNCK</italic> gene</title><p>Pregnancy upregulated non-ubiquitous calmodulin kinase PNCK is a calcium/calmodulin-dependent protein kinase belonging to a calcium-triggered signaling cascade. It phosphorylates and activates CAMK1 that, upon calcium influx, regulates transcription activators activity, cell cycle, hormone production, and cell differentiation.</p><p>Several lines of evidence suggest that PNCK promotes carcinogenesis.</p><p>PNCK has been found to be highly overexpressed in human primary human breast cancers compared with benign mammary tissue (<xref ref-type="bibr" rid="bib74">Gardner et al., 2000</xref>). Increased expression of PNCK is associated with poor prognosis in clear cell renal cell carcinoma. The mRNA level of PNCK was significantly higher in tumorous tissues than in the adjacent non-tumorous tissues. Multivariate analysis indicated that PNCK expression was an independent predictor for poor survival of clear cell renal cell carcinoma patients (<xref ref-type="bibr" rid="bib285">Wu et al., 2013</xref>). Overexpression of PNCK in breast cancer cells was shown to result in increased proliferation, clonal growth, and cell-cycle progression (<xref ref-type="bibr" rid="bib55">Deb et al., 2015</xref>).</p><p>Recent studies have shown that <italic>PNCK</italic> depletion inhibits proliferation and induces apoptosis of human nasopharyngeal carcinoma cells in vitro and in vivo, suggesting that it might be a novel therapeutic target for treatment of nasopharyngeal carcinoma (<xref ref-type="bibr" rid="bib293">Xu et al., 2019</xref>).</p></sec><sec id="s12-10"><title>Runt-related transcription factor 2, encoded by the <italic>RUNX2</italic> gene</title><p>The protein is a member of the RUNX family of transcription factors and has a Runt DNA-binding domain. RUNX2 is a transcription factor involved in osteoblastic differentiation and skeletal morphogenesis. RUNX2 plays a cell proliferation regulatory role in cell cycle entry and exit in osteoblasts. These functions are especially important when discussing bone cancer, particularly osteosarcoma development that can be attributed to aberrant cell proliferation control.</p><p>Several studies indicate that RUNX2 plays a key role in carcinogenseis. RUNX2 overexpression was found to promote aggressiveness and metastatic spreading, whereas <italic>RUNX2</italic> knockdown inhibits tumor growth and metastasis suggesting an oncogenic role for the protein (<xref ref-type="bibr" rid="bib240">Tandon et al., 2014</xref>; <xref ref-type="bibr" rid="bib241">Tandon et al., 2016</xref>; <xref ref-type="bibr" rid="bib221">Shin et al., 2016</xref>; <xref ref-type="bibr" rid="bib134">Li et al., 2016</xref>; <xref ref-type="bibr" rid="bib266">Wang et al., 2016</xref>; <xref ref-type="bibr" rid="bib205">Sancisi et al., 2017</xref>; <xref ref-type="bibr" rid="bib148">Lu et al., 2018</xref>; <xref ref-type="bibr" rid="bib107">Ji et al., 2019</xref>; <xref ref-type="bibr" rid="bib96">Herreño et al., 2019</xref>).</p><p>Although strong purifying selection would not contradict the tumor promoting role of RUNX2, the high silent to missense ratio of substitution mutations is not a reflection of the strength of negative selection of missense and nonsense substitutions.</p><p>A noteworthy feature of the <italic>RUNX2</italic> gene is that its translated region contains a long stretch of CAG repeats (encoding the polyQ segment of the protein, residues 49–71). Interestingly, substitutions are not randomly distributed along the sequence of <italic>RUNX2</italic>: they are clustered in the polyQ tract of the protein encoded by the imperfect polymorphic CAG microsatellite region of the <italic>RUNX2</italic> gene. Since in cancer cells defective in mismatch-repair, microsatellites are known to become unstable due to increased frequency of replication error (<xref ref-type="bibr" rid="bib20">Benachenhou et al., 1998</xref>), it seems likely that this increases and distorts mutation pattern in the polyQ region of <italic>RUNX2</italic>, and this mutation hotspot may give the false impression of strong purifying selection.</p></sec><sec id="s12-11"><title>Monocarboxylate transporter 4 (MCT 4), encoded by the <italic>SLC16A3</italic> gene</title><p>Monocarboxylate transporter 4 (MCT4) or Solute carrier family 16 member 3 (SLC16A3) is a member of the proton-linked monocarboxylate transporter. Protein family. It catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate.</p><p>Since due to abnormal conversion of pyruvic acid to lactic acid by tumor cells even under normoxia, the altered metabolism of glucose consuming tumors must rapidly efflux lactic acid to the microenvironment to maintain a robust glycolytic flux and to prevent poisoning themselves (<xref ref-type="bibr" rid="bib154">Mathupala et al., 2007</xref>). Survival and maintenance of the glycolytic phenotype of tumor cells is ensured by monocarboxylate transporter 4 (MCT4, encoded by the <italic>SLC16A3</italic> gene) that efficiently transports L-lactate out of the cell (<xref ref-type="bibr" rid="bib71">Ganapathy et al., 2009</xref>).</p><p>As high metabolic and proliferative rates in cancer cells lead to production of large amounts of lactate, extruding transporters are essential for the survival of cancer cells. This point may be illustrated by the fact that knockdown of MCT4 increased tumor-free survival and decreased in vitro proliferation rate of tumor cells (<xref ref-type="bibr" rid="bib11">Andersen et al., 2018</xref>).</p><p>Using a functional screen <xref ref-type="bibr" rid="bib15">Baenke et al., 2015</xref> have also demonstrated that monocarboxylate transporter four is an important regulator of breast cancer cell survival: MCT4 depletion reduced the ability of breast cancer cells to grow, suggesting that it might be a valuable therapeutic target.</p><p>In harmony with the essentiality of MCT4 for tumor growth, several studies indicate that expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in tumors and its expression correlates with clinical outcome, thus it may serve as a valuable prognostic factor (<xref ref-type="bibr" rid="bib283">Witkiewicz et al., 2012</xref>; <xref ref-type="bibr" rid="bib64">Doyen et al., 2014</xref>; <xref ref-type="bibr" rid="bib14">Baek et al., 2014</xref>)</p><p>Consistent with the key importance of MCT4 for the survival of tumor cells, its selective inhibition to block lactic acid efflux appears to be a promising therapeutic strategy against highly glycolytic malignant tumors (<xref ref-type="bibr" rid="bib245">Todenhöfer et al., 2018</xref>; <xref ref-type="bibr" rid="bib48">Choi et al., 2016</xref>; <xref ref-type="bibr" rid="bib49">Choi et al., 2018</xref>; <xref ref-type="bibr" rid="bib315">Zhao et al., 2019b</xref>)</p></sec><sec id="s12-12"><title>Solute carrier family 2, facilitated glucose transporter member 1, encoded by the <italic>SLC2A</italic>1 gene</title><p>SLC2A1 functions as a facilitative glucose transporter, which is responsible for glucose uptake.</p><p>Significantly, several nutrient transporter protein genes were found among the genes showing the strongest signs of purifying selection. The most likely explanation for the selective pressure to preserve their integrity is that tumor cells have an increased demand for nutrients and this demand is met by enhanced cellular entry of nutrients through upregulation of specific transporters (<xref ref-type="bibr" rid="bib71">Ganapathy et al., 2009</xref>).</p><p>The uncontrolled cell proliferation of tumor cells involves not only deregulated control of cell proliferation but also major adjustments of energy metabolism in order to fuel cell growth and division in the hypoxic microenvironments in which they reside. Otto Warburg was the first to observe an anomalous characteristic of cancer cell energy metabolism: even in the presence of oxygen, cancer cells limit their energy metabolism largely to glycolysis, leading to a state that has been termed 'aerobic glycolysis' (<xref ref-type="bibr" rid="bib276">Warburg, 1956b</xref>). Cancer cells are known to compensate for the lower efficiency of ATP production through glycolysis than oxidative phosphorylation by upregulating glucose transporters, such as GLUT1, thus increasing glucose import into the cytoplasm (<xref ref-type="bibr" rid="bib114">Jones and Thompson, 2009</xref>; <xref ref-type="bibr" rid="bib56">DeBerardinis et al., 2008</xref>; <xref ref-type="bibr" rid="bib102">Hsu and Sabatini, 2008</xref>).</p><p>The markedly increased uptake of glucose has been documented in many human tumor types, by noninvasively visualizing glucose uptake through positron emission tomography using a radiolabeled analog of glucose as a reporter. This reliance of tumor cells on glycolysis is also supported by the hypoxia response system: under hypoxic conditions not only glucose transporters but also multiple enzymes of the glycolytic pathway are upregulated (<xref ref-type="bibr" rid="bib114">Jones and Thompson, 2009</xref>; <xref ref-type="bibr" rid="bib56">DeBerardinis et al., 2008</xref>; <xref ref-type="bibr" rid="bib211">Semenza, 2010a</xref>; <xref ref-type="bibr" rid="bib212">Semenza, 2010b</xref>; <xref ref-type="bibr" rid="bib127">Kroemer and Pouyssegur, 2008</xref>)</p><p>In our view, the central role of GLUT1 in cancer metabolism is reflected by the fact that the gene (<italic>SLC2A1</italic> gene of solute carrier family member two protein) encoding this glucose transporter is among the genes that show the strongest signatures of purifying selection (see <xref ref-type="supplementary-material" rid="supp31">Supplementary file 31</xref>).</p><p>The key importance of GLUT1 in cancer may be illustrated by the fact that high levels of GLUT1 expression correlates with a poor overall survival and is associated with increased malignant potential, invasiveness, and poor prognosis (<xref ref-type="bibr" rid="bib267">Wang et al., 2017a</xref>; <xref ref-type="bibr" rid="bib58">Deng et al., 2018</xref>; <xref ref-type="bibr" rid="bib52">de Castro et al., 2019</xref>).</p><p>The strict requirement for GLUT1 in the early stages of mammary tumorigenesis highlights the potential for glucose restriction as a breast cancer preventive strategy (<xref ref-type="bibr" rid="bib281">Wellberg et al., 2016</xref>). The tumor essentiality of GLUT1 may also be illustrated by the fact that knockdown of GLUT1 inhibits cell glycolysis and proliferation and inhibits the growth of tumors (<xref ref-type="bibr" rid="bib289">Xiao et al., 2018</xref>). In view of its essentiality for tumor growth, GLUT1 is a promising target for cancer therapy (<xref ref-type="bibr" rid="bib220">Shibuya et al., 2015</xref>; <xref ref-type="bibr" rid="bib169">Noguchi et al., 2016</xref>; <xref ref-type="bibr" rid="bib41">Chen et al., 2017d</xref>)</p><p>Recent studies suggest that the YAP1-TEAD1-GLUT1 axis plays a major role in reprogramming of cancer energy metabolism by modulating glycolysis (<xref ref-type="bibr" rid="bib143">Lin and Xu, 2017</xref>). These authors have shown that YAP1 and TEAD1 are involved in transcriptional control of the the glucose transporter GLUT1, whereas knockdown of YAP1 inhibited glucose consumption, and lactate production of breast cancer cells. Overexpression of GLUT1 restored glucose consumption and lactate production.</p></sec><sec id="s12-13"><title>Solute carrier family 2, facilitated glucose transporter member 8, encoded by the <italic>SLC2A8</italic> gene</title><p>The SLC2A8/GLUT8 is a member of the glucose transporter superfamily that mediates the transport of glucose and fructose.</p><p>In harmony with the strong signatures of negative selection, there is evidence that GLUT8 plays an important role in carcinogenesis: it is overexpressed in and is required for proliferation and viability of tumors (<xref ref-type="bibr" rid="bib80">Goldman et al., 2006</xref>; <xref ref-type="bibr" rid="bib157">McBrayer et al., 2012</xref>).</p></sec><sec id="s12-14"><title>TATA-box-binding protein, encoded by the <italic>TBP</italic> gene</title><p>The <italic>TBP</italic> gene has been selected as a gene showing very high values of rSMN, suggesting negative selection of missense and nonsense mutations (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). It must be pointed out that based on the high silent/missense ratio <italic>TBP</italic> (as well as <italic>DSPP</italic> and <italic>MLLT3</italic>) has also been identified by others as a gene subject to negative selection (<xref ref-type="bibr" rid="bib318">Zhou et al., 2017</xref>).</p><p>The protein is a general transcription factor that functions at the core of the DNA-binding multiprotein factor TFIID. Binding of TFIID to the TATA box is the initial transcriptional step of the pre-initiation complex, playing a role in the activation of eukaryotic genes transcribed by RNA polymerase II. In view of such a basic cell essential function, it seemed justified to assume that it is the indispensability of the gene for the survival of tumor cells (just like any other cell) that subjects it to strong purifying selection and the high silent/missense ratio is a reflection of this negative selection. TBP has been thought to be an invariant housekeeping protein, however, several studies have shown that TBP expression is significantly increased in both colon adenocarcinomas as well as adenomas relative to normal tissue, supporting the idea that increases in TBP expression actually drive tumorigenesis (<xref ref-type="bibr" rid="bib111">Johnson et al., 2003a</xref>; <xref ref-type="bibr" rid="bib112">Johnson et al., 2003b</xref>; <xref ref-type="bibr" rid="bib113">Johnson et al., 2017</xref>).</p><p>Inspection of the spectrum of somatic mutations of the <italic>TBP</italic> gene suggests that the high silent/missense ratio is unlikely to be simply due to negative selection that may hold for both OGs and TEGs. A noteworthy feature of the <italic>TBP</italic> gene is that its translated region contains a long stretch of CAG repeats (encoding the polyQ segment of the protein, residues 57–95). The distribution of silent mutations is markedly non-random: they are clustered in the polyQ tract of the protein encoded by the imperfect polymorphic CAG microsatellite region of the <italic>TBP</italic> gene. Since in cancer cells defective in mismatch-repair, microsatellites are known to become unstable due to increased frequency of replication error (<xref ref-type="bibr" rid="bib20">Benachenhou et al., 1998</xref>), it seems likely that this is why the rate of mutation in the polyQ region of TBP is much higher than in other regions of the gene. The high silent to missense rate is thus not due to negative selection acting on missense and nonsense substitutions. Rather, it may reflect the fact that the imperfect polymorphic CAG microsatellite region of the <italic>TBP</italic> gene serves as a mutation hotspot, with a biased substitution pattern.</p></sec><sec id="s12-15"><title>Thromboxane A2 receptor, encoded by the <italic>TBXA2R</italic> gene</title><p>TBXA2R is a plasma membrane protein that serves as a receptor for thromboxane A2, a potent stimulator of platelet aggregation. The activity of this receptor is mediated by a G-protein that activates a phosphatidylinositol-calcium second messenger system.</p><p>Studies on the expression of thromboxane A2 receptor, TBXA2R in a cohort of human breast cancer patients revealed that breast tumor tissues expressed higher levels of TBXA2R compared with normal mammary tissues and that TBXA2R expression was most significantly increased in grade three tumors. Kaplan-Meier survival analysis has also shown that patients with high levels of TBXA2R had significantly shorter disease-free survival. The observation that TBXA2R is highly expressed in aggressive tumors and linked with poor prognosis indicates that TBXA2R has a significant prognostic value in clinical breast cancer (<xref ref-type="bibr" rid="bib277">Watkins et al., 2005</xref>).</p><p>The role of TBXA2R in carcinogenesis is also supported by the observation that Thromboxane A2 was shown to enhance tumor metastasis and that the tumor promoting activity required intact TBXA2 receptor (<xref ref-type="bibr" rid="bib155">Matsui et al., 2012</xref>). These studies revealed that TBXA2-TBXA2R signaling plays a critical role in tumor colonization through P-selectin-mediated interactions between platelets-tumor cells and tumor cells-endothelial cells, suggesting that blockade of this signaling might be useful in the treatment of tumor metastasis.</p><p>Although the involvement of TBXA2-TBXA2R signaling in cancer invasion and metastasis apperars to be clearly established, there may be other mechanisms by which TBXA2 promotes these processes. <xref ref-type="bibr" rid="bib139">Li and Tai, 2013</xref> have shown that a TBXA2 mimetic induced the expression of the monocyte chemoattractant chemokine ligand protein CCL2, suggesting that TBXA2 may also stimulate invasion of cancer cells through CCL2-CCR2 mediated macrophage recruitment.</p><p>Recent studies on Triple Negative Breast Cancer (TNBC) cell lines revealed that TBXA2R expression was higher in these cell lines and that <italic>TBXA2R</italic> knockdowns consistently showed dramatic cell killing in TNBC cells (<xref ref-type="bibr" rid="bib172">Orr et al., 2016</xref>). It has also been shown that TBXA2R enhanced TNBC cell migration, invasion, indicating that the gene is required for the survival and migratory behavior of a subset of TNBCs.</p><p>A phenome-wide association study has shown that a single-nucleotide polymorphism in the gene <italic>TBXA2R</italic> is associated with increased metastasis in multiple primary cancers, suggesting the requirements for thromboxane A2 (TXA2) and TBXA2R in the basic mechanism of metastasis, and the clinical applicability of TBXA2R antagonists as adjuvant therapy in multiple cancers (<xref ref-type="bibr" rid="bib191">Pulley et al., 2018</xref>).</p></sec><sec id="s12-16"><title>Tumor protein p73, encoded by the <italic>TP73</italic> gene</title><p>The protein is known to participate in the apoptotic response to DNA damage: isoforms containing the N-terminal transactivation domain are pro-apoptotic, isoforms lacking the transactivation domain are anti-apoptotic.</p><p>Although p73 shows substantial homology with p53, despite the established role of p53 as a tumor suppressor, p73 does not have a similar tumor suppressor role in malignancy: unlike p53-/- mice, p73 knockout mice do not develop tumors. In fact, N-terminally truncated p73 isoforms, lacking the transactivation domain were shown to possess oncogenic potential (<xref ref-type="bibr" rid="bib228">Stiewe and Pützer, 2002</xref>; <xref ref-type="bibr" rid="bib227">Stiewe et al., 2002</xref>).</p><p>Numerous studies have shown that ΔNp73, the oncogenic isoform of p73 lacking the transactivation domain, is frequently upregulated in many carcinomas and is indicative of poor prognosis (<xref ref-type="bibr" rid="bib305">Zaika et al., 2002</xref>; <xref ref-type="bibr" rid="bib182">Petrenko et al., 2003</xref>; <xref ref-type="bibr" rid="bib63">Domínguez et al., 2006</xref>; <xref ref-type="bibr" rid="bib91">Hassan et al., 2014b</xref>; <xref ref-type="bibr" rid="bib90">Hassan et al., 2014a</xref>; <xref ref-type="bibr" rid="bib149">Lucena-Araujo et al., 2015</xref>).</p><p>Our observation that p73, an oncogenic protein, shows only strong signatures of purifying selection provides one of the clearest examples illustrating the point that in the case of OGs purifying selection is not necessarily associated with positive selection for driver mutations. It must be pointed out here that it has been noted earlier by others that, despite its clear role in carcinogenesis, the <italic>TP73</italic> gene is almost never mutated (<xref ref-type="bibr" rid="bib25">Bisso et al., 2011</xref>; <xref ref-type="bibr" rid="bib152">Maas et al., 2013</xref>). One may argue that in this case the molecular change that drives carcinogenesis is the change of splicing that favors the formation of the oncogenic isoform of p73.</p></sec><sec id="s12-17"><title>Tribbles homolog 2, encoded by the <italic>TRIB2</italic> gene</title><p>TRIB2 is a pseudokinase member of the pseudoenzyme class of signaling/scaffold proteins. It interacts with MAPK kinases and regulates activation of MAP kinases.</p><p>TRIB2 has been shown to be important in the maintenance of the oncogenic properties of melanoma cells, as its silencing reduces cell proliferation, colony formation. Tumor growth was also substantially reduced upon RNAi-mediated TRIB2 knockdown in an in vivo melanoma xenograft model, suggesting that TRIB2 provides the melanoma cells with growth and survival advantages (<xref ref-type="bibr" rid="bib306">Zanella et al., 2010</xref>).</p><p>TRIB2 expression is elevated in primary human lung tumors and in NSCLC cells, resulting from gene amplification. <italic>TRIB2</italic> knockdown was found to inhibit cell proliferation and in vivo tumor growth, indicating that TRIB2 is a potential driver of lung tumorigenesis (<xref ref-type="bibr" rid="bib83">Grandinetti et al., 2011</xref>).</p><p>High TRIB2 expression is observed in T cell acute lymphoblastic leukemias (<xref ref-type="bibr" rid="bib88">Hannon et al., 2012</xref>). TRIB2 has been shown to be critical for both solid and non-solid malignancies and is functionally important for liver cancer cell survival and transformation. TRIB2 was found to be upregulated in liver cancer cells compared with other cells (<xref ref-type="bibr" rid="bib262">Wang et al., 2013a</xref>; <xref ref-type="bibr" rid="bib263">Wang et al., 2013b</xref>).</p><p>TRIB2 is emerging as a pivotal target of transcription factors in acute leukemias as evidenced by the fact <italic>TRIB2</italic> knockdown resulted in a block in acute myeloid leukemia cell proliferation (<xref ref-type="bibr" rid="bib198">Rishi et al., 2014</xref>)</p><p>In the case of lung adenocarcinoma, patients with higher TRIB2 levels had poorer survival (<xref ref-type="bibr" rid="bib312">Zhang et al., 2016</xref>). The tumor-promoting role of this protein is supported by the observation that TRIB2 expression is significantly increased in tumor tissues from patients with extremely poor clinical outcome (<xref ref-type="bibr" rid="bib98">Hill et al., 2017</xref>; <xref ref-type="bibr" rid="bib274">Wang et al., 2020</xref>).</p><p>TRIB2 has been shown to be important for the survival of leukemia cells during MLL-TET1-related leukemogenesis and for maintaining differentiation blockade of leukemic cells: <italic>TRIB2</italic> knockdown relieved the inhibition of myeloid cell differentiation induced by the MLL-TET1 fusion protein (<xref ref-type="bibr" rid="bib121">Kim et al., 2018</xref>).</p><p>TRIB2 expression has been shown to be elevated in colorectal cancer tissues compared to normal adjacent tissues and high TRIB2 expression indicated poor prognosis of colorectal cancer patients (<xref ref-type="bibr" rid="bib101">Hou et al., 2018</xref>). Depletion of TRIB2 inhibited cancer cell proliferation, induced cell cycle arrest and promoted cellular senescence, whereas overexpression of TRIB2 accelerated cell growth, cell cycle progression and blocked cellular senescence.</p></sec><sec id="s12-18"><title>Twist-related protein 1, encoded by the <italic>TWIST1</italic> gene</title><p>The <italic>TWIST1</italic> gene is characterized by very high value of rSMN (<xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>), indicating strong signature of purifying selection, suggesting that it plays an important role in promoting tumorigenesis.</p><p>Twist-related protein 1, TWIST1 is a transcription factor and master regulator of the epithelial-to-mesenchymal transition that significantly contributes to tumor growth and metastasis. TWIST1 is overexpressed in a variety of tumors and numerous studies have shown that targeting TWIST1 significantly inhibits tumor growth (<xref ref-type="bibr" rid="bib287">Wushou et al., 2014</xref>; <xref ref-type="bibr" rid="bib319">Zhu et al., 2016</xref>; <xref ref-type="bibr" rid="bib291">Xu et al., 2017a</xref>; <xref ref-type="bibr" rid="bib292">Xu et al., 2017b</xref>; <xref ref-type="bibr" rid="bib164">Mikheev et al., 2018</xref>).</p><p>Recent studies have revealed that AURKA and TWIST1 are linked in as much as ablation of either AURKA or TWIST1 completely inhibits epithelial-to-mesenchymal transition (<xref ref-type="bibr" rid="bib268">Wang et al., 2017b</xref>).</p></sec></sec></boxed-text></app><app id="appendix-2"><title>Appendix 2</title><boxed-text><sec id="s13" sec-type="appendix"><title>Analyses of somatic substitutions and subtle indel mutations of human protein-coding genes of tumor tissues</title><p>We have used two major types of analyses of silent, amino acid changing and truncating somatic mutations of human protein-coding genes of tumor tissues: one in which we have restricted our analyses to single -nucleotide substitutions (SO or’ substitution only’ analyes, for details, see main text).</p><p>Here, we describe the analyes that also take into account subtle indels (SSI or’ substitutions and subtle indels’ analyses). In these analyses, subtle mutations affecting the coding sequences of protein coding genes were assigned to three categories: SIL, silent synonymous substitutions, MIS, merging nonsynonymous substitutions and short inframe indels that alter but do not disrupt coding sequence, and NON, merging nonsense substitutions and short frame-shift indels as both types of mutations lead eventually to stop codons that truncate the protein. Unless otherwise idicated, we have used datasets containing transcripts with at least 100 confirmed somatic, non-polymorphic mutations identified in tumor tisses.</p><p>We have used several approaches to analyze the contribution of silent, amino acid changing and truncating mutations to somatic mutations of human protein-coding genes during tumor evolution.</p><p>In the simplest case, we have calculated for each transcript the fraction of somatic mutations that could be assigned to the synonymous (indel_fS), nonsynonymous (indel_fM), and nonsense mutation (indel_fN) category.</p><p>Our analyses have shown that in the 3D representation of SSI mutations (see <xref ref-type="fig" rid="app2fig1">Appendix 2—figure 1</xref>, Panel A) genes are present in a cluster characterized by fraction values of 0.24082 ± 0.06203, 0.70086 ± 0.05701 and 0.05832 ± 0.04151 for indel_fS, indel_fM and indel_fN category, respectively. The mean values for indel_fS, indel_fM and indel_fN in this cluster are very similar to those observed for fS, fM, and fN in SO analyses (<xref ref-type="supplementary-material" rid="supp29">Supplementary file 29</xref>), consistent with the observation that in the dataset containing transcripts with at least 100 confirmed somatic, non-polymorphic mutations identified in tumor tissues subtle indels are much rarer than single-nucleotide substitutions (<xref ref-type="supplementary-material" rid="supp8">Supplementary file 8</xref>).</p><fig id="app2fig1" position="float"><label>Appendix 2—figure 1.</label><caption><title>Analyses of indel_fS, indel_fM and indel_fN parameters of human protein-coding genes of tumor tissues.</title><p>The figure shows the results of the analysis of 13,930 transcripts containing at least 100 subtle, confirmed somatic non-polymorphic mutations from tumor tissues. Axes <italic>x, y</italic> and <italic>z</italic> represent the fractions of somatic mutations that are assigned to the indel_fS, indel_fM and indel_fN categories. In Panel A, each ball represents a human transcript; note that the majority of human genes are present in a dense cluster. The positions of transcripts of the genes defined by <xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref> as oncogenes (OGs, large red balls) or tumor suppressor genes (TSGs, large blue balls) are highlighted. It is noteworthy that these driver genes separate significantly from the central cluster and from each other: OGs have an increased fraction of indel_fM, whereas TSGs have markedly increased fraction of indel_fN. Panel B shows data only for candidate cancer genes present in the CG_SO<sup>2SD</sup>_SSI<sup>2SD</sup> list (see <xref ref-type="supplementary-material" rid="supp31">Supplementary file 31</xref>). The positions of transcripts of the genes identified by <xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref> as OGs (large red balls) or TSGs (large blue balls) are highlighted. The positions of novel cancer gene transcripts validated in the present work are highlighted as large green balls.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59629-app2-fig1-v2.tif"/></fig><p>It is noteworthy, however, that the pattern of indel_fS, indel_fM and indel_fN of the best known cancer genes (<xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref>) deviates significantly from that characteristic of the majority of human genes (see <xref ref-type="fig" rid="app2fig1">Appendix 2—figure 1</xref>, Panel A). The values for OGs show a marked incease in indel_fM, reflecting positive selection for missense mutations, whereas the values for TSGs show significant increase in indel_fN, reflecting primarily positive selection for truncating nonsense mutations (<xref ref-type="supplementary-material" rid="supp29">Supplementary file 29</xref>).</p><p>The set of genes (6139 transcripts) with values that deviate from mean values of indel_fS, indel_fM and indel_fN by more than 1SD have also included the majority of OGs and TSGs (only 5 OG and 1 TSG transcripts remained in the central cluster). It is noteworthy that the 6139 transcripts also contained the vast majority (443 out of 748) of the transcripts of CGC genes, suggesting that the mutation pattern of most CGC genes also deviates significantly from that of passenger genes (PGs; <xref ref-type="supplementary-material" rid="supp29">Supplementary file 29</xref>). The genes in the central cluster (<xref ref-type="supplementary-material" rid="supp29">Supplementary file 29</xref>) is hereafter referred to as PG_SSI<sup>f_1SD</sup> (for Passenger Gene_Substitution and Subtle Indels deviating from mean indel_fS, indel_fM and indel_fN values by ≤1 SD).</p><p>The set of genes (1211 transcripts) with values that deviate from mean values of indel_fS, indel_fM and indel_fN by more than 2SD included 62 OG and 123 TSG driver gene transcripts (see <xref ref-type="fig" rid="app2fig1">Appendix 2—figure 1</xref>, Panel B). Using this more stringent cut-off value, the number of CGC genes identified in the 1211 transcripts was reduced to 153 out of 748 (<xref ref-type="supplementary-material" rid="supp29">Supplementary file 29</xref>). The non-PG set defined by 2SD cut-off value is hereafter referred to as CG_SSI<sup>f_2SD</sup> for Cancer Gene_ Substitution and Subtle Indels deviating from mean indel_fS, indel_fM and indel_fN values by more than 2SD (<xref ref-type="supplementary-material" rid="supp29">Supplementary file 29</xref>).</p><p>The 1211 transcripts in the gene set of CG_SSI<sup>f_2SD</sup> has 873 transcripts not found in the OG, TSG, and CGC cancer gene lists (<xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>). Since the majority of these 873 transcripts (derived from 743 genes) have parameters that assign them to the OG or TSG clusters, we assume that they also qualify as candidate OGs or TSGs. There is, however, a third group of genes that deviate from both the central PG cluster and the clusters of OGs and TSGs: their high indel_fS and low indel_fM and indel_fN values suggest that they experience purifying selection during tumor evolution, suggesting that they may correspond to TEGs important for the growth and survival of tumors. The 743 putative cancer genes listed in CG_SSI<sup>f_2SD</sup> of <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>, were subjected to further analyses to decide whether they qualify as candidate OGs, TSGs, TEGs or the deviation of their mutation pattern from those of PGs is not the result of natural selection. For some typical examples of these analyses see Appendix 1.</p><p>Known cancer genes (OGs and TSGs) also separate from the majority of human genes in 3D representations of parameters indel_rSM, indel_rNM, indel_rNS defined as the ratio of indel_fS/indel_fM, indel_fN/indel_fM, indel_fN/indel_fS, respectively (see <xref ref-type="fig" rid="app2fig2">Appendix 2—figure 2</xref>). In these representations (see <xref ref-type="fig" rid="app2fig2">Appendix 2—figure 2</xref>, Panels A1, A2), OGs separate from the central cluster in having significantly lower indel_rSM and indel_rNM values, whereas TSGs had significantly higher indel_rNS and indel_rNM values than those of the central cluster.</p><fig id="app2fig2" position="float"><label>Appendix 2—figure 2.</label><caption><title>Analyses of indel_rSM, indel_rNM, indel_rNS parameters of human protein-coding genes of tumor tissues.</title><p>The figure shows the results of the analysis of 13930 transcripts containing at least 100 subtle, confirmed somatic mutations from tumor tissues, including only mutations identified as not SNPs. Axes <italic>x, y</italic>, and <italic>z</italic> represent the indel_rSM, indel_rNM, indel_rNS values defined as the ratio of indel_fS/ indel_fM, indel_fN/ indel_fM, indel_fN/ indel_fS, respectively. Each ball represents a human transcript; the positions of transcripts of the genes identified by <xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref> as oncogenes (OGs, large red balls) or tumor suppressor genes (TSGs, large blue balls) are highlighted. Panels A1, A2 show the distribution of the 13,930 transcripts at different magnification. Note that the majority of human genes are present in a dense cluster but known OGs and TSGs separate significantly from the central cluster and from each other. The rNS and rNM values of TSGs are higher, whereas the rSM and rNM values of OGs are lower than those of passenger genes. Panels B1,B2 show data only for candidate cancer genes present in the CG_SO<sup>2SD</sup>_SSI<sup>2SD</sup> list (see <xref ref-type="supplementary-material" rid="supp31">Supplementary file 31</xref>). The positions of transcripts of the genes identified by <xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref> as OGs (large red balls) or TSGs (large blue balls) are highlighted. The positions of novel cancer gene transcripts validated in the present work are highlighted as large green balls.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59629-app2-fig2-v2.tif"/></fig><p>The set of genes (4518 transcripts) with values that deviate from the mean by more than 1SD contained 78 OG transcripts, 132 TSG transcripts, and 368 CGC gene transcripts (<xref ref-type="supplementary-material" rid="supp29">Supplementary file 29</xref>). The central cluster of genes (that deviate from mean rSM, rNM and rNS values by ≤1 SD) is hereafter referred to as PG_SSI<sup>r2_1SD</sup> (for Passenger Gene_Substitution and Subtle Indels deviating from mean indel_rSM, indel_rNM, indel_rNS values by ≤1 SD).</p><p>The non-PG set defined by 2SD cut-off value (see <xref ref-type="fig" rid="app2fig2">Appendix 2—figure 2</xref>, B1, B2, <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>) is hereafter referred to as CG_SSI<sup>r2_2SD</sup> for Cancer Gene_ Substitution and Subtle Indels deviating from mean indel_rSM, indel_rNM, indel_rNS values by more than 2SD (<xref ref-type="supplementary-material" rid="supp29">Supplementary file 29</xref>). This gene set has a total of 861 transcripts, containing 40 transcripts of OGs, 98 transcripts of TSGs genes, 86 transcripts of CGC genes and 637 transcripts (derived from 546 genes) not found in the OG, TSG, and CGC cancer gene lists (<xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>).</p><p>The mean parameters of TSGs differ markedly from those of PGs in that rNS and rNM values are higher, reflecting the dominance of positive selection for inactivating mutations. The parameters for OGs on the other hand, differ from those of PGs in that indel_rSM values of OGs are significantly lower, reflecting positive selection for missense mutations (see <xref ref-type="fig" rid="app2fig2">Appendix 2—figure 2</xref>, Panels A1, A2). Interestingly, in this representation some OGs (e.g. <italic>BCL2</italic>) have unusally high scores of indel_rSM suggesting that in the case of these OGs purifying selection may override positive selection for amino acid changing mutations.</p><p>As mentioned above, the non-PG set defined by a cut-off values of 2SD contains 637 transcripts (derived from 546 genes) not found in the OG, TSG, or CGC lists. Since the majority of these genes have paramerters that assign them to the OG or TSG clusters, they can be regarded as candidate OGs or TSGs. There is a group of genes that deviate from the clusters of PGs, OGs, and TSGs (see <xref ref-type="fig" rid="app2fig2">Appendix 2—figure 2</xref>, Panels B1, B2) in that they have unusually high indel_rSM values. Since high indel_rSM values may be indicative of purifying selection we assume that they may correspond to TEGs important for the growth and survival of tumors. The 546 putative cancer genes listed in CG_SO<sup>indel_r2_2SD</sup> of <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>, were subjected to further analyses to decide whether they qualify as candidate OGs, TSGs, TEGs or the deviation of their mutation pattern from those of PGs is not the result of natural selection. For examples of these analyses see Appendix 1.</p><p>The separation of known cancer genes from the majority of human genes is also observed in 3D representations of parameters indel_rSMN, indel_rMSN and indel_rNSM defined as the ratio of indel_fS/(indel_fM+indel_fN), indel_fM/(indel_fS+indel_fN) and indel_fN/(indel_fS+indel_fM), respectively (see <xref ref-type="fig" rid="app2fig3">Appendix 2—figure 3</xref>, Panels A1, A2). In this representation the genes are present in a three pronged cluster.</p><fig id="app2fig3" position="float"><label>Appendix 2—figure 3.</label><caption><title>Analyses of indel_rSMN, indel_rMSN and indel_rNSM parameters of human protein-coding genes of tumor tissues.</title><p>The figure shows the results of the analysis of 13930 transcripts containing at least 100 subtle, confirmed somatic mutations from tumor tissues. Axes <italic>x, y</italic>, and <italic>z</italic> represent paramerters indel_rSMN, indel_rMSN and indel_rNSM defined as the ratio of indel_fS/(indel_fM+indel_fN), indel_fM/(indel_fS+indel_fN) and indel_fN/(indel_fS+indel_fM), respectively. Each ball represents a human transcript; the positions of transcripts of the genes defined by <xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref> as oncogenes (OGs, red balls) or tumor suppressor genes (TSGs, blue balls) are highlighted. Panels A1 and A2 show the distribution of the 13,930 transcripts at different magnification. Note that the majority of human genes are present in a dense cluster but known OGs and TSGs separate significantly from the central cluster and from each other. The indel_rNSM values of TSGs are higher, their indel_rMSN and indel_rSMN are lower than those of passenger genes. OGs also separate from passenger genes in that their indel_rMSN values are higher and their indel_rSMN values are lower than those of passenger genes. Panels B1,B2 show data at different magnification only for candidate cancer genes present in the CG_SO<sup>2SD</sup>_SSI<sup>2SD</sup> list (see <xref ref-type="supplementary-material" rid="supp31">Supplementary file 31</xref>). The positions of transcripts of the genes identified by <xref ref-type="bibr" rid="bib255">Vogelstein et al., 2013</xref> as OGs (large red balls) or TSGs (large blue balls) are highlighted. The positions of novel cancer gene transcripts validated in the present work are highlighted as large green balls.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-59629-app2-fig3-v2.tif"/></fig><p>The set of genes (4369 transcripts) with values that deviate from the mean by more than 1SD contained 78 OG transcripts, 132 TSG transcripts and 354 CGC gene transcripts (<xref ref-type="supplementary-material" rid="supp29">Supplementary file 29</xref>). The central cluster of genes, deviating from mean rSMN, rMSN and rNSM values by ≤1 SD is hereafter referred to as PG_SO<sup>indel_r3_1SD</sup> (for Passenger Gene_ Substitution and Subtle Indels deviating from mean indel_rSMN, indel_rMSN and indel_rNSM values by ≤1 SD).</p><p>The non-PG set defined by 2SD cut-off value (see <xref ref-type="fig" rid="app2fig3">Appendix 2—figure 3</xref>, Panels B1, B2, <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>) is hereafter referred to as CG_SSI<sup>r3_2SD</sup> for Cancer Gene_ Substitution and Subtle Indels deviating from mean indel_rSMN, indel_rMSN, and indel_rNSM values by more than 2SD (<xref ref-type="supplementary-material" rid="supp29">Supplementary file 29</xref>). This gene set has a total of 823 transcripts, containing transcripts of 37 OGs, 100 TSGs, 86 CGC genes and 600 transcripts (derived from 510 genes) not found in the OG, TSG, and CGC cancer gene lists (<xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>).</p><p>The mean parameters of TSGs differ markedly from those of PGs in as much as indel_rNSM values of TSGs are higher and indel_rSMN values are lower, reflecting the dominance of positive selection for inactivating mutations. In the case of OGs on the other hand, indel_rMSN values are higher and indel_rNSM values are lower than those of PGs, reflecting positive selection for missense mutations and purifying selection avoiding nonsense mutations. Interestingly, some OGs have unusally high scores of indel_rSMN suggesting that in these cases (e.g. <italic>BCL2</italic>) purifying selection may override positive selection for amino acid changing mutations.</p><p>As mentioned above, the non-PG set defined by a cut-off value of 2SD contains 600 transcripts (derived from 510 genes) not found in the OG, TSG or CGC lists. Since the majority of these genes have paramerters that assign them to the OG or TSG clusters, they can be regarded as candidate OGs or TSGs.</p><p>In this representation, we also note the existence of a group of genes that deviates from the clusters of PGs, OGS, and TSGs (see <xref ref-type="fig" rid="app2fig3">Appendix 2—figure 3</xref>): their high indel_rSMN and low indel_rMSN and indel_rNSM values suggest that they experience purifying selection during tumor evolution, suggesting that they may be essential for the survival of tumors as OGs or TEGs. The 510 putative cancer genes listed in CG_SSI<sup>r3_2SD</sup> of <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>, were subjected to further analyses to decide whether they qualify as candidate OGs, TSGs and TEGs or the deviation of their mutation pattern from those of PGs is not the result of natural selection. For some typical examples of these analyses see Appendix 1.</p></sec></boxed-text></app></app-group></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.59629.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Eyras</surname><given-names>Eduardo</given-names></name><role>Reviewing Editor</role><aff><institution>Australian National University</institution><country>Australia</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This article describes a new method to re-examine the role of negative selection in cancer. The authors find new evidence of negative selection against inactivating somatic mutations, thus highlighting new mechanisms of tumor survival.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Use of signals of positive and negative selection to distinguish cancer genes and passenger genes&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Patricia Wittkopp as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>As the editors have judged that your manuscript is of interest, but as described below that additional experiments are required before it is published, we would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). First, because many researchers have temporarily lost access to the labs, we will give authors as much time as they need to submit revised manuscripts. We are also offering, if you choose, to post the manuscript to bioRxiv (if it is not already there) along with this decision letter and a formal designation that the manuscript is &quot;in revision at <italic>eLife</italic>&quot;. Please let us know if you would like to pursue this option. (If your work is more suitable for medRxiv, you will need to post the preprint yourself, as the mechanisms for us to do so are still in development.)</p><p>Summary</p><p>This work describes a novel approach to address the important and still open question of the extent of negative selection in cancer and the potential implications. The authors use data from the catalogue of somatic mutations (COSMIC) and a straightforward approach comparing synonymous, nonsynonymous and nonsense mutation counts to separate genes into Oncogenes, Tumor suppressors and Essential genes. The authors conclude that negative selection plays an important role during tumor evolution.</p><p>Essential revisions</p><p>Reviewers agreed that this work is timely and relevant, but also agreed that there are several important aspects that need revision/improvement before it can be accepted for publication in <italic>eLife</italic>.</p><p>Structure of the paper</p><p>1) The reviewers agreed that there are various aspects of the structure of the paper that require especial attention. The Introduction is a bit lengthy and very focused. It introduces different questions, e.g. hallmarks, prediction of oncogenes and tumor suppressors, prediction of selection, etc and it reads like multiple introductions to different articles. Many parts (e.g. the discussion of cancer hallmarks) could be shortened substantially, which would make it easier to read the paper. One suggestion is to mainly introduce the models of cancer evolution with respect to the SNVs and indels, and the different models and limitations in the estimation of negative selection in cancer and why it is difficult to detect, see e.g. (Zapata et al., 2018, Lopez et al., 2020, Tilk et al., 2019).</p><p>2) Additionally, it will be important to include citations to previous work on the detection of negative selection in cancer that has been omitted. For example, in paragraph five of “Carcinogenesis as an evolutionary process” they should add the work from (Zapata et al., 2018, Van den Eynden et al., 2017, Martincorena et al., 2017, Pyatnitskiy et al., 2015).</p><p>3) Both reviewers agreed that the Results section is repetitive and unbalanced with respect to the Materials and methods section. The work would benefit from streamlining the Results part and moving details to the Materials and methods section.</p><p>4) Regarding the Discussion, it is also very lengthy and lack focus. The authors should make clearer the main results and take-home messages from their work. At the moment, this is not very clear.</p><p>5) For simplicity and to improve readability of the manuscript, it was suggested that the authors focus on 2 standard deviation through the manuscript, instead of describing repetitively the results with 1SD and 2SD.</p><p>6) Regarding the presentation of the results, the reviewers suggested to redesign the figures in such a way that they describe the methodological approach, present the major results of their analysis, and show a comparison of these results with previous methods, and lastly (currently as a table) show the association between the identified genes and the hallmarks of cancer.</p><p>Comparisons with previous studies</p><p>7) One of the problems with the present work raised by the reviewers is that the authors did not performed sufficient comparisons of their results with previous studies. The authors used a seemingly simple approach to measure selection, dividing fractions of frequencies of different mutation classes by each other, with relatively arbitrary cutoffs, e.g. 1 or 2 standard deviations from the mean, to define gene sets. The manuscript does not show the advantages of this method over previous approaches. The authors should clearly show that there is an advantage of their approach by comparing with previous approaches.</p><p>8) The authors should also compare their results with previous publications. One of them, which is cited in the manuscript, is Weghorn and Sunyaev. In fact, this work seems to be misquoted. The authors claim that Weghorn and Sunyaev &quot;identified 147 genes with strong negative selection&quot;, but that study in fact found very few genes under significant negative selection (&lt;10 applying a q-value cutoff of 0.1) and Weghorn and Sunyaev concluded that &quot;the signal of negative selection is very subtle&quot;. Zapata et al., 2018 identified stronger signals of negative selection. The identified genes and functions were partly the same as in the here presented work (eg GLUT1). The authors should compare their results to these and other previous results.</p><p>9) Furthermore, there is recent evidence that correcting for mutational signatures and nucleotide-context composition has a large impact when quantifying selection (see e.g. Zapata et al., 2018, van den Eynden et al., 2017, Martincorena et al., 2017), and this is a relevant aspect in the current lines of discussion in the context of negative selection in tumor evolution (see for example Van den Eynden et al., Nature Genetics. 2019). The authors should show that their main observations hold when the mutational signatures and/or trinucleotide context is taken into account.</p><p>10) Related to this, the authors described a clustering-based method to detect genes that deviate from an average proportion of mutations (nonsynonymous, nonsense and synonymous) to infer selection. However, by only using the observed mutations (nonsyn, syn, nonsense), the underlying base-pair composition is ignored. Genes that have a high likelihood of acquiring nonsense mutations will show a deviation from the rest of the genes due to their composition and not due to selection. The authors should recalculate their metrics by performing this correction before reaching the conclusion on the number and identity of the genes.</p><p>Use of controls</p><p>11) The reviewers also indicated the lack of sufficient controls. To improve the robustness of their method, it was suggested to assess the results after varying several of the conditions. For instance, to circumvent the limitation of the lack of mutations to detect negative selection, the authors study only transcripts with more than 100 mutations. The authors should compare their results using different cut-offs for the minimum number of mutations (50,100,500), and check the performance of their method and whether their results are robust.</p><p>12) Other variations that the authors should consider is to stratify data based on tumor type and mutation burden, since mixing samples with different evolutionary histories might confound the signal of negative selection. As an additional control, a reviewer suggested to perform the same analyses using the germline mutations to separate the genes into cancer specific or cell essential.</p><p>13) An additional control to be performed by the authors was related to the origin of the mutations. The file CosmicMutantExport.tsv contains both mutation data from targeted and genome- / exome-wide screens. Targeted data should be excluded (if the authors didn't do so already). Otherwise their analysis will be highly biased towards well characterized cancer genes.</p><p>Statistical tests</p><p>14) The reviewers also agreed that there is a general lack of statistical tests in the results. For instance, &quot;the mean parameters of TSGs differ markedly from those of passenger genes in that rNS and rNM values are higher&quot;, but these comparisons should be done with appropriate statistical tests to assess the significance. Similar tests should be performed throughout the manuscript.</p><p>15) A very interesting idea in the paper highlighted by the reviewers is that by combining their proposed metrics they can differentiate between oncogenes and tumor suppressors. It would be convenient to have a visual interpretation on how different genes can be only oncogenic, only tumor suppressors, or both, depending on which sites are hit. It is important to note though that similar classifiers have been developed (Schroeder et al., 2014), so it would strengthen the claims of the study to provide a comparison with those methods.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.59629.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions</p><p>Reviewers agreed that this work is timely and relevant, but also agreed that there are several important aspects that need revision/improvement before it can be accepted for publication in eLife.</p><p>Structure of the paper</p><p>1) The reviewers agreed that there are various aspects of the structure of the paper that require especial attention. The Introduction is a bit lengthy and very focused. It introduces different questions, e.g. hallmarks, prediction of oncogenes and tumor suppressors, prediction of selection, etc and it reads like multiple introductions to different articles. Many parts (e.g. the discussion of cancer hallmarks) could be shortened substantially, which would make it easier to read the paper. One suggestion is to mainly introduce the models of cancer evolution with respect to the SNVs and indels, and the different models and limitations in the estimation of negative selection in cancer and why it is difficult to detect, see e.g. (Zapata et al., 2018, Lopez et al., 2020, Tilk et al., 2019).</p></disp-quote><p>We agree that the Introduction is a bit longer than usual. Our excuse is that the Introduction intends to provide answers to questions that are likely to be raised by readers, some of which have been raised by the reviewers. (See for example, Comment 15, Response 15 as to why we do not propose that our approach should be used as a tool to classify oncogenes and tumor suppressors.)</p><p>We think that the major part of the Introduction is essential for understanding the rationale and novelty of our approach (prediction of selection), the difficulties of detection of negative selection (detection of purifying selection) and the rationale for the biological interpretation of our results (cancer hallmarks).</p><p>Re: prediction of selection</p><p>Although this part of the Introduction might appear superfluous, we think that it is important for several reasons.</p><p>First, it allows us to present clear definitions for the terms used in the paper (cancer gene, driver gene, tumor essential gene, cell-essential gene, passenger gene, driver mutation, passenger mutation, deleterious mutation etc.). Second, this part of the Introduction explains the relationship of these terms to negative selection, positive selection or neutral evolution in the case of germline cells or tumor cells. We believe that these parts are important since in the scientific literature authors use some of these terms in a different sense and this may lead to significant confusion. Finally, the discussion of “prediction of selection” is important as it permits us to highlight differences between our approach and earlier approaches used for detection of signals of selection during tumor evolution.</p><p>Re: detection of negative selection</p><p>In accordance with the suggestion of the reviewers, we now discuss the various models of cancer evolution (with respect to point mutations) in detail with major emphasis on the problems associated with the estimation of negative selection in cancer. As recommended by the reviewers, in this section we also discuss the papers of Zapata et al., 2018, Lopez et al., 2020 and Tilk et al., 2019.</p><p>Re: cancer hallmarks</p><p>We think that a short introduction to cancer hallmarks (subsection “Hallmarks of cancer and the function of genes involved in carcinogenesis” and Figure 1 summarizing these hallmarks) is necessary as we have assigned (see Appendix 1) the various novel cancer genes identified in the present study (oncogenes, tumor suppressor genes, tumor essential genes) to cancer hallmarks defined in this section.</p><disp-quote content-type="editor-comment"><p>2) Additionally, it will be important to include citations to previous work on the detection of negative selection in cancer that has been omitted. For example, in paragraph five of “Carcinogenesis as an evolutionary process” they should add the work from (Zapata et al., 2018, Van den Eynden et al., 2017, Martincorena et al., 2017, Pyatnitskiy et al., 2015).</p></disp-quote><p>We have added discussion of these earlier studies to the Introduction (and to other sections of the revised manuscript as appropriate).</p><disp-quote content-type="editor-comment"><p>3) Both reviewers agreed that the Results section is repetitive and unbalanced with respect to the Materials and methods section. The work would benefit from streamlining the Results part and moving details to the Materials and methods section.</p></disp-quote><p>We have streamlined and restructured the Results and Materials and methods sections by moving all methodological details of our analyses from the Results section to the Materials and methods section. The revised version of Materials and methods also incorporates various analyses requested by the reviewers (see below).</p><disp-quote content-type="editor-comment"><p>4) Regarding the Discussion, it is also very lengthy and lack focus. The authors should make clearer the main results and take-home messages from their work. At the moment, this is not very clear.</p></disp-quote><p>We have restructured the Results, Discussion and Conclusion sections of the earlier version in accordance with the suggestion of the reviewers. The main results of our analyses of candidate cancer gene sets (previously constituting the major part of Discussion) are now included in the Results section, whereas the take-home message (previously found in Conclusion) is now included in the Discussion. Note that the Results section of the revised manuscript also incorporates the results of the analyses requested by the reviewers (see below).</p><disp-quote content-type="editor-comment"><p>5) For simplicity and to improve readability of the manuscript, it was suggested that the authors focus on 2 standard deviation through the manuscript, instead of describing repetitively the results with 1SD and 2SD.</p></disp-quote><p>In the revised manuscript, where we discuss candidate cancer genes, we just focus on 2 standard deviations throughout the manuscript.</p><disp-quote content-type="editor-comment"><p>6) Regarding the presentation of the results, the reviewers suggested to redesign the figures in such a way that they describe the methodological approach, present the major results of their analysis, and show a comparison of these results with previous methods, and lastly (currently as a table) show the association between the identified genes and the hallmarks of cancer.</p></disp-quote><p>In our presentation of the results (Results section) we have followed the advice of the reviewers (approach &gt; results &gt;comparison &gt;hallmarks).</p><disp-quote content-type="editor-comment"><p>Comparisons with previous studies</p><p>7) One of the problems with the present work raised by the reviewers is that the authors did not performed sufficient comparisons of their results with previous studies. The authors used a seemingly simple approach to measure selection, dividing fractions of frequencies of different mutation classes by each other, with relatively arbitrary cutoffs, e.g. 1 or 2 standard deviations from the mean, to define gene sets. The manuscript does not show the advantages of this method over previous approaches. The authors should clearly show that there is an advantage of their approach by comparing with previous approaches.</p></disp-quote><p>Re: comparison of results with those of previous studies; advantage compared with previous approaches</p><p>As mentioned above (Comment 2/Response 2) in the revised version we have included additional analyses comparing our results with those of previous studies. These comparisons have shown that our analyses led to the identification and validation of several novel candidate cancer genes (oncogenes, tumor suppressor genes, tumor essential genes that show significant signs of positive and/or negative selection during tumor evolution) most of which were missed by earlier studies. Furthermore, detailed annotation (Appendix 1) of candidate cancer genes identified in the present study has provided support for their role in carcinogenesis, verifying their cancer gene status and validating the approach we have used.</p><p>Re: use of arbitrary cutoffs to define gene sets</p><p>Just like all previous studies that measured positive or negative selection of genes during tumor evolution (by exploiting some signals of selection), we have also ranked the genes according to some measures of selection. All such studies generate gene lists in which genes are ranked according to the parameters defined in the actual study. Rather than discussing thousands of genes of such gene lists, authors use cut offs to focus on genes that show the strongest signs of selection. As will be mentioned below (e.g. Comment 8, Response 8) in many cases a single study uses different cut-offs, permitting the authors to focus on just the genes showing the strongest signs of selection, but also allows them to discuss genes that are included only in a larger gene set defined by less stringent cut-offs.</p><p>In the previous version we have also referred to different primary cut-offs (1SD, 2SD to define candidate cancer gene sets). In the revised manuscript, we focus on 2 standard deviation, as recommended by the reviewers.</p><disp-quote content-type="editor-comment"><p>8) The authors should also compare their results with previous publications. One of them, which is cited in the manuscript, is Weghorn and Sunyaev. In fact, this work seems to be misquoted. The authors claim that Weghorn and Sunyaev &quot;identified 147 genes with strong negative selection&quot;, but that study in fact found very few genes under significant negative selection (&lt;10 applying a q-value cutoff of 0.1) and Weghorn and Sunyaev concluded that &quot;the signal of negative selection is very subtle&quot;. Zapata et al., 2018 identified stronger signals of negative selection. The identified genes and functions were partly the same as in the here presented work (eg GLUT1). The authors should compare their results to these and other previous results.</p></disp-quote><p>Re: possible misquotation of Weghorn and Sunyaev</p><p>In the earlier version we wrote “Based on pergene estimates of negative selection inferred from the pan-cancer analysis the authors have identified 147 genes with strong negative selection. The authors have noted that among the 13 genes showing the strongest signs of negative selection there are several genes (ATAT1, BCL2, CLIP1, GALNT6, CKAP5 and REV1) that are known to promote carcinogenesis.” We wrote: “Although Weghorn and Sunyaev [65] have acknowledged that in their analyses the signals of purifying selection were exceedingly weak, they have identified a group of negatively selected genes that was enriched in cell-essential genes [66].”</p><p>In the main text of the paper of Weghorn and Sunyaev we find: “Supplementary file 7 shows the pergene estimates of negative selection inferred from the pan-cancer analysis. Here, among 13 genes with qneg &lt;0.4, we found 6 (46%) cancer-promoting genes (ATAT1, BCL2, CLIP1, GALNT6, CKAP5, and REV1).” In their Supplementary file 7, Weghorn and Sunyaev do list 147 “Negatively selected genes (q_neg&lt;0.6), sorted by q_neg from pan-cancer analysis” so the essence of this critical remark of the reviewers is that it is not justified to call q_neg&lt;0.6 as strong sign and qneg &lt;0.4 as strongest sign of negative selection. In response to this criticism, in the revised version we have corrected the text by replacing the word “strong” by “significant”.</p><p>Re: comparison of our results with the results of others</p><p>In the Results section of the revised version, we have also compared our results with those of Pyatnitskiy et al., 2015 and Zapata et al., 2018.</p><p>Note that we do not fully agree with the reviewers’ comment on GLUT1. Zapata et al., have identified 39 significantly selected genes, 14 was found to be under positive selection and 25 to be under negative selection, but GLUT1 is not listed among the significantly selected genes (see their Table 1). Nevertheless, the authors discuss several negatively selected genes (including GLUT1) that are not included in their list of significantly selected genes. To acknowledge this, in the revised version we wrote: “(It must be mentioned here that Zapata et al., [x] have also noted that the glucose transporters SLC2A1 and SLC2A8 and the lactate transporter SLC16A3 show signs of purifying selection, although these genes are not listed among the 25 genes with significant negative selection.)”</p><disp-quote content-type="editor-comment"><p>9) Furthermore, there is recent evidence that correcting for mutational signatures and nucleotide-context composition has a large impact when quantifying selection (see e.g. Zapata et al., 2018, van den Eynden et al., 2017, Martincorena et al., 2017), and this is a relevant aspect in the current lines of discussion in the context of negative selection in tumor evolution (see for example Van den Eynden et al., Nature Genetics. 2019). The authors should show that their main observations hold when the mutational signatures and/or trinucleotide context is taken into account.</p><p>10) Related to this, the authors described a clustering-based method to detect genes that deviate from an average proportion of mutations (nonsynonymous, nonsense and synonymous) to infer selection. However, by only using the observed mutations (nonsyn, syn, nonsense), the underlying base-pair composition is ignored. Genes that have a high likelihood of acquiring nonsense mutations will show a deviation from the rest of the genes due to their composition and not due to selection. The authors should recalculate their metrics by performing this correction before reaching the conclusion on the number and identity of the genes.</p></disp-quote><p>In the Materials and methods and Results sections of the revised version, we have included detailed analyses that show that the main observations hold when mutational signatures and compositional biases are taken into account.</p><disp-quote content-type="editor-comment"><p>Use of controls</p><p>11) The reviewers also indicated the lack of sufficient controls. To improve the robustness of their method, it was suggested to assess the results after varying several of the conditions. For instance, to circumvent the limitation of the lack of mutations to detect negative selection, the authors study only transcripts with more than 100 mutations. The authors should compare their results using different cut-offs for the minimum number of mutations (50,100,500), and check the performance of their method and whether their results are robust.</p></disp-quote><p>We have included the requested analyses in the Materials and methods section. We have used different cut-offs for the minimum number of mutations (0, 50,100,500), as suggested by the reviewers. These studies show that increasing the minimum number of mutations increases the reliability of the detection of signals of selection, but diminishes the number of novel cancer genes detected, especially those subject to negative selection. Our analyses confirm that the choice of 100 as the minimum number of somatic mutations per transcript represents an acceptable trade-off between statistical power and loss of negatively or positively selected genes.</p><disp-quote content-type="editor-comment"><p>12) Other variations that the authors should consider is to stratify data based on tumor type and mutation burden, since mixing samples with different evolutionary histories might confound the signal of negative selection. As an additional control, a reviewer suggested to perform the same analyses using the germline mutations to separate the genes into cancer specific or cell essential.</p></disp-quote><p>Re: stratify data based on tumor type</p><p>We agree with the reviewers that mixing tumor samples with different evolutionary histories affects the detection of signals of selection as they may differ significantly in mutation signatures (see also Response 9).</p><p>In fact, there is evidence that even in the case of a given tumor-type different samples may have evolved by different evolutionary trajectories and this is reflected in differences in patterns of mutational signatures (see PCAWG_sigProfiler_SBS_signatures_in_samples). In the revised manuscript, we have calculated the probabilities of different substitution classes of different tumor types and used metrics that have taken into account these mutation probabilities.</p><p>Re: analyses of germline mutations</p><p>To decide how the “essentiality” of genes may differ from the perspective of the tumor cell and the entire organism, in the revised manuscript we have compared the per-gene selection signals manifested in the patterns of somatic mutations of tumor cells with those manifested in the patterns of germline mutations. These comparisons have revealed that – relative to other genes – tumor essential genes identified in the present study display significantly stronger signals of purifying selection during tumor evolution than during organismal evolution, indicating that they serve cancer-specific functions in tumors.</p><disp-quote content-type="editor-comment"><p>13) An additional control to be performed by the authors was related to the origin of the mutations. The file CosmicMutantExport.tsv contains both mutation data from targeted and genome- / exome-wide screens. Targeted data should be excluded (if the authors didn't do so already). Otherwise their analysis will be highly biased towards well characterized cancer genes.</p></disp-quote><p>We have carried out the analyses recommended by the reviewers. These analyses have led to the following conclusions (for details see Materials and methods):</p><p>The COSMIC database of somatic mutations used in the present study contains data obtained by three main types of sequencing: whole-genome sequencing (WGS), whole-exome sequencing (WES) and targeted sequencing. The contribution of targeted screens to somatic point mutations is very restricted: only 508124 (8.3%) of the 6141650 somatic point mutations of the entire COSMIC database were identified by targeted sequencing.</p><p>To check the impact of targeted sequencing on the dataset, in some analyzes we have used somatic mutation data only from genome-wide screens, excluding those obtained by targeted sequencing. We have found that omission of the data from targeted screens had no effect on the conclusions drawn from our analyses. Several factors explain this observation. First, targeted screens usually focus on known cancer genes and they usually just reinforce the “known cancer gene” status of the targeted genes. Second, since only a small fraction of the somatic mutations originates from targeted screens their impact is limited even in the case of the targeted genes. Finally, inclusion or omission of data from targeted screens has no impact on the number and pattern of mutations of non-targeted genes identified in genome wide screens.</p><disp-quote content-type="editor-comment"><p>Statistical tests</p><p>14) The reviewers also agreed that there is a general lack of statistical tests in the results. For instance, &quot;the mean parameters of TSGs differ markedly from those of passenger genes in that rNS and rNM values are higher&quot;, but these comparisons should be done with appropriate statistical tests to assess the significance. Similar tests should be performed throughout the manuscript.</p></disp-quote><p>The results of statistical tests are indicated throughout the manuscript. Details of the statistical tests are reported in the Supplementary files of the respective sections.</p><disp-quote content-type="editor-comment"><p>15) A very interesting idea in the paper highlighted by the reviewers is that by combining their proposed metrics they can differentiate between oncogenes and tumor suppressors. It would be convenient to have a visual interpretation on how different genes can be only oncogenic, only tumor suppressors, or both, depending on which sites are hit. It is important to note though that similar classifiers have been developed (Schroeder et al., 2014), so it would strengthen the claims of the study to provide a comparison with those methods.</p></disp-quote><p>We are glad that the reviewers find it interesting that our proposed metrics can differentiate oncogenes and tumor suppressors. Despite characteristic differences in selection signals of oncogenes/tumor suppressors, we did not want to claim that these features should be used directly as classifiers of oncogenes and tumor suppressors. As we emphasized in the Background section of the original version of our manuscript, cancer driver genes may be activated/inactivated by several alternative mechanisms other than subtle mutations in their coding region. All these mechanisms have to be taken into account to decide whether a given driver gene qualifies as an oncogene or as a tumor suppressor gene. Such a complex analysis is beyond the scope of the present work.</p></body></sub-article></article>